Derivatives of dimethyl-oxo-dihydro-(pyridine-3 or 4-yl)- phenyl- 6- methyl-6 - phenyl -[1,3]- oxazine -2- one, pharmaceutical compositions comprising them and their use in the manufacture of medicaments

1 ηωητηι ϊν tr>bpnr ο*«>» CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1

Boehrineer Ingelheim International GmbH

Vitae Pharmaceuticals, Inc. C.207198 210452/2 - 1 - CYCLIC INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1

FIELD OF THE INVENTION

The present invention relates to inhibitors of 11 β-hydroxysteroid dehydrogenase type 1 (1 Ιβ-HSDI), pharmaceutical compositions thereof and methods of using the same. 20

BACKGROUND OF THE INVENTION

Glucocorticoids, such as cortisol (hydrocortisone), are steroid hormones that regulate fat metabolism, function and distribution, and play a role in carbohydrate, protein and fat metabolism. Glucocorticoids are also known to have physiological 25 effects on development, neurobiology, inflammation, blood pressure, metabolism, and programmed cell death. Cortisol and other corticosteroids bind both the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR), which are members of the nuclear hormone receptor superfamily and have been shown to mediate cortisol function in vivo. These receptors directly modulate transcription via DNA-binding zinc 30 finger domains and transcriptional activation domains.

Until recently, the major determinants of glucocorticoid action were attributed to three primary factors: (1) circulating levels of glucocorticoid (driven primarily by the WO 2010/011314 PCT/US2009/004261 -2- hypothalamic-pituitary-ad renal (HPA) axis); (2) protein binding of glucocorticoids in circulation; and (3) intracellular receptor density inside target tissues. Recently, a fourth determinant of glucocorticoid function has been identified: tissue-specific pre-receptor metabolism by glucocorticoid-activating and -inactivating enzymes. These 5 11β-hydroxysteroid dehydrogenase (1 Ιβ-HSD) pre-receptor control enzymes modulate activation of GR and MR by regulation of glucocorticoid hormones. To date, two distinct isozymes of 11-beta-HSD have been cloned and characterized: 11p-HSD1 (also known as 11-beta-HSD type 1,11betaHSD1, HSD11B1, HDL, and HSD11L) and 11P-HSD2. 11p-HSD1 is a bi-directional oxidoreductase that 10 regenerates active cortisol from inactive 11-keto forms, whereas 11p-HSD2 is a unidirectional dehydrogenase that inactivates biologically active cortisol by converting it into cortisone.

The two isoforms are expressed in a distinct tissue-specific fashion, consistent with the differences in their physiological roles. 11β-HSDI is widely distributed in rat 15 and human tissues; expression of the enzyme and corresponding mRNA have been detected in human liver, adipose tissue, lung, testis, bone and ciliary epithelium. In adipose tissue, increased cortisol concentrations stimulate adipocyte differentiation and may play a role in promoting visceral obesity. In the eye, 11β-HSDI may regulate intraocular pressure and may contribute to glaucoma; some data suggest that 20 inhibition of 11 β-HSDI may cause a drop in intraocular pressure in patients with intraocular hypertension (Kotelevstev et al. (1997), Proc. Natl. Acad. Sci. USA 94(26):14924-9). Although 11p-HSD1 catalyzes both 11-beta-dehydrogenation and the reverse 11-oxoreduction reaction, 11p-HSD1 acts predominantly as a NADPH-dependent oxoreductase in intact cells and tissues, catalyzing the formation of active 25 cortisol from inert cortisone (Low et al. (1994) J. Mol. Endocrin. 13: 167-174). In contradistinction, 11p-HSD2 expression is found mainly in mineralocorticoid target tissues such as kidney (cortex and medulla), placenta, sigmoid and rectal colon, salivary gland and colonic epithelial cell lines. 11P-HSD2 acts as an NAD-dependent dehydrogenase catalyzing the inactivation of cortisol to cortisone (Atbiston et al.

30 (1994) Mol. Cell. Endocrin. 105: R11-R17), and has been shown to protect the MR from glucocorticoid excess (e.g., high levels of receptor-active cortisol) (Blum, et al. (2003) Prog. Nucl. Acid Res. Mol. Biol. 75:173-216). WO 2010/011314 PCT/US2009/004261 -3-

Mutations in either the 11β-HSDI or the 11p-HSD2 genes result in human pathology. For example, individuals with mutations in 11 p-HSD2 are deficient in this cortisol-inactivation activity and, as a result, present with a syndrome of apparent mineralocorticoid excess (also referred to as 'SAME') characterized by hypertension, 5 hypokalemia, and sodium retention (Edwards et al. (1988) Lancet 2: 986-989; Wilson et al. (1998) Proc. Natl. Acad. Sci. 95: 10200-10205). Similarly, mutations in 11 β-HSDI and in the gene encoding a co-localized NADPH-generating enzyme, hexose 6-phosphate dehydrogenase (H6PD), can result in cortisone reductase deficiency (CRD); these individuals present with ACTH-mediated androgen excess 10 (hirsutism, menstrual irregularity, hyperandrogenism), a phenotype resembling polycystic ovary syndrome (RCOS) (Draper et al. (2003) Nat. Genet. 34: 434-439),

Notably, disruption of homeostasis in the HPA axis by either deficient or excess secretion or action results in Cushing's syndrome or Addison's disease, respectively (Miller and Chrousos (2001) Endocrinology and Metabolism, eds. Felig and Frohman 15 (McGraw-Hill, New York), 4th Ed.: 387-524). Patients with Cushing’s syndrome or receiving glucocorticoid therapy develop reversible visceral fat obesity. The phenotype of Cushing's syndrome patients closely resembles that of Reaven's metabolic syndrome (also known as Syndrome X or insulin resistance syndrome), the symptoms of which include visceral obesity, glucose intolerance, insulin resistance, 20 hypertension, type 2 diabetes and hyperlipidemia (Reaven (1993) Ann. Rev. Med. 44: 121-131). Although the role of glucocorticoids in human obesity is not fully characterized, there is mounting evidence that 11 β-HSDI activity plays an important role in obesity and metabolic syndrome (Bujalska et al. (1997) Lancet 349: 1210-1213); (Livingstone et al. (2000) Endocrinology 131: 560-563; Rask et al. (2001) J. 25 Clin. Endocrinol. Metab. 86: 1418-1421; Lindsay et al. (2003) J. Clin. Endocrinol.

Metab. 88:2738-2744; Wake et al. (2003) J. Clin. Endocrinol. Metab. 88: 3983-3988),

Data from studies in mouse transgenic models supports the hypothesis that adipocyte 11p-HSD1 activity plays a central role in visceral obesity and metabolic syndrome (Alberts et al. (2002) Diabetologia. 45(11): 1526-32). Over-expression in 30 adipose tissue of 11 β-HSDI under the control of the aP2 promoter in transgenic mice produced a phenotype remarkably similar to human metabolic syndrome (Masuzaki et al. (2001) Science 294: 2166-2170; Masuzaki et al. (2003) J. Clinical Invest. 112: 83- WO 2010/011314 PCT/US2009/004261 -4- 90). Moreover, the increased activity of 11p-HSD1 in these mice is very similar to that observed in human obesity (Rask et al. (2001) J. Clin. Endocrinol. Metab. 86: 1418- 1421). In addition, data from studies with 11p-HSD1-deficient mice produced by homologous recombination demonstrate that the loss of 11p-HSD1 leads to an 5 increase in insulin sensitivity and glucose tolerance due to a tissue-specific deficiency in active glucocorticoid levels (Kotelevstev et al. (1997) Proc. Natl. Acad. Sci. 94: 14924-14929; Morton et al. (2001) J. Biol. Chem. 276: 41293-41300; Morton et al. (2004) Diabetes 53: 931-938).

The published data supports the hypothesis that increased expression of 10 11p-HSD1 contributes to increased local conversion of cortisone to cortisol in adipose tissue and hence that 11p-HSD1 plays a role in the pathogenesis of central obesity and the appearance of the metabolic syndrome in humans (Engeli, et al., (2004)

Obes. Res. 12: 9-17). Therefore, 11β-HSDI is a promising pharmaceutical target for the treatment of the metabolic syndrome (Masuzaki, et al., (2003) Curr. Drug Targets 15 Immune Endocr. Metabol. Disord. 3: 255-62). Furthermore, inhibition of 11p-HSD1 activity may prove beneficial in treating numerous glucocorticoid-related disorders.

For example, 11p-HSD1 inhibitors could be effective in combating obesity and/or aspects of the metabolic syndrome cluster, including glucose intolerance, insulin resistance, hyperglycemia, hypertension, and/or hyperlipidemia (Kotelevstev et al. 20 (1997) Proc. Natl. Acad. Sci. 94:14924-14929; Morton et al. (2001) J. Biol. Chem. 276: 41293-41300; Morton et al. (2004) Diabetes 53: 931-938). In addition, inhibition of 11p-HSD1 activity may have beneficial effects on the pancreas, including the enhancement of glucose-stimulated insulin release (Billaudel and Sutter (1979) Horm. Metab. Res. 11: 555-560; Ogawa etal. (1992) J. Clin. Invest. 90: 497-504; Davani et 25 al. (2000) J. Biol. Chem. 275: 34841-34844).

Furthermore, given that inter-individual differences in general cognitive function have been linked to variability in the long-term exposure to glucocorticoids (Lupien et al. (1998) Nat. Neurosci. 1: 69-73) and dysregulation of the HPA axis resulting in chronic exposure to glucocorticoid excess in certain brain subregions has been 30 theorized to contribute to the decline of cognitive function (McEwen and Sapolsky (1995) Curr. Opin. Neurobiol. 5: 205-216), one might predict that inhibition of 11P-HSD1 could reduce exposure to glucocorticoids in the brain and thereby protect WO 2010/011314 PCT/US2009/004261 -5 - against deleterious glucocorticoid effects on neuronal function, including cognitive impairment, dementia, and/or depression. Notably, it is known that stress and glucocorticoids influence cognitive function (de Quervain et al. (1998) Nature 394; 787-790); and it has been shown that Ιΐβ-HSDI, through its control of glucocorticoid 5 action in the brain, may have effects on neurotoxicity (Rajan et al, (1996)

Neuroscience 16: 65-70; Seckl (2000) Neuroendocrinol. 18:49-99).

There is also evidence that glucocorticoids and 11 β-KSDI play a role in regulation of in intra-ocular pressure (IOP) (Stokes et al. (2000) Invest. Ophthalmol. Vis. Sci. 41: 1629-1683; Rauz et al. (2001) Invest. Ophthalmol. Vis. Sci. 42: 2037- 10 2042); if left untreated, elevated IOP can lead to partial visual field loss and eventually blindness. Thus, inhibition of Ιΐβ-HSDI in the eye could reduce local glucocorticoid concentrations and IOP, and 11p-HSD1 hence could potentially be used to treat glaucoma and other visual disorders.

Transgenic aP2-1 ΙβΗβϋΙ mice exhibit high arterial blood pressure and have 15 increased sensitivity to dietary salt. Moreover, plasma angiotensinogen levels are elevated in the transgenic mice, as are angiotensin II and aldosterone; and treatment of the mice with an angiotensin II antagonist alleviates the hypertension (Masuzaki et al. (2003) J. Clinical Invest. 112: 83-90). This suggests that hypertension may be caused or exacerbated by Ιΐβ-HSDI activity. Thus, 11p-HSD1 inhibitors may be 20 useful for treatment of hypertension and hypertension-related cardiovascular disorders. Inhibition of 11p-HSD1 in mature adipocytes is also expected to attenuate secretion of plasminogen activator inhibitor 1 (PAI-1), which is an independent cardiovascular risk factor (Halleux et al. (1999) J. Clin. Endocrinol. Metabl. 84: 4097-4105). 25 Glucocorticoids can have adverse effects on skeletal tissues; and prolonged exposure to even moderate glucocorticoid doses can result in osteoporosis (Cannalis (1996) J. Clin. Endocrinol. Metab. 81: 3441-3447). In addition, 11p-HSD1 has been shown to be present in cultures of human primary osteoblasts as well as cells from adult bone (Cooper et al. (2000) Bone 27: 375-381), and the Ιΐβ-HSDI inhibitor 30 carbenoxolone has been shown to attenuate the negative effects of glucocorticoids on bone nodule formation (Bellows et al. (1998) Bone 23:119-125). Thus, inhibition of 11p-HSD1 is predicted to decrease the local glucocorticoid concentration within WO 2010/011314 PCT/US2009/004261 -6- osteoblasts and osteoclasts, thereby producing beneficial effects in various forms of bone disease, including osteoporosis. 11β-HSDI inhibitors may also be useful for immunomodulation. Although glucocorticoids are perceived to suppress the immune system, in actuality, there is a 5 complex, dynamic interaction between the HPA axis and the immune system (Rook (1999) Baillier's Clin. Endocrinol. Metabl. 13: 576-581). Glucocorticoids playa role in modulating the balance between cell-mediated and humoral immune response, with high glucocorticoid activity normally associated with a humoral response. Inhibition of 11p-HSD1 therefore can be used a means of shifting the immune response towards a 10 cell-mediated response. Certain disease states, such as tuberculosis, leprosy (Hansen's disease) and psoriasis, trigger immune responses that are biased towards a humoral response whereas the more effective immune response may be a cell-mediated response. Hence, 11p-HSD1 inhibitors may be useful for treating such diseases. 15 It has been reported that glucocorticoids inhibit wound healing, especially in diabetic patients with ulcers (Bitar et al. (1999) J. Surg. Res. 82: 234-243; Bitar et al. (1999) Surgery 125: 594-601; Bitar (2000) Surgery 127: 687-695; Bitar (1998) Am. J. Pathol. 152: 547-554). Patients that exhibit impaired glucose tolerance and/or type 2 diabetes often also have impaired wound healing. Glucocorticoids have been shown 20 to increase the risk of infection and delay wound healing (Anstead (1998) Adv. Wound Care 11:277-285). Moreover, there is a correlation between elevated levels of cortisol in wound fluid and non-healing wounds (EP Patent App. No. 0 902 288). Recent published patent applications have suggested that certain 11p-HSD1 inhibitors may be useful for promoting wound healing (PCT/US2006/043,951). 25 As evidenced herein, there is a continuing need for new and improved drugs that inhibit 11β-HSDI. The novel compounds of the instant invention are effective inhibitors of 11 β-HSDI.

SUMMARY OF THE INVENTION

It has now been found that compounds of Formula lm1 or pharmaceutically acceptable 30 salts thereof, are effective inhibitors of 11 p-HSD1. WO 2010/011314 PCT/US2009/004261

The invention is a compound represented by Formula (Im1) 0 R1

<img img-format="tif" img-content="drawing" file="IL210452AD00021.tif" id="idf0001" />

',A

<img img-format="tif" img-content="drawing" file="IL210452AD00022.tif" id="idf0002" />

(Im1); or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

In a first embodiment of the invention, Formula Im1 and its constituent 5 members are defined herein as follows: R1 is (a) absent or (b) is selected from (CrCeJalkyl, (C2-Ce)alkenyl, (C2-C6)alkynyl, (CrC3)atkoxy(Ci-C3)alkoxy, or (CrC3)alkoxy(CrC3)alkyl and is optionally substituted with up to four groups independently selected from fluorine, cyano, oxo, R4, R4O-, (R4)2N-, R4O2C-, R4S, R4S(=O)-, R4S(=O)2-, R4C(=O)NR4-, 10 (R4)2NC(=O)-, (R4)2NC(=O)O-, (R4)2NC(=O)NR4-, R4OC(=O)NR4-, (R4) 2NC(=NCN)NR4-, (R4O)2P(=O)O-, (R4O)2P(=O)NR4-, R4OS(=O)2NR4-, (R4)2NS(=O)2O-, (R4)2NS(=O)2NR4-, R4S(=O)2NR4-, R4S(=O)2NHC(=O)·, R4S(=0)2NHC(=0)O-, R4S(=O)2NHC(=O)NR4-, R4OS(=0)2NHC(=O)-. R4OS(=O)2NHC(=O)O-, R4OS(=0)2NHC(=O)NR4-, (R4)2NS(=O)2NHC(=O)-, 15 (R4)2NS(=O)2NHC(=O)O-, (R4)2NS(=O)2NHC(=O)NR4-, R4C(=O)NHS(=O)2-, R4C(=O)NHS(=O)2O-, R4C(=0)NHS(=O)2NR4-, R40C(=0)NHS(=O)2-, R40C(=O)NHS(=O)2O-, R40C(=0)NHS(=O)2NR4-, (R4)2NC(=O)NHS(=O)2-, (R4)2NC(=O)NHS(=O)2O-, (R4)2NC(=O)NHS(=O)2NR4-, heterocyclyl, heteroaryl, aryl-amino and heteroarylamino; 20 A1 is (a) a bond, or (b) (Ci-C3)alkylene, CH2CH2O, wherein the oxygen is attached to Cy1, or CH2C(=O), wherein the carbonyl carbon is attached to Cy1;

Cy1 is aryl, heteroaryl, monocyclic cycloalkyl or monocyclic heterocyclyl and is optionally substituted with 1 to 4 groups independently selected from fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (Ci-C6)alkyl, 25 hydroxy(Ci-C6)alkyl, (C3-C6)cyc1oalkyl, hydroxy(C3-C6)cycloalkyl, (C4-C7)cycloalkylalkyl, (C2-C6)alkenyl, halo(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, (C2-Ce)alkynyl, (C3-C6)cycloatkyl(C2-C4)alkynyl, halo(Ci-C6)alkyl, halo(C3-Ce)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (CrC6)alkoxy, (C3-C6)cycloalkoxy( WO 2010/011314 PCT/US2009/004261 -8- (C4-C7)cycloalkylalkoxy, halo(Ci-C6)alkoxy, halo(C3-C6)cycloalkoxy, halo(C4-C7)cycloalkylalkoxy, (CrC6)alkylthio, (C3-C6)cycloalkythio, (C4-C7)cycloalkylalkylthio, halo(CrC6)alkylthio, halo(C3-C6)cycloalkythio, halo(C4-C7)cycloalkylalkylthio, (Ci-Ce)alkanesulfinyl, (C3-C6)cycloalkanesulfinyl, 5 (C4-C7)cycloalkylalkanesulfinyi, halo(Ci-Ce)alkanesulfinyl, halo(C3-C6)cycloalkanesulfmyl, halo(C4-C7)cycloalkylalkanesulfinyl, {Ci-C6)alkanesutfonyl, (C3-C6)cycloalkanesulfonyl, {C4-C7)cycloalkylalkanesulfonyl, halo(CrC6)alkanesulfonyl, halo(C3-C6)cycloalkanesutfonyl, halo(C4-C7)cyclo-alkylalkanesulfonyl, (CrC6)alkylamino, di(CrC6)alkylamino, 10 (Ci-C6)alkoxy(Ci-C6)alkoxy, halo(Ci-C6)alkoxy(Ci-C6)aikoxy, (Ci-Cejalkoxycarbonyl, H2NCO, H2N$O2, (CrC6)alkylaminocarbonyl, di(Ci-C6)alkylaminocarbonyl, (Ci-C3)alkoxy(CvC3)alkylaminocarbonyl, heterocyclylcarbonyl, (Ci-C6)alkylaminosulfonyl, di(CrC6)alkylaminosulfonyl, heterocyclylsutfonyl, (Ci-Ce)alkylcarbonylamino, (Ci-C6)alkylcarbonylamino(Ci-C6)aJkyl, 15 (CrCeJalkylsulfonylamino, (CrC6)alkylsulfonylamino(Ci-C6)alkyl, (Ci-Ce)alkoxycarbonyl(Ci-C6)alkoxy, {Ci-Ce)alkoxy(Ci-C6)aikyl, halo{Ci-Ce)alkoxy(Ci-C6)alkyl, hydroxy(CvC6)alkoxy, heteroaryl oxo, amino(Ci-C6)alkyl, (Ci-C6)alkylamino(CrC6)alkyl, di(Ci-C6)alkylamino(Ci-Ce)alkyl amino(C2-C6)alkoxy, (CrC6)alkylamino(C2-C6)alkoxyt 20 di(Ci-C6)alkylamino(C2’C6)alkoxy, (CrC6)alkylcarbonyl, (C3-C6)cycloalkylcarbonyl, (C3-C6)cycloalkylaminocarbonyl, {(C3-C6)cycloalkyl}{(C1-C6)alkyl}aminocarbonyl, di(C3-C6)cycloalkylamtnocarbonyl, (C3-C6)cycloalkylaminosulfonyl, {(C3-C6)cycloalkylK(Ci-C6)alkyl}aminosulfonyl, di(C3-C6)cycloalkylaminosulfonyl1 cyano(Ci-C6)alkyl, aminocarbonyl(Ci-C6)alkyl, (CrCeialkylaminocarbonyKCi-CeJalkyl 25 di(CrC6)alkylaminocarbonyl(Ci-C6)alkyl, (C3-C6)cycloalkylaminocarbonyl(Ci-C6)aikyl, {(C3-C6)cycloatkyl}{{C1-C6)alkyl}aminocarbonyl{CrC6)alkyl and di(C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl;

The oxodihydropyridyl ring in Formula lm1 is optionally substituted with 1 to 4 groups independently selected from fluorine, chlorine, bromine, iodine, cyano, nitro, 30 amino, hydroxy, carboxy, (CrC6)alkyl, hydroxy(Ci-C6)alkyl, (C3-C6)cycloalkyl, hydroxy(C3-Ce)cycloalkyl, (C4-C7)cycloalkylalkyl, (C2-C6)alkenyl, halo(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, {C2-C6)alkynyl, (C3-C6)cycloalkyl(C2-C4)alkynyl, halo(CrC6)alkyl, halo(C3-C6)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (CrC6)alkoxy, WO 2010/011314 PCT/US2009/004261 -9- (C3-C6)cycloalkoxy, (C4-C7)cycloalkylalkoxy, halo(Ci-C6)alkoxy, halo(C3-C6)cycloalkoxy, halo(C4’C7)cycloalkylalkoxy, (CrC6)alkylthio, (Ca-Celcycloalkythio, (C4-C7)cycloalkylalkylthio, halo(Ci-Cs)alkylthio, halo(C3-C6)cycloalkythio, halo(C4-C7)cycloalkylalkylthio, (CrCe^lkanesulfinyl, 5 (C3-C6)cycloalkane$ulflnyl, (C4-C7)cycloalkylalkanesulfinyl, halo(Ci-C6)alkanesulfinyl, halo(C3-C6)cycloalkanesutfinyl, halo(C4-C7)cycloalkylalkanesulfinyl, (CrC6)alkanesulfonyl, {C3-C6)cycloalkanesulfonyl, (C4-C7)cycloalkylalkanesulfonyl, halotCrCeJalkanesulfonyl, halo(C3-C6)cycloalkanesulfonyl, halo(C4-C7)cyclo-alkylatkanesulfonyl, (Ci-C6)alkylamino, di(Ci-C6)atkylamino, 10 (Ci-C6)alkoxy(Ci-C6)alkoxyt halo(Ci-C6)alkoxy(CrC6)alkoxy, (CvC6)alkoxycarbonyl, H2NCO, H2NSO2i (CrCeJalkylaminocarbonyl, di(Ci-C6)alkylaminocarbonyl, (Ci-C3)alkoxy(Ci-C3)alkylaminocarbonyl, heterocyclylcarbonyl, (Ci-C6)alkylaminosulfonyl, di(Ci-C6)alkylaminosulfonyl, heterocyclylsulfonyl, (CrCeJalkylcarbonylamino, (Ci-C6)alkylcarbonylamino(Ci-C6)alkyl, 15 (CrC6)alkylsulfonylamino, (Ci-C6)alkylsulfonylamino(Ci-C6)alkyl, (CrC6)alkoxycarbonyl(CrC6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, halo(C1-C6)alkoxy(C1-C6)alkyl, hydroxy(Ci-C6)alkoxy, heteroaryl, oxo, amino(Ci-C6)alkyl, (Ci-C6)alkylamino(Ci-C6)alkyl, di(Ci-C6)aikylamino(Ci-C6)alkyl amino(C2-C6)alkoxy, (Ci-C6)alkylamino(C2-Ce)alkoxy, 20 di(CrC6)alkylamino(C2-C6)alkoxy, (Ci-C6)alkylcarbonyl, (C3-C6)cycloalkylcarbonyl, (C3-Ce)cycloalkylaminocarbonyl, {(C3-C6)cycloalkyl}{(Ci-C6)alkyl}aminocarbonyl, di(C3-C6)cycloalkylaminocarbonyl, (C3-C6)cycloalkylaminosulfonyl, {(C3-C6)cycloalkylX(Ci-C6)alkyl}aminosulfonyl, di(C3-C6)cycloalkylaminosulfonyl, cyano(Ci-C6)alkyl, aminocarbonyl(Ci-C6)alkyl, (CrC6)alkylaminocarbonyl(Ci-C6)alkyl, 25 di(CrC6)alkylaminocarbonyl(Ci-C6)alkyl, (C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl, {(C3-C6)cycloalkylX(Ci’C6)alkyl}aminocarbonyl(Ci-C6)alkyl and di(C3-C6)cycloalkylaminocarbonyl(Ci-C6)a!kyl; E is (a) a bond or (b) (Ci-C3)alkylene or (Ci-C2)alky1enyloxy, wherein the O is attached to R2, each of which is optionally substituted with 1 to 4 groups 30 independently selected from methyl, ethyl, trifluoromethyl or oxo; R2 is (Ci-Ce)alkyI, aryl, heteroaryl, cycloalkyl or heterocyclyl and is optionally substituted with up to 4 groups independently selected from fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (Cn-Csjalkyl, WO 2010/011314 PCT/US2009/004261 - 10- hydroxy(Ci-C6)alkyl, (C3-C6)cycloalkyl, hydroxy(C3-C6)cycloalkyl, (C4-C7)cycloalkylalkyl, (C2-C6)alkenyl, halo(C2-C6)alkenyl, hydroxy(C2-Ce)alkenyl, (Ci-CeJalkynyl, (C3-C6)cycloalkyl(C2-C4)alkynyl, halo(CrC6)alkyl, halo(C3-Ce)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (Ci-C6)alkoxy, (C3-C6)cycloalkoxy, 5 (C4-C7)cycloalkylalkoxy, halo(CrC6)alkoxy, halo(C3-C6)cycloalkoxy, halo(C4-C7)cycloalkylalkoxy, (Ci-C6)alkylthio, (C3-C6)cycloalkythio, (C4-C7)cycloalkyl-alkylthio, halo(Ci-C6)alkylthio, halo{C3-C6)cycloalkythio, halo(C4-C7)cycloalkylalkylthio, (Ci-Cejalkanesulftnyl, (C3-Ce)cycloalkanesulfinyl, (C4-C7)cycloalkylalkanesulfinyl, halo(Ci-C6)alkanesulfinyl, halo(C3-C6)cycloalkanesulfinyl, halo(C4-C7)cycloalkyt- 10 alkanesulfinyl, (CrCe)alkanesulfonyl, (C3-C6)cycloalkanesulfonyl, (C4-C7)cycloalkyl-alkanesulfonyl, halo(Ci-C6)alkanesulfonyl, halo(C3-C6)cycloalkanesulfonyl, halo(C4-C7)cyclo-alkylalkanesulfonyl, (Ci-C6)alkylamino, di(Ci-C6)alkylamino, (CrC6)alkoxy(Ci-C6)alkoxy, halo(Ci-C6)alkoxy(Ci-C6)alkoxy, (Ci-C6)alkoxycarbonylt H2NCO, H2NSO2i (CrC6)alkylaminocarbonyl, di(Ci-C6)alkytaminocarbonyl, 15 (CrC3)alkoxy(CrC3)alkylaminocarbonyl, heterocyclylcarbonyl, (CrC6)alkylaminosulfonyl, di(C-i“C6)alkylaminosulfonyl, heterocyclylsutfonyl, (Ci-Cejalkylcarbonylamino, (Ci-C6)alkylcarbonylamino(CrCe)alkyl, (CrCeJafkylsulfonylamino, (CrCeJalkylsulfonylaminotCi-CeJalkyl, (Ci-C6)alkoxycarbonyl(CrC6)alkoxy, (CrC6)alkoxy(Ci-Ce)alkyl, 20 halo(Ci-C6)alkoxy(Ci-Ce)alkyl, hydroxy(Ci-C6)alkoxy, heteroaryl, oxo, amino(Ci-Ce)alkyl, (Ci-C6)alkylamino(CrC6)alkyl, di(Ci-C6&gt;alkylamino(Ci-C6)alkyl amino(C2-Ce)alkoxy, (Ci-C6)alkylamino(C2-C6)alkoxy, di(CrC6)alkylamino(C2-C6)alkoxy, (Ci-CeJalkylcarbonyl, (C3-C6)cycloalkylcarbonyl, (C3-C6)cycloalkylaminocarbonyl, {(C3-C6)cycloalkyl}{(Ci-C6)alkyl}aminocarbonyl, 25 di(C3-C6)cycloalkylaminocarbonyl, (C3-C6)cycloalkylaminosulfonyl, {(C3-C6)cycloalkylX(Ci-C6)alkyl}aminosulfonyl, di(C3-C6)cycloalkylaminosulfonyl, cyano(CrC6)alkyl, aminocarbonyl(Ci-C6)alkyl, (Ci-C6)alkylaminocarbonyl(Ci-C6)alkyl, di(CrC6)alkylaminocarbonyl(CrC6)alkyl, (C3^e)cycloalkylaminocarbonyl{Ci-Ce)a!kyl, {(C3-C6)cycloalkylX(Ci-C6)alkyl}aminocarbonyl(Ci-C6)alkyl and 30 di(C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl; R3 is selected from (Ci-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C5)cycloalkyl(CrC4)alkyl, {Ci-C3)alkoxy(Ci-C3)alkoxy, or (Ci-C3)alkoxy(Ci-C3)alkyl and is optionally substituted with up to four groups WO 2010/011314 PCT/US2009/004261 - 11 - independently selected from fluorine, cyano, oxo, R4, R4O-, (R4)2N-, R4O2C-, R4C(=O)O-, R4S, R4S(=O)-, R4S(=O)2-, R4C(=O)NR4-, (R4)2NC(=O)-, (R4)2NC(=O)O-, (R4)2NC(=O)NR4-, R4OC(=O)NR4-, (R4)2NC(=NCN)NR4-, (R4O)2P(=O)O-, (R4O)2P(=O)NR4-, R4OS(=O)2NR4-, (R4)2NS(=O)2O-, (R4)2NS(=O)2NR4-, R4S(=O)2NR4-, R4S(=O)2NHC(=O)-, R4S(=O)2NHC(=O)O-, R4S(=O)2NHC(=O)NR4-, R4OS(=O)2NHC(=O)-, R4OS(=O)2NHC(=O)O-, R4OS(=O)2NHC(=O)NR4-, (R4)2NS(=O)2NHC(=O)-, (R4)2NS(=O)2NHC(=O)O- (R4)2NS(=O)2NHC(=:O)NR4-, R4C(=O)NHS(=O)2- R4C(=0)NHS(=O)2O-, R4C(=O)NHS(=O)2NR4-, R4OC(=O)NHS(=O)2-, R40C(=0)NHS(=O)20-, R4OC(=O)NHS(=O)2NR4-, (R4)2NC(=O)NHS(=O)2-, (R4)2NC(=O)NHS(=O)2O-, (R4)2NC(=O)NHS(=O)2NR4-, spirocycloalkyl; heterocyclyl (which in turn may be optionally substituted with alkyl, haloalkyl, halogen or oxo), heteroaryl (which in turn may be optionally substituted with alkyl, haloalkyl, alkoxy, alkylthio, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO2H, CONH2, N-monoalkyl-substituted amido, N,N-dialkyl-substituted amido, or oxo), arylamino (which in turn may be optionally substituted with alkyl, alkoxy, alkylthio, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO2H, CONH2, N-monoalkyl-substituted amido and Ν,Ν-dialkyl-substituted amido) and heteroarylamino (which in turn may be optionally substituted with alkyl, haloalkyl, alkoxy, alkylthio, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO2H, CONH2i N-monoalkyl-substituted amido, Ν,Ν-dialkyl-substituted amido, or oxo); and R4 is independently selected from H, (CrC6)alkyl, halo(Ci-C6)alkyl, amino(CrC6)alkyl, (Ci-C6)alkylamino(CrC6)alkyl, di(Ci-C6)alkylamino(Ci-Ce)alkyl, hydroxy(Ci-Ce)alkyl and (Ci-C6)alkoxy(Ci-C6)alkyl.

Alternatively, the first embodiment above excludes the compounds of structural formulas PR-221 and PR-313, or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

Another embodiment of the invention is a pharmaceutical composition comprising i) a pharmaceutically acceptable carrier or diluent, and ii) a compound of Formulas Ik, lm1, lm2, lm5, In’, In2, In5, Io1, Io2, Io5, Ip1 or Ip3, ora pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

Another embodiment of the invention is a method of inhibiting 11p-HSD1 activity comprising the step of administering to a mammal in need of such treatment WO 2010/011314 PCT/US2009/004261 -12- an effective amount of a compound of Formulas Ik, Im1, lm2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1 or Ip3, or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

Another embodiment of the invention is a method of treating a subject with a 5 disease associated with the activity or expression of 11p-HSD1, comprising the step of administering to the subject an effective amount of a compound of Formulas Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1 or Ip3, ora pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

Another embodiment of the invention is the use of a compound of Formulas Ik, 10 Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1 or Ip3, or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof for the manufacture of a medicament for inhibiting 1Ιβ-HSDI activity in a mammal in need of such treatment.

Another embodiment of the invention is the use of a compound of Formulas Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1 or Ip3, or a pharmaceutically acceptable salt, 15 enantiomer or diastereomer thereof for the manufacture of a medicament for treating a subject with a disease associated with the activity or expression of 11p-KSD1.

Another embodiment of the invention is a compound of Formulas Ik, Im1, Im2, Im5, In1, In2, In5, Io1, Io2, Io5, Ip1 or Ip3, or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof for use in inhibiting Ήβ-HSDI activity in a 20 mammal in need of such treatment.

Another embodiment of the invention is a compound of Ik, Im1, Im2, Im5, In1,

In2, In5, Io1, Io2, Io5, Ip1 or Ip3, or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof for use in for treating a subject with a disease associated with the activity or expression of 11β-HSDI.

25 DETAILED DESCRIPTION OF THE INVENTION

Another embodiment of the invention is a compound of Formula Ik:

<img img-format="tif" img-content="drawing" file="IL210452AD00023.tif" id="idf0003" />

Ik WO 2010/011314 PCT/US2009/004261 - 13- 10 15 20 or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof; R1a is absent or is methyl or ethyl;

Cy2 is 2-oxo-1,2-dihydropyridyl optionally substituted by t to 4 groups independently selected from halo, hydroxy, methoxy, hydroxymethyl, methoxycarbonyl, amino, carbamoyl, methylcarbamoyl, dimethylcarbamoyl, (2-methoxyethyl)aminocarbonyl, acetylaminomethyl, methylsulfonyl, methylsulfonylamino, methylaminosulfonyl, isopropylaminostlfonyl, dimethylaminosulfonyl, pyrrolidine-1-sulfonyl, methylsulfonylaminomethyl, tetrazolyl, methyl, trifluoromethyl, acetyl, 2-hydroxyethyl and 1-aminoethyl; R2 is phenyl, thienyl, pyridyl or isopropyl each optionally substituted with halo, methyl, methylthio or (4-morpholino)methyl; and R3 is methyl, ethyl, propyl, butyl, vinyl, allyl or ethoxyethyl each optionally substituted with up to two groups independently selected from Methyl, HO-, MeO-, K2N-, MeC(=O)NH-, MeS(=O)2NH-, H2NC(=O)-, MeNHC(=O)-, HO2C-, (HO)2P(=O)O-, H2NS(=O)2O-, H2NS{=O)2NH-t MeNHC(=O)NH-, MeNHC(=O)O-, oxo, cyano, KOZC-, HOCH2CH2NH-, 4-morpholino, HOCH2C(=O)NH-, H2NCH2C(=O)NH-, EtNHC(=O)NH, MeOC(=O)NH-, MeNHC(=NC=N)NH-, Me-, MeS-, MeSO2-MeSO2N(Me)-, MeS(=O)2NHC(=O)-, imidazolylamino-, imidazolyl, tetrazolyl, H2NCONH-, H2NCO2-, HOCH2CH2O-, MeNH-, Me2N- and MeCONMe.

Another embodiment of the invention is a compound of any one of Formulas Im1, Im2 and lm5 or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof:

<img img-format="tif" img-content="drawing" file="IL210452AD00024.tif" id="idf0004" />

WO 2010/011314 PCT/US2009/004261 -14-

<img img-format="tif" img-content="drawing" file="IL210452AD00025.tif" id="idf0005" />

<img img-format="tif" img-content="drawing" file="IL210452AD00026.tif" id="idf0006" />

ln Formulas lm\ 1m2 and Im5, the oxodihydropyridyl ring is optionally substituted (substitution at ring carbons bonded to hydrogen and ring nitrogen atoms bonded to hydrogen atoms are encompassed, he., a “substitutable ring nitrogen atom”) with up 5 to four substituents as described above. Suitable substituents for the oxodihydropyridyl ring and suitable values for R1, R2, R3, A1, Cy1 and E are as defined above in the first embodiment. Alternatively, suitable substituents for Cy1 and the oxodihydropyridyl ring in Formulas Im1, Im2 and Im5 are independently fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (Ct-C6)alkyl, 10 hydroxy(Ci-C6)alkyl, (C3-C6)cycloalkyl, hydroxy(C3-C6)cycloalkyl, (C4-C7)cycloalkylalkyl, (C2-C6)alkenyl, halo(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl(C2-C4)alkynyl, halo(Ci-C6)alkyl, halo(C3-C6)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (Ci-C6)alkoxy, (C3-C6)cycloalkoxy, (C4-C7)cycloalkylalkoxy, halo(Ci-C6)alkoxy, halo(C3-C6)cycloalkoxy, 15 halo(C4-C7)cycloalkylalkoxy, (CrC6)alkylthio, (C3-C6)cycloalkythio, (C4-C7)cycloalkyl-alkylthio, halo(CrC6)alkylthio, halo(C3-C6)cycloalkythio, halo(C4-C7)cycloalkylalkylthio (Ci-Cejalkanesulfinyl, (C3-C6)cycloalkanesulfinyl, (C4-C7)cycloalkylalkanesulfinyl, halo(Ct-C6)alkanesulfinyl, halo(C3-C6)cycloalkanesulfinyl, halo(C4-C7)cycloalkyl-alkanesulfinyl, (CrCeJalkanesulfonyl, (C3-C6)cycloalkanesulfonyl, (C4-C7)cycloalkyl- 20 alkanesulfonyl, halo(CrCe)alkanesulfonyl, halo(C3-C6)cycloalkanesulfonyl, halo(C4-C7)cyclo-alkylalkanesulfonyl, (Ci-C6)alkylamino, di(Ci-Cs)alkylamino, (Ci-C6)alkoxy(Ci-C6)alkoxy, halotCi-CeJalkoxyiC-i-CeJalkoxy, (Ci-Ce)alkoxycarbonyl, H2NCO, H2NSO2, (CrC6)alkylaminocarbonyl, di(Ci-C6)alkylaminocarbonyl, (Ci-C3)alkoxy(Ci-C3)alkylaminocarbonyl, heterocyclylcarbonyl, 25 (Ci-C6)alkylaminosulfonyl, di(Ct-C6)alkylaminosulfonyl, heterocyclylsulfonyl, (Ci-C6)alkylcarbonylamino, (Ci-C6)alkylcarbonylamino(Ci-C6)alkyl, (CrCeJalkylsulfonylamino, (Ci-C6)alkylsulfonylamino(Ci-C6)alkyl, (Ci-Ce)alkoxy-carbonyl(CrC6)alkoxy, (Ci-Ce)alkoxy(Ci-C6)alkyl, halo(C1-C6)alkoxy(Ci-C6)alkyl, WO 2010/011314 PCT/US2009/004261 - 15- hydroxy(Ci-C6)alkoxy, heteroaryl, amino(Ci-C6)alkyl, (CvC6)alkylamino(CrC6)afkyl, di{Ci-C6)alkylamino(CrC6)alkyl amino(C2-C6)alkoxy, (C1-C6)alkylamino(C2-C6)alkoxy, di(Ci-C6)alkylamino(C2-C6)alkoxy, (C-i-CeJalkylcarbonyl, (C3-C6)cycloalkylcarbonyl, (C3-C6)cycloalkylaminocarbonyl, {(C3-C6)cycloalkyl}{(Ci-C6)alky1}aminocarbonyl, 5 di(C3-C6)cycloalkylaminocarbonyl, (C3-C6)cycloalkylaminosulfonyl, {(C3-C6)cycloalkylX(Ci-C6)aIkyJ}aminosulfonyl, di(C3-C6)cycIoalkylaminosulfonyl, cyano(Ci-C6)alkyl, aminocarbonyl(Ci-C6)alkyl, (Ci-C6)alkylaminocarbonyl(Ci-C6)alkyl, di(Ci-Ce)alkylaminocarbonyl(CrC6)alkyl, (C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl, {(C3-C6)cycloalkyl}{(Ci-C6)aikyl}aminocarbonyl(CrC6)alkyl and 10 di(C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl; and values for R1, R2, R3, A1, Cy1 and E are as defined above in the first embodiment. Alternatively, suitable substituents for Cy1 include (C1-C4 )alkyl, (C1-C4 )alkoxy, (C1-C4 )haloalkyl, (Ci-C4)haloalkoxy, halogen, cyano and nitro; suitable substituents for a substitutable ring nitrogen atom in the oxodihydropyridyl ring in Formulas lm1, lm2 and lm5 include (CrC4)alkyl, 15 (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(Ci-C2)alkyl, and (Ci-C4)haloalkyl; suitable substituents for a ring carbon atom in the oxodihydropyridyl ring in Formulas lm1, lm2 and lm5 include fluorine, chlorine, cyano, hydroxy, amino, (Ci-C4)alkyl, {C3-C4)cycloalkyl, (C3-C4)cyctoalkyl(Ci-C2)alkyl, halo(Ci-C4)alkyl, (C-i-C^alkoxy, (Ci-C4)haloalkoxy, CONH2, (Ci-C4)alkylaminocarbonyl, di(Ci-C4)alkylaminocarbonyl 20 and (Ci-C4)alkylcarbonylamino; and suitable values for R1, R2, R3, A1, Cy1 and E are as defined above in the first embodiment. In another alternative, the embodiments in this paragraph exclude the following compounds: (R)-6-(3-hydroxypropyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one 25 (PR-221); and {R)-6-(3-hydroxypropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one WO 2010/011314 PCT/US2009/004261 - 16-

<img img-format="tif" img-content="drawing" file="IL210452AD00027.tif" id="idf0007" />

(PR-313); or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

For each of the embodiments described in the previous paragraph, R1 is preferably methyl or ethyl. 5 For each of the embodiments described in the paragraph immediately following

Formulas lm1, lm2 and lm5, R1 is preferably methyl or ethyl; and R3 is MeSO2NHCH2CH2CH2, H2NC(=O)CH2CH2, H2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methylbutyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl. 10 For each of the embodiments described in the paragraph immediately following

Formulas lm1, lm2 and lm5, R1 is preferably methyl or ethyl; and R3 is H2NC(=O)CMe2CH2, 3-hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following 15 Formulas lm1, lm2 and lm5, R1 is preferably methyl or ethyl; R2 is phenyl optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, CONH2, {Ci-C4)alkyl, (CrC4)haloalkyl, and SO2Me; and R3 is MeSO2NHCH2CH2CH2, H2NC(=O)CH2CH2, H2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methylbutyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl, 20 For each of the embodiments described in the paragraph immediately following

Formulas lm1, lm2 and lm5, R1 is preferably methyl or ethyl; R2 is phenyl optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, CONH2, (Ci-C4)alkyl, (Ci-C4)haloalkyl, and SO2Me; and R3 is H2NC(=O)CMe2CH2, 3-hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl. 25 For each of the embodiments described in the paragraph immediately following

Formulas lm1, lm2 and lm5, R1 is preferably methyl or ethyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl. WO 2010/011314 PCT/US2009/004261 -17-

For each of the embodiments described in the paragraph immediately following Formulas Im1, lm2 and Im5, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following 5 Formulas Im1, Im2 and Im5, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; the substituent on the substitutable ring nitrogen atom in the oxodihydropyridyl ring in Formulas Im1, Im2 and Im5 is (C1-C4 )alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(Ci-C2)alkyl, or (CrC2 Jhaloalkyl; and one or two ring carbon atoms 10 in the oxodihydropyridyl ring in Formulas Im1, Im2 and Im5 are optionally substituted with methyl or ethyl.

Another embodiment of the invention is a compound of any one of Formulas In1, In2 and In5, or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof:

<img img-format="tif" img-content="drawing" file="IL210452AD00028.tif" id="idf0008" />

In Formulas In1, In2 and In5, the oxodihydropyridyl ring is optionally substituted (substitution at ring carbons bonded to hydrogen and at nitrogen atoms bonded to 20 hydrogen atoms are encompassed, i.e., a “substitutable ring nitrogen atom”) with up to four substituents as described above for Cy2. Suitable substituents for the oxodihydropyridyl ring and suitable values for R1, R2, R3 and Cy1 are as defined above in the first embodiment. Alternatively, suitable substituents for Cy1 and the WO 2010/011314 PCT/US2009/004261 - 18- oxodihydropyridyl ring in Formulas In1, In2 and In5 are independently fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, (C3-C6)cycloalkyl, hydroxy(C3-C6)cycloalkyl, (C4-C7)cycloalkylalkyl, (Cz-Cejalkenyl, halo(C2-C6)alkenyl, hydroxy(C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl(C2-C4)alkynyl, halo(Ci-C6)alkyl, halo(C3-C6)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (CrC6)alkoxy, (C3-C6)cycloalkoxy, (C4-C7)cycloalkylalkoxy, halo(C1-C6)alkoxy, halo(C3-Ce)cycloalkoxy, halo(C4-C7)cycloalkylalkoxy, (Ci-C6)alkylthio, (C3-C6)cycloafkythio, (C4-C7)cycloalkyl-alkylthio, halo(Ci-C6)alkylthio, halo(C3-C6)cycloaikythio, halo(C4-C7)cycloalkylalkylthio, (CrCe)alkanesulfinyl, (C3-C6)cycloalkanesulfinyl, (C4-C7)cycloalkylalkanesulfinyl, halo(Ci-C6)alkanesulfinyl, halo{C3-C6)cycloalkanesulfinyl, halo(C4-C7)cycloalkyl-alkanesulfinyl, (CvC6)alkanesulfonyl, (C3-C6)cycloalkanesulfonyl, (C4-C7)cycloalkyl-alkanesulfonyl, halo(Ci-C6)alkanesulfonyl, halo(C3-C6)cycloalkanesulfonyl, halo(C4-C7)cyclo-alkylalkanesulfonyl, (Ci-C6)alkylamino, di(Ci-C6)alkylamino, (Ci-C6)alkoxy(Ci-C6)alkoxy, halofCrCeJalkoxyiCrCgJalkoxy, (Ci-C6)alkoxycarbonyl, H2NCO, H2NSO2, (Ci-Cejalkylaminocarbonyl, di(Ci-C6)alkylaminocarbonyl, (CrC3)alkoxy(Ci-C3)alkylaminocarbonyl, heterocyclylcarbonyl, (CrCelalkylaminosulfonyl, di(Ct-C6)alkylaminosulfonyl, heterocyclylsulfonyl, (CrC6)alkylcarbonylamino, (Ci-C6)alkylcarbonylarnino(C-i-C6)alky1, (CrCeJalkylsulfonylamino, (Ci-C6)alkylsulfonylamino(Ci-C6)alkyl, (CrC6)alkoxy-carbonyl(Ci-C6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, halo(Ci-C6)alkoxy(Ci-C6)alkyl, hydroxy(CrC6)alkoxy, heteroaryl, amino(Ci-C6)alkyl, (Ci-C6)alkylamino(Ci-C6)alkyt, di(CrCs)alkylamino(Ci-C6)alkyl amino(C2-C6)alkoxy, (Ci-C6)alkylamino(C2-C6)alkoxy, di(CrC6)alkylamino(C2-C6)alkoxy, (Ci-C6)alkylcarbonyl, (C3-C6)cycloalkylcarbonyl, (C3-C6)cycloalkylaminocarbonyl, {(C3-C6)cycloalkylX(Ci-C6)alkyl}aminocarbonyl, di(C3-C6)cycloalkylaminocarbonyl, (C3-C6)cycloalkylaminosulfonyl, {(C3-C6)cycloalkyl}{(Ci-C6)alkyl}aminosulfonyl, di(C3-C6)cycloalkylaminosulfonyl, cyano(CrC6)alkyl, aminocarbonyl(Ci-C6)alkyl, (Ci-C6)alkylaminocarbonyl(Ci-Ce)alkyl, di(CrC6)alkylaminocarbonyl(CrCe)alkyl, (C3-C6)cyc1oalkylaminocarbonyl(CrC6)alkyl, {(C3-Ce)cycloalkyl}{(Ci-C6)alkyl}arninocarbonyl(Ci-Ce)alkyl and di(C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl; and values for R1, R2, R3 and Cy1 are as defined above in the first embodiment. Alternatively, suitable substituents for Cy1 include (CrC4 )alkyl, (Ci-C4 )alkoxy, (C!-C4 Jhaloalkyl, (CpC^haloalkoxy, halogen,

I WO 2010/011314 PCT/US2009/004261 - 19- cyano and nitro; suitable substituents for a substitutable ring nitrogen atom in the oxodihydropyridyl ring in Formulas In1, In2 and In5 include (C1-C4 )alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(C-t-C2)alkyl and (Ci-C4)haloalkyl; suitable substituents for a ring carbon atom in the oxodihydropyridyl ring in Formulas In1, In2 5 and In5 include fluorine, chlorine, cyano, hydroxy, amino, (Ci-C4)alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(Ci-C2)alkyl, halo(Ci-C4)alkyl, (CrC4)alkoxy, (CrC4)haloalkoxy, CONH2, (Ci-C4)alkylaminocarbonyl, di(Ci-C4)aIkylamtnocarbonyl and (Ci-C4)alkylcarbonylamino; and suitable values for R1, R2, R3, and Cy1 are as defined above in the first embodiment. In another alternative, the embodiments 10 described in this paragraph exclude the compounds PR-221 and PR-313; or a pharmaceutically acceptable salt, enantiomer or diastereomer thereof.

For each of the embodiments described in the previous paragraph, R1 is preferably methyl or ethyl.

For each of the embodiments described in the paragraph immediately following 15 Formulas In1, In2 and In5, R1 is preferably methyl or ethyl; and R3 is

MeSO2NHCH2CH2CH2, H2NC(=O)CH2CK2, H2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methylbutyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following 20 Formulas In1, In2 and In5, R1 is preferably methyl or ethyl; and R3 is H2NC(=O)CMe2CH2, 3-hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas In1, In2 and In5, R1 is preferably methyl or ethyl; R2 is phenyl optionally 25 substituted with 1,2 or 3 substituents selected from halo, cyano, CONH2, (Ci-C4)alkyl, (Ci-C4)haloalkyl and SOzMe; and R3 is MeSO2NHCH2CH2CH2, H2NC(=O)CH2CH2, K2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methytbutyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following 30 Formulas In1, In2 and In5, R1 is preferably methyl or ethyl; R2 is phenyl optionally substituted with 1,2 or 3 substituents selected from halo, cyano, CONH2] (Ci-C4)alkyl, (Ci-C4)haloalkyl and SO2Me; and R3 is H2NC(=O)CMe2CH2, 3-hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl. WO 2010/011314 PCT/US2009/004261 -20-

For each of the embodiments described in the paragraph immediately following Formulas In1, In2 and In5, R1 is preferably methyl or ethyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following 5 Formulas In1, In2 and In5, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas In1, In2 and In5, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; the substituent on the 10 substitutable ring nitrogen atom in the oxodihydropyridyl rings in Formulas In1, In2 and In5 is (Ci-C4)alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(Ci-C2)alkyl, or (Ci-C2)haloalkyl; and one or two ring carbon atoms in the oxodihydropyridyl rings in Formulas In1, In2 and In5 are optionally substituted with methyl or ethyl.

Another embodiment of the invention is a compound of any one of Formulas 15 Io1, Io2 and Io5, or a pharmaceutically acceptable salt thereof:

<img img-format="tif" img-content="drawing" file="IL210452AD00029.tif" id="idf0009" />

<img img-format="tif" img-content="drawing" file="IL210452AD000210.tif" id="idf0010" />

<img img-format="tif" img-content="drawing" file="IL210452AD000211.tif" id="idf0011" />

WO 2010/011314 PCT/US2009/004261 -21 -

In Formulas Io1, Io2 and Io5, the oxodihydropyridyl ring in Formulas Io1, Io2 and Io5 is optionally substituted (substitution at ring carbons bonded to hydrogen and at nitrogen atoms bonded to hydrogen atoms are encompassed, i.e., a "substitutable ring nitrogen atom”) with up to four substituents as described above in the first embodiment; suitable values for G1 are fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (Ci-Ce)alkyl, hydroxy(Ci-C6)alkyl, (C3-C6)cycloalkyl, hydroxy(C3-C6)cycloalkyl, (C4-C7)cycloalkylalkyl, (C2-C6)alkenyl, halo(C2-C6)alkenyl, hydroxy(C2-Ce)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl(C2-C4)alkynyl, halo(Ci-C6)alkyl, halo(C3-C6)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (Ci-C6)alkoxy, (C3-C6)cycloalkoxy, (C4-C7)cycloalkylalkoxy, halo(Ci-C6)alkoxy, halo(C3-C6)cycloalkoxy, halo(C4-C7)cycloalkylalkoxy, (Ci-Ce)alkylthio, (C3-C6)cycloalkythio, (C4-C7)cycloalkylalkylthio, halo(CrC6)alkylthio, halo(C3-C6)cycloalkythio, halo(C4-C7)cycloalkylalkylthio, (CpCeJalkanesulfinyl, (C3-C6)cycloalkanesulfinyl, (C4-C7)cycloalkylalkanesulfinyi, halo(Ci-C6)alkanesulfinyI, halo(C3-C6)cycloalkanesulfinyl, halo(C4-C7)cycloalkylalkanesulfinyl, (Ci-C6)alkanesulfonyl, (C3-C6)cycloalkanesulfonyl, (C4-C7)cycloalkylalkanesulfonyl, halo(CrCeJalkanesulfonyl, halo(C3-C6)cycloalkanesulfonyl, halo(C4-C7)cyclo-alkylalkanesulfonyl, (Ci-C6)alkylamino, di(Ci-C6)alkylamino, (Ci-C6)alkoxy(Ci-C6)alkoxy, halo(Ci-C6)alkoxy(Ci-C6)alkoxy, (CrC6)aIkoxycarbonyl, H2NCO, H2NSO2, (CrCe)alkylaminocarbonyl, di(Ci-C6)alkylaminocarbonyl, (Ci-C3)alkoxy(CrC3)alkylaminocarbonyl, heterocyclylcarbonyl, (Ci-C6)alkylaminosulfonyl, difCrCeJalkylaminosulfonyl, heterocyclylsulfonyl, (Ci-C6)alkylcarbonylamino, (Ci-C6)alkylcarbonylamino(Ci-C6)alkyl, (CrC6)alkylsulfonylamino, (Ci“C6)alkylsulfonylamino(Ci-C6)alkyl, (Ci-C6)alkoxy-carbonyl(Ci-Ce)alkoxy, (CrCe)alkoxy(Ci-C6)alkyl, halo(Ci-C6)alkoxy(Ci-C6)alkyl, hydroxy(C-i-C6)alkoxy, heteroaryl, amino(Ci-C6)alkyl, (Ci-C6)alkylamino(Ci-C6)alkyl, di(Ci-C6)alkylamino(Ci-C6)alkyl amino(C2“C6)alkoxy, (Ci-C6)alkylamino(C2-C6)alkoxyt di(CrC6)alkylamino(C2-C6)alkoxy, (Ci-C6)alkyJcarbonyl, (C3-C6)cycloalkylcarbonyl, (Cs-CeJcycloalkylaminocarbonyl, {(C3-Ce)cycloalkylX(Ci-C6)alkyl}aminocarbonyl, di(C3-C6)cycloalkylaminocarbonyl, (C3-C8)cycloalkylaminosulfonyl, {(C3-C6)cycloalkyl}{(Ci-C6)alkyl)aminosulfonyl, di(C3-C6)cycloalkylaminosulfonyl, cyano(CrCe)alkyl, aminocarbonyl(CrC6)alkyl, (Ci-C6)alkylaminocarbonyl(CrC6)alkyl, di(CrCe)alkylaminocarbonyl(Ci-C6)alkyl, (C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl, WO 2010/011314 PCT/US2009/004261 -22- {(C3-C6)cycloalkyl}{(Ci-C6)alkyl}aminocarbonyl(Ci-C6)alkyl and di(C3-C6)cycloalkylaminocarbonyl(Ci-C6)alkyl; n is 0, 1,2 or 3; and suitabie substituents for the oxodihydropyridyl ring and suitable values for R1, R2 and R3 are as defined above in the first embodiment. Alternatively, n is 0, 1, 2 or 3; suitable values for G1 and substituents for the oxodihydropyridyl ring in Formulas lo\ Io2 and Io5 are independently fluorine, chlorine, bromine, iodine, cyano, nitro, amino, hydroxy, carboxy, (Ci-C6)alkyl, hydroxy(Ci-C6)alkyl, (C3-C6)cycloalkyl, hydroxy(C3-C6)cycloalkyl, (C4-C7)cycloalkylalkyl, (C2-C6)alkenyl, halo(C2-Ce)alkenyl, hydroxy(C2-C6)alkenyl, (C2-C6)alkynyl, (C3-C6)cycloalkyl(C2-C4)alkynyl, halofCrCejalkyl, halo(C3-C6)cycloalkyl, halo(C4-C7)cycloalkylalkyl, (Ci-Ce)alkoxy, (C3-C6)cycloalkoxy, (C4-C7)cycloalkylalkoxy, halo(Ci-C6)alkoxy, halo(C3-C6)cycloalkoxy, halo(C4-C7)cycloalkylalkoxy, (Ci-C6)alkylthio, (C3-C6)cycloalkythio, (C4-C7)cycloalkylalkylthio, halo(CrC6)alkylthio, halo(C3-C6)cycloalkythio, halo(C4-C7)cycloalkylalkylthio, (Ci-C6)alkanesulfinyl, (C3-C6)cycloalkanesulfinyl, (C4-C7)cycloalkylalkanesulfinyl, halo(Ci-C6)alkanesulfinyl, halo(C3-C6)cycloalkanesulfinyl, halo(C4-C7)cycloalkylalkanesulfinyl, (Ci-C6)alkanesulfonyl, (C3-C6)cycloalkanesulfonyl, (C4-C7)cycloalkylalkanesulfonyl, halo{Ci-C6)alkanesulfonyI, halo(C3-C6)cycloalkanesulfonyl, halo(C4-C7)cyclo-alkylalkanesulfonyl, (Ci-C6)alkylamino, di(CrC6)alkylamino, (CrCe)alkoxy(Ci’C6)alkoxy, halo(CrC6)alkoxy(Ci -Ce)alkoxy, (Ci-C6)alkoxycarbonyl, H2NCO, H2NSO2, (Ci-C6)alkylaminocarbonyl, di(Ci-C6)alkylaminocarbonyl, (CrC3)alkoxy(CrC3)alkylaminocarbonyl, heterocyclylcarbonyl, (CrC6)alkylaminosulfonyl, di{CrC6)alkylaminosulfonyl, heterocyclylsulfonyl, (CrCeJalkylcarbonylamino, (Ci-C6)alkylcarbonylamino{Ci-C6)alkyl, (CrCeJalkylsulfonylamino, (Ci-C6)alkylsulfonylamino(Ci-Cs)alkyl, (Ci-C6)alkoxy-carbonyl(CrC6)alkoxy, (Ci-C6)alkoxy(Ci-C6)alkyl, halo(CrC6)alkoxy(Ci-C6)alkyl, hydroxy(Ci-C6)alkoxy, heteroaryl, amino(Ci-C6)alkyl, (Ci-C6)alkylamino(Ci-C6)alkyl, di(Ci-C6)alkylamino(Ci-C6)alkyl amino(C2-C6)alkoxy, (Ci-C6)alkylamino(C2-C6)alkoxy, di(Ci-C6)alkylamino(C2-C6)alkoxy and (CrC6)alkylcarbonyl; and values for R1, R2 and R3 are as defined above in the first embodiment. Alternatively, n is 0,1,2 or 3; suitable values for G1 include (Ci-C4 )alkyl, (C1-C4 )alkoxy, (C1-C4 )haloalkyl, (C1-C4 Jhaloalkoxy, halogen, cyano and nitro; suitable substituents for a substitutable ring nitrogen atom in the oxodihydropyridyl ring in Formulas Io1, Io2 and Io5 include C1-C4 WO 2010/011314 PCTAUS2009/004261 . 30 - 210452/2 henyl)ethyl)-6-phenyl-1,3-oxazinan-2-one, (S)-6-(2-hydroxy-2-methyipropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one, 3-{(S)-1 -[4-(1 -Cyciopropyf-2-oxo-1,2-dihydro-pyridin-4-yl)~phenyi]-ethy!}-(S}-6-(2-hydroxy-2-methyl-propyl)-6-pheny!-[1,3]oxazinan-2-one and pharmaceutically acceptable salts thereof. Both, neutral and salt forms of the hydrate and monohydrate are also included. Preferably, the salt form is pharmaceutically acceptable.

Compounds of the invention are also disclosed in INHIBITORS OF 11P-HYDROXYSTEROID DEHYDOGENASE I, U.S. Provisional Application Mo. 61/ 61/135,933, Filed July 25, 2008 (Attorney Docket No. 4370.1000-000); Cyclic Inhibitors Of 11β-Hydroxysteroid Dehydrogenase 1, U.S. Provisional Application No. 61/135,933, filed May 1, 2008; Cyclic Inhibitors Of 11B-Hydroxysteroid

Dehydrogenase 1, U.S. Provisional Application No. 61/137,148, filed July 25, 2008; and Cyclic Inhibitors Of 11 β-Hydroxysteroid Dehydrogenase 1, International Application No. PCT/US2008/009017, filed July 25, 2008,

DEFINITIONS

The term "alkyl” means a straight or branched hydrocarbon radical having 1-10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.

The term "cycloalkyl” means a monocyclic, bicyclic or tricyclic, saturated hydrocarbon ring having 3-10 carbon atoms and includes, for example, cyclopropyl (c-Pr), cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, spiro [4.4]nonane, adamantyl and the like.

The term “aryl" means an aromatic radical which is a phenyl group, a naphthyl group, an indanyl group or a tetrahydronaphthalene group. An aryl group is optionally substituted with 1-4 substituents. Exemplary substituents include alkyl, alkoxy, alkylthio, alkytsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO2H, CONH2, N-monoalkyl-substituted amido and Ν,Ν-dialkyl-substituted amido.

The term "heteroaryl” means a 5- and 6-membered heteroaromatic radical which may optionally be fused to a saturated or unsaturated ring containing 0-4 heteroatoms selected from N, O, and S and includes, for example, a heteroaromatic WO 2010/011314 PCT/US20O9/O04261 -24-

For each of the embodiments described in the paragraph immediately following Formulas Io1, Io2 and Io5, R1 is preferably methyl or ethyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas Io1, Io2 and Io5, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas lo\ Io2 and Io5, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; the substituent on the substitutable ring nitrogen atom in the oxodihydropyridyl ring in Formulas Io1, Io2 and Io5 is (C1-C4 )alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(CrC2)alkyl, or (Ci-C2 )haloalkyl; and one or two ring carbon atoms in the oxodihydropyridyl rings in Formulas Io1, Io2 and Io5 are optionally substituted with methyl or ethyl.

Another embodiment of the invention (referred to herein as the “First Alternate Embodiment”) is a compound represented by Structural Formulas Io1, Io2 and Io5, wherein: n is 0 or 1, preferably 0; each G1 is independently (C1-C4 )alkyl, (Ci-C4)alkoxy, (C1-C4 )haloalkyl, (Ci-C4)haloalkoxy, halogen, cyano or nitro; the oxodihydropyridyl is substituted at its ring nitrogen atom with hydroxy(Ci-C6)alkyl, (Ci-C6)alkylcarbonylamino(Ci-C6)alkyl, (Ci-C6)alkylsulfonylamino(Ci-C6)alkyl, (Ci-C6)alkoxy(Ci-C6)alkyl, amino(Ci-C6)alkyl, (Ci-C6)alkylamino(CrC8)alkyl, di(Ci-C6)alkylamino(CrC6)alkyl. cyano(Ci-C6)alkyl, aminocarbonyl(Ci-C6)alkyl, (Ci-C6)alkylaminocarbonyl(Ci-Ce)alkyl, di(Ci-C6)alkylaminocarbonyl(Ci-C6)alkyI, (C3-Ce)cycloaIkylaminocarbonyl(Ci-C6)alkyl, {(C3-C6)cycloalkylX(Ci-C6)alkyl}aminocarbonyl(Ci-C6)alkyl or di(C3-C6)cycloalkylaminocarbonyl(CrCe)alkyl; the oxodihydropyridyl is optionally substituted at one or more substitutable ring carbon atoms with a group independently selected from fluorine, chlorine, cyano, hydroxy, amino, (Ci-C4)alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(Ci-C2)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)haloalkoxy, CONH2, (Ci-C4)alkylaminocarbonyl, di(Ci-C4)alkylaminocarbonyl -and (Ci-C4)alkylcarbonylamino; R1 is methyl or ethyl; R2 is phenyl, thienyl, pyridyl or isopropyl each optionally substituted with up to three groups independently selected from halo, methyl, methylthio, (4-morpholino)methyl or cyclopropyl; and R3 is methyl, ethyl, propyl, butyl, vinyl, allyl or ethoxyethyl each optionally substituted with up to two WO 2010/011314 PCT/US2009/004261 -25- groups independently selected from methyl, HO-, MeO-, H2N-, MeC(=O)NH-, MeS(=O)2NH-, H2NC(=O)-, MeNHC(=O)-t HO2C-, (HO)2P(=O)O-, H2NS{=O)2O-, H2NS(=O)2NH-, MeNHC(=O)NH-, MeNHC(=O)O-, oxo, cyano, HO2C-( HOCH2CH2NH-, 4-morphoIino, HOCH2C(=O)NH-, H2NCH2C(=O)NH-, EtNHC(=O)NH MeOC(=O)NH-, MeNHC(=NC=N)NH-, Me-, MeS-, MeSO2- MeSO2N(Me)-, Me$(=O)2NHC(=O)-, imidazolylamino-, imidazolyl, tetrazolyl, K2NCONH-, H2NCO2-, HOCH2CH2O-, MeNH-, Me2N-and MeCONMe.

Alternatively for Structural Formulas Io1, Io2 and Io5, R2 is phenyl optionally substituted with 1, 2 or 3 substituents independently selected from halo, cyano, CONH2, (Ci-C4)alkyl, (CrC4)haloalkyl and SO2Me; and R3 is is

MeSO2NHCH2CH2CH2, H2NC(=O)CH2CH2, H2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methylbutyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl or 2- cyano-2-methylpropyl; and the remainder of the variables are as described above for the First Alternate Embodiment.

Alternatively for Structural Formulas Io1, Io2 and Io5, R3 is H2NC(=O)CMe2CH2, 3- hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described above for the First Alternate Embodiment.

Alternatively for Structural Formulas Io1, Io2 and Io5, R2 is phenyl optionally substituted with 1, 2 or 3 substituents independently selected from halo, cyano, CONH2, (Ci-C4)alkyl, {Ci-C4)haloalkyl and SO2Me; and R3 is H2NC(=O)CMe2CH2l 3-hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or2-cyano-2-methylpropyl; and the remainder of the variables are as described in the First Alternate Embodiment

Alternatively for Structural Formulas Io1, Io2 and Io5, R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described in the First Alternate Embodiment.

Alternatively for Structural Formulas Io1, Io2 and Io5, R2 is phenyl or fluorophenyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described in the First Alternate Embodiment.

Alternatively for Structural Formulas Io1, Io2 and Io5, R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; one or two ring carbon atoms in the oxodihydropyridyl rings are optionally substituted with WO 2010/011314 PCT/US2009/004261 -26- fluorine, methyl or ethyl; and the remainder of the variables are as described in the First Alternate Embodiment.

For the embodiment described in the previous seven paragraphs, n is 0 and all of the substitutable ring carbons in the oxodihydropyridyl are preferably unsubstituted. 5 Another embodiment of the invention is a compound represented by any one of

Formulas Ip1 and Ip3, or a pharmaceutically acceptable salt thereof:

<img img-format="tif" img-content="drawing" file="IL210452AD000212.tif" id="idf0012" />

In Formulas Ip1 and Ip3, G1 is (Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)haloalkyl, (Ci-C4)haloalkoxy, halogen, cyano or nitro; n is 0, 1 or 2; G2a is (Ci-C4 )alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(Ci-C2)alkyl or (Ci-C4)haloalkyl; G2b is hydrogen, fluorine, chlorine, cyano, hydroxy, amino, (Ci-C4)alkyl, (C3-C4)cycloalkyl, 15 (C3-C4)cycloalkyl(CrC2)aIkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)haioalkoxy, CONH2, (CrC4)alkylaminocarbonyl, dt(Ci-C4)alkylaminocarbonyl or (Ci-C4)alkylcarbonylamino; and suitable values for R1, R2 and R3 are as defined above in the first embodiment. In another alternative, the embodiments described in this paragraph exclude the compounds PR-221 and PR-313; or a pharmaceutically 20 acceptable salt, enantiomer or diastereomer thereof.

For each of the embodiments described in the previous paragraph, R1 is preferably methyl or ethyl. WO 2010/011314 PCT/US2009/004261 -27-

For each of the embodiments described in the paragraph immediately following

Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; and R3 is

MeSO2NHCH2CH2CH2, H2NC(=O)CH2CH2, H2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methylbutyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyI or 2- cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; and R3 is H2NC(=O)CMe2CH2, 3- hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; R2 is phenyl optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, CONH2, (Ci-C4)alkyl, (Ct-C4)haloalkyl and SO2Me; and R3 is MeSO2NHCH2CH2CH2, H2NC(=O)CH2CH2, H2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methylbutyl, 2-hydroxyethyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; R2 is phenyl optionally substituted with 1, 2 or 3 substituents selected from halo, cyano, CONH2, (Ci-C4)alkyl, (Ci-C4)haloalkyl and SO2Me; and R3 is H2NC(=O)CMe2CH2, 3-hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiments described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl.

For each of the embodiment described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; the substituent G2a is selected from (Ci-C4 )alkyl, &lt;C3-C4)cycloalkyl, (C3-C4)cycloalkyl(CrC2)alkyl, and (Ci-C2)haloalkyl; and GZb is optionally selected from hydrogen, methyl or ethyl.

For each of the embodiment described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; the substituent G2a is selected WO 2010/011314 PCT/US2009/004261 -28- from haloalkyl, (Ci-C4 )alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(CrC2)alkyl, and (Ci-C2)haloalkyl; and G2b is optionally selected from hydrogen, methyl or ethyl.

For each of the embodiment described in the paragraph immediately following Formulas Ip1 and Ip3, R1 is preferably methyl or ethyl; R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; the substituent G2a is selected from difluoromethyl, ethyl substituted with one to three fluorine (preferably, 2-fluoroethyl or 2,2,2-fluoroethyl), (C1-C4 )alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(Ci-C2)alkyl, and (Ci-C2)haloalkyl; and G2b is optionally selected from hydrogen, methyl or ethyl.

Another embodiment of the invention (referred to herein as the “Second Alternate Embodiment”) is a compound represented by Structural Formulas Ip1 and Ip3, wherein: n is 0 or 1, preferably 0; each G1 is independently (C1-C4 )alkyl, (Ci-C4)alkoxy, (C1-C4 Jhaloalkyl, (Ci-C4 )haloalkoxy, halogen, cyano or nitro; G2a is hydroxy(Ci-Ce)alkyl, (Ci-C6)alkylcarbonylamino(Ci-C6)alkyl, (Ci-Ce)alkyl-sulfonylamino(Ci-C6)alkyl, (Ci-C6)alkoxy(Ci-C6)aIkyl, amino(Ci-C6)alkyl, (Ci-C6)alkylamino(Ci-C6)alkyl, di(Ci-C6)alkylamino(Ci-C6)alkyl, cyano(Ci-C6)alkyl, aminocarbonyl(Ci-C6)alkyl, (Ci-C6)alkylaminocarbonyl(Ci-C6)alkyl, di(Ci-Ce)alkylaminocarbonyl(Ci-C6)alkyl, (C3-Ce)cycloalkylaminocarbonyl(CrC6)alkyl, {(C3-Cs)cycloalkylK(CrC6)alkyl}aminocarbonyl(Ci-Ce)alkyl or di(C3-Ce)cycloalkylaminocarbonyl(Ci-C6)alkyl; G2b is hydrogen, fluorine, chlorine, cyano, hydroxy, amino, (Ci-C4)alkyl, (C3-C4)cycloalkyl, (C3-C4)cycloalkyl(C1-C2)alkyl, halo(Ci-C4)alkyl, (Ci-C4)alkoxy, (Ci-C4)haloalkoxy, CONH2, (CrC4)alkylaminocarbonyl, di(Ci-C4)alkylaminocarbonyl or (Ci-C4)alkylcarbonylamino; R1 is methyl or ethyl; R2 is phenyl, thienyl, pyridyl or isopropyl each optionally substituted with up to three groups independently selected from halo, methyl, methylthio or (4-morpholino)methyl; and R3 is methyl, ethyl, propyl, butyl, vinyl, allyl or ethoxyethyl each optionally substituted with up to two groups independently selected from methyl, HO-, MeO-, H2N-, MeC(=O)NH-, MeS(=O)2NH-, H2NC(=O)-, MeNHC(-O)-, HO2C-, (HO)2P(=O)O-, H2NS(=O)2O-, H2NS(=O)2NH-,

MeNHC(=O)NH-, MeNHC(=O)O-, oxo, cyano, HO2C-, HOCH2CH2NH- 4-morpholino, HOCH2C(=O)NH-, H2NCH2C(=O)NH-, EtNHC(=O)NH, MeOC(=O)NH-, MeNHC(=NC=N)NH-, Me-, MeS-, MeSO2- MeSO2N(Me)-t MeS(=O)2NHC(=O)-, WO 2010/011314 PCT/US2009/004261 -29- imidazolylamino-, imidazolyl, tetrazolyl, H2NCONH-, H2NCO2-, HOCH2CH2O-, MeNH-, Me2N- and MeCONMe.

Alternatively for Structural Formulas Ip1 and Ip3, R2 is phenyl optionally substituted with 1, 2 or 3 substituents independently selected from halo, cyano, CONH2f (Ci-C4)alkyl, (Ci-C4)haloalkyl and SO2Me; and R3 is MeSO2NHCH2CH2CH2, H2NC(=O)CH2CH2l H2NC(=O)CMe2CH2, 3-hydroxypropyl, 3-hydroxy-3-methylbutyl, 2- hydroxyethyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described above for the Second Alternate Embodiment.

Alternatively for Structural Formulas Ip1 and Ip3, R3 is H2NC(=O)CMe2CH2, 3- hydroxy-3-methylbutyl, 2-hydroxy-2-methyl propyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described above for the Second Alternate Embodiment.

Alternatively for Structural Formulas Ip1 and Ip3, R2 is phenyl optionally substituted with 1,2 or 3 substituents independently selected from halo, cyano, CONH2, (CrC4)alkyl, (Ci-C4)haloalkyl and SO2Me; and R3is H2NC(=O)CMe2CH2, 3-hydroxy-3-methylbutyl, 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described in the Second Alternate Embodiment.

Alternatively for Structural Formulas Ip1 and Ip3, R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described in the Second Alternate Embodiment

Alternatively for Structural Formulas Ip1 and Ip3, R2 is phenyl or fluorophenyl; and R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; and the remainder of the variables are as described in the Second Alternate Embodiment.

Alternatively for Structural Formulas Ip1 and Ip3, R2 is phenyl or fluorophenyl; R3 is 2-hydroxy-2-methylpropyl or 2-cyano-2-methylpropyl; one or two substitutable ring carbon atoms in the oxodihydropyridyl rings are optionally substituted with fluorine, methyl or ethyl; and the remainder of the variables are as described in the Second Alternate Embodiment.

For the embodiment described in the previous seven paragraphs, n is 0 and G2bis preferably -H.

Another embodiment of the invention is a hydrate or monohydrate of (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)p WO 2010/011314 PCT/US2009/004261 -30- heny!)ethyl)-6-phenyl-1,3-oxazinan-2-one, (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihyd ropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one, 3-{(S)-1 -[4-( 1 -Cyclopropyl-2-oxo-1,2-dihyd ro-py ridin-4-y l)-phenyl]-et hy l}-(S)-6-{2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one and pharmaceutically acceptable salts thereof. Both, neutral and salt forms of the hydrate and monohydrate are also included. Preferably, the salt form is pharmaceutically acceptable.

Compounds of the invention are also disclosed in INHIBITORS OF 11P-HYDROXYSTEROID DEHYDOGENASE I, U.S. Provisional Application No. 61/ 61/135,933, filed July 25, 2008 (Attorney Docket No. 4370.1000-000); Cyclic Inhibitors Of 11β-Hydroxysteroid Dehydrogenase 1, U.S. Provisional Application No. 61/135,933, filed May 1, 2008; Cyclic Inhibitors Of 118-Hydroxysteroid Dehydrogenase 1, U.S. Provisional Application No. 61/137,148, filed July 25, 2008; and Cyclic Inhibitors Of 11 U-Hydroxysteroid Dehydrogenase 1, International Application No. PCT/US2008/009017, filed July 25, 2008; the entire teachings of these applications are incorporated herein by reference in their entirety.

DEFINITIONS

The term “alkyl" means a straight or branched hydrocarbon radical having 1-10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl and the like.

The term “cycloalkyl" means a monocyclic, bicyclic or tricyclic, saturated hydrocarbon ring having 3-10 carbon atoms and includes, for example, cyclopropyl (c-Pr), cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1 Jheptyl, spiro [4.4]nonane, adamantyl and the like.

The term "aryl” means an aromatic radical which is a phenyl group, a naphthyl group, an indanyl group or a tetrahydronaphthalene group. An aryl group is optionally substituted with 1-4 substituents. Exemplary substituents include alkyl, alkoxy, alkylthio, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO2H, CONH2, N-monoalkyl-substituted amido and Ν,Ν-dialkyl-substituted amido.

The term “heteroaryl” means a 5- and 6-membered heteroaromatic radical which may optionally be fused to a saturated or unsaturated ring containing 0-4 heteroatoms selected from N, O, and S and includes, for example, a heteroaromatic WO 2010/011314 PCT/US2009/004261 -31 - radical which is 2- or 3-thienyl, 2- or 3-furanyl, 2- or 3- pyrrolyl, 2-,3-, or 4-pyridyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl, 3-or 4-pyridazinyl, 1 H-indol-6-yl, 1 H-indol-5-yl, 1H-benzimidazol-6-yl, 1H-benzimidazol-5-yl, 2-, 4-, 5-, 6-, 7-or 8-quinazolinyl, 2-, 3-, 5-, 6-, 7- or 8-quinoxalinyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7- or 8- 5 isoquinolinyl, 2-, 4-, or 5-thiazolyl, 2-, 3-, 4-, or 5-pyrazolyl, 2-, 3-, 4-, or 5-imidazolyl. A heteroaryl is optionally substituted. Exemplary substituents include alkyl, alkoxy, alkylthio, alkylsulfonyl, halogen, trifluoromethyl, dialkylamino, nitro, cyano, CO2H, CONH2, N-monoalkyl-substituted amido and Ν,Ν-dialkyl-substituted amido, or by oxo to form an N-oxide. 10 The term “heterocyclyl" means a 4-, 5-, 6- and 7-membered saturated or partially unsaturated heterocyclic ring containing 1 to 4 heteroatoms independently selected from N, O, and S. Exemplary heterocyclyls include pyrrolidine, pyrrolidin-2-one, 1-methylpyrrolidin-2-one, piperidine, piperidin-2-one, dihydropyridine, tetrahydropyridine, piperazine, 1-(2,2,2-trifluoroethyl)piperazine, 15 1,2-dihydro-2-oxopyridine, 1,4-dihydro-4-oxopyridine, piperazin-2-one, 3,4,5,6-tetrahydro-4-oxopyrimidine, 3,4-dihydro-4-oxopyrimidine, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, isoxazolidine, 1.3- dioxolane, 1,3-dithiolane, 1,3-dioxane, 1,4-dioxane, 1,3-dithiane, 1,4-dithiane, oxazolidin-2-one, imidazolidin-2-one, imidazolidine-2,4-dione, 20 tetrahydropyrimidin-2(1H)-one, morpholine, N-methylmorpholine, morpholin-3-one, 1.3- oxazinan-2-one, thiomorpholine, thiomorpholine 1,1-dioxide, tetra hydro-1,2,5-thiaoxazole 1,1-dioxide, tetrahydro-2H-1,2-thiazine 1,1-dioxide, hexahydro-1,2,6-thiadiazine 1,1-dioxide, tetrahydro-1,2,5-thiadiazole 1,1-dioxide isothiazolidine 1,1-dioxide, 6-oxo-1,6-dihydropyridazin-3-yl, 6-oxo-1,6-dihydropyridazin-4-yl, 5-oxo-4,5- 25 dihydro-1H-1,2,4-triazol-3-yl and 5-oxo-4,5-dihydro-1H-imidazol-2-yl. A heterocyclyl can be optionally substituted with 1-4 substituents. Exemplary substituents include alkyl, haloalkyl, halogen and oxo.

The term “spirocycloalkyl" means a cycloalkyl group which shares one ring carbon with another alkyl or cycloalkyl group. 30 As used herein the terms “subject” and “patient” may be used interchangeably, and means a mammal in need of treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, pigs, horses, sheep, goats and the like) and WO 2010/011314 PCT/US2009/004261 -32- laboratory animals (e.g., rats, mice, guinea pigs and the like). Typically, the subject is a human in need of treatment.

When a disclosed compound or its pharmaceutically acceptable salt ts named or depicted by structure, it is to be understood that solvates or hydrates of the 5 compound or its pharmaceutically acceptable salts are also included. “Solvates" refer to crystalline forms wherein solvent molecules are incorporated into the crystal lattice during crystallization. Solvate may include water or nonaqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and EtOAc. Solvates, wherein water is the solvent molecule incorporated into the crystal lattice, are typically 10 referred to as “hydrates." Hydrates include stoichiometric hydrates as well as compositions containing variable amounts of water. Some of the compounds disclosed in the exemplification may be in the anhydrous form..

The term "compound" also includes labeling at one or more positions with deuterium. "Labeled with deuterium at a position" means that the amount deuterium at 15 the position is greater than the amount that is present at natural abundance. In certain instances, the deuterium at each position in a "compound" is at natural abundance.

Certain of the disclosed compounds may exist in various stereoisomeric forms. Stereoisomers are compounds that differ only in their spatial arrangement. Enantiomers are pairs of stereoisomers whose mirror images are not superimposable, 20 most commonly because they contain an asymmetrically substituted carbon atom that acts as a chiral center. “Enantiomer** means one of a pair of molecules that are mirror images of each other and are not superimposable. Diastereomers are stereoisomers that are not related as mirror images, most commonly because they contain two or more asymmetrically substituted carbon atoms. The symbol “*” in a structural formula 25 represents the presence of a chiral carbon center. “R” and “S" represent the configuration of substituents around one or more chiral carbon atoms. Thus, “R*" and “S*M denote the relative configurations of substituents around one or more chiral carbon atoms. "Racemate" or "racemic mixture" means a compound of equimolar quantifies of 30 two enantiomers, wherein such mixtures exhibit no optical activity; i.e., they do not rotate the plane of polarized light. “Geometric isomer” means isomers that differ in the orientation of substituent atoms in relationship to a carbon-carbon double bond, to a cycloalkyl ring, or to a WO 2010/011314 PCT/US2009/004261 -33- bridged bicyclic system. Atoms (other than H) on each side of a carbon-carbon double bond may be in an E (substituents are on opposite sides of the carbon-carbon double bond) or Z (substituents are oriented on the same side) configuration. “R,” “S,” US*,“ MR*,n Έ," "Z," “cis,” and “trans," indicate configurations relative to the core molecule.

The compounds of the invention may be prepared as individual isomers by either isomer-specific synthesis or resolved from an isomeric mixture. Conventional resolution techniques include forming the salt of a free base of each isomer of an isomeric pair using an optically active acid (followed by fractional crystallization and regeneration of the free base), forming the salt of the acid form of each isomer of an isomeric pair using an optically active amine (followed by fractional crystallization and regeneration of the free acid), forming an ester or amide of each of the isomers of an isomeric pair using an optically pure acid, amine or alcohol (followed by chromatographic separation and removal of the chiral auxiliary), or resolving an isomeric mixture of either a starting materia, or a final product using various well known chromatographic methods.

When the stereochemistry of a disclosed compound is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enantiomer over the weight of the enantiomer plus the weight of its optical isomer.

When a disclosed compound is named or depicted by structure without indicating the stereochemistry, and the compound has at least one chiral center, it is to be understood that the name or structure encompasses one enantiomer of compound free from the corresponding optical isomer, a racemic mixture of the compound and mixtures enriched in one enantiomer relative to its corresponding optical isomer.

When a disclosed compound is named or depicted by structure without indicating the stereochemistry and has at least two chiral centers, it is to be understood that the name or structure encompasses a diastereomer free of other WO 2010/011314 PCT/US2009/004261 -34- diastereomers, a pair of diastereomers free from other diastereomeric pairs, mixtures of diastereomers, mixtures of diastereomeric pairs, mixtures of diastereomers in which one diastereomer is enriched relative to the other diastereomer(s) and mixtures of diastereomeric pairs in which one diastereomeric pair is enriched relative to the other 5 diastereomeric pair(s).

The compounds of the invention may be present in the form of pharmaceutically acceptable salts. For use in medicines, the salts of the compounds of the invention refer to non-toxic “pharmaceutically acceptable salts."

Pharmaceutically acceptable salt forms include pharmaceutically acceptable 10 acidic/anionic or basic/cationic salts.

Pharmaceutically acceptable basic/cationic salts include, the sodium, potassium, calcium, magnesium, diethanolamine, n-methyl-D-glucamine, L-lysine, L-arginine, ammonium, ethanolamine, piperazine and triethanolamine salts.

Pharmaceutically acceptable acidic/anionic salts include, the acetate, 15 benzene sulfonate, benzoate, bicarbonate, bitartrate, bromide, calcium edetate, camsylate, carbonate, chloride, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, glyceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, malate, maleate, malonate, mandelate, mesylate, 20 methylsulfate, mucate, napsylate, nitrate, pamoate, pantothenate, phosphate/diphospate, polygalacturonate, salicylate, stearate, subacetate, succinate, sulfate, hydrogensulfate, tannate, tartrate, teoclate, tosylate, and triethiodide salts.

The following abbreviations have the indicated meanings:

Abbreviation Meaning A% Area percentage Boc terf-butoxy carbonyl or f-butoxy carbonyl (Boc)20 di-terf-butyI dicarbonate Cbz Benzyloxycarbonyl CbzCI Benzyl chloroformate WO 2010/011314 PCT/US2009/004261 -35- c-Pr

DAST

DBU

DCC

DCU

DIAD

DIBAL-H

DIEA

DMAP

DMF

DMPU

2,4-DNP dppf

DPTBS dr

EDC.HCI, EDCI

Equiv

EtOAc

Fmoc

Fmoc-OSu h, hr HOBt

HATU

HBTU cyclopropyl diethylaminosulfur trifluoride 1,8-dtazabicyclo[5.4.0]undec-7-ene N.N’-dicyclohexylcarbodiimide N, N -d icyclohexy lu rea diisopropyl azodicarboxylate diisobutylaluminum hydride N, N-diisopropyiethylamine 4-(dimethylamino)pyridine Ν,Ν-dimethylformamide 1.3- dimethyl-3,4,5,6-tetrahydro-2(1 H)-pyrimidinone 2.4- dinitrophenyl hydrazine 1,1 -Bis(diphenylphosphino)ferrocene

Diphenyl-t-butylsilyl diastereomer ratio 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride equivalents

Ethyl acetate 1-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]- 1-[[(9H-fluoren-9-ylmethoxy)carbonyl]oxy]-2,5- pyrrolidinedione hour(s) 1- hydroxy benzotriazole 2- (7-Aza-1 H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 2-(1 H-Benzotriazol-1 -yl)-1,1,3,3-tetramethyluronium WO 2010/011314 PCT/US2009/004261 -36- hexafluorophosphate KHMDS potassium hexamethyldisilazane LAH or LiAIH4 lithium aluminum hydride LC-MS liquid chromatography-mass spectroscopy LHMDS lithium hexamethyldisilazane m-CPBA meta-chloroperoxybenzoic acid Me methyl MsCl methanesulfonyl chloride Min minute MS mass spectrum NaH sodium hydride NaHCO3 sodium bicarbonate NaN3 sodium azide NaOH sodium hydroxide Na2SO4 sodium sulfate NMM N-methylmorpholine NMP N-methylpyrrolidinone Pd2(dba)3 tris(dfbenzylideneacetone)dipalladium{0) PE petroleum ether Quant quantitative yield rt room temperature Satd saturated SOCI2 thionyl chloride SFC supercritical fluid chromatography SPA scintillation proximity assay SPE solid phase extraction WO 2010/011314 PCT/US2009/004261

TBAF

TBS

TBDPS

TBSCI

TBDPSCI

TEA

TEMPO

Teoc

Teoc-OSu

Te)rt

Tint

TFA

Tic, TLC

TMS

TMSCI (r

TsOH -37- tetrabutylammonium fluoride t-butyldimethylsilyl t-butyldiphenylsilyl t-butyldimethylsilyl chloride t-butyldiphenylsilyl chloride

triethylamine or Et3N 2,2,6,6-tetramethyl-1-piperidinyloxy free radical 1-[2-(trimethylsilyl)ethoxycarbonyloxy]-1-[2-(trimethylsilyl)ethoxycarbonyloxy]pyrrolidin-2,5-dione External temperature

Internal temperature trifluoroacetic acid thin layer chromatography trimethylsilyl chlorotrimethylsilane or trimethylsilyl chloride retention time p-toluenesulfonic acid

GENERAL DESCRIPTION OF SYNTHETIC METHODS

Compounds of Formula I* can be prepared by several processes. In the discussion below, A\ Cy1, E, R1, R2, R3 * 5 * * * * 10, Y and n have the meanings indicated above 5 unless otherwise noted. Cy2 is an optionally substituted 2-oxo-1,2-dihydropyridyl group. In cases where the synthetic intermediates and final products of Formula I* described below contain potentially reactive functional groups, for example amino, hydroxyl, thiol and carboxylic acid groups, that may interfere with the desired reaction, it may be advantageous to employ protected forms of the intermediate. Methods for 10 the selection, introduction and subsequent removal of protecting groups are well known to those skilled in the art. (T.W. Greene and P. G. M. Wuts "Protective Groups WO 2010/011314 PCT/US2009/004261 -38- 10 15 in Organic Synthesis" John Wiley &amp;amp; Sons, Inc., New York 1999). Such protecting group manipulations are assumed in the discussion below and not described explicitly. Generally, reagents in the reaction schemes are used in equimolar amounts; however, in certain cases it may be desirable to use an excess of one reagent to drive a reaction to completion. This is especially the case when the excess reagent can be readily removed by evaporation or extraction. Bases employed to neutralize HCI in reaction mixtures are generally used in slight to substantial excess (1.05 - 5 equivalents).

In a first process a compound of Formula I*, can be prepared by reaction of an aminoalcohol intermediate of Formula II with a reagent of Formula III, wherein Z1 and Z2 are leaving groups such as chloride, 1-imidazolyl or aryloxide in an inert solvent such as THF, CH2CI2, toluene or MeCN, usually in the presence of an organic or inorganic base such as triethylamine or NaHCO3 respectively, at -10 °C to 120 °C:

<img img-format="tif" img-content="drawing" file="IL210452AD000213.tif" id="idf0013" />

Cy1-Cy2

<img img-format="tif" img-content="drawing" file="IL210452AD000214.tif" id="idf0014" />

Cy1-Cy2 r2 || m

Certain instances of reagent III are especially convenient because they are commercially available. For example when Z1 and Z2 are both chloride, III is phosgene. When Z1 and Z2 are both 1-imidazolyl, III is carbonyl diimidazole. When Z1 is chloride and Z2 is p-nitrophenoxide, III is p-nitrophenyl chloroformate. When Z1 and Z2 are both OCCI3, III is triphosgene and as little as one third of molar equivalent can be used.

Aminoalcohol intermediates of Formula II can be prepared by reduction of amides of Formula IV using a hydride reagent such as BH3.THF solution, BH3.Me2S or LiAIH^ in an inert solvent ethereal such as THF or DME at 20 °C to 100 °C for between 1 h and 48 h; 20 WO 2010/011314 PCT/US2009/004261 -39- R1

<img img-format="tif" img-content="drawing" file="IL210452AD000215.tif" id="idf0015" />

Intermediates of Formula IV can be prepared by coupling of a β-hydroxyacid of Formula V with an amine of Formula VI using standard peptide coupling reagents such as EDC in the presence of HOBt and Ν,Ν-diisopropylethylamine in an inert solvent such as CH2CI2 at 0 - 30 °C for between 1 h and 24 h: 10

<img img-format="tif" img-content="drawing" file="IL210452AD000216.tif" id="idf0016" />

Amine intermediates of Formula VI, wherein A1 = CH2 and R1 is absent, can be prepared by reduction of amides of Formula VII using a hydride reagent such as BH3.THF solution, BH3.Me2S or LiAIH4 in an inert solvent ethereal such as THF or DME at 20 °C to 100 °C for between 1 h and 48 h: R1 o

<img img-format="tif" img-content="drawing" file="IL210452AD000217.tif" id="idf0017" />

Al

H2N 'Cy1-Cy2

VII VI

Amine intermediates of Formula VI, wherein A1 is a bond, R1 is absent and Cy1

is not an aromatic or heteroaromatic ring, can be prepared from ketones of formula VIII via oximes of Formula IX or by reductive amination of a ketone of Formula VIII 15 with ammonia: WO 2010/011314 PCT/US2009/004261 -40-

<img img-format="tif" img-content="drawing" file="IL210452AD000218.tif" id="idf0018" />

H2N Cy1-Cy2 viri ix vi

Methods for the conversion of ketones to oximes are described in Smith, Μ. B. and March, J. "March’s Advanced Organic Chemistry” pp 1194-1195, 5th Edition, Wiley, New York, NY, 2001. Methods for the reduction of oximes to primary amines are 5 described in Smith, Μ. B. and March, J. “March’s Advanced Organic Chemistry" p 1555, 5th Edition, Wiley, New York, NY, 2001. Methods for the reductive amination of ketones are described in Baxter, E. W. and Reitz, A. B. "Organic Reactions” Volume 59, Ed. Overman, L. E., Wiley Interscience, 2002.

Similarly amine intermediates of Formula VI, wherein A1 is CH and R1 is methyl 10 or ethyl, can be prepared by reduction t-butylsulfinylimines of Formula VIJib which can be prepared from ketones of Formula Villa and f-butylsulfinamide or by addition of organometallic reagents of Formula R1M, wherein R1 is Me or Et and M is Li, MgCI, MgBror Mgl, to t-butylsulfinylimines of Formula Vllld which can be prepared from aldehydes of Formula Vlllc.

<img img-format="tif" img-content="drawing" file="IL210452AD000219.tif" id="idf0019" />

VIHc Vllld

High stereoselectivity is often achieved in such reactions using chiral f-butylsulfinylimines. WO 2010/011314 PCT/US2009/004261 -41 -

Intermediates of Formula II, wherein n = 0, can be prepared by reaction of oxetanes of Formula X with amines of Formula VI as described in Smith, Μ. B. and

March, J. “March's Advanced Organic Chemistry” p 505, 5th Edition, Wiley, New York, NY, 2001: R3- H2N' R2

X R1

I .Ai 'Cy1-Cy2

VI

<img img-format="tif" img-content="drawing" file="IL210452AD000220.tif" id="idf0020" />

Intermediates of Formula II can also be prepared by reductive amination of β-hydroxyaldehydes of Formula Xa with amines of Formula VI. Methods for the reductive amination of aldehydes are described in Baxter, E. W. and Reitz, A. B. “Organic Reactions” Volume 59, Ed. Overman, L. E., Wiley Interscience, 2002. R1

I

At R3-

OH^/CHO R1

I

Ai ’\ H,N‘ 'Cy1-Cy2

<img img-format="tif" img-content="drawing" file="IL210452AD000221.tif" id="idf0021" />

'Cy1-C R2

Xa

VI II

Aldehydes of Formula Xa can be prepared from homoallylic alcohols of Formula XXI by treatment with OsO4 and NalO4.

Intermediates of Formula II, wherein A1 = CH2 and R1 is absent, can be prepared by reduction of amide intermediates of formula XI using a hydride reagent 15 such as BH3.THF solution, BHa.Me2S or LiAIH4 in an inert solvent ethereal such as TKF or DME at 20 °C to 100 °C for between 1 h and 48 h: 10

<img img-format="tif" img-content="drawing" file="IL210452AD000222.tif" id="idf0022" />

<img img-format="tif" img-content="drawing" file="IL210452AD000223.tif" id="idf0023" />

XI R2 WO 2010/011314 PCT/US2009/004261 -42-

Amide intermediates of Formula XI can be prepared by reaction of an amino

alcohol intermediate of Formula XII with activated carboxylic acid of Formula XIII wherein Z3 = chloride or an activated ester, such as an N-hydroxysuccinimide ester: o

<img img-format="tif" img-content="drawing" file="IL210452AD000224.tif" id="idf0024" />

<img img-format="tif" img-content="drawing" file="IL210452AD000225.tif" id="idf0025" />

t_r&gt;,,2

Amino-alcohol intermediates of Formula XII, wherein n = 0, can be prepared by reaction of an epoxide of Formula XIV with cyanide ion followed by reduction of the resulting hydroxynitrile of Formula XV with hydrogen gas in the presence of a catalyst or with a hydride source such as LiAlH4:

<img img-format="tif" img-content="drawing" file="IL210452AD000226.tif" id="idf0026" />

Epoxide compounds of formula XIV can, in turn, be prepared in a number of ways including, as described in Aube, J. “Epoxidation and Related Processes” Chapter 3.2 in Volume 1 of “Comprehensive Organic Synthesis” Edited by B. M. Trost, I. Fleming and Stuart L. Schreiber, Pergamon Press, New York, 1992. 15 Hydroxynitrile intermediates of Formula XV can be prepared by treatment of ketones of Formula XVI with acetonitrile anion, formed by treatment of acetonitrile with n-BuLi or LDA, in an inert, anhydrous solvent such as THF at low temperature:

<img img-format="tif" img-content="drawing" file="IL210452AD000227.tif" id="idf0027" />

XVI XV

Amino-alcohol intermediates of Formula XII, wherein n is 0, can be prepared by 20 treatment of sulfonate intermediates of Formula XVII, wherein RA is for example methyl, trifluoromethyl or p-methylphenyl, with ammonia: WO 2010/011314 PCT/US2009/004261

<img img-format="tif" img-content="drawing" file="IL210452AD000228.tif" id="idf0028" />

-43- OH NH2 R3- OSO2Ra r2^ r2' XVII X,l

Amino-alcohot intermediates of Formula XII can be prepared by treatment of sulfonate intermediates of Formula XVII with sodium azide to give an azide intermediate of Formula XVIII, followed by catalytic hydrogenation or by Staudinger 5 reduction with PPh3 in wet THF:

OH R3- (Y)n 10

<img img-format="tif" img-content="drawing" file="IL210452AD000229.tif" id="idf0029" />

OSO,RA

c 3H OH nh2 R3— R3— r*"E r2"E (Ό XVIII XII

XVII

Sulfonate intermediates of Formula XVII can be prepared from diol intermediates of Formula XIX with a sulfonyl chloride RASO2CI:

OH OH

<img img-format="tif" img-content="drawing" file="IL210452AD000230.tif" id="idf0030" />

RASO?CI

<img img-format="tif" img-content="drawing" file="IL210452AD000231.tif" id="idf0031" />

OSO2R' xix xvii

Diol intermediates of Formula XIX can be prepared by hydroboration of allyl alcohols of Formula XX:

OH R3-

<img img-format="tif" img-content="drawing" file="IL210452AD000232.tif" id="idf0032" />

R2 R2'

XX XIX

Diol intermediates of Formula XIX can be prepared by ozonolysis and reduction of homoallyl alcohols of Formula XXI:

0H OH

<img img-format="tif" img-content="drawing" file="IL210452AD000233.tif" id="idf0033" />

<img img-format="tif" img-content="drawing" file="IL210452AD000234.tif" id="idf0034" />

XXI

XIX 15 -44- WO 2010/011314 PCT/US2009/004261

Aminoalcohol intermediates of Formula II, wherein A1 is a bond, R1 is absent, and Cy1 is a heteroaryl group or an aryl group bearing at least one strongly electron withdrawing group such as CF3, can be prepared by reaction of an aminoalcohol intermediate of Formula XII with a compound of Formula XXII, wherein Cy1 is a heteroaryl group or an aryl group bearing at least one strongly electron withdrawing group such as CF3 and RB is a leaving group such a fluoro, chloro, bromo or iodo: R1

OH NH, rb. R3-

Cy1-Cy2 R2' (On

<img img-format="tif" img-content="drawing" file="IL210452AD000235.tif" id="idf0035" />

10 XII XXII 'R2

Aminoalcohol intermediates of Formula II, wherein A1 is (Ci)alkylene can be prepared by reaction of an aminoalcohol of Formula XII with an aldehyde or methyl ketone of Formula XII in the presence of a reducing agent such as NaCNBH3 or Na(OAc)3BH: R1

<img img-format="tif" img-content="drawing" file="IL210452AD000236.tif" id="idf0036" />

15

Methods for the reductive amination of aldehydes and ketones are described in Baxter, E. W. and Reitz, A. B. "Organic Reactions*’ Volume 59, Ed. Overman, L. E., Wiley Interscience, 2002.

In a second process a compound of Formula I* can be prepared by reaction of a ketocarbamate of Formula XXIV, wherein R° is alkyl or arylalkyl group such as methyl, t-butyl or benzyl, with an organometallic reagent of Formula XXV wherein M includes, but is not limited to, MgCI, MgBr, Mg I or Li:

<img img-format="tif" img-content="drawing" file="IL210452AD000237.tif" id="idf0037" />

20 WO 2010/011314 PCT/US2009/004261 -45-

In specific examples, organometallic reagent XXV is allylmagnesium bromide, allylzinc(ll) bromide, (2-methylallyl)magnesium chloride or (2-methoxy-2- oxoethyl)zinc(II) bromide. In certain cases when M is MgCI, MgBr or Mgl, it is advantageous to add CeCfe to the reaction mixture.

Ketocarbamates of Formula XXIV can be prepared by reaction of aminoketones of Formula XXVI with intermediates of Formula XXVII wherein RE is a leaving group such as chloride, succinyloxy, imidazolyl ort-butoxycarboxycarbonyl: 10 R1

<img img-format="tif" img-content="drawing" file="IL210452AD000238.tif" id="idf0038" />

<img img-format="tif" img-content="drawing" file="IL210452AD000239.tif" id="idf0039" />

XXVII

<img img-format="tif" img-content="drawing" file="IL210452AD000240.tif" id="idf0040" />

Aminoketones of Formula XXVI, wherein n = 0, can be prepared by reaction of α,β-unsaturated ketones of Formula XXVIII with amines of Formula VI: R1

<img img-format="tif" img-content="drawing" file="IL210452AD000241.tif" id="idf0041" />

A1 + H2N/" XCy1-Cy2

XXVII

VI

<img img-format="tif" img-content="drawing" file="IL210452AD000242.tif" id="idf0042" />

Aminoketones of Formula XXVI, wherein n = 0, can be prepared by reaction of β-dialkylaminoketones of Formula XXVIII, wherein RF is lower alkyl especially methyl, with amines of Formula VI:

<img img-format="tif" img-content="drawing" file="IL210452AD000243.tif" id="idf0043" />

β-Dialkylaminoketones of Formula XXVIII are in turn derived from a, β-unsaturated ketones of Formula XXVII with dialkylamines of Formula RFNHRF. 15 WO 2010/011314 PCT/US2009/004261 -46- ., 210452/2 in a third process a compound of Formula I* can be prepared by reaction of a compound of Formula XVII with an isocyanate of Formula XXIX in the presence of a base: o r'

<img img-format="tif" img-content="drawing" file="IL210452AD000244.tif" id="idf0044" />

5 isocyanates of Formula XXIX can be prepared from amines of Formula VI by treatment with phosgene, diphosgene or triphosgene. This third process is described in greater detail in U.S. Provisional Application Serial No. 61/137,013, filed July 25, 2008 entitled SYNTHESIS OF INHIBITORS OF 11p-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (Attorney Docket No. 4370,1001-000). 0

In a fourth process a compound of Formula Γ can be prepared by reaction of a halo compound of Formula, wherein Hal is chlorine or bromine, with an isocyanate of Formula XXIX in the presence of a base: O R1

<img img-format="tif" img-content="drawing" file="IL210452AD000245.tif" id="idf0045" />

15 Halo compounds of Formula XXX can be prepared by reaction of β-haloketones of Formula XXXI with organometallic reagents of Formula XXV wherein M is a metal containing radical including MgCI, MgBr, Mgl or Li. The reaction is optionally carried out in the presence of anhydrous cerium trichloride:

<img img-format="tif" img-content="drawing" file="IL210452AD000246.tif" id="idf0046" />

XXXI xxv

XXX i -47-

In a fifth process a compound of Formula Γ, wherein A1 is CH2 or CH2CH2 and R1 is absent, can be prepared by reaction of a compound of Formula XXXII, with a compound of Formula XXXIII, wherein A1 is CH2 or CH2CH2 and RG is a leaving group

such as Br, I, OSO2Me, OSO2CF3 or OSO2Ph, in the presence of a base such as NaH WO 2010/011314 PCT/US2009/004261 10 5

<img img-format="tif" img-content="drawing" file="IL210452AD000247.tif" id="idf0047" />

XXXII rg' "Cy1-Cy2

XXXIII

<img img-format="tif" img-content="drawing" file="IL210452AD000248.tif" id="idf0048" />

Compounds of Formula XXXII can be prepared by treatment of compounds of Formula XII with various reagents of Formula III, wherein Z1 and Z2 are leaving groups such as chloride, 1-imidazolyl or aryloxide in an inert solvent such as THF, CH2CI2, toluene or MeCN, usually in the presence of an organic or inorganic base such as triethylamine or NaHCO3 respectively, at -10 °C to 120 °C: OH NH2 R3- R2' (On

XII 0 zv "z2 A.

III R2' 0

X

O^^NH

-M (Y)n 15

XXXII

In a sixth process a compound of Formula Γ, wherein A’is a bond and R1 is absent, can be prepared by reaction of a compound of Formula XXXII, with a compound of Formula XXII, wherein RB is a leaving group such as chloro, bromo, iodo or OSO2CF3, in the presence of a base such as K2CO3 and a copper or palladium catalyst in an inert solvent such as dioxane, DMF or NMP at elevated temperature:

<img img-format="tif" img-content="drawing" file="IL210452AD000249.tif" id="idf0049" />

WO 2010/011314 PCT/US2009/004261 -48- ln a seventh process a compound of Formula I* can be prepared by Suzuki coupling of a compound of Formula XXXIV, wherein Cy1 is aryl or heteroaryl and Rx is bromo, iodo, or trifluoromethanesulfonyloxy, with a boronic acid (RY is hydrogen) or a boronate ester of Formula XXXV (RY is (CrCe)alkyl and the two groups RY taken 5 together form a (CrCi2)alkylene group).

<img img-format="tif" img-content="drawing" file="IL210452AD000250.tif" id="idf0050" />

In an eighth process a compound of Formula XXXIV, wherein Cy1 is aryl or heteroaryl and Rx is bromo, iodo, or trifluoromethanesulfonyloxy, can be reacted with 10 bis(pinacolato)diboron in the presence of a palladium catalyst to give a boronate ester of Formula XXXVI which can be further reacted with a heterocyclic compound of Formula XXXVII, wherein Rx is bromo, iodo, or trifluoromethanesulfonyloxy, again in the presence of a palladium catalyst, to give a compound of Formula I*.

<img img-format="tif" img-content="drawing" file="IL210452AD000251.tif" id="idf0051" />

<img img-format="tif" img-content="drawing" file="IL210452AD000252.tif" id="idf0052" />

Rx-Cya

XXXVII

<img img-format="tif" img-content="drawing" file="IL210452AD000253.tif" id="idf0053" />

WO 2010/011314 PCT/US2009/004261 -49- ln a ninth process a compound of Formula I* can be prepared from another compound of Formula I*. For example: (1) a compound of Formula Γ, wherein R1 or R3 is co-hydroxy(C2-C6)alkyl, can be oxidized to a compound of Formula Γ, wherein R1 or R3 is a-carboxyfCrCsJalkyl, using Jones reagent (2) a compound of Formula Γ, wherein R1 or R3 is a&gt;-carboxy(Ci-C6)alkyl, can be coupled with ammonia or a (Ci-C6)alkylamine using a standard peptide coupling reagent such as EDC to afford a compound of Formula Γ, wherein R1 or R3 is o-H2NC(=0)(Ci-C6)alkyl or w-{(Ci-C6)alkylNHC(=O)}(Ci-C6)alkyl. (3) a compound of Formula I*, wherein R1 or R3 is co-hydroxy(Ci-C6)alkyl, can be converted to its methanesulfonate or trifluoromethanesulfonate, treated with sodium azide and reduced to give a compound of Formula I*, wherein R1 or R3 is Q-amino(Ci-C6)alkyl. (4) a compound of Formula Γ, wherein R1 or R3 is amino(CvC6)alkyl, can be reacted with acetic anhydride or acetyl chloride to give a compound of Formula I*, wherein R1 or R3 is {acetylamino}(Ci-C6)alkyl. (5) a compound of Formula I*, wherein R1 or R3 is amino(Ci-C6)alkyl, can be reacted with methanesulfonyl chloride to give a compound of Formula Γ, wherein R1 or R3 is {methanesulfonylamino}(CvC6)alkyt (6) a compound of Formula I*, wherein R1 is (C2-Ce)alkenyl, is hydroborated to afford a compound of Formula Γ, wherein R1 is hydroxy(C2-Ce)alkyl. (7) a compound of Formula Γ, wherein R3 is (C2-C6)alkenyl, is hydroborated to afford a compound of Formula Γ, wherein R3 is hydroxy(C2-C6)alkyl. (8) a compound of Formula Γ, wherein R1 is (Cs-CeJalkenyl, can be reacted with osmium tetroxide and N-methylmorpholine-N-oxide to afford a compound of Formula Γ, wherein R1 is vicinal dihydroxy(C2-C6)alkyl,. (9) a compound of Formula I*, wherein R3 is (C2-C6)alkenyl, can be reacted with osmium tetroxide and N-methylmorpholine-N-oxide to afford a vicinal diol compound of Formula Γ, wherein R3 is vicinal dihydroxy(C2-C6)alkyl,. (10) a compound of Formula Γ, wherein R1 is (C2-C6)alkenyl, can be reacted with ozone followed by NaBH4 to give a compound of Formula Γ, wherein R1 is w-hydroxy(Ci-C5)alkyl. WO 2010/011314 PCT/US2009/004261 - 50 - (11) a compound of Formula Γ, wherein R3 is (Cz-CeJalkenyl, can be reacted with ozone followed by NaBhU to give a compound of Formula Γ, wherein R3 is co-hydroxy(CrC5)alkyl. (12) a compound of Formula I*, wherein R1 or R3 is amino(Ci-C6)alkyl, can be 5 reacted with an (Ci-Ce)alkyl isocyanate to give a compound of Formula Γ, wherein R1 or R3 is (CrC6)alkylaminocarbonylamino(Ci-C6)alkyl. (13) a compound of Formula Γ, wherein R1 or R3 is amino(CrC6)alkyl, can be reacted with an (Ci-C6)alkyl chloroformate to give a compound of Formula I*, wherein R1 or R3 is (Ci-C6)alkoxycarbonylamino(CrC6)alkyl. 10 (14) a compound of Formula Γ, wherein R1 or R3 is amino(CrC6)alkyl, can be reacted with chlorosutfonyl isocyanate or sulfamide to give a compound of Formula I*, wherein R1 or R3 is aminosulfonylamino(Ci-C6)alkyl. (15) a compound of Formula Γ, wherein R1 or R3 is amino(CrC6)alkyl, can be reacted with a (CrC6)alkylsulfamoyl chloride to give a compound of Formula I*, 15 wherein R1 or R3 is (Ci-C6)alkylaminosulfonylamino(Ci-C6)alkyl. (16) a compound of Formula Γ, wherein R1 or R3 is hydroxyiCpCeialkyl, can be reacted with chlorosulfonyl isocyanate to give a compound of Formula I*, wherein R1 or R3 is aminosulfonyloxy(Ci-C6)alkyl. (17) a compound of Formula I*, wherein R1 or R3 is hydroxyfCi-CeJalkyl, can be 20 reacted with p-nitrophenyl chloroformate, pentafluorophenyl chloroformate or carbonyl diimidazole, followed by ammonia, a (CrCeJalkylamine or a di(Ci-C6)aIkylamine to give a compound of Formula I*, wherein R1 or R3 is aminocarboxy(Ci-C6)alkyl, (CrCe)alkyl aminocarboxy(Ci-C6)alkyl or di(Ci-C6)alkyl aminocarboxy(Ci-C6)alkyl. (18) a compound of Formula Γ, wherein R1 or R3 is hydroxy(Ci-C6)atkyl, can be 25 reacted with POCI3 to give a compound of Formula Γ, wherein R1 or R3 is

(HO)2P(=O)O(CrC6)alkyL (19) a compound of Formula I*, wherein R3 is allyl or homoallyl, can be reacted with oxygen in the presence of PdCb and CuCI to afford a compound of Formula I*, wherein R3 is 2-oxopropyl or 3-oxobutyl respectively. 30 (20) a compound of Formula l\ wherein R3 is 2-oxopropyl or 3-oxobutyl, can be reacted with MeMgX, wherein X is Cl, Br or I, to give a compound of Formula I*, wherein R3 is 2-hydroxy-2-methylpropyl or 3-hydroxy-3-methylpropyl respectively. WO 2010/011314 PCT/US2009/004261 -51 - (21) a compound of Formula I*, wherein R3 is -CH2CO2Me can be treated with MeMgX, wherein X is Cl, Br or I, to give a compound of Formula I*, wherein R3 is 2-hydroxy-2-methylpropyl. (22) a compound of Formula Γ, wherein R3 is allyl or -CH2C(Me)=CH2, can be 5 hydrocyanated with TsCN in the presence of triphenylsilane and various cobalt catalysts to afford compounds of Formula I*, wherein R3 is -CH2CH(CN)Me or -CH2CMe2CN respectively. (23) a compound of Formula Γ, wherein R3 is CH2C(Me)2CN, can be treated with acetamide in the presence of PdCI2 to give a compound of Formula Γ, wherein R3 10 is CH2CMe2CONH2. (24) a compound of Formula Γ, wherein R3 is -CH2C(Me)=CH2 can be treated with m-CPBA followed by lithium triethylborohydride to afford a compound of Formula I*, wherein R3 is 2-hydroxy-2-methylpropyl.

In a tenth process, certain compounds of the invention of Formula I** are 15 prepared as follows:

<img img-format="tif" img-content="drawing" file="IL210452AD000254.tif" id="idf0054" />

WO 2010/011314 PCT/US2009/004261 -52-

Halo compounds of Formula LII1 can be formed by the treatment of β-haloketones of Formula XXXI with organometallic reagents of Formula LU, wherein M denotes MgCI, MgBr, Mgl, ZnBr or Znl and the reaction is optionally performed in the presence of anhydrous cerium trichloride in an inert anhydrous solvent, such as 5 tetrahydrofuran, at about -25 to 0 °C for about 0.5 h.

Cyclic carbamates of Formula LIV can be prepared from the reaction between β-haloalcohols of Formula LIII where Hal is a chloride and isocyanates of Formula XXXIX in the presence of a base, such as but not limited to DBU (f ,8-diazabicyclo[5.4.0]undec-7-ene), in a refluxing inert solvent, such as but not 10 limited to tetrahydrofuran.

Tertiary alcohols of Formula LVII can be derived from trisubstituted alkenes of Formula LIV by first epoxidizing the alkene with an epoxidation reagent, such as m-CPBA (3-chloroperbenzoic acid), in an inert solvent, such as dichloromethane to produce the corresponding epoxides of Formula LV. The resulting epoxide is then 15 reductively ring opened to provide the corresponding tertiary alcohol Γ via treatment with a strong hydride reagent, such as lithium triethylborohydride, in an anhydrous inert solvent, such as tetrahydrofuran.

In a variation of the tenth process, a compound of the invention of Formula Γ** is prepared by using a "Suzuki" coupling reaction of a boronate ester of Formula LIX 20 with a haloheterocycle of Formula LX. WO 2010/011314 PCT/US2009/004261 210452/2 R’

<img img-format="tif" img-content="drawing" file="IL210452AD000255.tif" id="idf0055" />

The boronate ester of Formula LIX is prepared by reaction of a bromide of Formula LVIII with bis(pinacolato)diboron. LVIli is prepared by epoxidation of alkene LVII, followed by reductive epoxide opening as described above, for 5 2-methyl-2-hydroxypropyl group is introduced via epoxidation and hydride ring opening as described above for conversion of LIV to I**.

This tenth process is described in greater detail in U.S. Provisional Application Serial No. 61/137,013, filed July 25, 2008 entitled SYNTHESIS OF INHIBITORS OF 11P-HYDROXYSTEROID DEHYDROGENASE TYPE 1.

I WO 2010/011314 PCT/US2009/004261 -54-

LC-MS METHODS

Method 1 [LC-MS (3 min)]

Column; Chromolith SpeedRod, RP-18e, 50 x 4.6 mm; Mobil phase: A: 0.01%TFA/water, B: 0.01%TFA/CH3CN; Flow rate: 1 mL/min; Gradient:

Time (min) A% B% 0.0 90 10 2.0 10 90 2.4 10 90 2.5 90 10 3.0 90 10

Method 2 (10-80)

Column YMC-PACK ODS-AQ , 50*2.0mm 5pm Mobile Phase A: water (4 L) + TFA (1.5 mL)) B: acetonitrile (4 L) + TFA (0.75 mL)) TIME(min) A% B% 0 90 10 2.2 20 80 2.5 20 80 Flow Rate 1 mL/min Wavelength UV 220 nm Oven Temp 50 °C MS ionization ESI WO 2010/011314 PCT/liS2009/004261 -55-

Method 3 ¢30-90)

Column YMC-PACK ODS-AQ , 50»2.0mm 5pm Mobile Phase A: water (4 L) + TFA (1.5 mL) ) B: acetonitrile (4 L) + TFA (0.75 mL)) TIME(min) A% B% 0 70 30 2.2 10 90 2.5 10 90 Flow Rate 1 mL/min Wavelength UV220 Oven Temp 50 °C MS ionization ESI

Method 4:

Column Waters Xbridge C18 30*4.6mm 2.5pm Mobile A: water + 0.1% F3CCO2H Phase B: acetonitrile TIME (min) A% B% 0 90 10 0.15 90 10 3.15 10 90 4.50 10 90 4.75 20 10 5.00 20 10 Flow Rate 1.2 mL/min Wavelength UV 220, 230, or 254 nm WO 2010/011314 PCT/US2009/004261 -56-

Method 5:

Column Merck Cromolith Speed ROD, RP18e, 50^4.6 mm Mobile A: water + 0.1% HCO2H Phase B: acetonitrile + 0.1% HCO2H TIME (min) A% B% 0.00 90 10 4.50 10 90 5.00 10 90 5.50 90 10 Flow Rate 1.5 mL/min Wavelength UV 220, 230, or 254 nm PREPARATION 1 (S)-3-((5)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-5 oxazinan-2-one

Method 1

<img img-format="tif" img-content="drawing" file="IL210452AD000256.tif" id="idf0056" />

WO 2010/011314 PCT/US2009/004261 -57-

Step 1; (S)-1-bromo-4-(1-isocyanatoethyl)benzene

To a solution of (S)-1-(4-bromophenyl)ethanamine (240 g, 1.2 mol) in methylene chloride (3 L) and satd aq NaHCO3 (3 L) solution was added triphosgene (118 g, 0.396 mol) at 0 °C. The mixture was stirred for 15 min. The organic phase 5 was separated, dried over Na2SO4 and concentrated to give 1 -bromo-4-(1-isocyanato-ethyl) -benzene (170 g, 63%).

Step 2: 1-chloro-3-phenylhex-5-en-3-ol

To a solution of 3-chloro-1-phenylpropan-1-one (170 g, 1.01 mol) in anhydrous 10 THF (1200 mL) was added allylmagnesium bromide (1.2 L, 1mol/L) at -78 °C under nitrogen. The formed mixture was stirred for 30 min at -78 °C. The reaction was quenched with aqueous NaHCO3 solution. The organic phase was separated, dried over Na2SO4 and concentrated to give the crude product, which was purified by column chromatography (petroleum ether/EtOAc= 100:1) to afford 15 1-chloro-3-phenylhex-5-en-3-ol {180 g, 86%). 1H NMR (CDCI3): 2.27 (m, 2H), 2.51 (m, 1H), 2.74 (m, 1H), 3.22 (m, 1H), 3.58 (m, 1H), 5.16 (m, 2H), 5.53 (m, 1H), 7.23 (m, 1H), 7.39 (m, 4H).

Step 3: (R)-6-allyl-3-((S)-1 -(4-bromophenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one 20 A mixture of 1-chloro-3-phenyl-hex-5-en-3-ol (105 g, 0.050 mmol), (S)-(-)-1-(- bromophenyl)ethyl isocyanate (170 g, 0.752 mol), and DBU (228 g, 1.5 mol) in THF (1700 mL) was heated to reflux overnight. The mixture was diluted with EtOAc and washed with 1/Vaq HCI. The aqueous phase was extracted with EtOAc (3 x). The combined organic phase was dried over Na2SO4. After the solvents were evaporated, 25 the crude product was purified by column chromatography (petroleum ether/EtOAc =20:1 to 5:1) to give (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (100 g, 34 %). 1H NMR (CDCI3): 1.39 (d, 3H), 2.14 (m, 1H). 2.24 (m, 2H), 2.48- 2.61 (m, 3H), 2.82 (m, 2H), 5.01 (m, 2H), 5.52 (q, 1H), 5.73 (m, 1H), 6.62 (d, 2H), 7.12 (m, 2H). 7.28 (m, 2H). 30 WO 20J0/011314 PCTZUS2009/004261 -58-

Step 4: (S)-3-(($)-1-(4-bromophenyl)ethyl)-6-(2-oxopropyl)-6-phenyl-1,3-oxazinan-2- one and 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6- yljpropanal

To a solution of (/?)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-phenyl-1,3- 5 oxazinan-2-one (31 g, 78 mmol) and CuCI (19.3 g, 195 mmol) in dry DMF (150 mL) was added H2O (50 mL) and PdCI2 (4.10 g, 23 mmol) at rt. After addition, the mixture was stirred overnight under oxygen. After TLC showed the starting material had disappeared, the solid was filtered off. Water (200 mL) and EtOAc (200 mL) was added, the organic layers were separated and the aqueous layer was extracted with 10 EtOAc (3 x 40 mL). The combined organic layer was washed with brine, dried over Na2SO4t filtered and concentrated to give a residue which was purified by column chromatography (petroleum ether/EtOAc =5:1 to 1:1) to give a mixture of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-oxopropyl)-6-phenyl-1,3-oxazinan-2-one and 3-((R)- 3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanal, (26 g, 81%). 15

Step 5: (S)-3-((S)-1 -(4-bromophenyl)ethyl)-6-(2-oxopropyl)-6-phenyl-1,3-oxazinan-2-one

To a mixture of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-oxopropyf)-6-phenyl- 1,3- oxazinan-2-one and 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3- 20 oxazinan-6- yl)propanal (20 g, 48.2 mmol) in t-BuOH (250 mL) and 2-methyl-2-butene (50 mL) was added a solution of NaCIOz (19.3 g, 0.213 mol) and NaH2PO4 (28 g, 0.179 mol) in H2O (300 mL) at 0 °C. The formed mixture was stirred for 1 h at 0 °C.

The mixture was treated with water (100 mL) and extracted with CH2CI2. The combined organic layer was dried over Na2SO4, filtered and concentrated to leave a 25 residue, which was purified by column chromatography (petroleum ether/EtOAc =5:1 to 2.5:1) to afford (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-oxopropyl)-6-phenyl-1,3-oxazinan-2-one (10.0 g, 83%). 1H NMR (CDCI3): 1.49 (d, 3H), 2.12 (s, 3H), 2.33 (m, 2H), 2.63 (m, 1H), 2.86-3.08 (m, 3H), 5.57 (q, 1H), 6.66 (d, 2H), 7.19 (m, 2H), 7.33 (m 5H). 30

Step 6: (S)-3-((S)-1- (4-bromophenyl) ethyl)-6- (2- hydroxy-2-methylpropyl)- 6- phenyl- 1,3- oxazinan-2- one WO 2010/011314 PCT/US2009/004261 -59-

To a solution of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-oxopropyl)-6-phenyl- 1,3-oxazinan-2-one (20 g, 46.4 mmol) in anhydrous THF (200 mL) was added dropwise methylmagnesium bromide (31 mL, 144 mmol) at -78 °C under nitrogen. Then the mixture was stirred at rt for 1 h. The reaction mixture was quenched with aq NaHCO3 (50 mL) under ice water bath. The organic layers were separated. The aqueous layer was extracted with EtOAc (150 mL). The combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo to give the crude product, which was purified column chromatography (petroleum ether/EtOAc =5:1 to 2:1) to afford (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)- 6-phenyl-1,3-oxazinan-2- one (13 g, 65%). After re-crystallization from EtOH, 4 g of the pure compound was obtained. 1H NMR (CDCb): 1.06 (s, 3H), 1.12 (s, 3H), 1.44 (d, 3H), 2.14 (m, 3H), 2.21 (m, 1H), 2.33 (m, 1H), 2.76 (m, 1H), 5.54 (q, 1H), 6.74 (d, 2H), 7.16 (d,2H), 7.28 (m, 5H).

Alternative Procedure for Method 1 Step 2 -1

Zn NH4CI(aq)

<img img-format="tif" img-content="drawing" file="IL210452AD000257.tif" id="idf0057" />

<img img-format="tif" img-content="drawing" file="IL210452AD000258.tif" id="idf0058" />

A solution of 3-chloro-1-phenylpropan-1-one (100 g, 0.595 mol) in THF (280 ml) was added dropwise to a well-stirred mixture of zinc powder (need not be activated) (40 g, 1.231 mol, satd aq NH4CI solution (1500 ml) and THF (400 ml). Allyl bromide (143 g, 1,19 mol) was dissolved in THF (200 ml) was slowly added to the reaction mixture. The reaction was mildly exothermic, and the mixture began to reflux spontaneously. After refluxing had ceased, the mixture was stirred for 1 h. The mixture was extracted with EtOAc, dried over anhydrous Na2SO4, and concentrated to give 1-chloro-3-phenylhex-5-en-3-ol (122 g, 97%). 1H NMR: (400MHz, CDCI3): 5=2.24(s, 1H), 2.34 (m, 2H), 2.53 (m, 1H), 2.75 (m, 1H), 3.20 (m, 1H), 3.58 (m, 1H), 5.18(1, 1H), 5.51 (m, 1H), 7.26 (m, 1H), 7.26-7.39 (m, 3H). (R)-6-allyl-3-((S)-1-(4-bromophenyl)propyl)-6-phenyl-1,3-oxazinan-2-one was prepared from (S)-1-(4-bromophenyl)propan-1-amine following procedures analogous to those described in Preparation 1 Method 1 Steps 1 to 3 above. WO 2010/011314 PCT/US2009/004261 -60- (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one was prepared from (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one following procedures analogous to those described in Preparation 1 Method 1 Steps 4 and 6.

Method 2

Me

HUN ct

<img img-format="tif" img-content="drawing" file="IL210452AD000259.tif" id="idf0059" />

Me triphosgene, CH2CI2 sat aq. NaHCO3

Br

Br

<img img-format="tif" img-content="drawing" file="IL210452AD000260.tif" id="idf0060" />

<img img-format="tif" img-content="drawing" file="IL210452AD000261.tif" id="idf0061" />

Super-Hydride 0 “C to rt

<img img-format="tif" img-content="drawing" file="IL210452AD000262.tif" id="idf0062" />

10 15

Step 1.1-Chloro-5-methyl-3-phenyl-hex-5-en-3-ol

To a stirred suspension of magnesium turnings (46.7 g, 1.94 mol) in 1500 mL ofTHF (H2O &lt;100 ppm based on Karl Fischer titration) was charged 53.0 mL of 1 M DIBAL-H in hexane under nitrogen at rt. Then 3-chloro-2-methylprop-1-ene (160 g, 1.77 mol) was introduced while maintaining the internal temperature below 30 °C. The resulting solution was agitated for 2 h at rt. The solution was titrated in the presence of 1.1’-bipyridine to indicate 0.8 M of the corresponding Grignard reagent. To a dry flask containing 307.0 g of anhydrous CeCb (1.25 mol) at rt under nitrogen was added 1556.8 mL of the Grignard reagent (0.8 M, 1.25 mol). The resulting slurry was cooled to -10 °C and agitated for 0.5 h. To the slurry was added 200 g of 3-chloro-1-phenylpropan-1-one (1.19 mol) in 200 mL ofTHF while maintaining the internal temperature below 0 °C. After the mixture was stirred for 0.5 h, 1200 mL of 1 M aq HCI was added to obtain a clear solution while maintaining the internal 20 WO 2010/011314 PCT/US2009/004261 -61 - temperature below 30 °C. After the phase cut, the aqueous layer was extracted with EtOAc (500 ml_). The combined organic layers were washed with brine and dried over sodium sulfate. Removal of the solvent under vacuum produced crude 1-chloro-5-methyl-3-phenyl-hex-5-en-3-ol, which was chased with THF to achieve 5 H2O &lt;500 ppm based on Karl Fischer titration. The crude product (306 g, 83wt%, 95% yield) was used directly in Step 3. ^-NMR spectroscopy (500 MHz, CDCb) δ 7.38-7,37 (d. J= 7.8 Hz, 2H), 7.33 (t, J= 7.9 Hz, 2H), 7.24 (t, J= 7.4 Hz, 1 H), 4.91 (s, 1H), 4.76 (s, 1H), 3.57 (ddd, J= 5.6,10.7, and 10.7,1H), 3.13 (ddd, J=4.7, 10.7 and 10.7 Hz, 1H), 2.66 (d, 13.3 Hz, 1H), 2.54 (d, J= 11.3 Hz, 1H), 2.53 (s, 1H), 2.36 10 (ddd, J= 5.4, 10.6 and 13.9 Hz. 1H), 2.29 (ddd, J=5.6, 11.3 and 13.3 Hz, 1H), 1.29 (s, 3H). 13C-NMR spectroscopy (125 MHz, CDCb) δ 144.3, 141.4, 128.0, 126.6, 124.8, 116.1,74.2, 51.2, 46.0, 39.9, 23.9.

Step 2.1-Bromo-4-((S)-1-isocyanato-ethyl)-benzene 15 To a 10 L jacketed reactor was charged 241 g of sodium bicarbonate (2.87 mol, 2.30 equiv) and 5 L of deionized water. The resulting solution was agitated for 10-20 min, until the solids dissolved (homogeneous). To the clear solution was charged 250 g (1.25 mol, 1.00 equiv) of (5)-(-)-1 -(4-bromophenyl)ethylamine as a solution in 1.00 L of dichloromethane. An additional 4 L of dichloromethane was 20 charged to the reactor. The biphasic solution was agitated and cooled to Tnt=2-3 °C. Triphosgene (126 g, 424 mmol, 0,340 equiv) was charged to the reactor in approximately two equal portions - 6 min apart. It should be noted that a slight exotherm was noted upon the addition of triphosgene. The resulting murky solution was agitated at Tint=2-5 °C for 30 min, at which point HPLC analysis indicates &gt;99 A% 25 conversion (220 nm). The dichloromethane layer was cut and dried with anhydrous sulfate. The resulting solution was passed through a ceiite plug and concentrated to -1.5 L which fine particles of a white solid developed. The solution was filtered and concentrated to a thick oil via reduced pressure to produce 239 g of

1-bromo-4-((S)-1-isocyanato-ethyl)-benzene (93.7 wt%, 79.4 % yield). 1H-NMR 30 spectroscopy ¢400 MHz, CD2CI2) δ 7.53 (d, J= 11.4 Hz, 2 H), 7.26 (d, J- 8.2 Hz, 2 H), 4.80 (q, J= 6.7 Hz, 1H), 1.59 (d, 6.7 Hz, 3 H). The material was used in Step 3 without further purification. WO 2010/011314 PCT/US2009/004261 -62-

Step 3. (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one

To a dried 10 Ljacketed reactor under a nitrogen atmosphere was charged 1-chloro-5-methyl-3-phenyl-hex-5-en-3-ol (167 g, 81.7 wt%, 610 mmol, 1.00 equiv), 5 1-bromo-4-((S)-1-isocyanato-ethyl)-benzene (219 g, 93.7 wt%, 911 mmol, 1.50 equiv), anhydrous tetrahydrofuran (3.00 L), and then 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 409 mL, 2.73 mol, 4.50 equiv). The resulting solution was agitated and refluxed (Tjnt= 67-69 °C, Text= 75 °C) for 19 h, at which point HPLC analysis indicated * 1A% (220 nm) of the 1-chloro-5-methyl-3-phenyl-hex-5-en-3-ol remained. The dark 10 solution was cooled to Tjnt= 20-25 °C. Two liters of tetrahydrofuran were removed by distillation under reduced pressure. The remaining dark solution was diluted with 4.0 L of ethyl acetate and 1.0 L of hexanes. The resulting solution was washed with 4.0 L of a 1.0 M aqueous solution of hydrogen chloride (note: the wash is slightly exothermic). The aqueous solution was cut and the remaining organic solution was 15 dried with anhydrous sodium sulfate, filtered and then concentrated to an oil via reduced pressure. The resulting material was subjected to flash silica chromatography (5-30 % ethyl acetate/hexanes, 1.74 kg of silica) to produce 137.8 g of material (59 wt%, 3.1:1 diastereomeric ratio favoring the desired diastereomer (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one, 20 32.3 % yield). The material was used in Step 4 without further purification.

Analytical data for (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6- phenyl-1,3-oxazinan-2-one: 1H-NMR spectroscopy ¢500 MHz, CD2CI2) δ 7.42-7.35 (m, 3 H), 7.33-7.31 (m, 2H), 7.25-7.23 (m, 2H), 6.80-6.74 (m, 2), 5.55 (q, J=7.1 Hz, 1 H), 5.37-5.36 (m, 1H), 4.89 (s, 1H),4.69 (s, 1H), 2.96-2.93 (m, 1H), 2.61 (dd, 13.8 and

25 26.4 Hz, 2 H), 2.37-2.25 (m, 3H), 1.68 (s, 3H), 1.50 (d, J= 7.1 Hz, 3 H). 13C-NMR spectroscopy (125 MHz, CD2CI2) δ 152.5, 141.5,140.1, 138.3,130.6,128.1, 128.0, 126.9,124.4, 120.2, 115.3, 82.4, 52.1, 50.1, 35.6, 29.8, 23.4, 14.5.

Analytical data for (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one: 1H-NMR spectroscopy (400 MHz, CD2CI2) δ 7.50-7.48 (m, 30 2H), 7.43-7.39 (m, 2H), 7.35-7.32 (m, 3H), 7.20-7.18 (m, 2H), 5.60 (q, J= 7.1 Hz, 1H), 4.85 (s, 1H), 4.66 (s, 1H), 2.73-2.67 (m, 2H), 2.60 (dd, J= 13.9 and 19.4 Hz, 2H), 2.28 (dt, J= 3.3 and 13.7 Hz, 1H), 2.14-2.05 (m, 1H), 1.66 (s, 3H), 1.24 (d, J= 7.2 Hz, 3 H). WO 2010/011314 PCT/US2009/004261 -63- 13C-NMR spectroscopy (100 MHz, CD2CI2) δ 153.4,142.5, 141.0,140.1, 131,8, 129.3, 128.9, 127.8, 125.3,121.5, 116.3, 83.9, 53.2, 51.0, 36.6, 31.3, 24.3, 15.4.

Step 4. (6S)-3-((S)-1 -(4-bromophenyl)ethyl)-6-((2-methyloxiran-2-yl)methyl)-6-phenyl- 5 1,3-oxazinan-2-one

To a 1.0 L 2-neck RBF was charged (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one (135.8 g, 59 wt%, 3.1:1 dr, 193 mmol, 1.00 equiv), dichloromethane (700 mL), and then 3-chloroperbenzoic acid (m-CPBA, 70%, 95.3 g, 386 mmol, 2.0 equiv). The resulting solution was agitated at rt (Tjnt=20-25 °C) 10 for 1 h, which HPLC analysis indicates &gt;99 A% (220 nm) conversion. The resulting solution was diluted with 700 mL of methyl iert-butyl ether (MTBE) and washed with 1x500 mL of 30 wt% solution of sodium thiosulfate and 1x500 mL of saturated aqueous solution of sodium bicarbonate. The wash sequence was repeated until the peak on an HPLC trace of the organic solution that corresponds to a HPLC sample 15 peak of m-CPBA is &lt;2.5 A% (220 nm), which in this example the wash sequence was repeated 3 times. The resulting organic layer was dried with anhydrous sodium sulfate, filtered and then concentrated to an oil via reduced pressure. The resulting material was diluted with 200 mL of anhydrous tetrahydrofuran and then concentrated to a thick oil via reduced pressure to provide (6S)-3-((S)-1-(4-bromophenyl)ethyl)-6- 20 ((2-methyloxiran-2-yl)methyl)-6-phenyl-1,3-oxazinan-2-one which was used directly in Step 5.

Step 5. (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl- 1,3-oxazinan-2-one 25 To a 2.0 L 3-neck oven-dried RBF was charged the crude (6S)-3-((S)-1 -(4- bromophenyl)ethyl)-6-((2-methyloxiran-2-yl)methyl)-6-phenyl-1,3-oxazinan-2-one and 750 mL of anhydrous THF. The resulting solution was agitated and cooled to Tint= 2-3 °C. To the agitated clear solution was charged 1.0 M lithium triethylborohydride in tetrahydrofuran (Super Hydride, 348 mL, 348 mmol; 1.8 equiv). The addition is 30 exothermic and addition was controlled to maintain Tjnt= &lt; 8 °C. The resulting solution was agitated at Tim= 2-3 °C for 1.5 h and then allowed to warm to Ttnt= 10-13 °C over a 2.5 h, which HPLC analysis indicates -*94 A% (220 nm) conversion. To the agitated solution was charged a solution of hydrogen peroxide (95.7 mL of a 35 wt% aqueous WO 2010/013314 PCT/US2009/004261 -64- solution diluted with 400 mL of water, 1.08 mol, 5.60 equiv). The addition is highly exothermic and addition was controlled to maintain T|nt= &lt; 25 °C. The resulting solution was diluted with 1.00 L of methyl tert-butyl ether (MTBE) and washed with 1.00 L of water followed by 500 mL of a -30 wt% solution of sodium thiosulfate. The 5 organic solution was dried with anhydrous sodium sulfate, filtered, and then concentrated via reduced pressure. The resulting material was subjected to flash silica chromatography (10-60% ethyl acetate, 600 g of silica) to produce 68 g of material consisting of both diastereomers (1.98:1 dr) and 41 g of the desired diastereomer, (&gt;99:1 dr). The material consisting of the mixed fractions was to recrystallized from 250 mL of isopropyl acetate (IPAC) and 200 mL of heptane (antisolvent) to produce upon filtration 31.3 g of product (95.7 A% at 220 nm, 74:1 dr).

The two samples were combined to produce 72.3 g of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (83.6 % yield for the two step operation). 1H-NMR spectroscopy (400 MHz, CDCI3) δ 7.37- 15 7.29 (m, 5H), 7.25-7.21 (m, 2H), 6.82-6.79 (m, 2H), 5.61 (q, J= 6.9 Hz, 1H), 2.83 (ddd, 7= 2.5, 5.4 and 11.6 Hz, 1H), 2.39 (ddd, J= 5.7,12.0 and 14.1 Hz, 1H), 2.27 (ddd, J= 2.6,4.8 and 14.0 Hz, 1H), 2.21-2.14 (m, 3H), 2.08 (s, 1H), 1.49 (d, 7= 7.0 Hz, 3H), 1.18 (s, 3H), 1.13 (s, 3H). 13C-NMR spectroscopy (100 MHz, CDCI3) δ 153.2, 142.6, 138.5, 131.6, 129.13, 129.10, 128.0, 125.3, 121.6, 84.2, 71.4, 54.1, 53.3, 36.4, 33.6, 20 32.1, 30.8, 15.6. PREPARATION 2 (S)-6-(2-hydroxy-2-methylpropyl)- 6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-an-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000263.tif" id="idf0063" />

To a solution of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (6.6 g, 15,2 mmol) and 4,4,4^,5,5,5^5-octamethyl- 2,2-bi(1,3,2- dioxaborolane) (6.1g, 24.3 mmol) in dry DMSO (20 mL) was WO 2010/011314 PCT/US2009/004261 -65- added KOAc (4.8 g, 48.6 mmol) and Pd(dppf)cl2 (372 mg, 0.46 mmol). After addition, the mixture was allowed to warm to 100 °C for 20 h. After TLC showed the starting material had disappeared, the solid was filtered off. Water (60 mL) and EtOAc (20mL) were added. The layers were separated and the aqueous layer was extracted with 5 EtOAc (3*15 mL). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to give a residue, which was purified by column chromatography to give (S)-6-(2-hydroxy-2-methylpropyl)- 6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-an-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (4.4 g, 60%). 10 (S)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one was prepared from (S)-3-((S)- 1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropy 1)-6-(4-fluorophenyl)-1,3-oxazinan-2-one following an analogous procedure. (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4l5,5-tetramethyl- 15 1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1,3-oxazinan-2-one was prepared from (S)-3- ((S)-1-(4-bromophenyl)propyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one following an analogous procedure. (R)-6-Methoxy methyl-6-p he nyl-3-{(S)-1 -(4-(4,4,5,5-tetram ethyl-11, 3,2]dioxaborolan-2-yl)-phenyl]-ethyl}-[1,3]oxazinan-2-one was prepared from 3-[1- 20 (4-bromo-phenyl)-ethyl]-6-methoxymethyl-6-phenyl-[1,3]oxazinan-2-one following an analogous procedure. PREPARATION 3 25 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2,2- dimethylpropanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD000264.tif" id="idf0064" />

-66- WO 2010/011314 PCT/US2009/004261

Preparation of Cobalt(II) Complex A 50 mL flask was charged with N,N-bis(3,5-di-tert-butylsalicylidene)-1,1,2,2-tetramethylethenediamine (0.430 g, 0.78 mmol, 1.0 equiv), EtOH (17 mL), and Co(OAc)2 (0.139 g, 0.78 mmol, 1.0 equiv). The mixture was degassed and then 5 heated to reflux under nitrogen for 3 h, cooled to room temperature. The precipitate was filtered and the purple solid was washed with EtOH (10 mL) and dried under high vacuum to give 0.353 g (75%) of the cobalt(ll) complex. A mixture of (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one (490 mg, 1.18 mmol), the cobalt(ll) complex whose preparation is 10 described immediately above (8 mg, 0.01 equiv), TsCN (257 mg, 1.2 equiv), and PhSiH3 (137 mg, 157 pL, 1.07 equiv) in ethanol (10 mL) was stirred 4 h at rt. After removing the solvent under reduced pressure, the residue was purified by chromatography on a 40g silica gel column, eluted with a 25-80% EtOAc in hexanes gradient to afford 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan- 15 6-yl)-2,2-dimethylpropanenitrile (267 mg, 51% yield). LC-MS (3min. method) tR = 1.89min., m/z 441,443 (M+1) PREPARATION 4 2,2-dimethyl-3-((R)-2-oxo-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-20 dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-6-yl)propanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD000265.tif" id="idf0065" />

<img img-format="tif" img-content="drawing" file="IL210452AD000266.tif" id="idf0066" />

<img img-format="tif" img-content="drawing" file="IL210452AD000267.tif" id="idf0067" />

Pd(dppf)CI2, KOAc, DMSO 90 °C

<img img-format="tif" img-content="drawing" file="IL210452AD000268.tif" id="idf0068" />

‘CN 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2t2-dimethylpropanenitrile (467 mg, 1.06 mmol), 4,4,4',4',5,5,5',5,-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (538mg, 2equiv), KOAc (333mg, 3.2 equiv), PdCI2(dppf)CH2Cl2 (27 25 mg, 0.033 equiv) were mixed with dry DMSO (6 mL). The mixture was degassed and refilled with N2 gas 3 times. The mixture was then heated overnight at 90 °C under protection of N2 gas. After being cooled to rt, the mixture was diluted with EtOAc (30 mL), washed with water (20 mL). The aqueous layer was extracted with EtOAc (2 x 15 mL). The combined organic layers were washed by water (15 mL), brine (2x10 WO 2010/011314 PCT/US2009/004261 -67- mL) and dried over Na2SO4. After filtration and concentration, the residue was purified chromatography on a 40g silica gel column, eluted with a 20-50% EtOAc in

Hexanes gradient, to afford 2,2-dimethyl-3-((R)-2-oxo-6-phenyl-3-((S)-1-(4-(4,4,5,5- tetramethyM ,3,2-dioxaborolan-2-yl)phenyt)ethyl)-1,3-oxazinan-6-yl)propanenitrile 5 (393 mg, 76% yield). PREPARATION 5 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)-2- methylpropanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD000269.tif" id="idf0069" />

Step 1. 1-chloro-3-(4-fluorophenyl)hex-5-en-3-ol A 250-mL flask was charged with anhydrous CeCb (5.58 g, 22.6 mmol) and 15 THF (40 mL). The mixture was vigorously stirred for 3.5 h at rt. The suspension was then cooled to -78 °C and a solution of allylmagnesium bromide (1.0 M in THF, 21 mL, 21.0 mmol) was added. After stirring for 2 h at -78 °C, a solution of 3-chloro-1-(4-fluorophenyl)propan-1-one (2.522 g, 13.5 mmol) in THF (30 mL) was added via cannula. The reaction mixture was allowed to slowly warm to 8 °C while stirring WO 2010/011314 PCT/US2009/004261 -68- ovemight (18 h). The reaction was then quenched with said aq NaHCO3, extracted with EtOAc, and dried over Na2SO4. After the solvents were evaporated, the residue was purified by chromatography on silica gel eluted with hexanes/EtOAc to afford of 1-chloro-3-(4-fluorophenyl)hex-5-en-3-ol (3.0049 g, 97%) as an oil. LC-MS Method 1 5 M = 1.79 min, 213, 211 (M-OH)+; 1H NMR (400 MHz, CDCb) δ 7.37-7.32 (m, 2H), 7.07-7.02 (m, 2H), 5.57-5.47 (m, 1H), 5.20-5.19 (m, 1H), 5.16 (m, 1H), 3.59-3.52 (m, 1H), 3.24-3.18 (m, 1H), 2.70 (dd, J = 13.8, 5.9 Hz, 1H), 2.50 (dd, J = 13.8, 8.5 Hz, 1H), 2.29 (t, J = 7.9 Hz, 2H), 2.22 (s, 1H); 19F NMR (376 MHz, CDCI3) δ -116.52 (m). 10 Step 2. (/?)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one and (S)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one. A mixture of 1-chloro-3-(4-fluorophenyl)hex-5-en-3-ol (0.4129 g, 1.8 mmol, 1.0 equiv), &lt;S)-(-)-1-(4-bromophenyl)ethyl isocyanate (0.5005 g, 2.2 mmol, 1.2 equiv), and 15 DBU (0.7375 g, 4.8 mmol, 2.7 equiv) in THF (10 mL) was heated to reflux for 25 h. The mixture was diluted with EtOAc and washed with 1 N aq HCI. The aqueous phase was extracted with EtOAc (2 x). The combined organic phase was dried over Na2SO4. After the solvents were evaporated, the crude product was directly used in the next step without further purification. 20 An analytical sample was purified by chromatography on silica gel eluted with hexanes/EtOAc to afford the two diastereomers of 6-allyl-3-(($)-1-(4-bromo-phenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one.

Isomer 1: (S)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one. LC-MS Method 1 fo = 2.03 min, m/2 420, 418 (MH+); 1H NMR (400 25 MHz, CDCb) δ 7.46 (d, J = 8.2 Hz, 2H), 7.31-7.28 (m, 2H), 7.17 (d, J = 8.2 Hz, 2H), 7.07 (t, J = 8.5 Hz, 2H), 5.76-5.66 (m, 2H), 5.10-4.99 (m, 2H), 2.75-2.52 (m, 4H), 2.23-2.19 (m, 1H), 2.08-2.00 (m, 1H), 1.24 (d, J = 7.0 Hz, 3H); 10F NMR (376 MHz, CDCb) δ-115.07 (m).

Isomer 2: (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-

30 oxazinan-2-one. LC-MS Method 1 fo = 1.98 min, m/7 420, 418 (MH+); 1H NMR (400 MHz, CDCb) δ 7.25-7.20 (m, 4H), 7.05-7.01 (m, 2H), 6.71 (d, J = 8.5 Hz, 2H), 5.74-5.64 (m, 1H), 5.58 (q, J - 7.0 Hz, 1H), 5.09-4.99 (m, 2H), 2.92-2.87 (m, 1H), 2.63-2.5C WO 2010/011314 PCT/US2009/004261 -69- (m, 2H), 2.33-2.16 (m, 3H), 1.47 (d, J = 7.0 Hz, 3H); 19F NMR (376 MHz, CDCI3) δ -114.91 (m).

Step 3 A mixture of (/?)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one (1,067 g, 2.55 mmol, 1.0 equiv), the cobalt(ll) catalyst described in Preparation 3 (0.016 g, 0.0264 mmol, 0.010 equiv), TsCN (0.555 g, 3.06 mmol, 1.2 equiv), and PhSiH3 (0.294 g, 2.72 mmol, 1.07 equiv) in EtOH (5 mL) was stirred at room temperature for 4 h. After the solvent was removed under reduced pressure, the residue was purified by chromatography on silica gel eluted with hexanes/ethyl acetate to afford 1.0130 g (89%) of 3-((/?)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)-2-methylpropanenitrile as a solid. LC-MS fa = 1.83, 1.86 min in 3 min chromatography, m/z 445, 447 (MH+); 1H NMR (400 MHz, CDCI3) δ 7.32-7.22 (m, 4H), 7.13-7.05 (m, 2H), 6.80-6.73 (m, 2H), 5.60-5.56 (m, 1H), 3.00-1.94 (m, 7H), 1.51-1.49 (m, 3H), 1.35-1.32 (m, 1.5H), 1.27-1.24 (m, 1.5H); 19F NMR (376 MHz, CDCh) δ -113.08 (m), -113.69(m).

Step 4

To a solution of 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-2-oxo 1,3-oxazinan-6-yl)-2-methylpropanenitrile (0.332 g, 0.746 mmol) and Mel (1.40 g, 13 equiv) in THF (12 mL) at -78 °C was added 2.4 mL (2.4 mmol, 3.2 equiv) of a 1.0 M □HMDS solution in THF. The resulting mixture was stirred overnight, with the temperature slowly rising to ambient. The reaction mixture was quenched with brine (1 mL), diluted with CH2CI2, and dried over NaiSCU. After the solvents were evaporated, the residue was purified by reversed-phase HPLC (SunFire™ Prep Ci8 OBD™ 5pm 19 x 50 mm column, 10% -&gt;90% CH3CN/H2O, 0.1% CF3COOH over 8 min and then 90% CH3CN/H2O, 0.1% CF3COOH over 2 min, flow rate 20 mL/min) to afford 0.255 g (74%) of 3-((/7)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile. LC-MS Method 1 fa = 1.89 min, m/z459, 461 (MH+); 1H NMR (400 MHz, CD3OD) δ 7.31-7.27 (m, 2H), 7.22-7.18 (m, 2H), 7.04-6.99 (m, 2H), 6.83 (d, J = 8.2 Hz, 2H), 5.41 (q, J = 7.0 Hz, 1H), 3.02-2.97 WO 2010/011314 PCT/US2009/004261 -70- (m, 1H), 2.42-2.36 (m, 1H), 2.29-2.08 (m, 4H), 1.42 (d, J = 7.0 Hz, 3H), 1.30 (s, 3H), 1.22 (s, 3H); 19F NMR (376 MHz, CD3OD) δ -116.50 (m).

Method 2

<img img-format="tif" img-content="drawing" file="IL210452AD000270.tif" id="idf0070" />

Step 1 A solution of 3-chloro-1-(4-fluorophenyl)-propan-1-one (18.6 g, 0.1 mol) in THF (50 mL) was added to a well-stirred suspension of zinc power (13 g, 0.2 mol) in a mixture of aqueous saturated NH4CI solution (260 mL) and THF (65 mL). A solution 10 of 3-iodo-2-methylprop-1-ene (36.4 g, 0.2 mol) in THF (50 mL) was added dropwise. The reaction mixture was mildly exothermic, and began to reflux spontaneously. After the refluxing had ceased, the mixture was stirred for 1 h. TLC showed the 3-chloro-1-(4-fluorophenyl)propan-1-one not reacted completely. A solution of 3-iodo-2-methylprop-1-ene (18.2 g, 0.1 mol) in THF (30 mL) was added, and the mixture was 15 stirred at rt overnight. The mixture was extracted with EtOAc (2 x 500 mL). The combined organic layer was dried and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/ EtOAc 50:1-*30:1-&gt;5:1, to give 1-chloro-3-(4-fluorophenyl)-5-methylhex-5-en-3-ol (17 g, yield 76 %) as an oil. 20

Step 2 A mixture of 1-chloro-3-(4-fluorophenyl)-5-methylhex-5-en-3-ol (3.15 g, 13 mmol), (S)-(-)-1-(- bromophenyl)ethyl isocyanate (3.5 g, 16 mmol), and DBU (8 g, 33 mmol) in THF (80 mL) was heated to reflux for 25 h. The mixture was diluted with 25 EtOAc and washed with 1 AZ aq HCI. The aqueous phase was extracted with EtOAc (3 x). The combined organic phase was dried over Na2SO4. After the solvents were WO 2010/011314 PCT/US2009/004261 -71 - evaporated, the crude product was purified by column to give (R)-3-((S)-1 -(4- bromophenyl)-ethyl)-6-(4-fluorophenyl)-6-(2-methylallyl)-1,3-oxazinan-2-one (2.13 g, yield: 38 %).

Step 3 5 A mixture of (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-6-(2- methylallyl)-1,3-oxazinan-2-one (2.13 g, 4.9 mmol), the cobalt(ll) catalyst described in Preparation 3 (0.032 g, 0.053 mmol), TsCN (1.11 g, 6.12 mmol), and PhSiH3 (0.6 g, 5.54 mmol) in EtOH (10 mL) was stirred at room temperature for 8 h. After the solvent was removed under reduced pressure, the residue was purified by column 10 chromatography to give 3-((R)-3-((S)-1-(4-bromophenyl)ethy1)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile (1.84 g, 81.1%). 15 PREPARATION 6 3-((R)-6-(4-fluorophenyl)-2-oxo-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl)-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD000271.tif" id="idf0071" />

To a solution of 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4~fluorophenyl)-2-oxo- 1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile (730 mg, 1.59 mmol) in DMSO (8 mL) 20 was added bis(pinacolato)diboron (480 mg, 1.89 mmol), KOAc (480 mg, 4.89 mmol) and Pd(dppf)Cl2 (45 mg, 0.042 mmol) under nitrogen atmosphere. The formed mixture was stirred at 90 °C for 20 h. The reaction was quenched with water and extracted with EtOAc. The combined organic phase was dried over anhydrous Na2SO&lt; and concentrated to give the crude product, which was purified by column 25 chromatography to give 3-((R)-6-(4-fluorophenyl)-2-oxo-3-((S)-1’(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile (191 mg, 23.7%). WO 2010/011314 PCT/US2009/004261 -72- PREPARATION 7 (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-

<img img-format="tif" img-content="drawing" file="IL210452AD000272.tif" id="idf0072" />

10 15 A mixture of (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one (0.4910 g, 1.17 mmol, 1.0 equiv), bis(pinacolato)diboron (0.3925 g, 1.55 mmol, 1.3 equiv), KOAc (0.3696 g, 3.76 mmol, 3.2 equiv), and

PdCI2(dppf)CH2CI2 (0.0316 g, 0.0386 mmol, 0.033 equiv) in DMSO (6 mL) was heated at 90 °C under N2 for 20 h. After cooling, the reaction mixture was partitioned between EtOAc and water. The organic phase was washed with brine, and dried over Na2SO4. After the solvents were evaporated, the residue was purified by chromatography on silica gel eluted with hexanes/ethyl acetate to give 0.4776 g (87%) of (fl)-6-allyl-6-(4-fluorophenyl)-3-((S)-1 -(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one as a white solid. PREPARATION 8 (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(3-hydroxypropyI)-6-pheny 1-1,3- oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000273.tif" id="idf0073" />

20

To a solution of (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-phenyl-1,3-oxazinan- 2-one (5 g, 12.5 mmol) in tetrahydrofuran (60 mL) was added BH3THF (25 mL, I mol/L, 25 mmol) at 0 °C under nitrogen atmosphere. The formed mixture was stirred for 2 h. The reaction was quenched with water. Then NaOH (3 mol/L, 10 mL) and H2O2 (15 mL) were added to the above mixture. When the reaction was over, the mixture was extracted with EtOAc. The combined organic phase was concentrated to give the crude product, which was purified by column chromatography to give (R)-3-((S)-1-(4-bromophenyl)ethy!)-6-(3-hydroxypropyl)-6-pheny 1-1,3- oxazinan-2-one (2.5 25 WO 2010/011314 PCT/US2009/004261 -73 - g, 40%). 1H NMR: (400MHz, CDCI3): 5=1.48 (t, 3H), 1.53 (m, 1H), 1.73 (m, 1H), 1.93-1.98(m, 2H), 2.17-2.28 (m,3H), 3.57 (t, 2H), 5.59 (m, 1H), 6.72 (m, 2H), 7.20(m, 2H), 7.25-7.37 (m, 5H). (R)-3-((S)-1-(4-bromophenyt)ethyl)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-5 oxazinan-2-one was prepared from (R)-6-allyl-3-((S)-1 -(4-bromophenyl)ethyl)-6-(4- fluoropheny))-1,3-oxazinan-2-one following an analogous procedure. (R)-3-((S)-1-(4-bromophenyl)propyl)-6-(3-hydroxypropyl)-6-phenyl-1,3- oxazinan-2-one was prepared from (R)-6-allyl-3-((S)-1-(4-bromophenyl)propyl)-6-pbenyl-1,3-oxazinan-2-one following an analogous procedure. 0 PREPARATION 9 (R)-6-(3-h ydroxypropyl)-6-phenyl-3-(( S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000274.tif" id="idf0074" />

15 To a solution of ((/7)-3-(( S)-1-(4-bromophenyl)ethyl)-6-(3-hydroxypropyl)-6- phenyl-1,3-oxazinan-2-one (2 g, 4.8 mmol) in DMSO (30 mL) were added bis(pinacolato)dlboron (1.58 g, 6.3 mmol), KOAc (1.51 g, 15.4 mmol) and PdCl2 (130 mg, 0.16 mmol) under nitrogen atmosphere. The formed mixture was stirred at 90 °C for 20 h. The reaction was quenched with water and extracted with EtOAc. The 20 combined organic phase was concentrated to give the crude product, which was purified by column chromatography to give(/?)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(4i4(5i5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (1.7 g, 77%). 1H NMR: (400MHz, CDCI3): 5=1.18 (t, 1H), 1.33 (S, 11 H&gt;, 1.43 (m, 2H), 1.48 (m, 3H), 1.71(m, 1H), 1.88 (m,2H), 2.1-2.3 (t, 3H), 2.7(m, 1H) , 3.5 (m, 2H), 5.5 (m, 25 1H),6.72 (m, 2H), 7.25-7.37 (m, 5H),7.48(m, 2H). (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one was prepared from (R)-3- WO 2010/011314 PCT/US2009/004261 -74- ((S)-144-bromophenyl)ethyl)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2- one following an analogous procedure. (R)-6-(3-hydroxypropyf)-5-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2-yl)phenyl)propyl)-1,3-oxazinan-2-one was prepared from (R)-3-((S)-1- 5 (4-bromophenyl)propyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one following an analogous procedure. (R)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(4,4,5l5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1,3-oxazinan-2-one was prepared from (R)-3-((S)-1-(4-bromophenyl)propyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one following an 10 analogous procedure. PREPARATION 10 (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(methoxymethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000275.tif" id="idf0075" />

15 Step 1. 1-Methoxy-2-phenyl-pent-4-en-2-ol 2-Methoxy-1-phenyl-ethanone (5.00 g) dissolved in tetrahydrofuran (50 mL) was added to 2 M allylmagnesium chloride in tetrahydrofuran (21 mL) at room temperature. The solution was stirred at room temperature for 3 h and then 10 % aqueous NH4CI solution (50 mL) was added. The resulting mixture was extracted with 20 tert-butyl methyl ether (3x 50 mL) and the combined extracts were washed with water (50 mL) and brine (50 mL). The solvent was evaporated to afford the title compound as a colorless oil.

Yield: 6.40 g (quantitative). Mass spectrum (ESI+): m/z = 175 [M+H-H2Of 25 Step 2. 5-Methoxy-4-phenyl-pentane-1,2,4-triol OSO4 (4% in water, 2 mL; alternatively, K2OSO4 may be used) followed by N- methyl-morpholine-N-oxide (5.20 g) was added to a solution of 1-methoxy-2-phenyl- WO 2010/011314 PCT/US2009/004261 -75- pent-4-en-2-ol (1.10 g) in tetrahydrofuran (10 mL) chilled in an ice bath. The cooling bath was removed and the solution was stirred at room temperature overnight. Then, 10% aqueous Na2S2O5 solution (10 mL) was added and the resulting mixture was stirred at room temperature for another 1.5 h. After removal of the organic solvent under reduced pressure, the remaining mixture was extracted with ethyl acetate. The combined extracts were washed with brine and dried (MgSO4). The solvent was evaporated to afford the title compound in good purity (ca. 95%). Yield: 1.20 g (96% of theory). Mass spectrum (ESI-): m/z = 225 [M-H]‘

Step 3. 3-Hydroxy-4-methoxy-3-phenyl-butyraldehyde

NalO4 (5.20 g) was added to a mixture of 5-methoxy-4-phenyl-pentane-1,2,4- triol (1.10 g), dichloromethane (10 mL), and water (5 mL) chilled in an ice bath. The mixture was stirred vigorously while warming to ambient temperature in the cooling bath and further stirred at this temperature overnight. Then, water (20 mL) and dichloromethane (50 mL) were added, the organic layer was separated, and the aqueous layer was extracted with dichloromethane (2x 25 mL). The combined organic phases were washed with water and dried (MgSO4). After removal of the solvent, the title compound was yielded which was directly submitted to the next reaction step (glycol cleavage).

Yield: 0.94 g (quantitative)

Step 4. 4-[(S)-1 -(4-Bromo-phenyl)-ethylamino]-1 -methoxy-2-phenyl-butan-2-ol (S)-1-(4-Bromo-phenyl)-ethylamine (0.93 g), NaB(OAc)3 (0.98 g), and acetic acid (0.27 mL) were added in the given order to a solution of 3-hydroxy-4-methoxy-3-phenyl-butyraldehyde (0.90 g) in tetrahydrofuran (20 mL) at ca. 10-15 °C. The cooling bath was removed and the mixture was stirred at room temperature for 2 h. Then, water (50 mL) and 1 M aqueous NaOH solution (20 mL) were added and the resulting mixture was stirred for another 30 min. The mixture was extracted with ethyl acetate and the combined extracts were washed with water and brine. After drying (MgSO4), the solvent was removed to give the title compound which was submitted to the subsequent reaction step without further purification. Yield: 1,80 g (quantitative).

Mass spectrum (ESI+): m/z = 378/380 (Br) [M+Hf WO 2010/011314 PCT/US2009/004261 -76-

Step 5. 3-[(S)-1-(4-Bromo-phenyl)-ethyl]-(R)-6-methoxymethyl-6-phenyl- [1.3] oxazinan-2-one and 3-[(S)-1-(4-Bromo-phenyl)-ethyl]-(S)-6-methoxymethyl-6-phenyl-[1,3]oxazinan-2-one

Triphosgene (157 mg) was added to an ice-cold solution of 4-[(S)-1-(4-bromo- 5 phenyl)-ethylamino]-1-methoxy-2-phenyl-butan-2-ol (1:1 diastereomeric mixture, 200 mg) and EtN/Pr2 (91 pL) in dichloromethane (5 mL). The resulting solution was stirred with cooling for 2 h and at room temperature overnight. Then, the solution was concentrated under reduced pressure and the residue was purified by HPLC on reversed phase (MeCN/H2O/NH3) to afford the title compounds in separate fractions. 10 Isomer 1: 3-[(S)-1-(4-Bromo-phenyl)-ethyl]-(R)-6-methoxymethyl-6-phenyl- [1.3] oxazinan-2-one. Yield: 45 mg (21% of theory). Mass spectrum (ESI*): m/z = 404 [M+HJ* 1H NMR (400 MHz, DMSO-cfe) δ 1.41 (d, J= 7.1 Hz, 3H), 2.19 (td, J = 11.2, 5,2 Hz, 1H), 2.24-2.34 (m, 1H), 2.34-2.41 (m, 1H), 3.02-3.09 (m, 1H), 3.27 (s, 3H), 3.49 (d, B part of an AB signal, J = 10.6 Hz, 1H), 3.53 (d, A part of an AB signal, J = 15 10.6 Hz, 1H), 5.34 (q, J = 7.0 Hz, 1H), 6.80 (dm, J = 8.4 Hz, 2H), 7.27 (dm, J = 8.4

Hz, 2H), 7.32-7.42 (m,5H).

Isomer 2: 3-[(S)-1-(4-Bromo-phenyl)-ethyl]-(S)-6-methoxymethyl-6-phenyl- [1,3]oxazinan-2-one. Yield: 45 mg (21% of theory). Mass spectrum (ESI*): m/z = 404 [M+H]* 1H NMR (400 MHz, DMSO-d6) δ 1.20 (d, J = 7.2 Hz, 3H), 2.13-2.23 (m, 1H), 20 2.32-2.40 (m, 1H), 2.63-2.72 (m, 1H), 2.73-2.81 (m, 1H), 3.26 (s, 3H), 3.48 (d, B part of an AB signal, J = 10.6 Hz, 1H), 3.55 (d, Apart of an AB signal, J = 10.6 Hz, 1H), 5.35 (q, J = 7.2 Hz, 1H), 7.19 (dm, J = 8.4 Hz, 2H), 7.32-7.45 (m, 5H), 7.53 (dm, J = 8.4 Hz, 2H). 25 PREPARATION 11 N-(3-«R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propyl)-N- methylacetamide ΌΗ

Br

<img img-format="tif" img-content="drawing" file="IL210452AD000276.tif" id="idf0076" />

Br WO 2010/011314 PCT/US20O9/004261 -77-

Step 1

To a solution of (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one (200 mg, 0.48 mmol) in CHsCfefS mL) was added EtsN (240 mg, 2.4 mmol) and methanesulfonyl chloride (164 mg, 1.4 mmol) at 0 °C. The 5 reaction solution was stirred at rt for 1 h. The reaction was quenched with H2O and the mixture was extracted with CH2CI2. The organic phase was concentrated to give 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propyl methanesulfonate (234 mg, 98%), which was used for the next step without further purification. 10

Step 2

To a solution of 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propyl methanesulfonate (234 mg, 0.24 mmol) in CH2CI2 (3 mL) was added NaH (82 mg, 3,4 mmol) at 0 °C. The mixture was stirred at rt for 30 min. Then 15 /V-methylacetamide (204 mg, 2.8 mmol) was added the above mixture. The formed mixture was stirred at 80 °C for 5 h. After the reaction was over, the reaction was quenched with water and the mixture was extracted with EtOAc. The combined organic phase was concentrated to give the crude product, which was purified by preparative TLC to give /V-(3-((fl)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3- 20 oxazinan-6-yl)propyl)-N-methylacetamide (150 mg, 68%). LC-MS Method 2 tR = 1.50 min, m/z = 497, 495, 475, 473. 1H NMR (400MHz, CDCI3): 6=1.41 (m, 1H), 1.48 (t, 3H), 1.73 (m, 1H), 1.83-1.95 (m, 2H), 2.01 (m, 3H), 2.1-2.3 (m, 3H), 2.71 (m, 1H), 2.81 (s, 3H), 3.1 (m, 1H), 3.2 (m, 1H), 5.5 (m, 1H), 6.72 (m, 2H), 7.10 (m, 2H), 7.20 (m, 2H), 7.37 (m, 3H). 25 (R)-3-((S)-1 -(4-bromophenyl)ethyl)-6-(3-(2-oxopyrrolidin-1 -yf)propyl)-6-phenyl- 1,3-oxazinan-2-one was prepared from (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-{3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one following an analogous procedure using pyrrol id in-2-one in Step 2. WO 2010/011314 PCT/US2009/004261 -78- PREPARATION 12 (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-(1,-dioxo-isothiazolidin-2-yl)ethyl)-6-phenyl- 1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000277.tif" id="idf0077" />

<img img-format="tif" img-content="drawing" file="IL210452AD000278.tif" id="idf0078" />

<img img-format="tif" img-content="drawing" file="IL210452AD000279.tif" id="idf0079" />

5 To a solution of (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-phenyl-1,3- oxazinan-2- one (3 g, 7.5 mmol) in CH2CI2 (50 mL) was treated with O3 at -78 °C till the mixture turned blue. Then NaBH4 (285 mg( 75 mmol) was added to the solution at 0 °C, and the reaction solution was stirred at room temperature for 3 hours. The reaction was quenched by HsO, and the mixture was extracted with EtOAc. The 10 combined organic phase was concentrated to give the crude product, which was purified by preparative TLC to give (S)-3-((S)-1-(4-bromo- phenyl)ethyl)-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one (2.5 g, 84%). 1H NMR (CDCI3): 1.48 (t, 3K), 2.05-2.41 (m, 4H), 2.71-2.92 (m, 2H), 3.51 (m, 1H), 3.71 (m, 1H), 5.58 (m, 1H), 6.73 (d, 2H), 7.12 (m, 2K), 7.23-7.45 (m, 6H). 15 &lt;S)-3-((S)-1-(4-bromophenyl)propyl)-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan- 2-one was prepared from (R)-6-allyl-3-((S)-1-(4-bromophenyl)propyl)-6-phenyl-1,3-oxazinan-2-one following a procedure analogous to that described immediately above. PREPARATION 13 20 (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-(1,1-dioxo-isothiazolidin-2-yl)ethyl)-6-phenyl- 1,3-oxazinan-2-one □

<img img-format="tif" img-content="drawing" file="IL210452AD000280.tif" id="idf0080" />

OH

Br

1. MeSO2CI

<img img-format="tif" img-content="drawing" file="IL210452AD000281.tif" id="idf0081" />

<img img-format="tif" img-content="drawing" file="IL210452AD000282.tif" id="idf0082" />

Step 1

To a solution of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxyethyl)-6-phenyl-1,3- oxazinan-2-one (300 mg, 0.75 mmol) in dichloromethane (20 mL) were 25 WO 2010/011314 PCT/US2009/004261 -79- added Et3N (390 mg, 3.75 mmol) and methanesulfonyl chloride (256 mg, 2.25 mmol) at 0 °C. The reaction solution was stirred at rt for 1 h. The reaction was quenched with H2O and the mixture was extracted with dichloromethane. The organic phase was concentrated to give 2-((S)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3- 5 oxazinan-6-yl)ethyl-methane sulfonate (352.8 mg, 98%), which was used for the next step without further purification.

Step 2

To a solution of 2-((S)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3- 10 oxazinan- 6-yl)ethyl-methanesulfonate (360 mg, 0.75 mmol) and K2CO3 (207 mg, 1.5 mmol) in acetonitrile (10 mL) was added isothiazolidine 1,1-dioxide (121 mg, 4.6 mmol), and the mixture was refluxed overnight. The mixture was filtered and the filtrate was concentrated to give the crude product, which was purified by preparative HPLC to afford compound (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-(1,1-dioxo- 15 isothiazolidin-2-yl)ethyl)-6-phenyl-1,3-oxazinan-2-one (2.43 mg, 1%). LC-MS Method 2 tR = 1.37 min, m/z = 509, 507. Ή NMR (CDCI3): 1.48 (t, 3H), 2.05-2.41 (m, 7H), 2.71-2.92 (m, 2H), 3.11 (m, 3H), 3.21 (m. 2H), 5.58 (m, 1H), 6.73 (d, 2H), 7.18 (m, 1H), 7.23 (m, 3H);7.35 (m, 3H). (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(3-(1,1-dioxo-isothiazolidin-2-yl)propyl)-6- 20 phenyl-1,3-oxazinan-2-one was prepared from from from (R)-3-((S)-1-(4- bromophenyl)ethyl)-6-(3-hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one following an analogous procedure. WO 2010/011314 PCT/US2009/004261 -80- PREPARATION 14 (S)-3-((S)-1 -(4-bromophenyl)ethy l)-6-(4-fluorophenyl)-6-(( 1 - hydroxycyclopropyl)methyl)-1,3-oxazinan-2-one

F

<img img-format="tif" img-content="drawing" file="IL210452AD000283.tif" id="idf0083" />

Br THW’rO),

<img img-format="tif" img-content="drawing" file="IL210452AD000284.tif" id="idf0084" />

Br

OH 5 Step 1

To a solution of (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)- 1,3 -oxazinan-2-one (450 mg, 1.01 mmol) in acetone (10 mL) was added a solution of KMnO4 (190 mg, 1.2 mmol) and NalO4 (1.5 g, 7.2 mmol) in water (10 mL). The mixture was stirred for 2 h at 0 °C. The mixture was filtered and the filtrate was 10 adjusted to pH 5-6 with aqueous 1 N aq HCI solution. The mixture was extracted with EtOAc. The organic phase washed with brine, dried over anhydrous Na2SO4 and concentrated to give 2-((S)-3-((S)-1-(4-bromophen-yl)ethyl)-6- (4-fluorophenyl)-2-oxo- 1,3-oxazinan-6-yl)acetic acid (540 mg, crude), which was used for the next step without purification. 15

Step 2

To a solution of 2-({S)-3-((S)-1-(4-bromophen-yl)ethyl)-6- (4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)acetic acid (540 mg, 1.24 mol) in MeOH (20 mL) was added SOCb (5 mL) at 0 °C, and the reaction mixture was stirred at rt for 2 h. The reaction 20 mixture was concentrated and the residue was purified by preparative TLC to give methyl 2-((S)-6-(4-fluorophenyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)-ethyl)-2-oxo-1,3-oxazinan-6-yl)acetate (150 mg, 27%). 1H NMR (CDCI3): 5=1.49 (d, 3H),2.19(m, 1H), 2.44 (m, 1H), 2.60 (m, 1H), 2.77-3.08 (m, 3H), 3.51 (s, 3H), 5.52 (m, 2H), 6.62 (d, 2H), 6.98 (t, 2H), 7.23 (t, 2H), 7.28 (m, 2H). 25 WO 2010/011314 PCT/US2009/004261 -81 -

Step 3

To a solution of methyl 2-((S)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-6-oxo- 1,6-dihydropyridin-3-yl)phenyl)-ethyl)-2-oxo-1,3-oxazinan-6-yl)acetate (150 mg, 0.33 mmol), and tetraisopropoxytitanium (189 mg, 0.66 mmol) in THF (20 mL) was added 5 3.0 M ethylmagnesium bromide (4 mL, 12 mmol) at rt under nitrogen. Then the mixture was stirred for 2 h. The reaction was quenched with aqueous NH4CI solution, and the mixture was filtered. The filtrate was extracted with EtOAc. The combined organic phase was washed with brine, dried over anhydrous NajSCV and concentrated to give the crude product, which was purified by preparative HPLC to 1 o give (S)-3-((S)-1 -(4-bromophenyl)ethy l)-6-(4-fluorophenyl)-6-((1 - hydroxycyclopropyl)methyl)-1,3-oxazinan-2-one (2.51 mg, 2%). 1H NMR(CDCl3): 0.03 (m, 1H), 0.18 (m, 1H), 0.49 (m, 1H), 0.60 (m, 1H), 1.43 (m, 3H), 2.08 (s, 2H), 2.26 (m, 1H), 2.37 (m, 2H), 2.Θ8 (m, 1H), 5.53 (m, 1H), 6.66 (d, 2H),6.97(t, 2H), 7.16 (m, 2H), 7.26 (m, 2H). 15 PREPARATION 15 N-(3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propyl)-N- methylmethanesulfonamide

<img img-format="tif" img-content="drawing" file="IL210452AD000285.tif" id="idf0085" />

<img img-format="tif" img-content="drawing" file="IL210452AD000286.tif" id="idf0086" />

20 To a solution of 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3- oxazinan-6-yl) propyl methanesulfonate (180 mg, 0.36 mmol) in DMF (5 mL) was added NaH (14.6 mg, 0.36 mmol) at 0 °C. The mixture was stirred at rt for 30 min. Then iodomethane (153 mg, 1.1 mmol) was added to the above mixture. The formed mixture was stirred at 40 °C for 3 h. After the reaction was over, the reaction was 25 quenched with NH4CI solution and the mixture was extracted with EtOAc. The combined organic phase was concentrated to give the crude product, which was purified by preparative TLC to give /V-(3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6- WO 2010/011314 PCT/US2009/004261 -82- phenyl-1,3-oxazinan-6- yl)propyl)-/V-methylmethanesulfonamide (100 mg, 55%). LC-MS Method 2 tR = 1.41 min, m/z = 511, 509. 1H NMR (400MHz, CDCI3): δ=1.45 (m, 1H), 1.48 (t, 3H), 1.83-1.97 (m, 3H), 2.1-2.2 (m, 3H), 2.61 (s, 3K), 2.71 (s, 3H), 2.91 (m, 1H), 3.0 (m, 2H), 5.5 (m, 1H), 6.72 (m, 2H), 7.10 (m, 2H), 7.20 (m, 2H), 7.37 5 (m, 3H). EXAMPLE 1 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3- yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000287.tif" id="idf0087" />

<img img-format="tif" img-content="drawing" file="IL210452AD000288.tif" id="idf0088" />

To a solution of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (112 mg, 0.259 mmol) in 1,4-dioxane (3 mL) was added 6-oxo-1,6-dihydropyridin-3-ylboronic acid (55 mg, 0.40 mmol), followed by Pd(dppf)CI2 (11 mg, 0.015 mmol), and an aq solution of CS2CO3 (0.48 mL, 15 2M in H2O). A reflux condenser was attached and the apparatus was degassed and flushed with N2three times. The reaction was heated to 90 °C for 24 h. After cooling to rt the mixture was diluted with water and extracted three times with EtOAc. The organic layers were washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by prep HPLC to afford the title compounds (21.6 mg) as an 20 oil. LC-MS Method 1 t« = 1.25 min, m/z = 447, 389; 1H NMR (CD3OD) 0.96 (s, 3H), 1.28 (s, 3H), 1.57 (d, 3H), 2.16 (s, 2H), 2.21 (m, 1H), 2.46 (m, 2H), 3.03 (m, 1H), 5.57 (q, 1K), 6.66 (d, 1H), 7.02 (d, 2H), 7.25-7.40 (7H), 7.66 (s, 1H), 7.90 (d, 1H). WO 2010/011314 PCT/US2009/004261 -83- EXAMPLE2 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(2-oxo-1,2-dihydropyridin-4- yl)phenyl)ethyl)-6-phenyl-i,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000289.tif" id="idf0089" />

5 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)- 6- phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1I3,2-dioxaborol-an-2-yl)phenyl)ethyl)-1l3-oxazinan-2-one and 4-iodopyridin-2(1 H)-one following a procedure analogous to that described in Example t. LC-MS Method 1 tp = 1.23 min, m/z = 389, 447 (M+1); 1H NMR (CD3OD) 7.40 (d. J = 6.7 Hz, 1H), 7.31 (d, J = 8.2 Hz, 2H), 7.29-7.20 (m, 5H), 10 6.96 (d, J = 8.2 Hz, 2H), 6.57-6.52 (m, 2H), 5.49 (q, J = 7.0 Hz, 1H), 2.98-2.93 (m, 1H), 2.47-2.34 (m, 2H), 2.16-2.09 (m, 1H), 2.07 &lt;s, 2H), 1.45 (d, J = 7.0 Hz, 3H), 1.19 (s, 3H), 0.87 (s, 3H). EXAMPLE 3 15 (S)-3-((S)-1-(4-(1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2- hydroxy-2-methylpropyt)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000290.tif" id="idf0090" />

H tx*“B(OH)2, Cu(OAc)2, BiPy Na2CO3, air, dichloroethane, 70 °C 58%

<img img-format="tif" img-content="drawing" file="IL210452AD000291.tif" id="idf0091" />

<img img-format="tif" img-content="drawing" file="IL210452AD000292.tif" id="idf0092" />

OH WO 2010/011314 PCT/US2009/004261 -84-

Step 1. 5-bromo-1-cyclopropylpyridin-2(1H)-one A mixture of 5-bromo-2-hydroxypyrtdine (0.8300 g, 4.77 mmol, 1.0 equiv),

Cu(OAc)2 (0.902 g, 4.96 mmol, 1.04 equiv), bipyridine (0.785 g, 5.03 mmol, 1.05 equiv), cyclopropylboronic acid (0.846 g, 9.85 mmol, 2.06 equiv) and Na2CC&gt;3 (1.110 5 g, 10.47 mmol, 2.20 equiv) in dichloroethane (30 mL) was stirred at 70 °C for 22 h under air. The reaction mixture was quenched with satd aq NH4CI, diluted with CH2CI2, dried over Na2SO4. After the solvent was removed under reduced pressure, the residue was purified by chromatography on silica gel eluted with hexanes/EtOAc to afford 0.585 g (58%) of 5-bromo-1-cyclopropylpyridin-2(1H)-one. LC-MS Method 1 10 ft, = 1.05 min, mfi 214, 216 (ΜΗ*); 'H NMR (400 MHz, CDCb) δ 7.41 (d, J = 2.7 Hz, 1H), 7.31 (dd, J = 9.7, 2.9 Hz, 1H), 6.47 (d, .7= 9.9 Hz, 1H), 3.33-3.27 (m, 1H), 1.17-1.12 (m, 2H), 0.89-0.84 (m, 2H); 13C NMR (100 MHz, CDCI3) δ 162.58, 142.29, 137.00,121.77, 97.92, 32.83,6.93. 15 Step 2. (S)-3-((S)-1-(4-(1-cyclopropyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

To a solution of (S)-6-(2-hydroxy-2-methylpropyl)-6-pheny 1-3-(( S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (0.729 g, 1.52 mmol) in 1,4-dioxane (16 mL) were added 5-b romo-1-cycl op ropy Ipy rid in-2 (1/7)-one 20 (0.323 g, 1.51 mmol), 2 M aq Cs2CO3 (4 mL), and PdCI2(dppf)CH2CI2 (0.079 g, 0.0964 mmol). The mixture was degassed and heated, under a nitrogen atmosphere, at 120 °C for 16 h. The mixture was diluted with CH2CI2, dried over Na2SO4. After the solvents were evaporated, the residue was purified by chromatography on silica gel eluted with MeOH/CH2CI2 to afford 0.543 g (74%) of (S)-3-((S)-1-(4-(1-cyclopropyl-6- 25 oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one. LC-MS Method 1 tR = 1.41 min, η?Δ487 (MH+); 1H NMR (400 MHz, CD3OD) δ 7.66-7.64 (m, 2H), 7.30-7.19 (m, 7H), 6.94 (d, 8.2 Hz, 2H), 6.52 (d, J = 10 Hz, 1H), 5.48 (q, J = 7.0 Hz, 1H), 3.32-3.26 (m, 1H), 2.97-2.92 (m, 1H), 2.46-2.32 (m, 2H), 2.16-2.09 (m, 1H), 2.08 (s, 2H), 1.45 (d, 7 = 7.0 Hz, 3H), 1.19 (s, 3H), 1.10- 30 1.05 (m, 2H), 0.90-0.86 (m, 5H); 13C NMR (100 MHz, CD3OD) δ 165.59, 155.82, 144.08, 141.05, 139.60, 136.60, 136.30, 129.77, 128.86, 128.64, 126.83, 126.15, WO 2010/011314 PCT/US2009/004261 -85 - 121.93, 120.53, 85.33, 71.67, 55.18, 54.78, 37.46, 34.10, 33.04, 31.79, 30.00,15.60, 7.49, 7,47. EXAMPLE 4 5 (S)-3-((S)-1 -(4-(1 -(difluoromethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2- hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000293.tif" id="idf0093" />

A microwave vial equipped with a flea stirbar was charged with (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-(($)-1-(4-(4,4,5,5-tetramethyl-1,3,2»dioxaborolan- 10 2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (20 mg, 0.047 mmol), 5-bromo-1- (difluoromethyl)pyridin-2(1H)-one (25 mg, 0.113 mmol), Cs2CO3 (27 mg, 0.083 mmol), H2O (0.1 mL) and dry dioxane (1 mL). The mixture was sparged with N2 for 10 min and heated at 110 °C in the microwave for 0.5 h. The mixture was diluted with glacial HOAc (0.1 mL) and MeOH (0.5 mL) and filtered. The filtrate was directly purified by 15 prep HPLC to afford (S)-3-((S)-1-(4-(1-(difluoromethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (11.8 mg, 57%) as an oil. LC-MS Method 1 to = 1.55 min. m/z = 497, 248; 1H NMR (CDCI3) 1.13 (s, 3H). 1.19 (s, 3H), 1.56 (d, 3H). 2.15-2.35 (s, 4H). 2.42 (m, 2H), 2.88 (m, 1H), 5.71 (q, 1H). 6.64 (d, 1H). 7.04 (d, 2H), 7.18 (d, 2H), 7.30-7.40 (5H), 7.52 (1H), 7.60 (m, 20 1H),7.75(t, 1H). 5-bromo-1-(difluoromethyl)pyridin-2(1H)-one was prepared as described in Ando, M.; Wada, T.; Sato, N. Org. Lett. 2006, 8, 3805-3808. WO 2010/011314 PCT/US2009/004261 -86- EXAMPLE 5 (S)-3-((S)-1-(4-(1-(difluoromethyl)-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2- hydroxy-2-methy!propyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000294.tif" id="idf0094" />

Step 1 A stirred mixture of 2-chloro-4-iodopyridine (1.33 g, 5.6 mmol) and powdered NaHCO3 (935 mg, 11.2 mmol) in MeCN (2 mL) was warmed to 40 °C in an oil bath and a solution of 2,2-difluoro-2-(fluorosulfonyl)acetic acid (0.57 mL, 5.6 mmol) in 10 MeCN (10 mL) was added dropwise over 10 min. The mixture was stirred at 40 °C for 2 h. LC-MS showed partial conversion to desired product. Powdered NaHCO3 (935 mg, 11.2 mmol) was added followed by a solution of 2,2-difluoro-2- (fluorosulfonyl)acetic acid (0.57 mL, 5.6 mmol) in MeCN (10 mL) dropwise over 10 min. The mixture was stirred at 40 °C for 2 h. The mixture was diluted with satd aq 15 NaHCO3 (25 mL) and concentrated under reduced pressure. The aqueous residue was extracted with EtOAc (90 mL). The organic extract was washed with brine (20 mL), dried over Na2SO4 and concentrated to afforded an amber oil (1.14 g). Chromatography on a 40-g silica gel cartridge, eluted with a 0-40% EtOAc in hexanes gradient, afforded 1-(difluoromethyl)-4-iodopyridin-2(1H)-one (255 mg, yield 16%, 20 estimated purity 45%) as yellow oil. LC-MS Method 1 tR = 1,23 min, m/z = 272. The material was used without further purification.

Step 2 A microwave vial equipped with a flea stir bar was charged with (S)-6-(2- 25 hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5(5-tetramethyl-1,3,2-dioxaborolan- WO 2010/011314 PCT/US2009/004261 -87- 2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (52 mg, 0.11 mmol), 1-(difluoromethyl)-4- iodopyridin-2(1H)-one (29 mg, 0.11 mmol), Cs2CO3 (71 mg, 0.22 mmol), H2O (0.1 mL) and dry dioxane (1 mL). The mixture was sparged with N2 for 5 min and PdCI2(dppf) (5 mg, 0.007 mmol) was added. The mixture was sparged with N2 for 5 min and 5 heated at 110 °C in the microwave for 1 h. The mixture was diluted with 5% aq HCI (0.2 mL) and MeOH (2 mL) and filtered. The filtrate was directly purified by prep HPLC to afford a brown oil (16.2 mg) which was applied to a 2-g silica SPE cartridge which was eluted sequentially with 25 and 50% EtOAc in hexanes (15 mL of each) and EtOAc (3x15 mL) to afford five fractions. Fractions 3 and 4 were pooled and 10 concentrated to afford (S)-3-((S)-1-(4-(1-(difluoromethyl)-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (13.4 mg, 25%) as a colorless oil. LC-MS Method 1 to = 1.57 min, m/z = 497, 439; 1H NMR (CD3OD) 0.96 (s, 3H), 1.27 (s, 3H), 1.56 (d, 3H), 2.15 (s, 2H), 2.21 (m, 1H), 2.40-2.60 (2H), 3.08 (m, 1H), 5.59 (q, 1H),6.66 (s, 1H), 6.74 (d, 1H), 7.07 (d, 2H), 7.30-7.40 15 (5H), 7.45 (d, 2H), 7.77 (1H), 7.79 (t, 1H). EXAMPLE 6 2,2-dimethyl-3-((R)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyndin-3-yl)phenyl)ethyl)- 2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanamide

<img img-format="tif" img-content="drawing" file="IL210452AD000295.tif" id="idf0095" />

Step 1

A mixture of 2,2-dimethyl-3-((R)-2-oxo-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1.3-oxazinan-6-yl)propanenitrile (392 mg, 0.775 mmol), 5-bromo-1-methylpyridin-2(1H)-one (220 mg, 1.5 equiv), 2M WO 2010/011314 PCT/US2009/004261 -88- aq CS2CO3 solution (900 pL), Pd(PPh3)2Cl2 (40 mg, 1 mol%) and anhydrous 1,4-dioxane (8.5 mL) was degassed and refilled with N2 gas 3 times. The mixture was then heated overnight at 85 °C under protection of N2 gas. After being cooled to rt, the mixture was diluted with EtOAc (20 mL), washed by water (20 mL). The aqueous 5 layer was extracted with EtOAc (2x10 mL). The combined organic layers were washed by water (10 mL), brine (2 x 10 mL) and dried over Na2SO4- After filtration and concentration, the residue was purified by Gilson to afford 34mg product (9% yield). LC-MS (3min. method) tp = 1.44min., m/z 470 (M+1). ’H NMR (CDCI3) δ 7.68(dd, 1H), 7.52(d, 1H), 7.31 (q, 2H), 7.16(d, 2H), 7.07(t, 2H), 6.97(d, 2H), 6.91(d, 10 1H), 5.66(q, 1H), 3.71(s, 3H), 2.99(dt, 1H), 2.47(dd, 2H), 2.27(m, 1H), 2.13{s, 2H), 1.55(d, 3H), 1.44(s, 3H), 1.24(s, 3H).

Step 2 ATHF:H2O (2mL, 3:1) solution of 2,2-dimethyl-3-((R)-3-((S)-1-(4-(1-methyl-6- 15 oxo-1,6-d»hydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6- yl)propanenitrile (55 mg, 0.12 mmol), acetamide (177 mg, 3 mmol) and PdCI2 (21 mg, 0.12 mmol) was stirred overnight. The solvent was removed and the crude material redissolved in CH3CN. The crude product was purified via prep HPLC to afford 2,2-dimethyl-3-((F?)-3-((S)-1-(4-(1-rnethy!-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2- 20 oxo-6-phenyl-1,3-oxazinan-6-yl)propanamide (28 mg). LC-MS Method 1 tR = 1.25 min, m/z = 488 (M+1); 1H NMR (CDCI3) 7.55 (dd, 1H, J = 9Hz, 3Hz), 7.42 (d, 1H, J = 3Hz), 7.32 (d, 1H, J = 4 Hz), 7.29 (m, 4H), 7.14 (d, 2H, 8Hz), 7.00 (d, 2H, J = 8Hz), 6.79 (d, 1H, J = 9 Hz), 5.66 (q, 1H, J = 8Hz), 3.62 (s, 3H), 2.95-2.89 (m, 1H), 2.5 (d, 1H, J = 15 Hz), 2.26-2.1 (m, 3H), 2.2 (d, 1H, J = 15 Hz), 2.5 (d, 1H, J = 15 Hz), 2.26- 25 2.10 (m, 3H), 2.2 (d, 1H, J = 15 Hz), 1.53 (d, 3H, J = 7Hz), 1.22 (s, 3H), 1.20 (s, 3H) WO 2010/011314 PCT/US2009/004261 -89- EXAMPLE 7 (S)-6-(2-amino-2-methylpropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-d ihydropy ridi n-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD000296.tif" id="idf0096" />

5 A foil covered flask charged with 2,2-dimethyl-3-((R)-3-((S)-1-(4-(1-methyl-6- oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanamide (20 mg, 0.04 mmol) in 1:1 CH3CN/H2O (1 mL) was treated with Phl(02CCF3)2 (31 mg, 0.07 mmol). The reaction was complete after 24 h. The solvent was removed and the crude material purified by prep HPLC to afford (5)-6-(2- 10 amino-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3- yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (16 mg). LC/MS ES+ - 460 (M+1). LC-MS Method 1 tR = 1.06 min, m/z = 460 (M+1); 1H NMR (CDCI3) 7.60 (dd, 1H, J = 9Hz, 2Hz), 7.46 (d, 1H, J = 3Hz), 7.39-7.27 (m, 5H), 7.20 (d, 2H, J = 7 Hz), 7.1 (d, 2H, J =8 Hz), 6.78 (d, 1H, J = 9Hz, 5.61 (q, 1H, J = 7Hz), 3.65 (s, 3H), 2.87 (m, 1H), 2.80 (d, 15 1H, J = 16Hz), 2.23 (d, 1H, J = 16 Hz), 2.19-2.08 (m, 3H), 1.54 (d, 3H, J =7Hz), 1.41 (s, 3H), 0,96 (s, 3H). EXAMPLE 8 N-(2-methyl-1-((S)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2- 20 oxo-6-phenyl-1,3-oxazinan-6-yl)propan-2-yl)acetamide

<img img-format="tif" img-content="drawing" file="IL210452AD000297.tif" id="idf0097" />

A CH2CI2 (1 mL) solution of (S)-6-(2-amino-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (5 mg, 0.009 mmol) was treated with DMAP (5mg, 0.04 mmol), i-P^NEt (10 drops), and 25 acetic anhydride (20 drops). The reaction was stirred overnight. The reaction solution WO 2010/011314 PCT/US2009/004261 -90- was washed with water. The organic layer was evaporated and the crude material purified by prep HPLC affording /V-(2-methy 1-1 -((5)-3-((5)-1 -(4-( 1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyi-1,3-oxazinan-6-yl)propan-2-yl)acetamide (0.88 mg). LC-MS Method 11« = 1.3 min, m/z = 502 (M+1). EXAMPLE 9

Methyl 2-methyl-1 -((S)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propan-2-ylcarbamate

<img img-format="tif" img-content="drawing" file="IL210452AD000298.tif" id="idf0098" />

10 A CH2CI2 (1 mL) solution of (S)-6-(2-amino-2-methylpropyl)-3-((S)-1-(4-(1- methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (5 mg, 0.009 mmol) was treated with DMAP (5mg, 0.04 mmol), i-Pr2NEt (10 drops), and methyl chloroformate (20 drops). The reaction was stirred overnight. The reaction solution was by prep HPLC affording methyl 2-methyl-1-((S)-3-((S)-1-(4-(1-methyl-6- 15 oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propan-2-ylcarbamate (2.58 mg). LC-MS Method 1 tR = 1.45 min, m/z = 518 (M+1); *H NMR (CDCI3) 7.66 (dd, 1H, J = 9Hz, 2Hz), 7.48 (d, 1H, J = 3Hz), 7.35-7.27 (m, 5H), 7.15 (d, 2H, J =8 Hz), 7.01 (d, 2H, J = 8 Hz), 6.87 (d, 1H, J = 9Hz), 5.67 (q, 1H, J = 7 Hz), 3.69 (s, 3H), 2.2 (s, 3H), 1.54 (d, 3H, J = 7 Hz), 1.46- 1.36 (m, 2H), 1.30 (s, 3H), 1.20 (s, 20 3H). WO 2010/011314 PCT/US2009/004261 -91 - EXAMPLE 10 N-(2-methyl-1-((S)-2-oxo-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6- phenyl-1,3-oxazinan-6-yl)propan-2-yl)methanesulfonamide

<img img-format="tif" img-content="drawing" file="IL210452AD000299.tif" id="idf0099" />

5 The title compound was prepared from N-(1-((S)-3-((S)-1-(4- bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2-methylpropan-2-yl)methanesulfonamide and 2-oxo-1,2-dihydropyridin-5-ylboronic acid following a procedure analogous to that described in Example 4. LC-MS Method 1 tR = 1.3 min, m/z = 524 (M+1); 1H NMR (CDCI3)7.81 (d, 1H, J = 9Hz), 7.63 (brs, 1H), 7.39-7.31 10 (m, 5H), 7.18 (d, 2H, J = 8Hz), 7.03 (d, 2H, J =7 Hz), 6.79 (d, 1H, J =9 Hz), 5.67 (q, 1H, J = 6Hz), 2.93 (s, 3H), 2.90 (m, 1H), 2.49 (d, 1H, J =15 Hz), 2.32 (d, 1H, J =15 Hz), 2.28-2.18 (m, 3H), 1.54 (d, 3H, J = 7Hz), 1.36 (s, 3H), 1.25 (s, 3H). N-(1-((S)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2-methylpropan-2-yl)methanesulfonamide was prepared from 3-((R)-3-((S)-1-(4- 15 bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile by sequential application of procedures analogous to those described in Examples 6 Step 2, Example 7 and Example 11. EXAMPLE 11 20 N-(2-methyl-1-((S)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2 oxo-6-phenyl-1,3-oxazinan-6-yl)propan-2-yl)methanesulfonamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002100.tif" id="idf0100" />

A CH2CI2 (1 mL) solution of (S)-6-(2-amino-2-methylpropyl)-3-(($)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyI)ethyl)-6-phenyl-1,3-oxaztnan-2-one (5 WO 2010/011314 PCT/US2009/004261 -92- mg, 0.009 mmol) was treated with DMAP (5mg, 0.04 mmol), i-P^NEt (10 drops), and MsCI (20 drops). The reaction was stirred overnight. The reaction solution was washed with water. The organic layer was evaporated and the crude material purified by prep HPLC affording N-(2-methyl-1-((S)-3-((S)-1-(4-(1-methyl-6-oxo-1,6- 5 dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propan-2- yl)methanesulfonamide (3.30 mg). LC-MS Method 1 tR = 1.39 min, m/z = 538 (M+1); 1H NMR (CDCh) 7.61 (dd, 1H, J = 9Hz, 3Hz), 7.46 (d, 1H, J = 2Hz), 7.40-7.27 (m, 5H), 7.17 (d, 2H, J = 8Hz), 7.04 (d, 2H, J = 8Hz), 6.79 (d, 1H, J = 9Hz), 5.67 (q, 1H, J = 7 Hz), 3.66 (s, 3H), 2.93 (s, 3H), 2.31-2.22(m, 2H), 1.55(d, 3H, J = 7Hz), 1.48-1.36 10 (m, 2H), 1.33 (s, 3H), 1.24 (s, 3H). EXAMPLE 12 N-methyl-N-(2-methyl-1 -((S)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-di hyd ropyrid in-3-yl)phenyl)ethyl)-2-oxo-6-phenyM,3-oxazinan-6-yl)propan-2-yl)methanesulfonamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002101.tif" id="idf0101" />

To a rt solution of /V-(2-methyl-1-((S)-2-oxo-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-6-yl)propan-2-yl)methanesulfonamide (7 mg, 0.013 mmol) in THF, NaH (10 mg, 0.20 mmol) was added followed by methyl iodide (30 uL, 0.080 mmol). The reaction was heated to 60 20 °C for 5 h. The flask was cooled to rt then to 0 °C before quenching with satd aq NH4CL The mixture was extracted with EtOAc (3x) and the combined organic layers were dried over Na2SO4, filtered, evaporated and purified by prep HPLC to afford N-methyl-A/-(2-methyl-1-({S)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propan-2-yl)methanesulfonamide 25 (4.63 mg). LC-MS Method 1 to = 1.45 min, m/z = 552 (M+1); Ή NMR (CDCI3) 7.55 (dd, 1K, J = 9Hz, 3Hz), 7.41 (d, 1H, J = 3 Hz), 7.35 -7.27 (m, 5H), 7.13 (d, 2H, J = 8Hz), 6.98 (d,2H, J = 8Hz), 6.79 (d, 1H, J =9 Hz), 6.55 (q, 1H, J = 7Hz), 3.62 (s, 3H), 2.91-2.86 (m, 1H), 2.86 (s, 3H), 2.73 (d, 1H, J = 15 Hz), 2.74 (s, 3H), 2.46 (d, 1H, J = WO 2010/011314 PCT/US2009/004261 -93- 15Hz), 2.39 -2.36 (m, 2H), 2.25-21.6 (m, 1H), 1.53 (d, 3H, J = 7 Hz), 1.53 (s, 3H), 1.22 (s, 3H). EXAMPLE 13 N-(2-methyl-1-((S)-3-((S)-1-(4-(1-methyl-2-oxo-1T2-dihydiOpyridin-4-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propan-2-yl)methanesulfonamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002102.tif" id="idf0102" />

Step 1 10 To a solution of 3-(R-3-S-1-(4-bromophenyl)-ethyl)-2-oxo-6-phenyl-1,3- oxazinan-6-yl)-2,2-dimethylpropanenitrile (1 g, 2.27 mmol) in a mixture of THF/H2O (3:1, 10 mL) was added acetamide (3.35 g, 56.75 mmol) and PdCb (0.402 g, 2.27 mmol). The reaction was stirred overnight. The solvent was removed, and the residue was purified by TLC to afford 3-(R-3-S-1-(4-bromophenyl)-ethyl)-2-oxo-6- 15 phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanamide (0.745 g, 71.6%).

Step 2

To a solution of 3-(f?-3-S-1-(4-bromophenyl)-ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanamide (0.74 g, 1.612 mmol) in a mixture of 20 CH3CN/H2O (20 mL, 1:1) was added Phl(OC2CCF3)2 (1.178 g, 2.74 mmol). The mixture reaction was stirred overnight. The mixture was extracted with EtOAc (30 mL). The organic layer was washed with brine, and concentrated to afford S-6-(2- WO 2010/011314 PCT/US2009/004261 -94- amino-2-methylpropyl)-3-S-1-(4-bromophenyl)-ethyl)-6-phenyl-1,3-oxazinan-2-one (0.6 g, 87%).

Step 3 5 To a solution of S-6-(2-amino-2-methylpropyl)-3-S-1-(4-bromophenyl)-ethyl)-6- phenyl-1,3-oxazinan-2-one (0.6 g, 1.39 mmol) in CH2CI2 (10 mL) was added Et3N (0.84 g, 8.34 mmol). The mixture was cooled at 0 °C, MsCI (0.48 g, 4.17 mmol) was added. The reaction was stirred at rt for 1 h. The mixture was evaporated to afford the crude product. The residue was purified by column to afford /V-1-S-3-S-1-(4- 10 bromophenyl)-ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2-methylpropan-2-yl)-methyl-sulfonamide (0.5 g, 70.4%).

Step 4

To a solution of /V-1-S-3-S-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3- 15 oxazinan-6-yl)-2-methylpropan-2-yl)-methyl-sulfonamide (0.5 g, 0.98 mmol) and 4,4,4^,5,5,5^- octamethyl- 2,2'-bi-(1,3t2-dioxaborolane) (0,399 g, 1.57 mmol) in dry DMSO (15 mL) was added KOAc (0.31 g, 3.14 mmol) and Pd(dppf)CI2 (0.025 g, 0.03 mmol) under N2 atmosphere. After addition, the mixture was stirred at 90 °C overnight. After TLC showed the starting material had disappeared, the solid was 20 filtered off. Water (30 mL) and EtOAc (50 mL) was added, the mixture was extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography to afford A/-{2-methyl-1-$-2-oxo-6-phenyl-3-S-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-6-yl)propan-2-yl)- 25 methyl-sulfonamide (0.2 g, yield: 37%).

Step 5

To a solution of A/-(2-methyl-1-S-2-oxo-6-phenyl-3-S-1-4-4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)ethyI)-1,3-oxazinan-6-yl)propan-2-yl)-methyl 30 sulfonamide (150 mg, 0.27 mmol) and 4-iodo-1-methylpyridin-2(1H)-one in dry 1,4-dioxane (5 mL) was added CS2CO3 (0.3 mL, 6 mmol) and Pd(PPh3)Cl2 (20 mg). After addition, the mixture was warmed at 110 °C for 2 min. After TLC showed the starting material had disappeared, the solid was filtered off. Water (20 mL) and EtOAc (30 WO 2010/011314 PCT/US2009/004261 -95- mL) were added. The organic layer was separated, and the aqueous layer was extracted with EtOAc (3 x 30 mL). The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to give the crude product, which was purified by preparative HPLC to provide /V-2-methyl-1-S-3-S-1-4-(1-methyl-2-oxo- 5 1,2-dihydropyridin-4-yl)-phenyl)-ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl) propan-2- yl) methyl sulfonamide (20 mg, 14%). LC-MS Method 2 tR = 1.154 min, m/z = 538.1; 1H NMR (CDCIs); 51.25 (s, 3H), 1.32 (s, 3H), 1.55 (d, 3H), 2.50 (d, 2H), 2.91 (s, 3H), 3.63 (s, 3H), 4.54 (b, 1H), 5.67 (m, 1H), 6.53 (d, 1H), 6.92 (s, 1H), 7.06 (d, 2H), 7.30-7.50 (m, 8H). 0 EXAMPLE 14 2,2-dimethyl-3-((R)-2-oxo-3-((S)-1-(4-(2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6- phenyl-1,3-oxazinan-6-yl)propanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD0002103.tif" id="idf0103" />

15 The title compound was prepared from 2,2-dimethyl-3-((R)-2-oxo-6-phenyl-3- ((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-6-yl)propanenitrile and 4-iodopyridin-2(1H)-one following a procedure analogous to that described in Example 4. LC-MS Method 1 tR = 1.36 min, m/z = 456(M+1); 1H NMR (CDCI3) 7.77(d, 1H), 7.43-7.32(m, 7H), 7.01(t, 4H), 5.67(q, 1H), 2.99(dd, 1H), 2.57- 20 2.43(m, 2H), 2.32{m, 1H), 2.17(s, 2H), 1.57(d, 3H), 1.40(s, 3H), 1.33(s, 3H). EXAMPLE 15 3-((R)-6-(4-fluorophenyl)-2-oxo-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3- yl)phenyl)ethyl)-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile

O □Λ

<img img-format="tif" img-content="drawing" file="IL210452AD0002104.tif" id="idf0104" />

N 25 WO 2010/011314 PCT/US2009/004261 -96-

The title compound was prepared from 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-2-oxo-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrileand 2-oxo-1,2-dihydropyridin-5-ylboronic acid following a procedure analogous to that described in Example 4. LC-MS Method 1 to = 137 min. m/z = 474(M+1); 1H NMR (CDCIj) 7.97, 5 (dd, 1H), 7.73(s, 1H), 7.33(m, 2H), 7.20(d, 2H), 7.17(t, 2H), 6.98(m, 3H), 5.67(q, 1H), 3.00(dt, 1H), 2.49(m, 2H), 2.30(m, 1H), 2.13(s, 2H), 1.55(d,3H), 1.45(s, 3H), 1.34(s, 3H). EXAMPLE 16 10 3-((R)-6-(4-fluorophenyl)-3-((S)-1-(4-( 1 -methyl-2-oxo-1,2-dihydropyridin-4- yl)phenyl)ethyl)-2-oxo-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD0002105.tif" id="idf0105" />

A mixture of 3-((R)-6-(4-fluorophenyl)-2-oxo-3-((S)-1-(4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-6-yl)-2,2-diniethylpropanenitrile 15 (100mg, 0.21 mmol) and 4-iodo-1-methyl-1H-pyridin-2-one (40 mg, 0.17 mmol),

Pd(PPh3)2CI2 (20 mg), and aq. Cs2CO3 solution (2.0 mL, 2M) in 1,4-dioxane (5 mL) was stirred at reflux for 2 h. The organic phase was separated and concentrated to give the crude product, which was purified by preparative TLC to give 3-((R)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-2-oxo- 20 1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile (55 mg, 66%). LC-MS Method 2 tR = 1.096 min, m/z = 488.3; 1H NMR (CDCI3): δ 1.27 (s, 3H), 1.40 (s, 3H), 1.48 (d,3H), 2.06 (s, 2H), 2.23 (m, 1H), 2.41 (m, 2H), 2.90 (m, 1H), 3.51 (s, 3H), 5.60 (m, 1H), 6.27 (m, 1H), 6.65 (d, 1H), 6.89 (d, 2H), 6.99 (t, 2H), 7.26 (m, 5H). WO 2010/011314 PCT/US2009/004261 6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1-(4-(1-methyl-2-oxo-1,2- dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one -97- EXAMPLE 17 '/Λ,,. H&gt;N\&gt;

OH

OH P-TsOH

Toluene, reflux OMo

KzCOj, CHjCN laih2

THF r~\ 0. ,0

MaCl, Et3N OH CH2CI2

ΓΛ °^O OMs

THF

Mg yl

<img img-format="tif" img-content="drawing" file="IL210452AD0002106.tif" id="idf0106" />

Br

m-CPBA ).0¼ super-hydride

<img img-format="tif" img-content="drawing" file="IL210452AD0002107.tif" id="idf0107" />

Pd(dppf)CI2 KOAc CHjCIj y.,y

<img img-format="tif" img-content="drawing" file="IL210452AD0002108.tif" id="idf0108" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002109.tif" id="idf0109" />

10

Step 1

To a solution of methyl 4-methyl-3-oxopentanoate (72 g, 0.5 mol), and ethylene glycol (56 g, 1 mol) in toluene (500 mL) was added 4-methylbenzenesulfonic acid (1.9 g, 0.01 mol). The mixture was stirred at reflux with a Dean-Stark trap to remove water. The reaction mixture was washed with a small amount of water and brine, dried over anhydrous Na2SO4, and concentrated in vacuum to give the crude methyl 2-(2-isopropyl-1,3-dioxolan-2-yl)-acetate (67 g 71% yield), which was used for the next step without further purification. 15 Step 2

In a flame-dried three neck flask equipped with an addition funnel, magnetic stirring bar, rubber septum, and a nitrogen inlet, was placed LiAIH4 (3.12 g, 82.1 mmol) and THF (700 mL). After being cooled at 0 °C, a solution of methyl 2-(2- WO 2010/011314 PCT/US2009/004261 -98- isopropyl-1,3-dioxolan-2-yl) acetate (12 g, 63.8 mmol) in THF (160 mL) was added dropwise with stirring. The mixture was warmed to rt, and stirred for 24 hours. The reaction was quenched by adding water (5 mL), 15% aqueous NaOH (10 mL), and water (5 mL) slowly. The organic layer was separated, and the residue was extracted with EtOAc (3*100 mL). The combined organic phase was dried over Na2SO4, and concentrated to afford the crude product, which was purified by column chromatography to give 2-(2-isopropyl-1,3-dioxotan-2-yl)-ethanol (6.8 g, 67%). 1H NMR (CDCh): δ 0.90 (d, 7= 6.8 Hz, 6H), 1.87-1.96 (m, 3H), 2.81 (br, 1H), 3.69-3.72 (m,2H), 3.92-4.01 (m, 4H).

Step 3

To a solution of 2-(2-isopropyl-1,3-dioxolan-2-yl)-ethanol (8.0 g, 50 mmol) and triethylamine (23.5 mL, 170 mmol) in anhydrous CH2CI2 (120 mL) was added methanesulfonyl chloride (11.6 mL, 150 mmol) at 0 °C, and the reaction mixture was stirred at rt till the reaction was finished. The reaction mixture was washed with water and brine, dried over Na2SO4, filtered, and concentrated to give the crude 2-(2-isopropyl-1,3-dioxolan-2-yl)ethyl methanesulfonate (12 g, crude), which was used for the next step without further purification.

Step 4

To a solution of 2-(2-isopropyl-1,3-dioxolan-2-yl)ethyl methanesulfonate (12 g, 50 mmol) and (S)-1-(4-methoxyphenyl)-ethyl amine (19.9 g, 100 mmol) in CH3CN (250 mL) was added K2CO3 (8 g, 58 mmol), and the mixture was refluxed for 10 h.

The solution was filtered, and the filtrate was concentrated to afford the crude product, which was purified by column chromatography to give (S)-1-(4-bromophenyl)-N-(2-(2-isopropyl-1,3-dioxolan-2-yl)ethyl)ethanamine (6.5 g, 38% yield).

Step 5

To a solution of (S)-1-(4-bromophenyl)-N-(2-(2-isopropyl-1,3-dioxolan-2-yl)ethyl)ethanamine (6.5 g, 19 mmol) in MeOH (60 mL) was added cone HCI (60 mL). The mixture was stirred at 65 °C till the reaction was finished. The mixture was cooled to 0 °C, and the pH of the mixture was adjusted to 7 by adding the satd aq NaHCO3. The mixture was concentrated, and the residue was extracted with EtOAc (3 WO 2010/011314 PCT/US2009/004261 -99- χ 100 mL). The organic layer was washed with brine, dried over Na2SO4, and concentrated to give (S)-1-(1-(4-bromophenyl)ethylamino)-4-methylpentan-3-one (5.5 g, 97% yield), which was used for the next step without further purification. 1H NMR (CDCI3): δ 1.07 (d, J = 6.8 Hz, 6H), 1.29 (d, J= 6.4 Hz, 3H), 1.89 (br, 1H), 2.54-2.62 (m, 4H), 2.66-2.69 (m, 1H), 3.68-3.72 (m, 1H), 7.18-7.20 (m, 2H), 7.41-7.44 (m, 2H).

Step 6

To a suspension of Mg (11g, 458 mmol) and h (0.5g) in anhydrous THF (50 mL) was added 3-chloro-2-methylprop-1-ene (1 mL) to initiate the reaction. THF (300 mL) was added, more solution of 3-chloro-2-methylprop-1-ene (15 mL) in THF (20 mL) was dropped into the reaction at 0 °C under N2 over 30 min. A solution of (S)-1-(1-(4-bromophenyl)-ethyl amino)-4-methylpentan-3-one (5g) in THF (50mL) was added dropwise at -78 °C over 45 min. The reaction was stirred at rt for 2 h, cautiously quenched with satd aq NH4CI, and filtered. The filtrate was extracted with EtOAc (3 x 100 mL), washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to give 1-(S-1-(4-bromophenylamino)-3-isopropyl-5-methylhex-5-en-3-ol (6.4 g, 90% yield ), which was used for the next step without further purification.

Step 7

To a solution of 1-(S-1-(4-bromophenylamino)-3-isopropyl-5-methylhex-5-en-3-ol (6.4 g, 16.8 mmol) and triethylamine (5.34 g, 52 mmol) in CH2CI2 (260 mL) was added triphosgene (2.52 g, 8.5 mmol) at 0 °C under N2, and the mixture was stirred at rt overnight. The reaction mixture was quenched with water, and extracted with CH2CI2(3 x 50 mL). The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to afford the crude product, which was purified by column chromatography to give two isomers of 3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl-6-(2-methylallyl)-1,3-oxazinan-2-one.

Isomer 1: (1.85 g, 27% yield) 1H NMR (CDCI3): 50.83(d, J = 7.2 Hz, 3H), 0.89 (d, J = 7.2 Hz, 3H), 1.45 (d. J = 6.8 Hz, 3H), 1.64-1.70 (m, 2H), 1.79 (s, 3H), 1.88-1.95 (m, 1H), 2.20 -2.34 (m, 2H), 2.59-2.65 (m, 1H), 3.01-3.08 (m, 1H), 4.70 (s, 1H), 4.87 (S, 1H), 5.68-5.77 (m, 1H), 7.14 (d, J= 8.4 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H). WO 2010/011314 PCT/US2009/004261 - 100-

Isomer 2: (1,25g, 18% yield) 'H NMR (CDCb): 50.87 (d, J = 6.8 Hz, 3H), 0.92(d, J = 6.8 Hz, 3H), 1.50 (d, J = 7.2 Hz, 3H), 1.60-1.66 (m. 1 Η), 1.78 (s, 3H), 1.73 1.79 (m, 1H), 1.78 -2.05 (m, 1H), 2.08 (d, J= 14.0 Hz, 1H), 2.30 (d, J = 14.0 Hz, 1H), 2.62-2.68 (m, 1H), 2.98-3.05 (m, 1H), 4.64 (s, 1H), 4.84 (s, 1H), 5.70-5.75 (m, 1H), . 5 7.13 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H).

Step 8

To a solution of 3-((S)-l-(4-bromophenyl)ethyl)-6-isopropyl-6-(2-methylallyl)- 1,3-oxazinan-2-one. isomer 1(500 mg, 1.32mmol) in dry CH2CI2 (64 mL) was added 10 m-CPBA (455 g, 2.64 mmol) at rt. The reaction mixture was stirred until the starting material was consumed (monitored by TLC). The mixture was diluted with (CH3)3COCH3 (70 mL), washed with 30% Na2S2O3, and aq NaHCO3(3 x), dried over Na2SO4, filtered, and concentrated to give 3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl- 6-((2-methyloxiran-2-yl)methyl)-1,3-oxazinan-2-one isomer 1 (520 mg, 99%), which 15 was used directly for the next step without further purification.

Step 9

To a solution of 3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl-6-((2-methyloxiran-2-yl)methyl)-1,3-oxazinan-2-one isomer 1 (520 mg, 1.32 mmol) in THF (32 mL) was 20 added dropwise LiEt3BH (Super-Hydride, 13.6 mL, 13.6mmol) at 0 °C under N2 over 30 min., the resulting solution was stirred at 10-13 °C for 21.5 h. To the mixture was added H2O2 (40 mL). The resulting solution was diluted with (CH3)3COCH3(380 mL), and washed with water, 30% aq Na2S2O3, and brine. The organic phase was dried over Na2SO4, and filtered. The filtrate was concentrated to give the crude product, 25 which was purified by column chromatography to afford 3-((S)-1 -(4- bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-isopropyl-1,3-oxazinan-2-one isomer 1 (320 mg, 61%). 1H NMR (CDCIj): 50.82 (d, J = 6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H), 1.31 (s, 3H), 1.34 (s, 3H), 1.51 (d, J = 10.0 Hz, 3H), 1.61 (d, J = 15.2 Hz, 1H), 1.78-1.84 (m,1H), 1.91 (d, J= 15.2 Hz, 1H), 2.02-2.15 (m,2H), 2.36 (br, 1H), 30 2.62-2.68 (m, 1H), 3.03-3.09 (m, 1H), 5.73 (t, J = 7.2 Hz, 1H), 7.17-7.19 (m, 2H), 7.44 7.48 (m, 2H). WO 2010/011314 PCT/US2009/004261 -101 -

Step 10

To a solution of 3-( (S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methyl propyl )-6-isopropyl-1,3-oxazinan-2-one isomer 1 (315 mg, 0.793 mmol) in DMSO (10 mL) was added 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (602 mg, 2.38 mmol), CH3CO2K (770 mg, 79.3 mmol), Pd(dppf)2CI2 (50 mg, 0.06 mmol) under N2, the reaction was stirred at 90 °C for 4 h. The mixture was quenched with NH4Ci, and extracted with EtOAc, washed with water and brine. The organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to give the crude product, which was purified by preparative TLC to give 6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 1 (250 mg, 71%).

Step 11

To a solution of 6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1 -(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethy[)-1,3-oxazinan-2-one isomer 1 (250 mg, 0.39mmol), 4-bromo-1-methylpyridin-2(1H)-one (127 mg, 0.68 mmol), CS2CO3 (2N, 4 mL) in 1,4-dioxane (20 mL) was added Pd(PPh3)2Cl2 (54 mg, 0.056 mmol) under N2. The reaction mixture was refluxed for 2h, quenched with water, and extracted with EtOAc. The organic phase was washed with H2O and brine, dried over Na2SO4, and filtered. The filtrate was concentrated to give the crude product, which was purified by preparative TLC and preparative HPLC to afford 6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1 -(4-(1 -methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 1 (79 mg, 47% yield). LC-MS Method 2 tR = 1.023 min, m/z = 427.6; 1H NMR (CDCb) 0.85 (d,, 3H), 0.96 (d, 3H), 1.26 (s, 3H), 1.28 (s, 3H), 1.54 (m, 4H), 1.84-1.88 (m, 2H), 2.04 (br, 1H), 2.01-2.18 (m, 2H), 2.75 (m, 1H), 3.10 (m, 1H), 3.52 (s, 3H), 5.80 (t, 1H), 6.37 (m, 1H), 6.74 (m, 1H), 7.28 (m, 1H), 7.25-7.37(m, 2H), 7.50 (m, 2H). 6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1 -(4-(1 -methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 2 was prepared from 3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl-6-(2-methylallyl)-1,3-oxazinan-2-one isomer 2 following procedures analogous to those described in Steps 8-11 above. LC-MS Method 2 tR = 1.023 min, m/z = 427.6; 1H NMR (CDCI3) 0.79 (d, 3H), 0.92 (d, 3H), 1.27 (s, 3H), 1.30 (s, 3H), 1.51 (d, 3H), 1.58 (d, 1H), 1.73-1.81 (m, 1H), 1.88 (d, 1H), WO 2010/011314 PCTZUS2009/004261 -102- 2.0 (br, 1H), 2.04-2.08 (m, 2H), 2.65-2.68 (m, 1H),3.04-3.07 (m, 1H), 3.52 (s, 3H), 5.75 (t, 1H), 6.37 (m, 1H), 6.74 (m, 1H), 7.21-7.35 (m, 3H), 7.51 (m, 2H). EXAMPLE 18 5 6-cyclopropyl-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2- dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002110.tif" id="idf0110" />

The two diastereomers of 3-((S)-1-(4-bromophenyl)ethyl)-6-cyclopropyl-6-(2-hydroxy-2-methy Ip ropy 1)-1,3-oxazinan-2-one were prepared from methyl 3- 10 cyclopropyl-3-oxopropanoate following procedures analogous to those described in Example 17 Steps 1 - 7. The title compound was prepared as follows.

Step 1

To a solution of 3-((S)-1-(4-bromophenyl)ethyl)-6-cyclopropyl-6-(2-hydroxy-2- 15 methylpropyl)-1,3-oxazinan-2-one isomer 1 (230 mg, 0.58 mmol) in DMSO (15 mL) was added 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (450 mg, 1.77 mmol), CH3CO2K (800 mg, 8.16 mmol), Pd(pddf)2CI2 (50 mg, 0.06 mmol) under N2. The reaction was stirred at 90°C for 34 h, quenched with NH4CI, and extracted with EtOAc. The organic phase was washed with water and brine, dried over Na2SO4, 20 and filtered. The filtrate was concentrated to give the crude product, which was purified by preparative TLC to give 6-cyclopropyl-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 1 (140 mg, 54.3%). WO 2010/011314 PCT/US2009/004261 - 103 -

Step 2

To a solution of 6-cyclopropyl-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 1 (140 mg, 0.316 mmol), 4-bromo-1-methylpyridin-2(1H)-one (74.3 mg, 0.316 mmol), 5 2 M aq Cs2CO3(3 mL) in 1,4-dioxane(20 mL) was added Pd(dppf)2CI2 (30 mg, 0.043 mmol) under N2. The reaction mixture was refluxed for 2h, quenched with water, and extracted with EtOAc. The organic phase was washed with H2O and brine, dried over Na2SO4, and filtered. The filtrate was concentrated to give the crude product, which was purified by preparative TLC and preparative HPLC to afford 6-cyclopropyl-6-(2- 10 hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4- yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 1 (49.5 mg, 37.7%). LC-MS Method 2 tR = 1.016 min, m/z = 367.2; ’H NMR (CDCI3) 0.50 (m, 2H), 0.62 (m, 2H), 0.97 (m,1 H), 1.32 (m, 6H), 1.58 (d, 3H), 1.97(m, 3H), 2.28 (m,1H), 2.78 (m, 1H), 3.40 (m, 1H), 3.58 (s,3H) ,5.85 (m, 1H), 6.41 (d, 1H), 6.79 (s, 1H), 7.33 (d, 1H), 7.41 (d, 1H), 7.56 (d, 1H) 15 6-cyclopropyl-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-( 1-methyl-2-oxo-1,2-

dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 2 was prepared from 3-((S)-1-(4-bromophenyl)ethyl)-6-cyclopropyl-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one isomer 2 following procedures analogous to those described in Steps 1 and 2 immediately above. LC-MS Method 2 tR - 0.99 min, m/z = 367.1; 1H NMR 20 (CDCI3) 0.02 (m, 3H), 0.23 (m, 1H), 0.51 (m,1H), 0.96 (s, 6H), 1.17 (d, 3H), 1.40-1.60 (m, 4H), 1.94 (m,1H), 2.55 (m, 1H), 2.73 (m, 1H), 3.20 (s,3H) ,5.41 (m, 1H), 6.03 (d, 1H), 6.40 (s, 1H), 6.98 (m, 1H), 7.03 (m, 2H), 7.18 (m, 2H) WO 2010/011314 PCT/US2009/004261 - 104- EXAMPLE 19 (R)-6-(2-(5-methyI-1,3,4-oxadiazol-2-yl)ethyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2- dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002111.tif" id="idf0111" />

5 Step 4

To a solution of N*-acetyl-3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl 1.3- oxazinan-6-yl)propanehydrazide (0.1 g, 0.21 mmol) in THF (2 ml_) was added Burgess Reagent (75 mg, 0.315 mmol). The sealed vial was irradiated in the microwave at 100 °C for 15 min. The mixture was extracted with EtOAc (3 x 30 mL). 10 The combined organic layer was washed with brine (50 mL), dried over NazSO*. filtered, and concentrated. The residue was purified by preparative TLC to afford (R)- 3-((S)-1-(4-bromophenyl)ethyl)-6-(2-(5~methyl-1 ,3,4-oxadiazol-2-yl)ethyl)-6-phenyl- 1.3- oxazinan-2-one (58 mg, yield: 59%). 1H NMR (CDCt3): 51.49-1.51 (m, 3K), 2.23-2.26 (m, 2H), 2.30-2.33 (m, 2H), 2.42 (s, 3H), 2.43-2.45 (m, 1H), 2.49-2.54 (m, 1H), 15 2.87-2.91 (m, 1H), 3.06-3.09 (m, 1H), 5.61-5.63 (m, 1H), 6.76-6.78 (d, 2H), 7.20-7.22 (m, 2H), 7.26-7.33 (m, 2H), 7.35-7.37 (m, 3H).

Step 5

To a solution of (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-(5-methyl-1,3,4- 20 oxadiazol-2-yl)ethyl)-6-phenyl-1,3-oxazinan-2-one (490 mg, 1.04 mmol), and WO 2010/011314 PCT/US2009/004261 -105- 4,4,4',4,,5,5,5,,5,-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (424 mg, 1.67 mmol) in dry DMSO (20 mL) was added KOAc (326 mg, 3.33 mmol) and Pd(dppf)Cl2 (25.3 mg, 0.031 mmol) under N2 atmosphere. The mixture was warmed at 100 °C for 3 h. After TLC showed the starting material had disappeared, the solid was filtered off, water 5 (50mL) and EtOAc (50 mL) were added, and the mixture was extracted with EtOAc (3 x 50 mL). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by prep TLC to afford (R)-6-(2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (0.395 g, 10 yield:73.6%).

Step 6

To a solution of (R)-6-(2-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazir»an-2-one (60 15 mg, 0.12 mmol) and 4-iodo-1-methylpyridin-2(1H)-one (33 mg, 0.14 mmol) in dry 1,4-dioxane (15 mL) were added CS2CO3 (2M, 1 mL) and Pd(PPh3)CI2 (7.7 mg, 0.01 mmol). The mixture was heated at reflux for 2 h under N2 atmosphere, the solid was filtered off, and the mixture was diluted with water (30 mL) and EtOAc (30 mL). The combined organic layers was washed with brine (50 mL), dried over Na2SO4, filtered, 20 and concentrated. The residue was purified by prep TLC to afford (R)-6-(2-(5-methyl- 1,3,4-oxadiazol-2-yl)ethyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (25 mg, yield: 41.8%). LC-MS Method 2 tR = 0.984 min, m/z = 499.1; lH NMR (CDCI3): 51.48-1.50 (m, 3H), 2.16-2.20 (m, 1H), 2.23-2.26 (m, 1H),2.27-2.32 (m, 2H), 2.39 (s, 3H), 2.40-2.47 (m, 1H), 2.49-2.54 (m, 25 1H), 2.87-2.90 (m, 1H), 2.98-3.01 (m, 1H), 3.58 (s, 3H), 5.62-5.64 (m, 1H), 6.45-6.48 (m, 1H), 6.87 (s, 1H), 6.92-6.94 (d, 2H), 7.20-7.24 (m, 4H), 7.25-7.35 (m, 4H). WO 2010/011314 PCT/US2009/004261 - 106- (S)-6-(2-hydroxy-2-methylpropy!)-3-((S)-1-(4-(1-(2-hydroxyethyl)-2-oxo-1,2- dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one EXAMPLE 20

<img img-format="tif" img-content="drawing" file="IL210452AD0002112.tif" id="idf0112" />

IH

ICH2CH2OH K2CO3

<img img-format="tif" img-content="drawing" file="IL210452AD0002113.tif" id="idf0113" />

'OH

HO

PdCPPhjhClj

CsjCOj οΛΝ^γ&gt; U-g.0 x

<img img-format="tif" img-content="drawing" file="IL210452AD0002114.tif" id="idf0114" />

OH 10

Step 1

To the mixture of 4-iodopyridin-2(1H)-one (50 mg, 0.213 mmol) in DMF (3mL) was added 2-iodoethanol (73 mg, 0.426mmoJ), K2CO3(88 mg, 0.638 mmol) at rt. The mixture was stirred for 2 h at rt. After the reaction was finished, the mixture was washed with water and extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated to give the crude product, which was purified by TLC to provide 1-(2-hydroxyethyl)-4-iodopyridin-2(1H)-one (60 mg 100 %). 15 Step 2 A mixture of compounds (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (72 mg 0.150 mmol), 1-(2-hydroxyethyl)-4-iodopyridin-2(1H)-one (48 mg 0.181 mmol), Pd(PPh3)2Cl2 (14 mg, 0.020 mmol), and Cs2CO3(2 mL) in 1,4-dioxane (8 mL) was 20 stirred at reflux for 2h. After the reaction was finished, the mixture was washed with water, and extracted with EtOAC. The organic phase was washed with brine, dried over Na2SO4t filtered, and concentrated to get the crude product, which was purified by TLC to provide compound (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-(2-hydroxyethy!)-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2- 25 one (19.7 mg, 28 %). LC-MS Method 2 tR = 1.065 min, m/z = 491.2; 'HNMR (CDCI3): 61.10 (d, 6H), 1.50 (d, 3H), 2.20 (m, 5H). 2.35 (m, 1H), 3.50 (m, 1H), 3.90 (m, 2H), 4.10 (m, 2H), 5.60 (m, 1H), 6.40 (m, 1H), 6.70 (s, 1H), 6.95 (d, 2H), 7.35 (m,8H). WO 2010/011314 PCT/US2009/004261 - 107 - EXAMPLE 21 (6S)-6-(2,3-dihydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin- 4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002115.tif" id="idf0115" />

Step 1 A solution of 3-chloro-1-phenylpropan-1-one (16.8 g, 0.1 mol) in THF (50 mL) was added to a well-stirred suspension of zinc powder (13 g, 0.2 mol) in a mixture of satd aq NH4CI solution (260 mL) and THF (65 mL). A solution of 3-iodo-2-methylprop 10 1-ene (36.4 g, 0.2 mol) in THF (50 mL) was added dropwise. The reaction was mildly exothermic, and the mixture began to reflux spontaneously. After refluxing had ceased, the mixture was stirred for 1 h, TLC showed the 3-chloro-1-phenylpropan-1-one had not reacted completely. A solution of 3-iodo-2-methylprop- 1-ene (18.2 g, 0.1 mol) in THF (30 mL) was added, and the mixture was stirred at rt overnight. The 15 mixture was extracted with EtOAc (2 x 500 mL). The combined organic layer was dried and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/ EtOAc 50.Ί—*30:1—*5:1, to give 1-chloro-5-methyl-3-phenylhex-5-en-3-ol (17 g, yield 76 %) as an oil. 1H NMR (CDCI3): ¢1.28 (s, 3H), 2.31 (m, 2H), 2.54 (m, 2H), 2.68 (d, 1H), 3.15 (m, 1H), 3.58 (m, 1H), 4.78 (m, 20 1H), 4.93 (m, 1H), 7.27 (t, 1H), 7.38 (m, 4H). WO 2010/011314 PCT/US2009/004261 -108-

Step2 A mixture of 1-chloro-5-methyl-3-phenylhex-5-en-3-ol (2.9 g, 13 mmol), (S)-1 -bromo-4-(1-isocyanatoethyl)benzene (3.5 g, 16 mmol), and DBU (8 g, 33 mmol) in THF (80 mL) was heated at reflux overnight. The mixture was diluted with EtOAc, and washed with 1/V aq HCI. The aqueous phase was extracted with EtOAc (3 x), and the combined organic phase was dried over Na2SO4. After the solvents were evaporated, the crude product was purified by column chromatography to give (ft)-3-((S)-1 -(4-bromophenyl)-ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one (1.62 g, yield: 30 %).

Step 3

To a solution of (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl- 1,3-oxazinan-2-one (300 mg, 0.726 mmol), 4-methylmorpholine 4-oxide (195 mg, 1.44 mmol) in a mixture of H2O (6 mL), THF (30 mL) and f-BuOH (12 mL) was added osmium (VIII) oxide (4%, 0.231 mL) at 0 °C. The mixture was stirred at rt overnight. The mixture was quenched with 3% NaHSO3 (15 mLx3) and extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated to give the crude product (S)-3-((S)-1-(4-bromophenyl)-ethyl)-6-(2,3-dihydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (242 mg, 74.5%).

Step 4

To a solution of (S)-3-((S)-1-(4-bromophenyl)-ethyl)-6-(2,3-dihydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (235 mg, 0.524 mmol) in DMSO (5 mL) were added KOAc (771.6 mg, 7.86 mmol), Pd(dppf)CI2 (40 mg) under N2. The mixture was stirred at 90 °C for 3 h. The reaction mixture was quenched with water and extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated to give the crude product, which was purified by preparative TLC to afford (S)-6-(2,3-dihydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (121 mg, 46.6%).

Step 5 A mixture of (S)-6-(2,3-dihydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborofan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (105 mg, 211.9 WO 2010/011314 PCT/US2009/004261 - 109 - mmol), 4-iodo-1-methylpyridin-2(1H)-one (65 mg, 275.5 mmol), Pd(PPh3)2Cl2(20 mg) in aq. CS2CO3 solution (3 mL) was stirred at reflux for 2 h. After the reaction was finished, the mixture was washed with water and extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated to give the crude product, which was purified by preparative HPLC to afford two isomers of (6S)-6-(2,3-dihydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

Isomer 1 (6.11 mg, 6%): LC-MS Method 2 tR = 0.84 min, m/z = 477.4; 1H NMR (CDCI3): δ 0.97 (s, 3H), 1.55 (d, 3H), 2.27 (m, 3H), 2.38 (m, 3H), 2.91 (m, 1H), 3.34 (d, 1H),3.58(s, 3H), 5.68 (m, 1H) ,6.35 (d, 1H),6.71 (s, 1H), 7.02 (d, 2H), 7.36 (m, 8H).

Isomer 2 (6.78 mg, 6.7%); LC-MS Method 2 tR = 0.832 min, m/z = 477; 1H NMR (CDCb): 51.14 (s, 3H), 1.48 (d, 3H), 2.09 (m, 1H), 2.14 (m, 2H), 2.31 (m, 2H), 2.81 (m, 1H), 3.24 (d, 1H), 3.27 (d, 1H), 3.50 (s, 3H), 5.62 (m, 1H), 6.28 (d, 1H), 6.63 (s, 1H),6.98 (d,2H), 7.27 (m, 8H). EXAMPLE 22 (6S)-6-(2-hydroxy-3-methoxy-2-methylpropyl)-3-((S)-1-(4-( 1-methyl-2-oxo-1,2-dihyd ropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002116.tif" id="idf0116" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002117.tif" id="idf0117" />

Step 1

Sodium (90 mg) was added to MeOH (5 mL). When sodium had disappeared, a solution of 6(S)-3-(S-1-(4-bromophenyl)ethyl)-6-((2-methyloxiran-2-yI)-methyl)-6-phenyl-1,3-oxa zinan-2-one (500 mg, 1,16mmol) was added to the mixture. The WO 2010/011314 PCT/US2009/004261 - 110- mixture was stirred at 65 °C for 5 h. The mixture was added Η2Ο and concentrated. The residue was extracted with EtOAc, the organic layer was dried over Na2SO4 and concentrated to give the crude product, which was purified by preparative TLC (2:1 ΡΕ/EtOAc) to afford (S)-3-($-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-3-methoxy-2- 5 methytpropyl)-6-phenyl-1,3-oxazinan-2-one (227 mg, 42.3%).

Step 2

To a solution of (S)-3-(S-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-3-methoxy-2-methylpropyl)-6-phenyl-1,3-oxaztnan-2-one (205 mg, 0.443 mmol) in DMSO (5 mL) 10 was added KOAc (435.13 mg, 4.43 mmol), Pd(dppf)Cl2 (45 mg) under N2. The mixture was stirred at 90°C for 3 hours. The reaction mixture was quenched by water and extracted with EtOAc. The organic layer was dried over Na2SO4 and concentrated to give the crude product, which was purified by preparative TLC (PE:EA=1:2) to afford (S)-6-(2-hydroxy-3-methoxy-2-methylpropyl)-6-phenyl-3-((S)-1- 15 (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (113 mg, 50%).

Step 3 A mixture of (S)-6-(2-hydroxy-3-methoxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4- 20 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (100 mg, 196.29 mmol), 4-iodo-1-methylpyridin-2(1H)-one (60.49 mg, 255,2mmol), Pd(PPh3)2Cl2 (20 mg), and aq CS2CO3 solution (2 mol/L, 3 mL) in 1,4-dioxane (4 mL) was stirred at reflux for 2 hours. After the reaction was finished, the mixture was washed with water and extracted with EtOAc. The organic layer was dried over 25 Na2SO4 and concentrated to give the crude product, which was purified by preparative HPLC to afford two isomers of (6S)-6-(2-hydroxy-3-methoxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one.

Isomer 1 (5.25 mg, 5.6%): LC-MS Method 2 tR = 0.921 min, m/z = 403.2; 1H NMR (CDCh): δ 0.94 (s, 3H), 1.47 (d, 3H), 2.28 (mt 4H), 2.35 (m, 1H), 2.82 (m,1H), 30 3.11 (d, 1H), 3.16 (s, 3H), 3.25 (d, 1H), 3.50 (s, 3H), 5.62 (m, 1H), 6.27 (d, 1H), 6.63 (s, 1H), 6.92 (d, 2H), 7.25 (m,8H).

Isomer 2 (5.40 mg, 5.8%): LC-MS Method 2 tR = 0.923 min, m/z = 513.1; 1H NMR (CDCb): δ 1.18 (s, 3H), 1.47 (d, 3H), 2.11 (m, 2H), 2.23 (m, 2H), 2.45 (m, 1H), WO 2010/011314 PCT/US2009/004261 -111- 2.81 (d, 2H), 2.96 (d, 1H), 3.15 (s, 3H), 3.50 (s, 3H), 5.62 (m, 1H), 6.27 (d, 1H). 6.65 (s, 1H), 6.90 (d, 2H), 7.26 (m, 8H). EXAMPLE 23 (S)-6-(2-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002118.tif" id="idf0118" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002119.tif" id="idf0119" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002120.tif" id="idf0120" />

10 15

Step 1

To a solution of 2-fluorobenzoyl chloride (50 g, 0.31 mol) in CH2CI2 (200 mL) was added /V,O-dimethylhydroxylamine (46 g, 0.47 mol), and a solution of triethylamine (127 g, 1.26 mol) in CH2CI2 (100 mL) at 0 °C. The reaction mixture was warmed slowly to rt, and stirred for 3 h. The mixture was quenched with iced water and extracted with CH2CI2 (200 mL). The organic layer was dried over Na2SO4, filtered, and concentrated to afford 2-fluoro-/V-methoxy-/V-methylbenzarnide (48 g, yield: 84.6 %).

Step 2 A solution of 2-fluoro-/V-methoxy-/V-methylbenzamide (16 g, 87.4 mmol) in THF (150 mL) was cooled to -78°C. Vinylmagnesium bromide (120 mL,120 mmol) was 20 slowly added, and the mixture stirred at -78 °C for 10 min, slowly warmed to rt, and stirred for another 3 h. The reaction mixture was quenched with 1 N aq HCI (100 mL) WO 2010/011314 PCT/US2009/004261 - 112- at 0 °C. The aqueous layer was extracted with EtOAc (100 mL). The combined organic phase was washed with brine (50 mL), dried over Na2SO4, and concentrated.

The residue was purified by column chromatography to afford 1-(2-fluorophenyl)-prop- 2-en-1-one (7.6 g, yield: 58.4 %) as a colorless oil.

Step 3

To a solution of 1-(2-fluorophenyl)-prop-2-en-1-one {5.6 g, 37.3 mmol) in CH3CN (50 mL) was added (S)-1-(4-bromophenyl)-ethylamine (7.4 g, 37 mmol), and the mixture was stirred for 12 h at 40 °C. The solution was concentrated to afford the crude product, which was purified by column chromatography to give (S)-3-(1-(4-bromophenyl)-ethylamino)-1-(2-fluorophenyl)-propan-1-one (4 g, yield: 30.7%) as a yellow liquid.

Step 4

To a suspension of Mg (2.5 g, 104 mmol), l2 (0.1 g) in anhydrous THF (15 mL) was added 3-chloro-2-methylprop-1-ene (0.6 mL, 6 mmol). After a solution of 3-chloro-2-methylprop-1-ene (9 mL, 90 mmol) in THF (120 mL) was dropped at 0°C under N2 in 30 min. (S)-3-(1-(4-bromophenyl)-ethylamino)-1-(2-fluorophenyl)-propan-1-one (3 g , 8.6 mmol) in THF (50 mL) was added dropwise at -78°C over 45 min.

The reaction mixture was stirred at rt for 2 h and cautiously quenched by addition of satd aq NH4CI. The mixture was extracted with EtOAc, and the organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to give 1-($-1-(4-bromophenyl)-ethylamino)-3-(2-fluorophenyl)-5-methylhex-5-en-3-ol (3.3 g , yield: 94.5%), which was used for the next step without further purification.

Step 5 A mixture of 1-(S-1-(4-bromophenyl)ethyIamino)-3-(2-fluorophenyl)-5-methylhex -5-en-3-ol (2 g, 5 mmol) in a solution of triethylamine (1.5 g, 15 mmol) in 1,2-dichloroethane (100 mL) was added triphosgene (1.46 g, 5 mmol) at 0 °C under N2, and the mixture was heated at 100 °C for 4 h. The reaction mixture was quenched with water, and extracted with ΟΗ2ΟΙ2(100 mL). The combined organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to afford WO 2010/011314 PCT/US2009/004261 - 113- the crude product (2.1 g , yield; 99 % ), which was used for the next step without further purification.

Step 6 5 To a solution of ($)-3-( 1-(4-b romophenyl)ethyl)-6-(2-fl uorophenyl)-6-(2- methylallyl) -1,3-oxazinan-2-one (3.2 g, 7.4 mmol) in dry CH2CI2 (100 mL) was added m-CPBA (2.6 g, 14.8 mmol) at rt and the mixture was stirred overnight The mixture was diluted with (CH3)3COCH3 (100 mL), washed with 30% aq Na2S2O3 and aq NaHCO3, dried over Na2SO4, filtered, and concentrated to give 3-(5-1-(4- 10 bromophenyl)-ethyl)-6-(2-fluorophenyl)-6-(2-methyloxiran-2-yl-methyI)-1,3-oxazinan-2-one (2.8 g, yield: 84.3%), which was used directly for the next step without further purification.

Step 7 15 To a solution of 3-(S-1 -(4-bromophenyl)-ethyl)-6-(2-fluorophenyl)-6-(2- methyloxiran -2-yl)-methyl)-1,3-oxazinan-2-one (2.2 g, 4.92 mmol) in THF (100 mL) was added dropwise LIEt3BH (Super-hydride, 50 mL, 50 mmol) at 0 °C under N2for 30 min., and the resulting mixture was stirred at 2-3°C for 1.5 h, and stirred for 2.5 h at 10-13’C . H2O2 (20 mL) was added dropwise and the reaction mixture was diluted

20 with (CH3)3COCH3 (280 mL). The mixture was washed with water, 30% aq Na2S2O3 and brine. The organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to give the crude product, which was purified by column chromatography to afford (S)-3-(S-1-(4-bromophenyl)-ethyI)-6-(2-fluorophenyl)-6-(2-hydroxy-2-methylpropyI)-1,3-oxazinan-2-one (550 mg, 23.9 %) as a white solid. ’H NMR 25 (CDCI3): &lt;51.03 (s, 3H), 1.14 (s, 3H), 1.43 (d, 7 = 6.8 Hz, 3H), 2.08-2.13 (m, 1H), 2.17 (d, 7 = 2.8 Hz, 1H), 2.21-2.22 (m, 1H), 2.31 (dd, J = 0.8, 15.2 Hz, 1H), 2.77-2. 81 (m, 1H), 5.56 (q, J = 2.8 Hz, 2 H), 6.82-6.83 (m, 2H), 6.85-6.94 (m, 1H), 7.08-7.13 (m, 1H), 7.18-7.25 (m, 1H), 7.26-7.40 (m, 2H), 7.42-7.44 (m, 1H). 30 Step 8

To a solution of (S)-3-(S-1-(4-bromophenyl)-ethyl)-6-(2-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one (540 mg, 1.2 mmol) in DMSO (15 mL) was added 4,4t5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (900 mg, 3.3 mmol), WO 2010/011314 PCT/US2009/004261 - 114- CH3CO2K (1,5 g, 16 mmol), Pd(dppf)Cb (108 mg, 0.13 mmol) under N2, and the reaction was stirred at 90 °C for 2.5 h. The mixture was quenched with water, and extracted with EtOAc (90 mL). The organic layer was washed with water and brine, dried over Na2SO4, and filtered. The filtrate was concentrated to give the crude 5 product, which was purified by preparative TLC to afford (S)-6-(2-fluorophenyl)-6-(2-hyd roxy-2-methylpropyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborola n-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (360 mg, 62 %) as a yellow liquid.

Step 9 10 To a solution of (S)-6-(2-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 - (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (120 mg, 0.24 mmol), 5-bromo-1-methylpyridin-2-(1H)-one (54 mg, 0.28mmo), 2N aq CS2CO3 (2 mL) in dioxane (8 mL) was added Pd(PPh3)2Cl2 (17 mg, 0.024 mmol) under N2. The reaction mixture was refluxed for 2 h and quenched by addition of water. 15 The mixture was extracted with EtOAc (30 mL), and the organic layer was washed with H2O and brine, dried over Na2SO4, and filtered. The filtrate was concentrated to give the crude product, which was purified by preparative TLC and preparative HPLC to afford (S)-6-(2-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (14 mg, yield:10 %). 20 LC-MS Method 2 tR = 1.2 min, m/z = 473.9; 1H NMR (CDCb): ¢1.21 (s, 3H), 1.30 (s, 3H), 1.48 (d, J = 7.2 Hz, 3H), 2.15-2.26 (m, 3H), 2.33 (dd, J= 11.2.26.4 Hz, 1H). 2.43-2.46 (m, 1H), 2.79-2.85 (m, 1H), 3.63 (s, 3H), 5.62 (q, J= 6.8 Hz, 1H), 6.58-6.60 (m, 1H), 6.89-6.94 (m, 1H), 7.00-7.02 (m, 2 H). 7.10-7.24 (m, 3H), 7.34-7.39 (m, 1H), 7.40-7.45 (m, 1H), 7.48-7.70 (m, 2H). 25 EXAMPLE 24 (S)-6-(3-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-( 1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002121.tif" id="idf0121" />

WO 2010/011314 PCT/US2009/004261 - 115 -

The title compound was prepared from (S)-3-(1-(4-bromophenyl)ethylamino)-1-(3-fluorophenyl)propan-1-one following procedures analogous to those described in Steps 4-9 in Example 23. LC-MS Method 2 Ir = 1.416 min, m/z = 500.9; 1H NMR (CDCI3) 1.18 (s, 3H), 1.29 (s, 3H), 1.47 (d, 3H), 2.05-2.28 (m, 4H), 2.31-2.39 (m, 1H), 5 2.82-2.87 (m, 1H), 3.58 (s, 3H), 5.64 (q, 1H), 6.57-6.59 (m, 1H), 6.88-7.19 (m, 5H), 7.21-7.25 (m, 2 H), 7.28 (m, 1H),7.36 (m, 1H), 7.40-7.45 (m, 1H), 7.45-7.48 (m, 1H) (S)-3-(1-(4-bromophenyl)ethylamino)-1-(3-fluorophenyl)propan-1-one was prepared as shown below.

<img img-format="tif" img-content="drawing" file="IL210452AD0002122.tif" id="idf0122" />

Step 1 A solution of 3-fluoro-N-methoxy-/V-methylbenzamide (16 g, 87.4 mmol) in THF (150 mL) was cooled to -78°C. Vtnylmagnesium bromide (120 mL,120 mmol) was added slowly. The mixture was stirred at -78°C for 10 min, at rt for 3 h, and quenched 15 by addition of 1 N aq HCI (100 mL) at 0°C. The aqueous layer was extracted with EtOAc (100 mL). The combined organic phase was washed with brine (50 mL), dried over Na2SO4, and concentrated. The residue was purified by column chromatography to afford 1-(3-fluorophenyl)ethanone (9.7 g, yield: 75 %) as a colorless oil. 20 Step 2 1-(3-Fluorophenyl)ethanone (17 g, 0.123 mol), dimethylamine (13.7 g, 0.172 mol), and paraformaldephyde (5,5 g, 0.185 mol) were suspended in ethanol (50 mL), and cone HCI solution (0.3 mL) was added. The mixture was heated at reflux overnight. The solvent was removed under vacuum, and the residue was washed 25 with EtOAc (3 x) to give 3-{dimethylamino)-1-(3-fluorophenyl)propan-1-one (20.7 g, 88%), which was used for the next step without purification. WO 2010/011314 PCT/US2009/004261 -116-

Step 3 A solution of 3-dimethylamino-1-(3-fluoro-phenyl)-propan-1-one (17 g, 0.087 mol) and (S)-1-(4-bromophenyl)-ethanamine (17 g, 0.087 mol) in a mixture of EtOH (50 mL) and H2O (50 mL) was refluxed at 80 °C overnight. The solvent was removed 5 under vacuum, and the residue was purified by column chromatography to afford (S)-3-(1-(4-bromophenyl)-ethylamino)-1-(3-fluorophenyl)-propan-1-one (6.2 g, 20%). EXAMPLE 25 (S)-3-((S)-1-(4-(1-(2-fluoroethyl)-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2-1 o hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002123.tif" id="idf0123" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002124.tif" id="idf0124" />

1-(2-fluoroethyl)-4-iodopyridin-2(1 K)-one was prepared from 4-iodopyridin-2(1H)-one and 2-fluoroethyl trifluoromethanesulfonate following a procedure analogous to that described in Example 20 Step 1. 15 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaboroian-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 1-(2-fluoroethyl)-4-iodopyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.09 min, m/z = 515, 493,475,435. 20 WO 2010/011314 PCT/US2009/004261 - 117 - EXAMPLE 26 (S)-6-(2-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2 dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002125.tif" id="idf0125" />

5 The title compound was prepared from (S)-6-(2-fluorophenyl)-6-(2-hydroxy-2- methylpropyl)-3-((S)-1-(4-(4,4,5,5-tetramethy 1-1,3,2-dioxaborolan-2-yI)phenyl)ethyl)- 1,3-oxazinan-2-one and 4-iodo-1-methylpyridin-2(1K)-one following a procedure analogous to that described in Example 23 Step 9. LC-MS Method 2 t« = 1.58 min, m/z = 501,479, 421. 0 EXAMPLE 27 (S)-6-(3-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-(1 -methyl-2-oxo-1,2 dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002126.tif" id="idf0126" />

15 The title compound was prepared from (S)-6-(3-fluorophenyl)-6-(2-hydroxy-2- methylpropyl)-3-((S)-1-(4-(4,4t5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)- 1,3-oxazinan-2-one and 4-iodo-1-methylpyridin-2(1 H)-one following a procedure analogous to that described in Example 23 Step 9. LC-MS Method 2 tR = 1.57 min, m/z = 501,479, 421. 20 WO 2010/011314 PCT/US2009/004261 -118- EXAMPLE 28 6-(3-hydroxypropyl)-6-isopropyl-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4- yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002127.tif" id="idf0127" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002128.tif" id="idf0128" />

To a mixture of 3-((S)-1-(4-bromophenyl)ethyl)-6-(3-hydroxypropyl)-6-isopropyl 1,3 -oxazinan-2-one (100 mg, 0.26 mmol), 4,4,4',4',5,5,5,,5,-octamethyl-2l2'-bi(1,3l2-dioxaborolane) (198 mg, 0.783 mmol), potassium acetate (256 mg, 2.61 mmol) in 10 DMSO {5 mL) was added Pd(dppf)CI2 (21 mg, 0.0261 mmol) under N2. The mixture was stirred at 85 °C for 3 h, treated with EtOAc (50 mL) and water (50 mL). The organic layer was washed with water (2*50 mL) and brine (50 mL), dried, and concentrated to give the crude product. The crude product was purified by preparative TLC to give 6-(3-hydroxypropyl)-6-isopropyl-3-((S)-1-(4-(4,4,5,5- 15 tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl)ethyl)-1,3-oxazinan-2-one (40 mg, 35%),

Step 2 A mixture of 6-(3-hydroxypropyl)-6-isopropyl-3-((S)-1-(4-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (40 mg, 0.092 mmol), 4-20 iodo-1-methylpyridin-2(1H)-one (20 mg, 0.085 mmol), Pd(PPh3)2CI2 (6 mg, 0.0085 mmol), and Cs2CO3 (2 N, 0.425 mL, 0.85 mmol) in 1,4-dioxane (2 mL) was refluxed for 3 h under N2. The reaction mixture was treated with EtOAc (20 mL) and water (20 mL), and the organic layer was dried and concentrated in vacuo. The residue was purified by preparative HPLC to give two isomers.

Isomer 1: (2.20 mg, 6%). LC-MS Method 2 tR = 1.06 min, m/z = 413; m/z = 1H NMR (CD3OD): δ 1.00 (m, 6H), 1.62 (m, 7H), 1.82 (m, 1H), 2.10 (m, 2H), 2.85 (m, 1H), 3.29 (m, 1H), 3.54 (t, 2H), 3.63 (s, 3H), 5.71 (q, 1H),6.78 (dd, 1H),6.83(d, 1H), 7.51 (d, 2H), 7.75 (m, 3H), 25 WO 2010/011314 PCT/US2009/004261 -119-

Isomer 2: (2.10 mg, 6%) LC-MS Method 2 tR = 1.03 min, m/z = 413; 1H NMR (CD3OD): δ 0.86 (m,6H), 1.53 (m, 5H), 1.71 (m,4H),1.92 (m, 1H), 2.82 (m, 1H), 3.25 (m, 1H), 3.49 (t, 2H), 3.52 (s, 3H), 5.59 (q, 1H), 6.67 (dd, 1H), 6.72 (d, 1H), 7.39 (d, 2H), 7.63 (m,3H), EXAMPLE 29 (R)-6-(3-hydroxypropyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002129.tif" id="idf0129" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002130.tif" id="idf0130" />

Step 1 A mixture of (R)-6-allyl-3-((S)-1 -(4-bromophenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (150 mg, 0.375 mmol) and 6-aminopyridin-3-ylboronic acid (56 mg, 0.45 mmol), 15 Pd(Ph3p)2Cl2 (15 mg), and aqueous CS2CO3 solution (0.5 mL, 2 M) in 1,4-dioxane (10 mL) was stirred and heated to reflux for 2 h. The organic phase was separated, and concentrated to give the crude product, which was purified by preparative HPLC to give (R)-6-allyl-3-((S)-1 -(4-(6- aminopyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (90 mg, 60%). 20

Step 2

To a solution of (R)-6-allyl-3-((S)-1-(4-(6-aminopyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3- oxazinan-2-one (90 mg, 0.23 mmol) in tetrahydrofuran (10 mL) was added BH3 THF (3.0 mL, I mol/L, 4 mmol) at 0 °C under nitrogen atmosphere. The formed 25 mixture was stirred for 2 h. The reaction was quenched by water. Then NaOH (2 mL, WO 2010/011314 PCT/US2009/004261 -120- 3 mol/L) and H2O2 (1 mL) was added to the above mixture. When the reaction was over, the mixture was extracted with EtOAc. The combined organic phase was concentrated to give the crude product, which was purified by preparative HPLC to give (/?)-3-(($)-1-(4-(6-aminopyridin -3-yl)phenyl)ethyl)-6-3-hydroxypropyl)-6-phenyl- 5 1,3-oxa zinan -2- one (40 mg, 41%).

Step 3 (R)-3-((S)-1-(4-(6-aminopyridin-3-yl)phenyl)ethyl)-6-(3-hydroxypropyl)-6-phenyl- 1,3-oxazinan-2-one (40 mg, 0.09 mmoL) was dissolved in 3.5 M H2SO4 (10 mL), and 10 2 M NaNO2 (10 mL) was added at 0 °C. The reaction mixture was stirred at rt for 2 h and treated with NaOH solution. The mixture was extracted with EtOAc. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated to afford the residue, which was purified by preparative HPLC to give (R)-6-(3-hydroxypropyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6- 15 phenyl-1,3-oxazinan-2-one (10 mg, 20%). LC-MS Method 2 tR = 1.66, min, m/z = 433, 455; 1H NMR (CDCI3): 1.36 (m, 2H), 1.50 (m, 3H), 1.68 (m, 2H), 1.92 (m, 2H), 2.10- 2.30 (m, 3H), 2.84 (m, 1H), 3.50 (m, 2H), 5.12 (m, 1H),6.62 (m, 1H), 6.86 (m, 2H), 7.08 (m, 2H), 7.18-7.32 (m, 5H), 7.46 (m, 1H), 7.62 (m, 1H). 20 EXAMPLE 30 (R)-6-(3-hydroxypropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002131.tif" id="idf0131" />

WO 2010/011314 PCT7US2009/004261 - 121 -

Step 1

To a suspension of NaH (4.8 g, 0.2 mol) in THF (10 mL) was added a solution of 5- bromopyridin-2(1H)-one (8.6 g, 0.05 mol) in THF (120 mL) at 0 °C. The resulting mixture was stirred for 1 h and CH3t (35.5 g, 0.25 mol) was added. The mixture was 5 stirred for 3 h. The reaction was quenched with aqueous NH4CI solution. The organic phase was concentrated to give the crude product, which was purified by column chromatography to give 5-bromo-1-methylpyridin-2(1H)-one (8.9 g, 96.78 %). 1H NMR (CDCI3): 6= 3.5 (S, 3H), 6.52 (m, 1H), 7.32 (m, 1H),7.45(m, 1H). 10 Step 2 A mixture of (R)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl· 1,3,2- dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (1.7 g, 3.7 mmol) and 5-bromo-1- methylpyridin-2(1H)-one (816 mg, 4.4 mmol), Pd(Ph3P)2CI2 (200mg), and aq CS2CO3 solution (4mL, 2M) in 1,4-dioxane (30 mL) was stirred and heated to reflux 15 for 2 h. When the reaction was over, the mixture was washed with water and extracted with EtOAc, and the organic phase was washed with brine, dried over Na2SO4, filtered and concentrated to give crude product, which was purified by preparative TLC to give (R)-6-(3-hydroxypropyl) -3-((S)-1-(4-(1 -methyl -6- oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (614 mg , 37%). 20 LC-MS Method 2 tR = 1.075 min, m/z = 447.1; 1H NMR(CDCL): 6=1.38 (m, 1H),1.47 (d, 3H), 1.73 (m, 2H), 1.98(m, 2H), 2.20 (m, 1H), 2.31 (m, 2H), 2.94 (m, 1H), 3.51 (m, 2H), 3.56 (s, 3H), 5.63 (m, 1H), 6.67 (m, 1H), 6.87 (m, 2H), 7.05 (m, 2H), 7.31-7.41(m, 6H), 7.48 (m, 1H). EXAMPLE 31 (S)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002132.tif" id="idf0132" />

1. NalO4. OsO4 2. NaBH4

<img img-format="tif" img-content="drawing" file="IL210452AD0002133.tif" id="idf0133" />

25 WO 2010/011314 PCT/US2009/004261 - 122-

To a solution of (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1 -(4-( 1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (0.064 g, 0.144 mmol, 1.0 equiv) in THF-H2O (1:1,6 mL) were added NalO4 (0.145 g, 0.678 mmol, 4.7 equiv) and OsO4 (2.5 wt.% solution in ί-BuOH, 0.048 g, 0.0047 mmol, 0.033 equiv), and the mixture 5 was stirred at rt for 1 h. The mixture was diluted with EtOAc, dried over Na2SO4, and concentrated under reduced pressure. The residue was dissolved in MeOH (3 mL) and NaBH4 (0.100 g) was added. After the mixture was stirred for 0.5 h at rt, acetone was added. The solvents were removed in vacuo, the residue was treated with saturated brine, extracted with CH2CI2, and dried over Na2SO4. After the solvent was 10 evaporated, the residue was purified by reversed-phase HPLC (SunFire™ Prep Cie OBD™ 5pm 19 x 50 mm column, 10% -*90% CH3CN/H2O, 0.1% CF3COOH over 8 min and then 90% CH3CN/H2O, 0.1% CF3COOH over 2 min, flow rate 20 mL/min) to afford (S)-6-(4-fluorophenyl)-6-(2-hydroxyethyl)-3-((S)-1-(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one. LC-MS Method 1 tR = 1.21 min, 15 m/z = 451 (M+1); 1H NMR (400 MHz, CD3OD) δ 7.80 (m, 1H), 7.69 (d, J = 9.4 Hz, 1H), 7.22-7.19 (m, 4H), 7.00-6.92 (m, 4H), 6.52 (d, J = 9.4 Hz, 1H), 5.45 (q, J= 7.0 Hz, 1H), 3.60-3.52 (m, 1H), 3.52 (s, 3H), 3.24-3.18 (m, 1H), 3.02-2.98 (m, 1H), 2.39-2.35 (m, 1H), 2.23-2.12 (m, 2H), 2.01 (t, J = 7.3 Hz, 2H), 1.43 (d, J = 7.0 Hz, 3H); 19F NMR (376 MHz, CD3OD) δ -117.19 (m). 20 WO 2010/011314 PCT/US2009/004261 -123- EXAMPLE 32 (S)-6-(4-fiuorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6- dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one 5 Method 1

<img img-format="tif" img-content="drawing" file="IL210452AD0002134.tif" id="idf0134" />

Step 1 A mixture of (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-1,3-10 oxa zinan- 2-one (1.6 g, 3.84 mmol) and 6-aminopyridin-3-ylboronic acid (1.0 g, 4.61 mmol), Pd(Ph3P)2Cl2 (150 mg), and aq CS2CO3 solution (3.84 mL, 2 M) in 1,4-dioxane (150 mL) was stirred and heated to reflux for 2 h. The mixture was filtered and the filtrate was extracted with EtOAc. The combined organic phase was washed with brine, dried over anhydrous Na2SO&lt; and concentrated to give (f?)-6-aflyl-3-((S)-1-(4- 15 (6-aminopyridin -3-yl) phenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one (1.5 g, 90%), which was used for the next step without purification. 1H NMR (CDCI3): 5=1.51 WO 2010/011314 PCT/US2009/004261 - 124- (d, 3H), 2.17-2.31 (m, 3H), 2.54-2.60 (m, 2H), 2.90 (m, 1H), 4.46 (s, 2H), 4.99-5.09 (m, 2H), 5.65-5.71 (m, 2H), 6.54 (m, 2H), 6.88 (d, 2H), 7.03 (t, 2H), 7.21-7.27 (m, 3H), 7.58 (d, 1H), 8.22 (d, 1H).

Step 2

To a solution of (R)-6-allyl-3-((S)-1-(4-(6-aminopyridin-3-yl)phenyl)ethyl)-6-(4-fluorophenyl)-1,3-oxazinan-2-one (1.5 g, 3.47 mmoL) in 3.5 M H2SO4 (25 mL) was added 2 M NaNO2 (15 mL) at 0 °C. The reaction mixture was stirred at rt overnight. The reaction was treated with aqueous NaOH solution (8%), and the mixture was extracted with CH2CI2. The combined organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated to give crude product, which was purified by preparative TLC to give (/?)-6-allyl-6-(4 -fluorophenyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl) ethyl)-1,3- oxazinan-2-one (891 mg, 59%). 1H NMR (CDCI3): 5=1.52 (d, 3H), 2.15-2.38 (m, 3H), 2.51-2.60 (m, 2H), 2.94 (m, 1H), 4.99-5.11 (m, 2H), 5.65-5.74 (m, 2H), 6.67 &lt;m, 1H), 6.89 (d, 2H), 7.00 (t, 2H), 7.13-7.20 (m, 2H), 7.20-7.27 (d, 2H), 7.33 (m, 1H), 7.46 (m, 1H), 7.77 (m, 1H).

Step 3

To a suspension of NaH (330 mg, 8.24 mmol) in THF (20 mL) was added a solution of (R)-6- allyl-6-(4-fluorophenyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3- oxazinan-2-one (891 mg, 0.174mmol) in THF (30 mL) at 0 °C, and the resulting mixture was stirred for 1h. CH3I (2 ml) was added and the mixture was stirred overnight. The reaction was quenched by aqueous NH4CI solution. The organic phase was separated, and concentrated to give the crude product, which was purified by preparative TLC to give (R)-6-allyl-6-(4-fiuorophenyl)-3-((S)-1 -(4-(1 -methyl- 6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (634 mg, 69%). 1H NMR (CDCb): 6=1.52 (d, 3H), 2.16-2.35 (m, 3H), 2.52-2.64 (m, 2H), 2.94 (m, 1H), 3.61 (s, 3H), 5.00-5.11 (m, 2H), 5.66-5.74 (m, 2H), 6.64 (d, 1H), 6.90 (d, 2H), 7.02 (t, 2H), 7.11-7.14 (d, 2H), 7.25-7.28 (m, 2H), 7.41 (m, 1H),7.53 (m, 1H).

Step 4

To a solution of (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (320 mg, 0.717mmol) in acetone WO 2010/011314 PCT/US2009/004261 -125- (20 mL) was added aqueous KMnO4 and Nal04 solution (15 mL). Then the formed mixture was stirred for 30 min at 0 °C. The mixture was filtered, and the filtrate was adjusted to pH = 5-6 with 1 N aq HCI solution. The mixture was extracted with EtOAc, and the combined organic phase was washed with brine, dried over anhydrous 5 Na2SO4 and concentrated to give 2-((S)-6-(4-fluorophenyl)-3-((S)-1-(4-( 1-methyI-6-oxo- 1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-1,3-oxazinan-6-yl)acetic acid.

Step 5

To a solution of 2-((S)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,διό dihydropyridin-3-yi)phenyl)ethyl)-2-oxo-1,3-oxazinan-6-yl)acetic acid (290 mg, 0.625 mol) in MeOH (20 mL) was added SOCI2 (2 mL) at 0 °C, and the reaction mixture was stirred at rt for 2 h. The reaction mixture was concentrated to give the residue, which was purified by preparative TLC to give methyl 2-((S)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-1,3-oxazinan-6-yl)acetate 15 ¢130 mg, 43.5%). 1H NMR (CDCl3): 6=1.52 (d, 3H), 2.36-2.55 (m, 3H), 2.67-2.71 (m, 2H), 2.90-3.04 (m, 3H), 3.68 (s, 3H), 3.71 (s, 3H), 5.66 (m, 2H), 6.66 (d, 1H), 6.90 (d, 2H), 7.03 (t, 2H), 7.13-7.15 (d, 2H), 7.23-7.29 (m, 2H), 7.42 (m, 1H), 7.56 (m, 1H).

Step 6 20 To a solution of methyl 2-((S)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-6-oxo~ 1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-1,3-oxazinan-6-yl)acetate (130 mg, 0.22 mmol) in dry THF (20 mL) was added MeMgBr (2 mL) at -78 °C, and the mixture was stirred under Njat rt overnight. The reaction was quenched with water, and the mixture was extracted with EtOAc. The combined organic phase was dried over 25 Na2SO4, and concentrated to give the residue, which was purified by preparative HPLC to give (S)-6-(4-fluorophenyl) -6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (24 mg, 30%). LC-MS Method 2¾ =1.116 min, m/z = 479.1; Ή NMR (CDCI3): 1.1 (m,6H), 1.18 (m, 1H), 1.48 (d, 3H), 1.58 (m, 1H), 1.80-2.00 (m, 2H), 2.21 (m, 3H), 2.85 (m, 1H), 5.55 30 (m, 1H), 7.72 (m, 2H), 7.00 (m, 2H), 7.18 (m, 4H). WO 2010/011314 PCT/US2009/004261 -126-

<img img-format="tif" img-content="drawing" file="IL210452AD0002135.tif" id="idf0135" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002136.tif" id="idf0136" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002137.tif" id="idf0137" />

CuCI, PdCI2

<img img-format="tif" img-content="drawing" file="IL210452AD0002138.tif" id="idf0138" />

Br

F

<img img-format="tif" img-content="drawing" file="IL210452AD0002139.tif" id="idf0139" />

Step 1

To a solution of (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fIuorophenyl) -1,3-oxazinan-2-one (5 g, 12 mmol) and CuCI (2.75 g, 27.8 mmol) in dry DMF (50 mL) was added H2O (20 mL) and PdCI2 (950 mg, 3.2 mmol) at room temperature. The mixture was vigorously stirred under a balloon of oxygen for 24 h. After TLC showed the starting material had disappeared, the solid was filtered off. Water (200 mL) and EtOAc (50 mL) was added, the layers were separated and the aqueous layer was extracted with EtOAc (3 χ 40 mL). The combined organic layer was washed with brine, dried over Na2SO4l filtered and concentrated to give (S)-3-((S)-1 -(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-6-(2-oxopropyl)-1,3-oxazinan -2-one (5.25 g, 92%), which was purified by column chromatography. 1H NMR (CDCb): 1.47 (s, 3H), 2.06 (s, 3H), 2.10-2.36 (m, 3H), 2.58 (m, 1H), 2.90 (m, 2H), 5.58 (m, 1H), 6.69 (m, 1H), 6.79 (m, 1H), 7.02 (m, 2H), 7.19-7.33 (m, 4H).

Step 2

To a solution of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-6-(2-oxopropyl)-1,3-oxazinan -2-one (5.25 g, 12.1 mmol) in anhydrous TKF (100 mL) was added dropwise methylmagnesium bromide (20 mL, 60 mmol) at -78 °C under nitrogen. Then the mixture was stirred at rt for 2 h. The reaction mixture was cooled in an ice bath and quenched with aqueous NH4CI. The layers were separated. The aqueous layer was extracted with EtOAc (15 mL) .washed with a brine (30 mL), dried over Na2SO4 and concentrated in vacuo to give the crude product, which was purified by preparative HPLC and chiral HPLC to afford (S)-3-((S)-1-(4-bromophenyl)ethyl)-6- WO 2010/011314 PCT/US2009/004261 -127-

(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one (2.5 mg, 46%). 1H NMR &lt;CDCf3): 1.08 (s, 3H), 1.12 (s, 3H), 1.48 (m, 3H), 1.99 (m, 1H), 2.10-2.24 (m, 4H), 2.35 (m, 1H), 2.85 (m, 1H), 5.61 (m, 1H), 6.80 (m, 2H), 6.99 (m, 2H), 7.15-7.28 (m, 5H). 5

Step 3 A mixture of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-6-(2-hydroxy-2- methylpropyl)-1,3-oxazinan-2-one (640 mg, 1.42 mmol), AA^’.S.S.S'.S'-octamethyl·^'- bi(1,3,2-dioxaborolane) (470 mg, 1.85 mmol), 10 PdCI2dppf (40 mg, 0.047mmol , KOAc (490 mg, 4.97 mmol) in DMSO (8 mL) was heated at 90 °C for 20 h. The mixture was diluted with EtOAc, and washed with water. The organic phase was separated, and concentrated to give the crude product, which was purified by preparative TLC to afford (S)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2- dioxaborolan-2- 15 yl)phenyl)ethyl)-1,3-oxazinan-2-one (700 mg, 99%). 1H NMR (CDCI3): 6=1.08 (s, 3H), 1.13 (s, 3H), 1.32 (s, 12H), 1.51 (t, 3H), 1.94 (m, 2H), 2.16 (m, 5H), 2.33 (m, 1H), 2.83 (m, 1H), 5.69 (m, 1K), 6.99 (m, 4H), 7.25 (m, 2H), 7.61 (m, 2H).

Step 4 20 A mixture of (S)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4- (4,4,5,5-tetramethyl-l ,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (700 mg, 1.41 mmol), 5-bromo-1-methylpyridin-2(1/-/)-one (398 mg, 2.12 mmol), PdCt2(Ph3P)2 (70 mg), Cs2CO3 (1.5 mL, 3.0 mmol) in 1,4-dioxane (15 mL) was heated under reflux for 2 h. The mixture was diluted with EtOAc, and washed with water. 25 The organic phase was separated, and concentrated to give the crude product, which was purified by preparative TLC to afford (S)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo- 1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (150 mg, 22%). 1H NMR (CDCI3): 6=1.12 (s, 3H), 1.13 (s, 3H), 1.51 (t, 3H), 2.16 (m, 2H), 2.21 (m, 2H), 2.41 (m. 1H), 2.92 (m, 1H), 3.63 (s, 3H), 5.69 (q, 30 1H), 6.69 (m, 1H), 6.99 (m, 4H), 7.18 (m, 2H)57.27 (m, 2H) δ 7.42 (m, 1H), 7.52 (m, 1H). WO 2010/011314 PCT/US2009/004261 -128 - EXAMPLE 33 (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6- dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002140.tif" id="idf0140" />

Step 1

To a solution of (R)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-

1,3- oxazinan -2-one (1.19g, 2.8mmol) in THF (30 mL) was added BH3 THF (8,5 mL, I 10 mol/L, 8.5mmol) at 0 °C under nitrogen atmosphere. The formed mixture was stirred for 2 h. The reaction was quenched with water. Then NaOH (1 mol/L, 6mL) and H2O2 (5 mL) were added to the above mixture. When the reaction was over, the mixture was extracted with EtOAc. The combined organic phase was concentrated to give the crude product, which was purified by preparative TLC to give (R)-3-((S)-1 -(4- 15 bromophenyl) ethyl)-6- (4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one (1.13 g, 92%). WO 2010/011314 PCT/US2009/004261 - 129-

Step 2 A mixture of (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one (520mgt t.2mmol) and 6-aminopyridin-3-ylboronic acid (280mg, 1.44mmol), Pd(Ph3P)2CI2 (100mg), and aq CS2CO3 solution (3mL, 2M) in 1,4-dioxane (20 mL) was stirred and heated to reflux for 2 h. The organic phase was separated, and concentrated to give crude product, which was purified by preparative TLC to give (R)-3-((S)-1-(4-(6-aminopyridin-3-yl)phenyl)ethyl)-6-(4-fluoophenyl)-6-(3-hydroxy propyl)-1,3-oxazinan-2-one .(400mg,74%).

Step 3 (R)-3-(($)-1-(4-(6-aminopyridin-3-yl)phenyl)ethyl)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-1,3-oxazinan-2-one (400 mg, 0.88 mmoL) was dissolved in 3.5 M H2SO4 (10 mL), and 2 M NaNC&gt;2 (6 mL) was added at 0 °C. The reaction mixture was stirred at rt for 20 min. The reaction mixture was then treated with aqueous NaOH solution (8%), and extracted with CK2CI2. The combined organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated to give crude product, which was purified by preparative TLC to give (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (350 mg, 0.78 mmol). NMR (CDCI3): 6=1.10-1.25 (m, 8H), 1.37 (m, 1H), 1.42-1.55 (m, 2H), 1.78-1.93 (m, 2H), 2.10-2.38 (m, 2H), 2.87 (m, 2K), 3.52-3.58 (m, 1H), 3.31-3.97 (m, 1H), 4.12-4.19 (m, 1H), 5.53-5.63 (m. 1H), 6.85-7.15 (m, 3H), 7.35- 7.55 (m, 1H), 7.75-7.89 (m, 1H), 8.10-8.12 (m, 1H).

Step 4 A mixture of (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (100 mg, 0.78 mmol), imidazole (142.8 mg, 2.1 mmol), and ferf-butylchlorodimethylsilane (350 mg, 2.34 mmol) in CH2CI2 (20 mL) was stirred overnight. The mixture was washed with water and extracted with EtOAc. The combined organic phase was washed with brine, dried over Na2SO4, filtered and concentrated to give crude (R)-6-(3-(ferf- butyldimethylsilyloxy)propyl)-6-(4-fluorophenyl)-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin- WO 2010/011314 PCT/US2009/004261 -130 - 3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (120 mg), which was used for the next step without further purification.

Step 5

To a suspension of NaH (18 mg, 0.72 mmol) in THF (0.5 mL) was added a 5 solution of (R)-6-(3-(ferf-butyldimethylsilyloxy)propyl)-6-(4-fluorophenyl)-3-((S)-1 -(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (100mg, 0.18 mmol) in THF (10 mL) at 0 °C. The resulting mixture was stirred for 1 h. Then CH3I (613 mg, 43.2 mmol) was added, and the mixture was stirred for 3 h. The reaction was quenched with aq NH4CI solution. The organic phase was separated, and 10 concentrated to give (R)-6-(3-(tert-butyldimethylsilyloxy)propyl)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (104 mg,100%), which was used for the next step without further purification.

Step 6 15 A mixture of (R)-6-(3-(tert-butyldimethylsilyloxy)propyl)-6-(4-fluorophenyl)-3-((S)-1 -(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (200 mg, 0.35 mmol) and TBAF (182 mg,0.7 mmol) in CH3CN was stirred and heated to reflux for 15 min. When the reaction was over, the mixture was washed with water and extracted with EtOAc. The combined organic phase was washed with brine, dried 20 over Na2SO4, filtered and concentrated to give crude product, which was purified by preparative HPLC to give (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (5.01 mg, 4%). LC-MS Method 2 tR = 1.065 min, m/z = 464.21; 'H NMR (CDCb): 6=1.38 (m, 1H),1.47 (d, 3H), 1.63 (m, 2H), 1.91 (m, 2H), 2.10-2.30 (m, 3H), 2.87 (m, 1H), 2.84 (m, 1H), 25 3.51 (m, 2H), 3.56 (s, 3H), 5.63 (m, 1H), 6.67 (m, 1H), 6.87-6.98 (m, 4H), 7.15 (m, 2H), 7.27 (m, 1H), 7.29(m, 1H), 7.32 (m, 1H), 7.55(m, 1K). WO 2010/011314 PCT/US2009/004261 -131 - EXAMPLE 34 N-(3-((R)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-6 -oxo-1,6-dihydropyridin-3- yl)phenyl)ethyl)-2-oxo-1,3-oxazinan-6-yl)propyl)methanesulfonamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002141.tif" id="idf0141" />

5 The title compound was prepared from (R)-6-(4-fluorophenyl)-6-(3- hydroxypropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one by treatment with (i) MeSOzCI and (it) MeSOzNHz- LC-MS Method 2 tR = 102 min, m/z = 542.3; 1H NMR (CDCI3) 1.35 (m, 1H), 1.53 (d, 3H), 1.69 (m, 1H), 1.89 (m, 1H), 2.00 (m, 1H), 2.17-2.33 (m, 3H), 2.89 (s, 3H), 2.97 (m, 1H), 3.06 (m, 10 2H), 3.66 (s, 3H), 4.38 (s, 1H). 5.67 (m, 1H), 6.82 (d, 1H), 6.99 (m, 4H), 7.15 (m, 2H), 7.22 (m, 2H), 7.47 (s, 1H), 7.63 (d, 1H). EXAMPLE 35 3-((R)-2-oxo-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyf)ethyl)-6-phenyl-113-15 oxazinan-6-yl)propanamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002142.tif" id="idf0142" />

The title compound was prepared from 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanamide following procedures analogous to those described in Example 33 Steps 2 and 3. LC-MS Method 2 tR = 0.999 min, m/z = 20 446.1; 1H NMR (CD3OD) 1.53 (d, 3H), 1.91-2.01 (m, 1H), 2,18-2.34 (m, 4H), 2.35-2.51 WO 2010/011314 PCT/US2009/004261 - 132- {m, 2H), 3.03-3.12 &lt;m, 1H), 5.56 (m, 1H), 6.62 (d, 2H), 7.03 (d, 2H), 7.24-7.44 (m, 7H), 7.59 (m, 1H),7.87 (m, 1H). EXAMPLE 36 (S)-6-(2-hydroxyethyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3- yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002143.tif" id="idf0143" />

The title compound was prepared from (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2 10 hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one using a procedure analogous to that described in Example 33 Steps 2 to 6. LC-MS Method 2 tR = 1.038 min, m/z - 433.1; Ή NMR(CDCI3) 1.48 (d, 3H), 2.06-2.19 (m, 2H), 2.11-2.31 (m, 3H), 2.84 (m, 1H), 3.50 (m ,1H), 3.54 (s, 3H), 3.72 (m, 1H), 5.62 (m, 1H),6.60 (d, 1H),6.86 (d, 2H), 7.06 (d, 2H), 7.26 (m, 3H), 7.32 (m, 3H), 7.47 (d, 1H). 15 WO 2010/011314 PCT/US2009/004261 -133 - EXAMPLE 37 (S)-6-(2-hydroxy-2-methytpropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-d ihyd ropy rid i n-3- yl)phenyl)ethyl)-6-pheny)-1,3-oxazinan-2-one

Method 1

<img img-format="tif" img-content="drawing" file="IL210452AD0002144.tif" id="idf0144" />

The title compound was prepared from (R)-6-allyl*3-((S)-1-(4-bromophenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one using procedures analogous to those described in Example 33 Steps 2, 3 and 5, followed by procedures analogous to 10 those described in Preparation 1 Method 1 Steps 4 and 6. LC-MS Method 2 tR = 1.116 min, m/z = 461.1; Ή NMR (CDCb) 1.09 (s, 3H), 1.16 (s, 3H), 1.51 (m, 3H), 2.05-2.20 (4H), 2.40 (m, 1H), 2.84 (m, 1H), 3.59 (s, 3H), 5.64 (m, 1H), 6.62 (m, 1H), 6.96 (m, 2H), 7.14 (m, 2H), 7.28-7.39 (m, 5H), 7.48 (m, 1H), 7.50 (m, 1H). WO 2010/011314 PCT/US2009/004261 - 134 -

Method 2

<img img-format="tif" img-content="drawing" file="IL210452AD0002145.tif" id="idf0145" />

Step 1

To a solution of (K)-6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-phenyl-1,3- 5 oxaztnan- 2-one (20 g, 50 mmol) and CuCI (12.4 g, 125 mmol) in dry DMF (50 mL) was added H2O (12 mL) and PdCI2 (2.66 g, 15 mmol) at 0 ~ -5 °C. After addition, the mixture was allowed to warm to rt gradually for 48 h under O2. After TLC showing the stating material had disappeared, the solid was filtered off. Water (200 mL) and EtOAc (50mL) were added. The layers were separated and the aqueous layer was 10 extracted with EtOAc (3 * 40 mL). The combined organic layer was washed with brine, dried over Na2SO4, filtered and concentrated to give a residue, which was purified by column chromatography to give (S)-3-((S)-1-(4-bromo-phenyl)ethyl)-6-(2-oxopropyl)-6-phenyl-1,3-oxazinan-2-one (12 g, 58%). 15 Step 2

To a solution of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-oxopropyl)-6-phenyl- 1,3- oxazinan- 2-one (12 g, 28.8 mmol) in anhydrous THF (100 mL) was added dropwise methylmagnesium bromide (48 mL, 144 mmol) at -78 °C under nitrogen.

The mixture was stirred at rt for 1 h. The reaction mixture was quenched with 20 aqueous NH4CI solution (50 mL) in ice water bath. The layers were separated and the aqueous layer was extracted with EtOAc (150 mL). The combined organic phases were washed with brine (30 mL), dried over Na2SO4 and concentrated in vacuo to give the crude product, which was purified by preparative HPLC and chiral HPLC to afford (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3- 25 oxazinan-2- one (6.6 g, 53%). WO 2010/011314 PCT/US2009/004261 - 135 -

Step 3

To a solution of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (6.6 g, 15.2 mmol) and 4,4,4^4^5,5,5',5'-octamethyl- 2,2'-bi(1,3,2- dioxaborolane) (6.1g, 24.3 mmol) in dry DMSO (20 mL) was 5 added KOAc (4.8 g, 48.6 mmol) and Pd(dppf)cl2 (372 mg, 0.46 mmol). After addition, the mixture was allowed to warm to 100 °C for 20 h. After TLC showed the starting material had disappeared, the solid was filtered off. Water (60 mL) and EtOAc (20mL) were added. The layers were separated and the aqueous layer was extracted with EtOAc (3 * 15 mL). The combined organic layer was washed with brine, dried over 10 Na2SO4, filtered and concentrated to give a residue, which was purified by column chromatography to give ($)-6-(2-hydroxy-2-methylpropyl)- 6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-an-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (4.4 g, 60%). 15 Step 4

To a solution of (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-((S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl)-1,3-oxazinan-2-one (2,2 g, 4.58 mmol) and 5-bromo-1-methylpyridin-2(1H)-one (1.37 g, 7.33 mmol) in dry 1,4-dioxane (4 mL) was added aqueous CSCO3 solution (10 mL, 10 mmol) and 20 Pd(PPh3)2Cl2 (967 mg, 1.38 mmol). After addition, the mixture was heated at 110 °C for 30 min in a microwave. After TLC showed the stating material had disappeared, the solid was filtered off. Water (20 mL) and EtOAc (10mL) were added. The layers were separated and the aqueous layer was extracted with EtOAc (3*10 mL). The combined organic layer was washed with brine, dried over Na2SO4, filtered and 25 concentrated to give a residue, which was purified by preparative HPLC to give (S)-6-(2-hydroxy-2- methylpropyl)-3-((S)-1-(4-(1 -methyl-6-oxo- 1,6-dihydropyrid in-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (730 mg, 35%). 1H NMR (CDCI3): 1.09 (s, 3H), 1.16 (s, 3H), 1.51 (m, 3H), 2.05-2.20 (4H), 2.40 (m, 1H), 2.84 (m, 1H), 3.59 (s, 3H), 5.64 (m, 1H), 6.62 (m, 1H), 6.96 (m, 2H), 7.14 (m, 2H), 7.28-7.39 (m, 5H), 30 7.48 (m, 1H), 7.50 (m, 1H). The compound was recrystallized by two methods.

Recrystallization Method A A mixture of (S)-6-(2-hydroxy-2- methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (ca. 2.94 g) and WO 2010/011314 PCT/US2009/004261 - 136 - isopropyl acetate (160 mL) was vigorously stirred at room temperature or warmed at 50 °C until most of the solid was dissolved. The resulting mixture was filtered through an HPLC filter and then the filtrate was slowly stirred at room temperature overnight.

The solids were filtered, washed with isopropyl acetate and dried at rt under high

5 vacuum to afford 1.43 g (49%) of a crystalline solid. M.p. 95-101 °C. This form was determined to be a hydrate which released 3.6% water by weight on heating. Recrystallization Method B A mixture of (S)-6-(2-hydroxy-2- methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (ca. 10.03 g) and 10 isopropyl acetate (600 mL) was heated to reflux in a 130 °C oil bath until the solid was completely dissolved to form a homogeneous solution. Heating was stopped and the resulting solution was slowly stirred while slowly cooling to room temperature in the oil bath overnight. The solids were filtered, washed with isopropyl acetate and dried at rt under high vacuum to afford 7.30 g (73%) of crystalline solid. M.p. 180-181 °C. This 15 form was determined to be anhydrous. EXAMPLE 38 3-((R)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethy1)-2-oxo-6- phenyl-1,3-oxazinan-6-yl)propanamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002146.tif" id="idf0146" />

The title compound was prepared from (R)-6-allyl-3-((S)-1-(4-(1-methyl-6-oxo-

1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one using a procedure analogous to that described in Example 29 Step 2 followed by treatment with (i) Jones reagent and (ii) NH3, EDC, HOBt. LC-MS Method 2 tR = 1.028 min, m/z = 460.2; 1H 25 NMR(CDCb) 1.53 (d, 3H), 1.91-2.01 (m, 1H), 2.11-2.42 (m, 5H), 2.46-2.54 (m, 1H), 2.88-2.96 (m, 1H), 3.60 (s, 3H). 5.26 (s, 1H), 5.42 (s, 1H), 5.66 (m, 1H), 6.69 (d, 1H), 6.95-7.03 (d, 2H), 7.12-7.20 (m, 2H), 7.24-7.41 (m, 5H), 7.52 (m, 1H). WO 2010/011314 PCT/US2009/004261 -137 - EXAMPLE 39 N-(3-((R)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6- phenyl-1,3-oxazinan-6-yl)propyl)methanesulfonamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002147.tif" id="idf0147" />

5 The title compound was prepared from (R)-6-(3-hydroxypropyl)-3-((S)-1 -(4-(1- methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one by treatment with (i) MeSO2CI and (ii) MeSO2NH2, K2CO3. LC-MS Method 2 tR = 1.095 min, m/z = 524.1; 1H NMR (CDCI3) 1.30-1.41 (m, 1H), 1.52 (d, 3H), 1.71 (m, 1H), 1.87-2.07 (m, 3H), 2.09-2.20 (m, 3H), 2.22-2.32 (m, 2H), 2.88 (s, 3H), 3.06 (m, 2H), 10 3.60 (s, 3H), 4.32 (s, 1H), 5.65 (m, 1H), 6.67 (d, 1H), 6.94 (m, 2H), 7.11 (d, 2H), 7.25 (m, 1H), 7.27-7.40 (m,4H), 7.53 (dd, 1H). EXAMPLE 40 (S)-6-(2-hyd ro xyethy I)-3-«S) -1 -(4-(1 -methy l-6-oxo-1,6-dihyd ropyrid in-3 -

<img img-format="tif" img-content="drawing" file="IL210452AD0002148.tif" id="idf0148" />

The title compound was prepared from (S)-3-((S)-1-(4-bromophenyl)propyl)-6-(2-hydroxyethyl)-6-phenyl-1,3-oxazinan-2-one following a procedure analogous to that described in Example 18 using 5-bromo-1-methylpyridin-2(1H)-one in Step 2. LC-MS 20 Method 2 tR= 1.627 min, m/z = 447.1; 1H NMR (CDCI3) 1-06 (m, 3H)t 1.87-2.06 (m, 2H), 2.11-2.28 (m, 2H), 2.33 (m, 3H), 2.96 (m, 1H), 3.53 (m, 1H), 3.62 (s, 3H), 3.78 (m, 1H), 5.48 (m, 1H), 6.69 (m, 1H),7.03 (m, 2H), 7.14 &lt;m, 2H), 7.21-7.38 (m, 4H), 7.41 (s, 1H), 7.56 (m, 1H). WO 2010/011314 PCT/US2009/004261 - 138 - EXAMPLE 41 (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1-(4-(2-oxo-1,2-dihydropyridin-3- yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002149.tif" id="idf0149" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002150.tif" id="idf0150" />

5 The title compound was prepared from (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1 - (4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 3-bromo-2-hydroxypyridine using a procedure analogous to that described in Example 3 Step 2, followed by a procedure analogous to that described in Example 29 Step 2. LC-MS Method 1 tR = 1.24, m/z = 452(M+1); 1H NMR (CDCI3) 7.76(d, 1H), 7.52(d, 10 1H), 7.42(dd, 2H), 7.24(m, 2H), 7.08-7.00(m, 4H), 6.75(t, 1H), 5.70(m, 1K), 3.58(t, 1H), 2.94(m, 1H), 1.54(d, 3H). EXAMPLE 42 (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1-(4-(1-methyl“2-oxo-1,2- 15 d ihyd ropyridi n-3-yl)p henyljethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002151.tif" id="idf0151" />

Step 1 (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (18 mg, 0.039 mmol), 3-bromo-2- 20 hydroxypyridine (14 mg, 2 equiv), Pd(dppf)Cl2 (3mg, 10%mol), 2M aq Na2CO3 solution (800 pL) and 1,4-dioxane (1.5mL) were mixed. The mixture was evacuated and WO 2010/011314 PCT/US2009/004261 - 139 - refilled with Nz gas (3 x) before being heated overnight at 85 °C. After being cooled to rt, the mixture was filtered and acidified with 5% aq HCI solution before being purified by prep HPLC to afford (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1-(4-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (7.2mg, 43% yield). LC-MS Method 1 tR=1.57min, m/z 433 (M+1).

Step 2 A solution of (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1-(4-(2-oxo-1,2-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (15.5 mg, 0.036 mmol) in dry DMF (1 mL) was cooled to 0 °C. Sodium hydride (60% in mineral oil, 3 mg, 2 equiv) was added. After 20 min, iodomethane (4.5 pL, 2 equiv) was added. The mixture was stirred another 20 min before being warmed to rt slowly and stirred for 2 h. LC-MS found the reaction completed. The mixture was quenched with satd aq NH4CI (1mL) and purified by prep HPLC to afford (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (13.3 mg, 83% yield). LC-MS Method 1 tR=1.63min, m/z 447 (M+1).

Step 3 A solution of (R)-6-allyl-6-(4-fluorophenyl)-3-((S)-1-(4-( 1-methyl-2-oxo-1,2-dihydropyridin-3-yl)phenyl)ethyl)-1,3-oxazinan-2-one (13.3mg, 0.030mmol) in dry THF (1.5mL) was cooled to 0 °C. Disiamyl borane (0.5M in THF, 500pL, excess) was added. After 10 min, the mixture was warmed to rt and stirred for 1 h. The mixture was cooled to 0 °C again, quenched with water (1 mL) and NaBOj (10mg). The mixture was concentrated and purified by prep HPLC to afford (R)-6-(4-fluorophenyl)-6-(3-hydroxypropyl)-3-((S)-1-(4-(1-methyl-2-oxo-t ,2-dihydropyridin-3-yl)phenyl)ethyl)- 1,3-oxazinan-2-one (4.2mg, 30% yield). LC-MS Method 1 tR = 1.33 min, m/z = 487(M+1); Ή NMR (CD3CI) δ 7.47(dd, 1H), 7.38(m, 3H), 7.24(m, 2H), 7.07(t, 2H), 6.96(d, 2H), 6.39(t, 1H), 5.65(m, 1H), 4.26(t, 1H), 3.66(S, 3H), 2.91(m, 1H), 2.40-2.14(m.3H), 1.54(d, 3H). WO 20107011314 PCT/US2009/004261 - 140- EXAMPLE 43 (R)-3-((S)-1-(4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(3- hydroxypropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002152.tif" id="idf0152" />

5 The title compound was prepared following procedures analogous to those described in Example 30 using ethyl iodide in Step 1, to afford 5-bromo-1-ethylpyridin 2(1H)-one which was used in Step 2. LC-MS Method 2 tR = 1.297 min, m/z - 461.1; ’H NMR (CDCI3) 1.31 (m, 1H), 1.36 (t, 3H), 1.51 (d, 3H), 1.68 (m, 1H), 1.86-2.01 (m, 2H), 2.18 (m, 1H), 2.27 (m, 2H), 2.91 (m, 1H), 3.52 (m, 2H), 4.18 (m, 2H), 5.13 (m, 10 1H), 5.62 (m, 1H), 6.91 (m, 3H), 7.08 (m, 2H), 7.18-7.33 (m, 5H), 7.41 (s, 1H), 7.61 (d 1H). EXAMPLE 44 (R)-6-(3-hydroxypropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3- 15 yl)phenyl)propyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002153.tif" id="idf0153" />

The title compound was prepared from (R)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1,3-oxazinan-2-one following procedures analogous to those described in Example 30 Step 2. LC- 20 MS Method 2 tR = 1.113 min, m/z = 461.1; Ή NMR (CDCI3) 0.95 (t. 3H). 1.30 (m. 1H) 1.68 (m, 1H), 1.81-1.99 (m, 2H), 2.11-2.32 (m, 3H), 2.88 (m, 1H), 3.50 (m, 2H), 3.58 (m, 2H), 5.43 (m, 1H), 6.49 (d, 1H), 6.98 (d, 2H), 7.08 (d, 2H), 7.19 (m, 1H), 7.25 (m, 4H). 7.32 (s. 1K), 7.47 (m. 1H). WO 2010/011314 PCT/US2009/004261 - 141 - EXAMPLE 45 (R)-6-(3-hydroxypropyl)-3-((S)-1-(4-(2-hydroxypyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3

<img img-format="tif" img-content="drawing" file="IL210452AD0002154.tif" id="idf0154" />

5 The title compound was prepared from (R)-6-(3-hydroxypropyl)-6-phenyl-3- ((S)-1-(4-(4,4,5,5-tetramethyl-t,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 4-bromo-2-hydroxypyridine following a procedure analogous to that described in Example 30 Step 2. LC-MS Method 2 tR = 1.019 min, m/z = 865.4; 1H NMR (CDCI3) 1.29-1.40 (m, 1H), 1.49 (d, 3H), 1.60-1.72 (m, 1H), 1.83-2.01 (m, 3H), 10 2.18 (m, 1H), 2.21-2.37 (m, 2H), 2.88 (m, 1H), 3.51 (m, 2H), 5.63 (m, 1H), 6.41 (d, 1H), 6.68 (s, 1H), 6.90 (d, 2H), 7.21-7.33 (m, 7H), 7.39 (d, 1H). EXAMPLE 46 (R)-6-(3-hydroxypropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-2- 15 yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002155.tif" id="idf0155" />

The title compound was prepared from (R)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(4t4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 6-bromo-1-methylpyridin-2(1H)-one following a procedure analogous to that 20 described in Example 30 Step 2. LC-MS Method 2 tR = 1.088 min, m/z = 447; ’H NMR (CDCb) 1.38 (m, 1H), 1.56(d,3H), 1.70 (m, 1H), 1.95-2.08 (m, 2H), 2.23 (m, 1K), 2.37 (s, 2H), 3.05 (m, 1H), 3.33 (s, 3H), 3.58 (m, 2H), 5.73 (m, 1H), 6.29 (d, 1H), 6.89 (d, 1H), 7.01-7.09 (m, 4H), 7.21-7.39 (m, 5H), 7.53 (t, 1H). 6-Bromo-1-methylpyridin-2(1 H)-one was prepared from 6-bromopyridin-2(1H)- 25 one following a procedure analogous to that described in Example 59 Step 1. WO 2010/011314 PCT/US2009/004261 - 142- EXAMPLE 47 (R)-6-(3-hydroxypropyl)-3-( (S)-1 -(4-(1 -methyl-2-oxo-1,2-dihydropyridin-4- yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one 10

<img img-format="tif" img-content="drawing" file="IL210452AD0002156.tif" id="idf0156" />

Mel

NaH

<img img-format="tif" img-content="drawing" file="IL210452AD0002157.tif" id="idf0157" />

5

<img img-format="tif" img-content="drawing" file="IL210452AD0002158.tif" id="idf0158" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002159.tif" id="idf0159" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002160.tif" id="idf0160" />

To a suspension of NaH (80 mg, 2 mmol) in THF (10 mL) was added 4-bromopyridin-2-ol (80 mg, 0.46 mmol) at 0 °C. The resulting mixture was stirred for 1 h. Then CH3I (355 mg, 2.5 mmol) was added to the above mixture, and the mixture was stirred overnight. The reaction was quenched with aqueous NH4CI solution. The organic phase was concentrated to give the crude product, which was purified by column to give 4-bromo-1-methylpyridin-2(1H)-one (42.3 mg, 50%).

Step 2 15 A mixture of (/?)-6-(3-hydroxypropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl- 1,3,2- dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (50 mg, 0.11 mmol) and 4-bromo-1- methylpyridin-2(1/7)-one (30 mg, 0.16 mmol), Pd(Ph3P)2Cl2 (10 mg), and aq. Cs2CO3 solution (4 mL, 2 M) in 1,4-dioxane (10 mL) was stirred and heated to reflux for 2 h. When the reaction was over, the mixture was washed with water and 20 extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered and concentrated to give the crude product, which was purified by preparative TLC to give (R)-6-(3-hydroxypropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (25 mg , 51%). 1H NMR (CDCI3): 0=1.35 (m, 1H), 1.47 (d, 3H), 1.63 (m,2H), 1.94 (m, 2H), 2.18 (m, 1H), 2.39 (m, 2H), WO 2010/011314 PCT/US2009/004261 - 143- 2.86 (m, 1H), 3.51 (m, 5H), 5.63 (m, 1H), 6.31 (m, 1H), 6.70 (m, 1H), 6.91 (m, 2H), 7.20-7.32 (m, 8H). EXAMPLE 48 5 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

Method 1

<img img-format="tif" img-content="drawing" file="IL210452AD0002161.tif" id="idf0161" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002162.tif" id="idf0162" />

Step 1 A solution of 4-bromopyridin-2-amine (600 mg, 3.5 mmol) in a mixture of 2 M H2SO4 (20 mL) and 2 M Na2NO2 (10 mL) was stirred at 0-5°C for 2 h. The reaction mixture was extracted with CH2CI2, and the organic layer was washed with a 15 saturated NaCI solution, dried over anhydrous Na2SO4 and concentrated. The residue was purified by preparative TLC to give 4-bromopyridin-2-ol (303 mg, 50%).

Step 2

To a suspension of NaH (300 mg, 7.5 mmol) in THF (10 mL) was added 4-20 bromopyridin-2-ol (303 mg, 1.73 mmol) at 0 °C. After the resulting mixture was stirred for 1 h, CH3I (491 mg, 3.46 mmol) was added, and the mixture was stirred overnight. The reaction was quenched with aqueous NH4CI solution. The organic phase was concentrated to give the crude product, which was purified by column to give 4-bromo-1-methylpyridin-2(1H)-one (161 mg, 50 %). 25 WO 2010/011314 PCT/US2009/004261 - 144 -

Step 3 A mixture of (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (200 mg, 0.42 mmol), 4-bromo-1- methylpyridin-2(1A7)-°ne (118 mg, 0.63 mmol), Pd(Ph3p)2Cl2 (20 5 mg), and 2 M aq Cs2CO3 solution (5 mL, 10 mmol) in 1,4-dioxane (20 ml.) was stirred and heated to reflux for 2 h. When the reaction was finished, the mixture was washed with water and extracted with EtOAc, The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated to give the crude product, which was purified by preparative TLC to give (S)-6-(2-hydroxy-2-methylpropyl)- 3-((S)-1-(4-(1- 10 methyl-2-oxo-1 ,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2One (83 mg, 43%). LC-MS Method 2 tR= 1.16 min, m/z = 921.5;’H NMR (CDCI3) 1.11 (s, 3H), 1.18 (s, 3H), 1.22 (t, 1K). 1.52 (m, 3H), 2.21 (s, 2H), 2.22-2.34 (m, 2H), 2.34-2.46 (m, 1H), 2.85 (m, 1H), 3.57 (s, 3H), 5.59 (m, 1K), 6.33 (d, 1H), 6.68 (S, 1H), 7.01 (d, 2H), 7.29-7.41 (m, 8H); ’H NMR (CD3OD) 0.98 (s, 3H), 1.29 (s, 3H), 1.58 (d, 3H), 15 2.17 (s, 2H), 2.22 (m, 1H), 2.50 (m, 2H), 3.08 (m, 1H), 3.59 (s, 3H), 5.59 (m, 1H),6.61 (d, 1H), 6.66 (S, 1H), 7.08 (m, 2H), 7.30-7.40 (5H), 7.42 (d, 2H), 7.70 (d, 1H).

Method 2

<img img-format="tif" img-content="drawing" file="IL210452AD0002163.tif" id="idf0163" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002164.tif" id="idf0164" />

To a solution of 4-iodopyridin-2(1H)‘°ne (3 9. 0.013 mol) and K2CO3 (3.55 g, 0.026 mol) in DMF (30 mL) was added iodomethane (4.7 g, 0.033 mmol). The mixture was stirred at room temperature overnight. Water and EtOAc were added. WO 2010/011314 PCT/US2009/004261 -145-

The organic phase was dried over Na2SO4 and concentrated to give 4-iodo-1- methylpyridin- 2(1H)-one (1.6 g, 53%).

Step 2 5 A mixture of 4-iodo-1-methylpyridin-2(1H)-one (0.909 g, 3.76 mmol), (5)-6-(2- hydroxy-2-methyIpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethy!-1,3,2-dioxaborolan’ 2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (1.5 g, 3.13 mmol), 2 M aq CS2CO3 (3 mL, 6 mmol), and PdCWPPthfe (0.201 g, 0.282 mmol) in 1,4-dioxane (15 mL) was refluxed under N2 for 2 hours. The reaction mixture was filtered, and the filtrate was extracted 10 with EtOAc. The combined organic layer was washed with brine, dried over Na2SO4 and concentrated to obtain the crude compound, which was purified by preparative HPLC and chiral HPLC to obtain (S)-6-(2-hydroxy -2- methylpropyl)-3-((S)-1 -(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl) phenyl)ethyl) -6-phenyl-1,3-oxaztnan-2-one (399 mg, 28%). LC-MS and 1H NMR (CD3OD) were the same as those of product made by 15 Method 1. The compound was recrystallized using below methods.

The compound was obtained as a crystalline monohydrate by dropwise addition of 60 mL of water to a solution of 7.6 g of compound in 15 mL of methanol. After stirring for 1 h, the solid is filtered by suction, washed with water and diethylether and dried in an exsiccator over cone, sulphuric acid/potassium hydroxide. The 20 compound was also recrystallized from water/ethanol (80:20) to also yield the monohydrate. Melting point: 118-122°C.

The compound was recrystallized from isopropyl acetate following a procedure analogous to that described for Example 37 in Recrystallization Method B to give a crystalline solid with mp 106-116 °C. The compound was also recrystallized by this 25 method from EtOAc (mp 90-93 °C, mp 102-122 °C) from isobutyl acetate (mp 108-126 °C),from EtOH/TBME (mp 108-126 °C) and from 2-butanone.. WO 2010/011314 PCT/US2009/004261 - 146- 10 15 20

<img img-format="tif" img-content="drawing" file="IL210452AD0002165.tif" id="idf0165" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002166.tif" id="idf0166" />

Step 1 A mixture of (S)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (100 mg, 0.23 mmol), 2-methoxy-4-(4,4,5,5-tetramethyl· 1,3,2-dioxaborolan-2-yl)pyridine (68 mg, 1.25equiv), Pd(dppf)CI2.CH2CI2 (19 mg, 10%mol), 2M aq Na2CO3 (1 mL), 1,4-dioxane (3mL) was degassed, refilled with N2 gas for 3 times before being put into microwave oven for 2 h at 130 °C. LC-MS found the reaction was completed. The mixture was diluted with EtOAc (50 mL), washed with water (10 mL) and brine (8 mL), and dried over Na2SO4. After filtration and concentration, the residue was purified by chromatography on a 12-g silica gel column, eluted with a 0 to 10% MeOH in CH2CI2 gradient to afford (S)-6-(2-hydroxy-2 methylpropyl)-3-((S)-1-(4-(2-methoxypyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan 2-one (112 mg, quant yield). LC-MS Method 1 tR = 1.66min, m/z = 461(M+1).

Step 2 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(2-methoxypyndin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (28 mg, 0.061 mmol), potassium carbonate (17 mg, 2equiv), and lodomethane (40 pL, 10 equiv) were mixed with acetonitrile (2.5 mL) and heated at reflux for 4 h. After being cooled to rt, the mixture was acidified with 5% aq HCI and purified by prep HPLC to afford (S)-6-(2-hydroxy-2 methylpropyl)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (14.4 mg. 52%). LC-MS and 1H NMR (CD3OD) were the same as those of product made by Method 1. 25 WO 2010/011314 PCT/US2009/004261 - 147 - EXAMPLE 49 2,2-dimethyl-3-((R)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)- 2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD0002167.tif" id="idf0167" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002168.tif" id="idf0168" />

5 Method 1

The title compound was prepared from 2,2-dimethyl-3-((R)-2-oxo-6-phenyl-3-((S)-1 -(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-6-yl)propanenitrile and 5-bromo-1-methylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.231 min, 10 m/z = 470.1; 1H NMR (CDCI3) 1-28 (s, 3H), 1.40 (s, 3H), 1.47 (d, 3H), 2.09 (s, 2H), 2.21 (m, 1H), 2.41 (m, 2H), 2.83 (m, 1H), 3.52 (s, 3H), 5.56 (m, 1H), 6.58 (d, 1H), 6.82 (d, 2H), 7.02 (d, 2H), 7.30 (m, 6H), 7.43 (m, 1H).

<img img-format="tif" img-content="drawing" file="IL210452AD0002169.tif" id="idf0169" />

yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-6-yl)propanenitrile (202 mg, 0.444 mmol) and Mel (110 pL, 4equiv) in dry THF (5 mL) was cooled to 0 °C. NaH (60% in mineral oil, 20 36mg, 2equiv) was added. After 10min, the mixture was warmed to rt slowly and stirred for 3 h. LC-MS showed about 50% conversion. The mixture was heated for 1 h at 60 °C. LC-MS found the reaction completed. After cooling to rt, the mixture was cooled to 0 °C and quenched with satd aq NH4CI (3 mL). The mixture was then diluted with CH2Cl2 (20mL), washed with 1% aq HCI (5 mL) and brine (4 mL), and dried over 25 Na2SO4. After filtration and concentration, the residue was purified by prep HPLC to afford 2,2-dimethyl-3-((R)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3- WO 2010/011314 PCT/US2009/004261 - 148 - yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanenitrile (177.4 mg, 85% yield) product as a light brown oil.

Method 3

<img img-format="tif" img-content="drawing" file="IL210452AD0002170.tif" id="idf0170" />

I I

Mass spectrum (ESt+): &lt;n/z = 4-43 [M+HJ+ Mass spectrum (ESI+): mtz = 470 [M+HJ* 2,2-Dimethyl-3-(3-{(S)-1-[4-(1-methyl-6-oxo-1l6-dihydro-pyridin-3-yl)-phenyl]-ethyt}-2-oxo-(S)-6-phenyl-[1,3]oxazinan-6-yl)-propionitrile was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-(1 -methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinar&gt;-2-one following procedures analogous to those 10 described Example 71 Method 2 to prepare 3-((R)-3-((S)-1-(4-bromophenyl)ethyt)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile. (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[4-(1-methyl-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one, is obtained from coupling (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-[(S)-1 -(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- 15 yl)phenyl)ethyl]-1,3-oxazinan-2-one with 5-iodo-1 -methyl-1 H-pyridin-2-one by the action of Pd(PPh3)4 and 2 M aqueous Na2COa solution in a mixture of methanol and dioxane (1:3) at 80 °C. The compound that had been obtained as a foam was dissolved in a small amount of ethyl acetate and stirred overnight at rt. The solid was filtered by suction, washed with a small amount of diethylether and dried. Melting

20 point: 143-145°C EXAMPLE 50 2,2-dimethyl-3-((R)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyt)- 2-oxo-6-phenyl-1,3-oxazinan-6-yl)propanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD0002171.tif" id="idf0171" />

WO 2010/011314 PCT/US2009/004261 - 149 -

Method 1

The title compound was prepared from 2,2-dimethyl-3-((R)-2-oxo-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-6-yl)propanenitrile and 4-bromo-1-methylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1, LC-MS Method 2 tR = 1.103, m/z = 470.4; 1H NMR (CDCI3) 1.26 (s, 3H). 1.41 (s, 3H), 1.49 (d, 3H), 2.09 (s, 2H), 2.24 (m, 1H), 2.53 (m, 2H), 2.88 (m, 1H), 3.56 (s, 3H), 5.59 (m, 1H), 6.38 (d, 1H), 6.78 (s, 1H), 6.84 (d, 2H), 7.19 (m, 2H), 7.31 (m, 6H). 10

Method 2

<img img-format="tif" img-content="drawing" file="IL210452AD0002172.tif" id="idf0172" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002173.tif" id="idf0173" />

Mass spectrum (ES1+): m/z = 443 [M+HJ+-

<img img-format="tif" img-content="drawing" file="IL210452AD0002174.tif" id="idf0174" />

Mass spectrum (ESI+): m/z = 470 [M+HJ+ 15 20 (S)-2,2-Dimethyl-3-(3-{ 1 -[(S)-4-( 1 -methyl-2-oxo-1,2-dihyd ro-pyridin-4-yl)-phenyl]-ethyl}-2-oxo-6-phenyl-[1,3]oxazinan-6-yl)-propionitrile was prepared from ($)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-( 1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one following procedures analogous to those described in Example 71 Method 2 to prepare 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile. The starting compound, (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-(4-(1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one, is obtained from coupling (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-[(S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yf)phenyl)ethylJ-1,3-oxazinan-2-one with trifluoro-methanesulfonic acid 1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl ester employing the standard conditions, Pd(dppf)Cl2*CH2Cl2, 2 M aqueous Na2CO3 solution, DMF, 90 °C, 2 h. The compound that had been obtained as a resin was dissolved in a small amount of EtOAc and stirred overnight at rt. The solid was filtered by suction, washed with a small amount of diethylether and dried. Melting point: 195-198 °C. 25 WO 2010/011314 PCTAJS2009/004261 -150- EXAMPLE 51 2,2-dimethyl-3-((R)-3-((S)-1-(4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3‘Oxazinan-6-yl)propanamide

<img img-format="tif" img-content="drawing" file="IL210452AD0002175.tif" id="idf0175" />

5 The title compound was prepared from 2,2-dimethyl-3-((R)-2-oxo-6-phenyl-3- ((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pheny l)ethyl)-1,3-oxazinan-6-yl)propanenitrile and 4-bromo-1-rnethylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1, followed by treatment with H2O2, K2CO3. LC-MS Method 2 te = 1.133 min, m/z = 488.1; 1H NMR (CDCb) 1.12 (s, 3H), 10 1.19 (s, 3H), 1.49 (d, 3H), 2.09-2.28 (m, 3H), 2.32-2.58 (m, 2H), 2.89 (m, 1H), 3.59 (s, 3H), 5.61 (m, 1H), 6.54 (m, 1H), 6.88 (m, 1H), 6.97-7.10 (m, 2H), 7.28 (m, 6H), 7.42 (m, 1H), 7.53 (m, 1H). EXAMPLE 52 15 (S)-3-((S)-1-(4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)propyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002176.tif" id="idf0176" />

The title compound was prepared from (R)-6-allyl-3-(($)-1 -(4-bromophenyl)propyl)-6-phenyl-1,3-oxazinan-2-one following a procedure analogous to 20 that described in Example 32 Method 2 using 5-bromo-1-ethylpyridin-2(1 H)-one in Step 4. LC-MS Method 2 tR = 1.732 min, m/z = 475.1; 'H NMR (CDCb) 0.95 (s, 31-1),1.01 (t, 3H), 1.26 (8, 3K), 1.38 (t, 3H), 2.06 (m, 2H), 2.18-2.31 (m, 3H), 2.36 (m, 1H). 2.55 (m, 1H), 3.04 (m, 1H), 4.11 (m, 2H), 5.37 (m, 1H), 6.66 (d, 1H), 7.11 (m, 2H), 7.20-7.33 (m, 7H), 7.76 (d, 1H), 7.88 (s, 1H). 25 WO 2010/011314 PCT/US2009/004261 - 151 - EXAMPLE 53 ($)-3-((S)-1 -(4-(1 -ethyl-6-oxo-1,6-dihydropyridin-3-y l)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002177.tif" id="idf0177" />

5 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-( (S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyI)-1,3-oxazinan-2-one and 5-bromo-1-ethylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR ~ 1.224 min, m/z = 475.1; 1H NMR (CDCI3) 1.11 (s, 3H), 1.19 (s, 3H), 1.39 (t, 3H), 1.56 (d, 3H), 10 2.20 (s, 2H), 2.26 (m, 1H), 2.36-2.57 (m, 2H), 2.87 (m, 1H), 4.03 (m, 2H), 5.69 (m, 1H), 6.62 (d, 1H), 7.00 (d, 2H), 7.17 (d, 2H), 7.28-7.51 (m, 6H), 7.50 (d, 1H). Recrystallization from isopropyl acetate following a procedure analogous to that described for Example 37 in Recrystallization Method B afforded a crystalline solid with mp 167-168 °C. 15 EXAMPLE 54 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3- yl)phenyl)propyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002178.tif" id="idf0178" />

20 The title compound was prepared from (R)-6-allyl-3-((S)-1 -(4- bromophenyl)propyl)-6-phenyl-1,3-oxazinan-2-one following a procedure analogous to that described in Example 32 Method 2 using 5-bromo-1-methylpyridin-2(1H)-one in Step 4. LC-MS Method 2 tR = 1.746 min, m/z = 475.2; Ή NMR (CD3OD) 1.04 (t, 3H), 1.11 (s, 3H). 1.24 (s, 3H), 1.95-2.04 (m, 2H), 2.13-2.26 (m, 4H), 2.44 (m, 1H), 2.91 (m, WO 2010/011314 PCT/US2009/004261 - 152- 1 Η), 3.61 (s, 3H), 5.36 (m, 1H), 6.67 (d, 1H), 7.10-7.33 (m, 8H), 7.42(s, 1H), 7.55 (d, 1H). EXAMPLE 55 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-( 1-methyl-2-oxo-1,2-dihydropyridin-4-

<img img-format="tif" img-content="drawing" file="IL210452AD0002179.tif" id="idf0179" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1I3,2-dioxaborolan-2-yl)phenyl)propyl)-1,3- 10 oxazinan-2-one and 4-bromo-1-methylpyridin-2(1H)-one following a procedure analogous to that described in Example 59 Step 2. LC-MS Method 2 tR = 1.203 min, m/z = 971.4; 1H NMR (CDCI3) 0.97 (t, 3H), 1.12 (s, 3H), 1.19 (s, 3H), 1.79-2.02 (m, 2H), 2.11-2.24 (m, 4H), 2.29-2.42 (m, 1H), 2.81 (m, 1H), 3.50 (s, 3H), 5.40 (m, 1H), 6,28 (d, 1 H&gt;, 6.64 (s, 1H), 7.02 (d, 2H), 7.18 (m, 3H), 7.20 (m, 2H), 7.28 (m, 3H). 15 EXAMPLE 56 (R)-6-ethyl-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)propyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002180.tif" id="idf0180" />

20 The title compound was prepared from (R)-3-((S)-1-(4-bromophenyl)propyl)-6- ethyl-6-phenyl-l ,3-oxazinan-2-one following procedures analogous to those described in Example 32 Method 2 Steps 3 and 4, LC-MS Method 1 tR = 1.6 min, m/z = 431 (M+1). WO 2010/011314 PCT/US2009/004261 - 153- (R)-3-((S)-1-(4-bromophenyl)propyt)-6-ethyl-6-phenyl-1,3-oxazinan-2-one was prepared from 1-chloro-3-phenylpentan-3-ol and (S)-1-(4-bromophenyl)propan-1-amine following a procedure analogous to that described in Example 71 Step 2. 1-chloro-3-phenylpentan-3-ol was prepared from 3-chloro-1-phenylpropan-1-5 one and ethylmagnesium bromide following a procedure analogous to that described in Preparation 1 Method 1 Step 2. EXAMPLE 57 (R)-6-ethyl-3-(($)-1-(4-(1-ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)propyl)-6-phenyl-10 1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002181.tif" id="idf0181" />

The title compound was prepared from (R)-3-((S)-1-(4-bromophenyl)propyl)-6-ethyl-6-phenyl-1,3-oxazinan-2-one following procedures analogous to those described in Example 32 Method 2 Steps 3 and 4 using 5-bromo-1-ethylpyridin-2(1H)-one in 15 Step 4. LC-MS Method 1 tR = 1.68 min, m/z = 445 (M+1). EXAMPLE 58 (R)-6-ethyl-3-((S)-1 -(4-(1 -methyl-2-oxo-1,2-d ihyd ropy rid i n-4-y I) phenyl) propyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002182.tif" id="idf0182" />

The title compound was prepared from (R)-3-((S)-1-(4-bromophenyl)propyl)-6-ethyl-6-phenyl-1,3-oxazinan-2-one following procedures analogous to those described in Example 32 Method 2 Steps 3 and 4 using 4-iodo-1-methylpyridin-2(1 H)-one in Step 4. LC-MS Method 1 tR = 1.58 min, m/z = 431 (M+1); 1H NMR(CDCb) 7.33 (1H, 25 d, J = 7.03 Hz), 7.29 - 7.21 (7H, m), 7.01 (2H, d, J = 8.20 Hz), 6.75 (1H, d, J = 2.05), WO 2010/011314 PCT/US2009/004261 -154- 6.39 (1H, dd, J = 2.05, 7.03), 5.48 (1H, ap dd, J = 6.44, 9.66), 3.58 (3H, s), 2.95-2,87 (1H, m), 2.37-2.14 (3H, m), 2.06-1.81 (m, 4H), 1.00 (3H, t, J = 7.32), 082 (3H, t, J = 7.61). EXAMPLE 59 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-( 1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002183.tif" id="idf0183" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002184.tif" id="idf0184" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002185.tif" id="idf0185" />

10 15

To a solution of 5-bromopyridin-2-ol (1 g, 5,75 mmol) in DMF (10 mL) were added 2-iodopropane (4.9 g, 28.75 mmol) and K2CO3 (4 g, 28.75 mmol). The mixture was stirred at rt overnight. The mixture was diluted with water (20 mL) extracted with EtOAc (3 x 25 mL), the combined organic phase was washed with brine, dried over Na2SO4, concentrated and purified by prep TLC to give 5-bromo-1-isopropylpyridin-2(1H)-one (380 mg, 31 %). 1H NMR (CDCI3): 1.35 (d, 6H), 5.65-5.75 (m, 1H), 6.48 (d, 1H),7.30 (m, 1H), 7.41 (d, 1H).

Step 2

To a solution of (S)-6»(2-hydroxy-2-rnethylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-20 tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (100 mg, 0.21 mmol) in 1,4-dioxane (2 mL) was added 5-bromo-1-isopropylpyridin-2(1W)-one (54.2 mg, 0.25 mmol). Then catalysts of Pd(PPh3)2Cl2 (14 mg, 0.02 mmol), CS2CO3 (1 mL, 2 M ) were added. The vessel was sealed with a septum and placed into the microwave cavity. Microwave irradiation of 100 W was used, the temperature being WO 2010/011314 PCT/US2009/004261 - 155 - ramped from room temperature to 120 °C. Once this temperature was reached, the reaction mixture was held at this temperature for 30 min. After the mixture cooled to rt, the mixture was filtered. The filtrate was extracted with EtOAc (20 mLx4), the organic layer was washed with brine, dried over Na2SO4 and concentrated to give the 5 crude product which was purified by preparative HPLC to give (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-isopropyl-6-oxo-1,6- dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (22 mg, 21%). 1H NMR (CDCb): 1.13 (s, 3H), 1.19 (s, 3H), 1.40 (6H), 1.53 (d, 3H), 2.18-2.30 (m, 4H), 2.40 (m, 1H), 2.88 (m, 1H), 5.31 (m, 1H), 570 (m, 1H), 6.73 (d, 1H), 7.02 (d, 2H), 7.15 (d, 2H), 7.27-7.38 (m, 5H), 7.43 (d, 10 1H), 7.50 (d, 1H). EXAMPLE 60 (R)-6-ethyl-3-((S)-1 -(4-(1 -isopropyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)propyl)-6-

<img img-format="tif" img-content="drawing" file="IL210452AD0002186.tif" id="idf0186" />

The title compound was prepared from (R)-3-((S)-1-(4-bromophenyl)propyl)-6-ethyl-6-phenyl-1,3-oxazinan-2-one following procedures analogous to those described in Example 32 Method 2 Steps 3 and 4 using 5-bromo-1-isopropylpyridin-2(1H)-one in Step 4. LC-MS Method 1 tR = 1.75 min, m/z = 459 (M+1); 1H NMR (CDCI3) 7.49, (1H, 20 dd, J = 2.34, 9.37 Hz), 7.42 (1H, d, J = 2.34 Hz), 7.32-7.24 (5H, m), 7.13 (1H, d, J = 8.20), 7.04 (1H, d, J =8.49), 6.66 (1H, d, J =9.37), 5.49 (1H, aq q, J = 6.44, 9.37), 5.33 (1H, m), 2.96-2.91 (1H, m), 2.39-2.32 (1H, m), 2.29-2.17 (2H, m), 2.05-1.85 (m, 4H), 1.41 (6H, dd, J = 1.17, 6.73), 1.01 (3H, t, J = 7.32 Hz), 0.832 (3H, t, J = 7.32 Hz). 5-bromo-1-isopropylpyridin-2(1H)-one was prepared from 5-bromopy rid in- 25 2(1 H)-one and isopropyl iodide following a procedure analogous to that described in

Example 59 Step 1. WO 2010/011314 PCT/US2009/004261 - 156- EXAMPLE 61 (S)-3-((S)-1 -(4-(1,5-dimethyt-6-oxo-1,6-dihyd ropy ridin-3-y t) phenyl )ethy I )-6- (2-hydroxy· 2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002187.tif" id="idf0187" />

5 The title compound was prepared following a procedure analogous to that described in Example 59 using 1 5-bromo-3-methylpyridin-2(1H)-one and methyl iodide in Step 1. LC-MS Method 2 tR = 1.197 min, m/z = 475.1; 1H NMR (CDCfe) 1.04 (s, 3H), 1.11 (s, 3H), 1.46 (d, 3H), 2.18 (m, 5H), 2.21 (m, 1H), 2.29-2.40 (m, 1H), 2.80 (m, 1H), 3.41 (s, 3H), 3.56 (s, 3H), 5.60 (m, 1H), 6.91 (d, 2H), 7.07 (d, 2H), 7.21-7.40 10 (m, 7H). EXAMPLE 62 (S )-3-((S)-1 -(4-(1 -ethyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethy1)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002188.tif" id="idf0188" />

The title compound was prepared following a procedure analogous to that described in Example 59, using 5-bromopyridin-2(1H)-one and ethyl iodide in Step 1 and (S)-6-(4-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl-1t3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one in Step 2. LC- 20 MS Method 2^ = 1.205 min, m/z = 493.2; 'K NMR (CDCIj) 1.16 (d, 6H), 1.39 (t, 3H), 1.52 {d, 3H), 2.19 (s, 4H), 2.20-2.31 (m, 2H), 2.38-2.50 (m, 1H), 2.90 (m. 1H), 4.04 (m, 2H), 5.69 (m, 1H),6.66(d, 1H), 7.00 (m,4H), 7.18 (d, 2H), 7.30 (m, 2H), 7.41 (s, 1H), 7.51 (d, 1H). Recrystallization from isopropyl acetate following a procedure analogous to that described for Example 37 in Recrystallization Method B afforded a 25 crystalline solid with mp 172-173.6 °C. WO 2010/011314 PCT/US2009/004261 - 157 - EXAMPLE 63 (R)~6-methyl-3-((S)-1 -(4-(1 -methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)propyl)-6-

<img img-format="tif" img-content="drawing" file="IL210452AD0002189.tif" id="idf0189" />

5 The title compound was prepared from (R)-3-((S)-1-(4-bromophenyl)propyl)-6- methy!-6-phenyl-1,3-oxazinan-2-one following procedures analogous to those described in Example 32 Method 2 Steps 3 and 4 using 4-iodo-1-methylpyridin-2(1H)-one in Step 4. LC-MS Method 1 tR = 1.55 min, m/z = 417 (M+1); 1H NMR (CDCI3)

7.41 (1H, d, J = 7.03 Hz), 7.33 (2H, d, J = 8.20 Hz), 7.29-7.19 (5H, m), 7.10(1H, d, J 10 = 8.20), 6.95 (1H, d = 1.76), 6.55 (1H, dd, J = 2, 7.03 Hz), 5.51 (1H, q, J =6.49, 9.66

Hz), 3.65 (3H, s), 3.00-2.95 (1H, m), 2.44-2.36 (1H, m), 2.33-2.15 (2H, m), 2.06-1.86 (2H, m), 1.64 (3H, s), 1.02 (3H, t, J = 7.32 Hz). (R)-3-((S)-1-(4-bromophenyl)propyl)-6-methyl-6-phenyi-1,3-oxazinan-2-one was prepared from 4-chloro-2-phenylbutan-2-ol and (S)-1-(4-bromophenyl)propan-1- 15 amine following a procedure analogous to that described in Example 71 Step 2. 4-chloro-2-phenylbutan-2-ol was prepared from 3-chloro-1-phenylpropan-1-one and methylmagnesium bromide following a procedure analogous to that described in Preparation 1 Method 1 Step 2. 20 EXAMPLE 64 (S)-3-((S)-1 -(4-(1,6-dimethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyt)-6-(2-hydroxy- 2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002190.tif" id="idf0190" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-25 phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1,3- WO 2010/011314 PCT/US2009/0O4261 - 158 - oxazinan-2-one and 4-bromo-1,6-dimethylpyridin-2( 1 H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.173 min, m/z = 475.2; 1HNMR (CDCI3) 1.10 (s, 3H),1.16 (s, 3H), 1.51 (d, 3H),2.18(m, 3H), 2.21 (m, 1H), 2.42 (m, 4H), 2.86 (m,1H), 3.54 {s, 3H), 5.66 (m, 1H), 6.21 (s, 1H), 6.60 5 (s, 1H), 6.97 (m, 2H), 7.23-7.34(m, 7H). 4-bromo-1,6-dimethylpyridin-2(1H)-one was prepared by methylation of 4- bromo-6-methylpyridin-2(1H)-one with methyl iodide using K2CO3 following a procedure analogous to that described in Example 59 Step 1. 10 EXAMPLE 65 (S)-3-((S)-1-(4-(1-ethyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2-hydroxy-2- methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002191.tif" id="idf0191" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-15 pheny l-3-((S)-1-(4-(4,4,5,5-tetramethy 1-1,3,2-dioxaborolan-2-yl)phenyl)propy 1)-1,3- oxazinan-2-one and 1-ethyl-4-iodopyridin-2{1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.228 min, m/z = 971.4; ΊΗ NMR (CDCI3) 1.10 (s, 3H), 1.14 (s, 3H), 1.36 (m, 3H), 1.53 (d, 3H), 2.17 (s, 2H), 2.21-2.32 (m, 2H), 2.32-2.48 (m, 1H), 2.88 (m, 1H), 4.00 (m, 2H), 5.68 (m, 1H), 6.39 20 (d, 1H), 6.78 (s, 1H), 6.99 (d, 2H), 7.27-7.38 (m, 8H). 1-ethyl-4-iodopyridin-2(1H)-one was prepared from 4-iodopyridin-2(1H)-one and ethyl iodide following a procedure analogous to that described in Example 59 Step 1. WO 2010/011314 PCT/US2009/004261 - 159- EXAMPLE 66 (S)-6-(2-hydroxy-2-metbylpropyl)-3-((S)-1 -(4-(2-oxo-1 -(2,2,2-trifl uoroet hyl)-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002192.tif" id="idf0192" />

5 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-S-KSJ-l-^-^AS.S-tetramethyl-I.S^-dioxaborotan^-yOphenyOpropylM.S-oxazinan-2-one and 4-iodo-1-(2,2,2-tnfluoroethyl)pyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.871 min, m/z = 471.1; 1H NMR(CDCI3) 1.11 (s, 3H), 1.17 (s, 3H), 1.53 (d, 3H), 2.16 10 2.33 (m, 4H), 2.35-2.47 (m, 1H), 2.89 (m, 1H), 4.58-4.70 (m, 2H), 5.69 (m, 1H), 6.71 (s, 1H), 7.00 (d, 2H), 7.19-7.38 (m, 8H). Recrystallization from isopropyl acetate following a procedure analogous to that described for Example 37 in Recrystallization Method B afforded a crystalline solid with mp 144-145.5 °C. 4-iodo-1-(2,2,2-trifluoroethyl)pyridin-2(1H)-one was prepared from 4- 15 iodopyridin-2(1 H)-one and 2,2,2-trifluoroethyl trifluoromethanesulfonate following a procedure analogous to that described in Example 59 Step 1. EXAMPLE 67 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(6-oxo-1-(2,2,2-trifluoroethyl)-1,6- 20 dihydropyridin-3-y!)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002193.tif" id="idf0193" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1,3-oxazinan-2-one and 5-bromo-1 -(2,2,2-trifluoroethyl)pyridin-2(1H)-one following a WO 2010/011314 PCT/US2009/004261 - 160- procedure analogous to that described in Example 6 Step 1 LC-MS Method 2 tR = 1.323 min, m/z = 471.1; Ή NMR (CDCI3) 1.13 (s, 3H), 1.19 (s, 3H), 1.53 (d,3H),2.19 2.30 (m, 4H), 2.40 (in, 1H), 2.89 (m, 1H), 4.67 (m, 2H), 5.69 (m, 1H), 6.70 (d, 1K), 7.03 (d, 2H), 7.13 (d, 2H), 7.29-7.38 (m, 6H), 7.55 (d, 1H). 5 5-bromo-1 -(2,2,2-trifluoroethyl)pyridin-2( 1 H)-one was prepared from 5- bromopyridin-2(1H)-one and 2,2,2-trifluoroethyltrifluoromethanesulfonate following a procedure analogous to that described in Example 59 Step 1. EXAMPLE 68 10 (S)-6-(2-hydroxy-2-methylpropyl)-3-«$)-1-(4~(1-isopropyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002194.tif" id="idf0194" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002195.tif" id="idf0195" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propyl)-1,3- 15 oxazinan-2-one and 4-iodo-1-isopropylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.846 min, m/z = 489.2; 1H NMR (CDCI3) 1.10 (s, 3H), 1.24 (s, 3H), 1.39 (d, 6H), 1.52 (d, 3H), 2.17-2.31 (m, 4H), 2.35-2.46 (m, 1H), 2.88 (m, 1H), 5.27 (m, 1H), 5.69 (m, 1H), 6.49 (d, 1H), 6.88 (s, 1H), 7.00 (d, 2H), 7.29-7.38 (m, 7H), 7,40 (d,1H). Recrystallization 20 from isopropyl acetate following a procedure analogous to that described for Example 37 in Recrystallization Method B afforded a crystalline solid with mp 134-139 °C. 4-iodo-1-isopropylpyridin-2(1 H)-one was prepared from 4-iodopyridin-2(1H)-one and isopropyl iodide following a procedure analogous to that described in Example 59 Step 1. 25 WO 2010/011314 PCTZUS2009/004261 -161 - EXAMPLE 69 3-((R)-6-(4-fluorophenyl)-3-((S)-1-(4-(1-methyl-6-oxo-1,6-dihydropyridin-3- yl)phenyl)ethyl)-2-oxo-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD0002196.tif" id="idf0196" />

The title compound was prepared from 3-((R)-6-(4-fluorophenyl)-2-oxo-3-((S)-1-(4-(4,4,5,5-tetramethyM A2&lt;iioxaborolan-2-yl)pbenyl)ethyl)-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile and 5-bromo-1-methylpyridin-2(1H)-one following a procedure analogous to that described in Example 3 Step 2. LC-MS Method 1 1r = 1.45 min, 10 m/z = 488; 'H NMR (CDCI3) 7.68(dd, 1H), 7.52(d, 1H), 7.32(q, 2H), 7.17(d, 2H)( 7.06(t, 2H), 6.97(d, 2H), 6.91 (d, 1H), 5.66(q, 1H), 3.72(s, 3H), 2.99(dt, 1H), 2.48(dd, 2H), 2.27(m, 1H), 2.11(s, 2H), 1.55(d, 3H), 1.44(s, 3H), 1.34(s, 3H). EXAMPLE 70 15 (S)-3-((S)-1 -(4-(1-ethyl-5-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2- hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002197.tif" id="idf0197" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-«S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3- 20 oxazinan-2-one and 5-bromo-1-ethyl-3-methylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.314 min, m/z = 489; 1H NMR (CDCI3) 1.09 (s, 3H), 1.15 (s, 3H), 1.35 (t, 3H), 1.50 (d, 3H),2.15-2.25 (m, 7H), 2.35 (m, 1H), 2.86 (m, 1H). 4.03 (m, 2H), 5.66 (q, 1H), 6.96 (d, 2H), 7.13 (d, 2H), 7.25-7.36 (m, 7H). WO 2010/011314 PCT/US2009/004261 - 162 - 5-Bromo-1-ethyl-3-methylpyridin-2(1H)-one was prepared by alkylation of 5-bromo-3-methylpyridin-2(1 H)-one with ethyl iodide following a procedure analogous to that described in Example 59 Step 1. 5 EXAMPLE 71 2,2-dimethyl-3-((R)-2-oxo-3-((S)-.1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6- phenyl-1,3-oxazinan-6-yl)propanenitrile

<img img-format="tif" img-content="drawing" file="IL210452AD0002198.tif" id="idf0198" />

Step 1 A 250 mL flask was charged with anhydrous CeCI3 (7.1890 g, 29.2 mmol) and THF (55 mL). The mixture was vigorously stirred for 2 h at rt. The suspension was 15 then cooled to -78 °C and a solution of 2-methylallylmagnesium chloride (0.5 M in THF, 56 mL, 28.0 mmol) was added. After stirring for 2 h at -78 °C, a solution of 3-chloropropiophenone (3.350 g, 19.8 mmol) in THF (30 mL) was added via cannula. The reaction mixture was allowed to slowly warm to 8 °C while stirring overnight (18 h). The reaction was then quenched with satd aq NaHCO3, extracted with EtOAc, and 20 dried over Na2SO4. After the solvents were evaporated, the crude 1-chloro-5-methyl-3-phenylhex-5-en-3-ol was directly used in the next step without further purification. LC-MS Method 1 fR = 1.91 min, m/z 248, 207 (M-OH)*; ’K NMR (400 MHz, CDCI3) 5 WO 2010/011314 PCT/US2009/004263 - 163 - 7.39-7.22 (m, 5H), 4.92 (m, 1H), 4.77 (m, 1H), 3.60-3.53 (m, 1H), 3.17-3.10 (m, 1H), 2.67 (d, J = 13.2 Hz, 1H), 2.55 (d, J = 13.2 Hz, 1H), 2.41-2.25 (m, 2H), 1.29 (s, 3H); 13C NMR (100 MHz, CDCI3) δ 144.55, 141.72, 128.32, 126.88, 125.07, 116.50, 74.44, 51.46, 46.34,40.19,24.22.

Step 2 1-chloro-5-methyl-3-phenylhex-5-en-3-ol (1.28 g, 5.7 mmol), (S)-1-(4-bromophenyl)ethanamine (1.37 g, 1.2 equiv), Kl (995 mg, 1.05 equiv), K2CO3 (1.57 g, 2 equiv) were mixed with acetonitrile (15 mL) and heated to reflux (oil bath 96°C) for overnight. After being cooled to rt, the mixture was filtered, concentrated, and purified by chromatography on a 40-g silica gel column, eluted with 0-8% MeOH in CH2CI2, to afford 1-((S)-1-(4-bromophenyl)ethylamino)-5-methyl-3-phenylhex-5-en-3-ol (1.33 g, 60%).

Step 3

To a solution of 1-((S)-1-{4-bromophenyl)ethylamino)-5-methyl-3-phenylhex-5-en-3-ol (1.33 g, 3.43 mmol) in CH2CI2 (100 mL) was added pyridine (277 pL, 1 equiv) and triethylamine (717 pL, 1 .Sequiv). The mixture was cooled to 0 °C, Methyl chloroformate (397 pL, 1.5 equiv) was added slowly. After 15 min, the mixture was warmed to rt slowly and stirred for 3 h. The mixture was then diluted with ether (200 mL), washed with 5% aq HCI (2 x 25 mL), satd aq NaHCOa (25 mL) and brine (20 mL), and dried over Na2SO4. After filtration and concentration, the crude methyl (S)-1-(4-bromophenyl)ethyl(3-hydroxy-5-methyl-3-phenylhex-5-enyl)carbamate was used for next steps without further purification.

Step 4

The crude methyl ($)-1-(4-bromophenyl)ethyl(3-hydroxy-5-methyl-3-phenylhex- 5-enyl)carbamate from above procedure was dissolved in dry THF (75 mL), NaH (60% in mineral oil, 274 mg, 2 equiv) was added slowly at rt. After 10 min, the mixture was heated to reflux for 2 h. LC-MS found reaction completed. The mixture was cooled to 0 °C, quenched with satd aq NH4CI (10 mL), diluted with ether (100 mL), washed with 1% aq HCI (25 mL) and brine (15 mL), and dried over Na2SO4. After filtration and concentration, the crude product was purified by by chromatography on a WO 2010/011314 PCT/US2009/004261 -164- 40-g silica gel column, eluted with 10-35% EtOAc in hexanes. The second UV active peak was collected to afford (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one (490mg 34.5% overall yield for Steps 3 and 4).

Step 5 A mixture of (R)-3-((S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-phenyl-1,3-oxazinan-2-one (490 mg, 1.18 mmol), TsCN (257 mg, 1.2 equiv), PhSiH3 (157 pL, 1.07 equiv) and the cobalt /V,W-bis(3,5-di-ferf-butylsalicylidene)-1,1,2,2-tetramethylethenediamine catalyst prepared as described in Preparation 3 (7.5 mg, 0.01 equiv) and ethanol (20 mL) was stirred 4 h at rt LC-MS found the reaction completed. The mixture was concentrated and purified by ISCO (40g column, 25-80% EtOAc in Hexanes) to afford 267mg product (51% yield). LC-MS Method 1 tR = 1.89min.( m/^441,443 (M+1).

Step 6

To a solution of 3-((R)-3-((S)-1-(4-bromophenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile (208mg, 0.47mmol) in 1,4-dioxane (5 mL) were added 6-oxo-1,6-dihydropyridin-3-ylboronic acid (98mg, 1.5 equiv), 2.0 M aq CS2CO3 solution (500 pL), and Pd(dppf)Cl2 (20mg, 0.06 equiv). The mixture was degassed and refilled with N2 gas 3 times, before being heated to 90 °C (oil bath) for 3 h. LC-MS found the reaction was complete. The mixture was cooled to rt, diluted with EtOAc (25 mL), and washed with water (10 mL). The aqueous layer was extracted with EtOAc (2x10 mL). The combined organic layers were washed with water (10 mL) and brine (8 mL), and dried over Na2SO4. After filtration and concentration, the residue was purified by chromatography (12-g silica gel cartridge, 0 -10% MeOH in CH2CI2, major UV peak) to afford 2,2-dimethyl-3-((R)-2-oxo-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-6-yl)propanenitriIe (202 mg, 94%) as a brown oil. LC-MS Method 1 tR = 1.34 min, m/z = 456 (M+1); 1H NMR (CDCI3) 8.01 (d, 1H), 7.80 (s, 1H), 7.36 (dt, 6H), 7.19 (d, 2H), 6.98 (m, 3H), 5.65 (d, 1H), 2.98 (d, 1H), 2.50 (m, 2H), 2.32 (m, 1H), 2.17 (s, 2H), 1.57 (d, 3H), 1.40 (s, 3H), 1.32 (s, 3H). WO 2010/011314 PCT/US2009/004261 - 165-

Method 2

<img img-format="tif" img-content="drawing" file="IL210452AD0002199.tif" id="idf0199" />

Br Co cat

TsCN

Ph3SiH

<img img-format="tif" img-content="drawing" file="IL210452AD0002200.tif" id="idf0200" />

Br

Step 1.3-[(S)-1-(4-Bromo-phenyl)-ethyl]-($)-6-(2-methyl-allyl)-6-phenyl-[1,3]oxazinan- 5 2-one (Methoxycarbonylsulfamoyl)triethylammonium hydroxide (1.38 g) was added to 3-[(S)-1-(4-bromo-phenyl)-ethyl]-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl- [1,3]oxazinan-2-one (2.0 g) dissolved in tetrahydrofuran (30 mL) and toluene (15 mL). The resulting solution was stirred at room temperature for 0.5 h and at 75 °C for 1 h. 10 After cooling to room temperature, the solution was concentrated and ethyl acetate was added to the residue. The resulting mixture was washed with aqueous NaHCCb solution and brine and dried (MgSO4). The title compound was obtained after removal of the solvent Yield: 1.9 g (quantitative). Mass spectrum (ESI*): m/z = 414/416 (Br) [M+Hf 15

Step 2. 3-{3-[(S)-1-(4-Bromo-phenyl)-ethyl]-2-oxo-(S)-6-phenyl-[1,3)oxazinan-6-yl}- 2,2-dimethyl-propionitrile 3-t(S)-1-(4-Bromchphenyl)-ethyl]-(S)-6-(2-methyl-atlyl)-6-phenyl-[1,3]oxazinan-2-one (0.21 g), p-toluenesulfonyl cyanide (143 mg), tert-BuOOH (5.5 M in decane, 27 20 pL), and phenylsilane (64 pL) were added in the given order to a flask charged with a stir bar, (1 /?,2/?)-(-)-1,2-cyclohexanediamino-N,N’-bis(3,5-di-tert~ butylsalicyliden)cobalt(ll) (3 mg) and ethanol (15 mL) in argon atmosphere. The resulting solution was stirred at room temperature for 3 h and then concentrated under reduced pressure. The residue was purified by chromatography on silica gel 25 (cyclohexane/ethyl acetate 60:40-&gt;0:100) to afford the title compound as a resin-like solid. Yield: 0,16 g (70% of theory). Mass spectrum (ESI*): m/z = 441/443 (Bf) [M+Hf WO 2010/011314 PCT/US2009/004261 - 166- EXAMPLE 72 (S)-3-((S)-1 -(4-( 1 -ethyl-6-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002201.tif" id="idf0201" />

5 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-((S)-1-(4-(414l5l5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl}-1,3-oxazinan-2-one and 4-bromo-1-ethyl-6-methylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 Ir = 1.211 min, m/z = 489.2; 1HNMR(CDCI3) 1.10 (s, 3H), 1.17 (s, 3H), 1.49 (s, 9H), 1.57 (d, 3H), 10 2.22 (m, 4H), 2.37 (m, 1H), 2.84 (m, 1H), 5.60 (m, 1H), 5.91 (s, 1H), 7.06 (d, 2H), 7.27-7.40 (m, 5H), 7.68 (d, 1H), 7.24 (d, 2H), 8.09 (d, 1H), 8.90 (s, 1H). 4-bromo-1-ethyl-6-methylpyridin-2(1H)-one was prepared by alkylation of 4-bromo-6-methylpyridin-2(1K)-one with ethyl iodide using K2CO3 following a procedure analogous to that described in Example 59 Step 1. 15 EXAMPLE 73 (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(1,5,6-trimethyl-2-oxo-1,2- dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002202.tif" id="idf0202" />

20 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-((S)-1-(4-(4,415,5-tetramethyl-1l3l2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 4-bromo-1I5,6-trimethylpyridin-2(1H)-one following a procedure analogous to that described in Example 6 Step 1. LC-MS Method 2 tR = 1.187 min, m/z = 489.2; Ή NMR (CDCI3) 1.10 (S, 3H),1.15 (S, 3H), 1.32 (m, 3H),1.52 (m, 3H), WO 2010/011314 PCT/US2009/004261 - 167 - 1.72 (s, 1 H),2.18 (m, 3H), 2.19 (m, 1H), 2.42 (m, 4H), 2.86 (m, 1H), 4.12 (m, 2H), 5.66 (m, 1H), 6.16 (s, 1H), 6.53 (s, 1H), 6.98 (m, 2H), 7.23-7.34 (m, 7H). 4-bromo-1,5l6-trimethylpyridin-2(1H)-one was prepared by alkylation of 4-bromo-5,6-dimethylpyridin-2(1H)-one with methyl iodide using K2CO3 following a 5 procedure analogous to that described in Example 59 Step 1. 4-bromo-5,6-dimethylpyridin-2(1H)-one was prepared following the procedure described in McElroy, W. T. and DeShong, P. Org. Lett. 2003, 5, 4779. EXAMPLE 74 10 3-((R)-3-((S)-1-(4-( 1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6- phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitnle

<img img-format="tif" img-content="drawing" file="IL210452AD0002203.tif" id="idf0203" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002204.tif" id="idf0204" />

2,2-diiTiethyl-3-((R)-2-oxo-3-((S)-1-(4-(6-oxo-1,6-dihydropyridin-3-yl)phenyI)ethyl)-6-phenyl-1,3-oxazinan-6-yl)propanenitrile (6 mg, 0.013 mmol) was 15 dissolved in DMF (2.5 mL). CS2CO3 (c.a. 15 mg, excess) and /-Prl (1 OOpL, excess) were added. The mixture was stirred for 3 h at rt. LC-MS found the reaction was complete. The mixture was purified by prep HPLC to afford 3-((R)-3-((S)-1 -(4-(1 -isopropyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-2-oxo-6-phenyl-1,3-oxazinan-6-yl)-2,2-dimethylpropanenitrile (1.99 mg, 30%). LC-MS Method 1 1r = 2.03 min, m/z = 20 498; 1H NMR (CDCI3) 8.35(d, 1H), 7.80(dd, 1H), 7.37(m, 5H), 7.22(d, 2H), 6.92(d, 2H),6.83(d, 1H), 5.66(q, 1H), 5.22(m, 1H), 2.93(m, 1H),2.16(s, 2H), 1.55(d, 3H), 1.46(s, 3H), 1.40(d, 6H), 1.33(s, 3H). WO 2010/011314 PCT/US2009/004261 - 168 - EXAMPLE 75 3-{(S)-1 -[4-(1 -Cyclopropyl-2-oxo-1,2-dihydro-py ridin-4-yl )-phenyI]-ethyl}-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002205.tif" id="idf0205" />

Method 1 2 M aqueous Na2CC&gt;3 solution (0.23 mL) was added to a solution of (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-[(S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl]-1,3-oxazinan-2-one (0.11 g) and trifluoro-methanesulfonic acid 1-cyclopropyt-2-oxo-1,2-dihydro-pyridin-4-yl ester (74 mg; alternatively, 4-bromo-1-cyclopropyl-1H-pyridin-2-one was used) in dimethylformamide (3 mL). The resulting mixture was sparged with argon for 15 min, before [1 ,T-bis(diphenylphosphino)-ferrocene]-dichloropalladium(ll) dichloromethane complex (10 mg) was added. The mixture was heated to 100 °C and stirred at this temperature overnight. After cooling to ambient temperature, water was added and the resulting mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO4), and concentrated. The residue was purified by chromatography on silica gel (CHzCb/MeOH 99:1-&gt;90:10) to afford the title compound as a foam-like solid which was crystallized with little ethyl acetate. Yield: 30 mg (27% of theory); Mass spectrum (ESI+): m/z = 487 [M+Hf. The compound (1.3 g) was recrystallized from 30 mL of isopropyl acetate. The hot solution, while being stirred, was slowly cooled down to room temperature overnight in the oil bath to yield the crystalline monohydrate. Mp 108-110qC.

The crystalline monohydrate was also obtained by recrystallization of 10.6 g of compound of Example 75 from 170 mL of isopropylacetate that had been saturated with water. The hot solution, while being stirred, was slowly cooled down to room temperature, stirred for 2 hours at room temperature and 1 hour in an ice-bath. The solid was filtered by suction and dried overnight at 50°C. Yield 10.2 g. Mp 112-114”C. WO 2010/011314 PCT/US2009/004261 - 169 -

The compound of Example 75 (2.0 g) was also recrystallized from a mixture of 30 mL of tert.butyl methylether and 15 mL of isopropanol. The solid was filtered by

suction, washed with tert.butyl methylether and dried at 45°C and then at 65°C overnight. 100 mg of this solid was stirred in 3 mL of water to first form a resinous 5 material that later on converts into a white solid. This was stirred for another hour, filtered by suction and dried overnight at room temperature and then at 65°C for 3 hours in a circulating air drier to yield a crystalline monohydrate. Mp 102-108°C.

Intermediate XX 10 1 -Cyclopropyl-4-(4-methoxy-benzyloxy)-1H-pyridin-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002206.tif" id="idf0206" />

A microwave-suited vessel charged with a stir bar, 4-(4-methoxy-benzyloxy)-1H-pyridin-2-one (0.60 g), cyclopropylboronic acid (0.45 g), pyridine (1.50 mL), triethylamine (1.50 mL), and toluene (4 mL) was sparged with argon for 5 min. Then, 15 Cu(OAc)2 (0.94 g) was added and the mixture was stirred in a microwave oven under microwave irradiation at 140 °C for 45 min. Then, the solvent was evaporated and water was added. The resultant mixture was extracted with ethyl acetate and the combined organic extracts were washed with water and aqueous NaHCO3 solution. After drying (MgSO4) and removing the solvent, the residue was purified by 20 chromatography on silica gel (CH2CI2/MeOH 99:1-&gt;95:5) to afford the title compound as a solid. Yield: 0.17 g (25% of theory); Mass spectrum (ESI*): m/z = 272 [M+H]*.

Intermediate XXI

1 -Cyclopropyl-4-hydroxy-1 H-pyridin-2-one OH

N O

A

Trifluoroacetic acid (1 mL) was added to a flask charged with a stir bar and 1-cyclopropyl-4-(4-methoxy-benzyloxy)-1H-pyridin-2-one (0.17 g) and chilled in an 25 WO 2010/011314 PCT/US2009/004261 - 170- ice/EtOH bath. The resulting mixture was stirred with cooling for 1.5 h and at ambient temperature for another 4.5 h. Then, the solution was concentrated under reduced pressure and the residue was triturated with tert-butyl methyl ether and dried to give the title compound as a solid. Yield: 0.10 g (quantitative). Mass spectrum (ESI*): m/z 5 = 152[M+Hf.

Intermediate XXII

Trifluoro-methanesutfonic acid 1-cyclopropyl-2-oxo-1,2-dihydro-pyridin-4-yl ester o

Trifluoromethanesulfonic anhydride (0.12 mL) was added to a flask charged 10 with a stir bar, 1-cyclopropyM-hydroxy-1H-pyridin-2-one (0.10 g), NEt3 (0.24 mL), and dichloromethane (8 mL) and chilled in an ice/EtOH bath. The resulting mixture was stirred with cooling for 2 h and at ambient temperature for another 2 h. Then, the solution was diluted with dichloromethane and washed in succession with water, aqueous NaHCO3 solution, and water. The organic solution was dried (MgSO*), the 15 solvent was removed, and the residue was purified by chromatography on silica gel (dichloromethane/methanol 99:1-&gt;90:10) to afford the title compound as a resin-like solid. Yield: 0.07 g (36% of theory). Mass spectrum (ESI*): m/z = 284 [M+H]* 20

Intermediate XXIII 4-Bromo-1 -cyclopropyl-1 H-pyridin-2-one Br A flask charged with a stir bar, 4-bromo-1H-pyridin-2-one (1.80 g), cyclopropylboronic acid (2.00 g), Cu(OAc)2 (2.00 g), 2,2’-bipyridine (1.70 g), NazCO3 (2.47 g), and 1,2-dichloroethane (75 mL) was heated to 70 °C and the mixture was 25 stirred at this temperature in air overnight. Then, another portion of cyclopropylboronic acid (0.50 g) and NazCO3 (0.55 g) were added and the mixture WO 2010/011314 PCT/US2009/004261 - 171 - was further stirred at reflux temperature for another 4 h. After cooling to ambient temperature, aqueous NH4CI solution was added and the resultant mixture was extracted with dichloromethane. The combined organic extracts were dried (MgSO4) and the solvent was evaporated. The residue was purified by chromatography on 5 silica gel (cyclohexane/ethyl acetate 50:50-&gt;35:65) to afford the title compound as an oil that crystallized on standing. Yield: 0.82 g (37% of theory); Mass spectrum (ESI*): m/z = 214/216 (Br) [M+Hf.

Method 2 10

Formic acid ci 38%

<img img-format="tif" img-content="drawing" file="IL210452AD0002207.tif" id="idf0207" />

[&gt;— B(OH)2t Cu&lt;OAc)2, BiPy Na2CO3, air, dichloroethane, 70 °C 85%

<img img-format="tif" img-content="drawing" file="IL210452AD0002208.tif" id="idf0208" />

<img img-format="tif" img-content="drawing" file="IL210452AD0002209.tif" id="idf0209" />

Step 1.4-lodopyridin-2(1H)-one A mixture of 2-chloro-4-iodopyridine (4.943 g, 20.6 mmol) and formic acid (88%, 10 mL) was stirred at 105 °C for 21 h. The excess of formic acid was removed in vacuo, and the mixture was quenched with 2 M aq Na2CO3, extracted with CH2CI2, dried over Na2SO4. After the solvent was removed under reduced pressure, the residue was purified by chromatography on silica gel eluted with CH2CI2/MeOH to afford 1.716 g (38%) of 4-iodopyridin-2(1W)-one as a solid. LC-MS Method 1 fR = 0.82 15 WO 2010/011314 PCT/US2009/004261 -172 - min, m/z = 222 (MH+); 1H NMR (400 MHz, (CD3)2SO) δ 7.14 (d, J = 6.5 Hz, 1H), 6.87 (s, 1H), 6.49 (d, 7=7.0 Hz, 1H).

Step 2. (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(2-oxo-1,2-dihydropyridin-4- 5 yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

To a solution of (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-(($)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyi)-1,3-oxazinan-2-one (2.646 g, 5.52 mmol) in 1,4-dioxane (60 mL) were added 4-iodopyridin-2(1W)-one (1.200 g, 5.43 mmol), 2 MCs2CO3 (14.5 mL), and PdCI2(dppf)CH2CI2 (0.230 g, 0.28 mmol). The

10 mixture was degassed and heated, under a nitrogen atmosphere, at 120 °C for 15 h. The mixture was diluted with CH2CI2, dried over Na2SO4. After the solvents were evaporated, the residue was purified by chromatography on silica gel eluted with MeOH/CH2Cl2 to afford 1.717 g (71%) of (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one. LC-MS 15 Method 1 fa = 1.23 min, m/z 389, 447 (MH+); 1H NMR (400 MHz, CD3OD) δ 7.40 (d, J = 6.7 Hz, 1H), 7.31 (d, 7= 8.2 Hz, 2H), 7.29-7.20 (m, 5H), 6.96 (d, 7= 8.2 Hz, 2H), 6.57-6.52 (m, 2H), 5.49 (q, 7 = 7,0 Hz, 1H), 2.98-2.93 (m, 1H), 2.47-2.34 (m, 2H), 2.16-2.09 (m, 1H), 2.07 (s, 2H), 1.45 (d, 7= 7.0 Hz, 3H), 1.19 (s, 3H), 0.87 (s, 3H). 20 Step 3. (S)-3-((S)-1 -(4-(1 -cyclopropyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one A mixture of (S)-6-(2-hydroxy-2-methylpropyl)-3-(($)-1-(4-(2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (1.683 g, 3.77 mmol, 1.0 equiv), Cu(OAc)2 (0.692 g, 3.81 mmol, 1.01 equiv), bipyridine (0.599 g, 3.83 mmol, 1.02 25 equiv), cyclopropylboronic acid (0.681 g, 7.93 mmol, 2.10 equiv) and Na2CO3 (0.890 g, 8.40 mmol, 2.23 equiv) in dichloroethane (40 mL) was stirred at 70 °C for 22 h under air. The reaction mixture was quenched with satd aq NH4CI, diluted with CH2CI2, dried over Na2SO4. After the solvent was removed under reduced pressure, the residue was purified by chromatography on silica gel eluted with MeOH/CH2CI2 to 30 afford 1.560 g (85%)of (S)-3-((S)-1-(4-(1-cyclopropyl-2-oxo-1,2-dihydropyridin-4- yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one. LC-MS fR = 1.41 min in 3 min chromatography, m/z 429, 487 (MH+); 1H NMR (400 MHz, WO 2010/011314 PCT/US2009/004261 • 173- CD3OD) δ 7.52 (d, J = 7.0 Hz, 1H), 7.29-7.18 (m, 7H), 6.92 (d, 8.2 Hz,2H), 6.54 (d, J= 1.8 Hz, 1H), 6.47 (dd, J = 7.3, 1.8 Hz, 1H), 5.47 (q, J = 7.0 Hz, 1H), 3.27-3.21 (m, 1H), 2.95-2.91 (m, 1H), 2.48-2.33 (m, 2H), 2.15-2.08 (m, 1H), 2.07 (s, 2H), 1.42 (d, 7.0 Hz, 3H), 1.20 (s, 3H), 1.05-1.00 (m, 2H), 0.87 (s, 3H), 0.83-0.79 (m, 2H); 5 13C NMR (100 MHz, CD3OD) 5 166.17, 155.63, 152.88, 144.03, 142.27, 138.90, 136.91, 129.71, 128.70, 128.58, 127.67, 126.09, 116.08, 107.10, 85.19, 71.49, 55.13, 54.62, 37.44, 33.24, 32.71,31.86, 30.03, 15.60, 7.27. ($)-3-((S)-1-(4-(1-cyclopropyl-2-oxo-1,2-dihyd ropy rid in-4-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-

1,3-oxazinan-2-one (ca. 1.5 g) and isopropyl acetate (30 mL) was heated in a 120 °C 10 oil bath, affording a homogeneous solution. Heating was discontinued and the resulting solution was slowly stirred while slowly cooling to rt in the oil bath overnight. The solids were filtered and washed with isopropyl acetate, dried at room temperature under high vacuum affording crystalline solid Mp 91-94 °C. 15 EXAMPLE 76 3-{(S)-1 -[4-{1 -Cyclopropylmethyl-6-oxo-1, 6-d ihydro-py r id ίπ-3-y l)-pheny IJ-ethy l}-(S)-6- (2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002210.tif" id="idf0210" />

2 M aqueous Na2CC&gt;3 solution (0.84 mL) was added to a solution of (S)-6-(2- 20 h ydroxy-2-methylpropyl)-6-phenyl-3-[(S)-1-(4-(4,4,5,5-tetra methyl-1,3,2-dioxaborolan- 2-yl)phenyl)ethyl]-1,3- oxazinan-2-one (0.40 g) and 5-bromo-1-cyclopropylmethyl-1H-pyridin-2-one (0.24 g) in dimethyl-formamide (4 mL). The resulting mixture was sparged with argon for 10 min, before [1,T-bis(diphenylphosphino)ferrocene]-dichloropalladium(ll) dichloromethane complex (34 mg) was added. The mixture was 25 heated to 100 °C and stirred at this temperature for 4 h. After cooling to ambient temperature, water was added and the resulting mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine, dried (MgSO4), and concentrated. The residue was purified by chromatography on silica gel WO 2010/011314 PCT/US2009/004261 - 174 - (dichloromethane/methanol 99:1-&gt;95:5) to afford the title compound that was crystallized with little ethyl acetate. Yield: 0.19 g (46% of theory); Mass spectrum (ESI+): m/z = 501 [M+Hf.

Intermediate XXIV 5-Bromo-1 -cyclopropylmethyl-1 H-pyridin-2-one KO*Bu (0.68 g) was added to a solution of 5-bromo-1H-pyridin-2-one (1.00 g) in tetrahydrofuran (20 mL) at room temperature. After stirring for 30 min, 10 cyclop ropy I methyl bromide (0.77 mL) and dimethylformamide (3 mL) were added to the suspension and the resulting mixture was warmed to 70 °C. After stirring the mixture at 70 °C for 2 h, the reaction was complete. The mixture was cooled to room temperature, diluted with ethyl acetate (50 mL), and washed with water (2x 20 mL) and brine (20 mL). Then, the solution was dried (MgSO4) and the solvent was 15 removed to give the title compound as a colorless oil. Yield: 1.18 g (90% of theory). Mass spectrum (ESI*): m/z = 228/230 (Br) (M-*-H]+ EXAMPLE 77 (R)-6-Methoxymethyl-3-{(S)-1 -(4-(1 -methyl-6-oxo-1,6-d ihyd ro-py rid in-3-y l)-p heny I]- 20 ethylJ-6-phenyl-[1,3]oxazinan-2-one

The title compound was prepared from (R)-6-(methoxymethyl)-6-phenyl-3-((S) 1 -(4-(4,4,5,5-tetra methyl-1,3,2-d ioxaborola n-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 5-bromo-1-methylpyridin-2(1H)-one following a procedure analogous to that 25 described in Example 76. Mass spectrum (ESI*): m/z = 433 [M+H]+ WO 2010/011314 PCT/US2009/004261 - 175 - EXAMPLE 78 (R)-6-Methoxymethyl-3-{(S)-1 -(4-(1 -methyl-2-oxo-1 ,2-dihydro-pyridin-4-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002211.tif" id="idf0211" />

o 5 The title compound was prepared from (R)-6-(methoxymethyl)-6-phenyl-3-((S)- 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and trifluoro-methanesulfonic acid 1-methyl-2-oxo-1,2-dihydro-pyridin-4-yl ester following a procedure analogous to that described in Example 76. Mass spectrum (ESP): m/z = 433 [M+Hf. 0 EXAMPLE 79 34(S)-1-[4-(5-Fluoro-1-methyl-2-oxo-112-dihydro-pyridin-4-yl)-phenyl]-ethy!}- (S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002212.tif" id="idf0212" />

15 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-[(S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl]-1,3-oxazinan-2-one and 4-bromo-5-fluoro-1 -methyl-1 H-pyridin-2-one following a procedure analogous to that described in Example 76. Mass spectrum (ESP): m/z = 479 [M+Hf. The compound that had been obtained as an oil crystallized on standing. 20 The solid was dried at 80°C under vacuum. Melting points: 120-125eC with evolution of gas followed by recrystallization and melting at 183-184°C. WO 2010/011314 PCT/US2009/004261 - 176 -

Intermediate XXV 4-Bromo-5-fluoro-1 -methyl-1 H-pyridin-2-one

F

<img img-format="tif" img-content="drawing" file="IL210452AD0002213.tif" id="idf0213" />

o

Methyl iodide (0.9 mL) was added to a mixture of potassium carbonate (2.34 g) 5 and 4-bromo-5-fluoro-1 H-pyridin-2-one (2.50 g) in dimethylformamide (25 mL) at room temperature. The mixture was stirred at room temperature overnight and then water was added. The resulting mixture was extracted with ethyl acetate and the combined extracts were washed with brine and dried (MgSO4). The solvent was evaporated to afford the crude title compound that was recrystallized from ΕΙςΟ. Yield; 1.22 g (45% 10 of theory); Mass spectrum (ESI*); m/z = 206/208 (Br) [M+Hf. EXAMPLE 80 (S)-6-(2-Hydroxy-2-methyl-propyl)-3-((S)-1-{4-[1-(2-hydroxy-2-methyl-propyl)-2- oxo-1,2-dihydro-pyridin-4-yl]-phenyl}-ethyl)-6-phenyl-[1(3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002214.tif" id="idf0214" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-[(S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl]-1,3-oxazinan-2-one and 4-b romo-1-(2-hydroxy-2-methyl-propyl)-1H-pyridin-2-one following a procedure analogous to that described in Example 75. Mass spectrum 20 (ESI*): m/z = 519 [M+Hf.

Intermediate XXVI 4-Bromo-1 -(2-hydroxy-2-methyl-propyl)-1 H-pyridin-2-one

'OH 25 A mixture of 4-bromo-1H-pyridin-2-one (0.25 g), 2,2-dimethyl-oxirane (0.26 mL), and potassium carbonate (0.40 g) in dimethylformamide (2.5 mL) was stirred WO 2010/011314 PCT/US2009/004261 -177- under microwave irradiation at 120 °C for 30 min. After cooling to ambient temperature, the mixture was concentrated and purified by HPLC on reversed phase (acetonitrile/water) to afford the title compound. Yield: 0.34 g (96% of theory); Mass spectrum (ESI+): m/z = 246/248 (Br) [M+Hf. EXAMPLE 81 (S)-6-(2-Hydroxy-2-methyl-propyi)-3-((S)-1-{4-[1-(3-methoxy-2-methyl-propyl)-2-oxo-1,2-dihyd ro-pyridin-4-yl]-phenyl}-ethyI)-6-phenyl-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002215.tif" id="idf0215" />

10 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-[(S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl]-1,3-oxazinan-2-one and 4-bromo-1-(3-methoxy-2-methyl-propyl)-1 H-pyridin-2-one following a procedure analogous to that described in Example 75 Method 1. Mass spectrum (ESf): m/z = 533 [M+Hf. 15

Intermediate XXVII 3-(4-Bromo-2-oxo-2H-pyridin-1-yl)-2-methyl-propionic acid methyl ester

<img img-format="tif" img-content="drawing" file="IL210452AD0002216.tif" id="idf0216" />

o A mixture of 4-bromo-1H-pyridin-2-one (0.50 g), methyl 2-bromoisobutyrate 20 (0.45 mL), and potassium carbonate (0.68 g) in dimethylformamide (5 mL) was stirred at 60 °C for 3 h. After cooling to ambient temperature, water was added and the resulting mixture was extracted with ethyl acetate. The combined extracts were washed with brine, dried (MgSO4), and concentrated. The residue was purified by chromatography on silica gel (cyclohexane/ethyl acetate 70:30-&gt;50:50) to afford the 25 title compound. Yield: 0.53 g (67% of theory); Mass spectrum (ESf): m/z = 274/276 (Br) [M+Hf. Additionally 2-(4-bromo-pyridin-2-yloxy)-2-methyl-propionic acid methyl ester was obtained {Yield: 0.15 g; Mass spectrum (ESI*): m/z = 274/276 (Br) [M+Hf} WO 2010/011314 PCT/US2009/004261 - 178-

Intermediate XXVIII 4-Bromo-1 -(3-hydroxy-2-methyl-propyl)-1 H-pyridin-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002217.tif" id="idf0217" />

OH

LiAlhU (1 M solution in tetrahydrofuran, 1.16 mL) was added to a solution of 3- 5 (4-bromo-2-oxo-2H-pyridin-1 -yl)-2-methyl-propionic acid methyl ester (0.53 g) in tetrahydrofuran (6 mL) chilled in an ice bath. After stirring the solution with cooling for 2 h, another portion of LiAIH4 (1 M in tetrahydrofuran, 0.29 mL) was added. After stirring with cooling for 1 more hour, the reaction was quenched by the addition of water. The resulting mixture was extracted with ethyl acetate and the combined 10 organic extracts were washed with brine and dried (MgSO4). The solvent was evaporated to give the title compound. Yield: 0.37 g (78% of theory); Mass spectrum (ESI+): m/z = 246/248 (Br) [M+H]+. 15

Intermediate XXIX 4-Bromo-1 -(3-methoxy-2-methyl-propyI)-1 H-py ridin-2-one

NaH (60% in mineral oil, 57 mg) was added to a solution of 4-bromo-1-(3-hydroxy-2-methyl-propyl)-1H-pyridin-2-one (0.53 g) in dimethylformamide (6 mL) chilled in an ice bath. After stirring the solution with cooling for 0.5 h, methyl iodide 20 (110 pL) was added. The cooling bath was removed and the solution was stirred at

room temperature overnight. Then, the solution was concentrated under reduced pressure and the residue was diluted with water. The resulting mixture was extracted with ethyl acetate and the combined organic extracts were washed with brine and dried (MgSO4). The solvent was evaporated and the residue was purified by HPLC 25 on reversed phase (acetonitrile/water) to give the title compound as an oil. Yield; 70 mg (30% of theory); Mass spectrum (ESI*): m/z = 260/262 (Br) [M+H]+. WO 2010/011314 PCT/US2009/004261 - 179- EXAMPLE 82 (S)-6-(2-Hydroxy-2-methyl-propyl)-3-((S)-1-{4-[1-(3-hydroxy-2-methyl-propyi)-2 oxo-1,2-dihydro-pyridin-4-yl]-phenyl}-ethyl)-6-phenyl-[1,3]oxa2inan-2-one'

<img img-format="tif" img-content="drawing" file="IL210452AD0002218.tif" id="idf0218" />

5 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-[(S)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl]-1,3-oxazinan-2-one and 4-bromo-1-(3-hydroxy-2-methyl-propyl)-1 H-pyridin-2-one following a procedure analogous to that described in Example 75. Mass spectrum (ESI+): m/z = 519 [M+Hf. 0 EXAMPLE 83 (S)-6-(2-Hydroxy-2-methyl-propyl)-3-(1-{4-[1-(2-methoxy-2-methyl-propyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-phenyf}-ethyl)-6-pheny!-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002219.tif" id="idf0219" />

15 The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6- phenyl-3-[($)-1-(4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2- yl)phenyl)ethyl]-1,3-oxazinan-2-one and 4-bromo-1 -(2-methoxy-2-methyl-propyl)-1 H-pyridin-2-one following a procedure analogous to that described in Example 75 Method 1. Mass spectrum (ESI+): m/z = 533 [M+H]+. 20 WO 2010/011314 PCT/US2009/004261 - 180-

Intermediate XXX 4-Bromo-1-{2-methoxy-2-methyl-propyl)-1H-pyridin-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002220.tif" id="idf0220" />

The title compound was prepared from 4-bromo-1-(2-hydroxy-2-methyl-propyl)-5 1H-pyridin-2-one and methyl iodide following a procedure analogous to that described in Intermediate XXIX. Mass spectrum (ESI+): m/z = 260/262 (Br) [M+H]\ EXAMPLE 84 6-(3-hydroxy-3-methylbutyl)-6-isopropyl-3-((S)-1 -(4-(1 -methyl-2-oxo-1,2-10 dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002221.tif" id="idf0221" />

Step 1

To a solution of (S)-1-(1-(4-bromophenyl)ethylamino)-4-methylpentan-3-one (740 mg, 2.5 mmol) in THF (25 mL) was added dropwise allylmagnesium bromide (25 15 mL, 25 mmol) under N2 at -78 °C. The reaction mixture was stirred at -78 °C for 2 h, quenched by addition of satd aq NH^Cl.and extracted with EtOAc. The organic layer was washed with brine, dried over NajSCU, and filtered. The solvent was removed WO 2010/011314 PCT/US2009/004261 - 181 - under vacuo to give 1-((S)-1-(4-bromophenyl)ethylamino)-3-isopropylhex-5-en-3-ol (802 mg, 95% yield), which was used directly in the next step.

Step 2 5 To a solution of 1-((S)-1-(4-bromophenyl)ethylamino)-3-isopropylhex-5-en-3-ol (802 mg, 2.366 mmol) and triethylamine (139 mg, 2.366 mmol) in CH2CI2 (20 mL) was added triphosgene (348 mg, 1.18 mmol) at 0 °C under N2, and the mixture was stirred at rt overnight. The reaction mixture was quenched with water, and extracted with CH2CI2, The organic layer was washed with brine, dried over Na2SO4, filtered, 10 concentrated, and purified by column chromatography to give 6-allyl-3-((S)-1 -(4-bromophenyl)ethyl)-6-isopropyl-1,3-oxazinan-2-one (480 mg, 56% yield),

Step 3

To a solution of 6-allyl-3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl-1,3- 15 oxazinan-2-one (480 mg, 1.315 mmol) in THF (5 mL) was added BH3.THF (5.3 mL, 5.3 mmol) at 0 °C under N2. The reaction mixture was stirred for 2 h, and quenched with water, 3 M aq NaOH (1 mL), and H2O2 (5 mL). The resulting mixture was stirred for 2 h, extracted with EtOAc, washed with brine, dried over Na2SO4, filtered, and concentrated to afford the crude product, which was purified by prep TLC to give 3- 20 ((S)-1-(4-bromophenyl)ethyl)-6-(3-hydroxypropyl)-6-isopropyl-1,3-oxazinan-2-one. (110 mg, 22% yield). 1H NMR (CDCI3): δθ.88 (m, 6H), 1.45 (m, 3H), 1.60 (m, 4H), 1,71 (m, 1H), 1.82 (m, 1H), 1.99 (m, 1H), 2.63 (m, 1H), 3.03 (m, 1H), 3.59 (m, 2H), 5.68 (m, 1H), 7.13 (d, 2H), 7.40 (d, 2H), 25 Step 4

To a mixture of 3-((S)-1-(4-bromophenyl)ethyl)-6-(3-hydroxypropyl)-6-isopropyl· 1,3-oxazinan-2-one. (41 mg, 0.1 mmol) in acetone (10 mL) was added Jones reagent (2.5 M, 1 mL) at 0 QC. The mixture was stirred at room temperature for 1 h, concentrated, and extracted with EtOAc. The organic layer was concentrated to give 30 the crude product 3-(3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl-2-oxo-1,3-oxazinan- 6-yl)propanoic acid (51 mg, 95% yield), which was used for the next step without further purification. WO 2010/011314 PCT/US2009/004261 - 182-

Step 5

To a solution of 3-(3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl-2-oxo-1,3-oxazinan-6-yl)propanoic acid (41 mg, 0.1 mmo!) in MeOH (10 mL) was added SOCI2 (5 mL) at 0°C. The reaction mixture was stirred at room temperature for 2 h, 5 concentrated, and purified by preparative TLC to give methyl 3-(3-( (S)-1-(4- bromophenyl)ethyl)-6-isopropyl-2-oxo-1,3-oxazinan-6-yl)propanoate (42 mg, 96% yield).

Step 6 10 To a solution of methyl 3-(3-((S)-1-(4-bromophenyl)ethyl)-6-isopropyl-2-oxo- 1,3-oxazinan-6-yl)propanoate (42 mg, 0.1 mmol) in dry THF (5 mL) was added MeMgBr (2.5 mL, 2.5 mmol, 1 M in THF) at -78°C. The mixture was stirred at rt for 0.5 h, quenched with satd aq NH4CI, and extracted with EtOAc. The organic layer was concentrated,and to afford crude 3-((S)-1-(4-bromophenyl)ethyl)-6-(3-hydroxy-3- 15 methylbutyl)-6-isopropyl-1,3-oxazinan-2-one.

The two isomers could be separated by preparative HPLC..

Isomer 1: (1.1 mg, 12% yield), 1H NMR (CDCb): 50.91 (m, 6H), 1.25 (m, 6H), 1.44 (d, 3H), 1.70 (m, 4H), 1.85 (m, 2H), 2.01 (m, 1H), 2.74 (m, 1H), 3.18 (m, 1H), 5.79 (m, 1H), 7.24 (d, 2H), 7.50 (d, 2H), 20 Isomer 2: (0.9 mg, 10% yield), 1H NMR (CDCb): 50.89 (m, 6H), 1.15 (s, 6H), 1.45 (m, 5H), 1.55 (m, 3H), 1.85 (m, 1H), 1.99 (m, 1H), 2.64 (m, 1H), 2.99 (m, 1H), 5.72 (m, 1H), 7.17 (d, 2H), 7.40 (d, 2H),

Step 7 25 To a solution of compound 3-((S)-l-(4-bromophenyl)ethyl)-6-(3-hydroxy-3- methylbutyl)-6-isopropyl-1,3-oxazinan-2-one (105 mg, 0.255 mmol) in DMSO (8 mL) was added compound 4,4,4l,4',5,5,5',5'-octamethyl-2,2,-bi(1,3,2-dioxaborolane) (198.5 mg, 0.781mmol), KOAc (351.6 mg, 3.587 mmol), and Pd(dppf)CI2 (21.9 mg, 0.027 mmol) under N2. The reaction mixture was stirred at 90 °C for 3.5 h added H2O, and 30 extracted with ethyl acetate. The organic layer was washed with water and brine, dried over Na2SO4, concentrated, and purified by preparative TLC to give the two isomers of 6-(3-hydroxy-3-methylbutyl)-6-isopropyl-3-((S)-1 -(4-(4,4,5,5-tetramethyl- 1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one WO 2010/011314 PCT/US2009/004261 - 183 -

Isomer 1 (17 mg, 15 %).

Isomer 2 (10.3 mg, 9 %).

Step 8 5 To a solution of compound 4-iodo-1-methylpyridin-2(1H)-one (17 mg, 0.074 mmol) in DME (4.6 mL) was added Pd(PPh3)4 (6.7 mg, 0.007 mmol) under nitrogen. The mixture was stirred at room temperature for 1 h, and a solution of compound 6-(3-hydroxy-3-methylbutyl)-6-isopropyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 1 (17 mg, 0.037 mmol) in 10 EtOH (2 mL) and satd aq NaHCO3 (1.5 mL) were added. The mixture was stirred at 100 °C for 2 h, quenched with water, and extracted with EtOAc. The combined organic layer was dried over anhydrous NajSCU and concentrated to give the compound 6-(3-hydroxy-3-methylbutyl)-6-isopropyl-3-((S)-1 -(4-( 1-methyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 1 (10.73 mg, 65.8%). 15 LC-MS Method 2 Method 2 tR = 1.03 min. m/z = 463, 441; Ή NMR (CD3OD): δ 0.89 (m, 6H). 1.11 (s, 6H), 1.42 (m, 2H), 1.51(m, 3H), 1.60 (m, 2H), 1.82-2.02 (m. 2H), 2.69 (m, 1H). 3.03 (m, 1H), 3.51 (s. 3H), 5.79 (m, 3H). 6.35 (d, 1H), 6.72 (s, 1H). 7.28 (d, 1H),7.39 (d, 2H), 7.49 (m,2H). 6-(3-hydroxy-3-methylbutyl)-6-isopropyl-3-((S)-1-(4-(1-methyl-2-oxo-1,2- 20 dihydropyridin-4-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer 2 was prepared from 6-(3-hyd roxy-3-methylbutyl)-6-isopropyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one isomer following a procedure analogous to that described in Step 8 immediately above. LC-MS Method 2 Method 2 tR = 1.00 min, m/z = 463, 441;'H NMR (CD3OD): δ 0.89 (m, 6H), 1.18 (m, 6H), 1.43 25 (m, 1H), 1.51 (m,3H), 1.63 (m, 2H), 1.76 (m, 2H), 1.92 (m, 1H), 2.61 (m, 1H), 3.12 (m, 1H), 3.51 (s, 3H), 5.79 (m, 1H), 6.37 (d, 1H), 6.72 (s, 1H), 7.28 (d, 1H),7.35(d, 2H), 7.51 (m, 2H). WO 2010/011314 PCT/US2009/004261 - 184 - EXAMPLE 85 (S)-3-((S)-1-(4-(1-cyclopropyl»2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2- hydroxy-2-methylpropyl)-6-isopropyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002222.tif" id="idf0222" />

said aq NaHCO3

DME

<img img-format="tif" img-content="drawing" file="IL210452AD0002223.tif" id="idf0223" />

10

Step 1 A mixture of 4-iodopyridin-2(1H)-°ne (0 2425 g, 1.10 mmol, 1.0 equiv), Cu(OAc)2 (0.2146 g, 1.18 mmol, 1.07 equiv), bipyridine (0.1832 g, 1.17 mmol, 1.07 equiv), cyclopropylboronic acid (0.2122 g, 2.47 mmol, 2.25 equiv) and Na2CO3 (0.2638 g, 2.49 mmol, 2.27 equiv) in dichloroethane (10 mL) was stirred at 70 °C for 18 h. The reaction mixture was quenched with satd aq NH4CI, diluted with CH2CI2, and dried over Na2SO4. After the solvent was removed under reduced pressure, the residue was purified by chromatography on silica gel eluted with hexanes/ethyl acetate to afford 0.2309 g (81%) of 1-cyclopropyl-4-iodopyridin-2(1H)-one. 15 Step 2

To a solution of compound 1-cyclopropyl-4-iodopyridin-2(1H)-one (17.60 mg, 0.067 mmol) in DME (2,5 mL) was added Pd(PPh3)4 (6,12 mg, 0.006 mmol) under nitrogen. The mixture was stirred at rt for 1 h. A solution of compound (S)-6-(2-hydroxy-2-methylpropyl)-6-isopropyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2- 20 dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (15 mg, 0.034 mmol) in EtOH (1 mL) and satd aq NaHCO3 (1 mL) were added. The mixture was stirred at 100 °C for 2 h, quenched with water and extracted with EtOAc, The combined organic layer was dried over anhydrous Na2SO4 and concentrated to give the final crude product, which was purified by preparative HPLC to afford the compound (S)-3-((S)-1-(4-(1- WO 2010/011314 PCT/US2009/004261 - 185 - cyclopropyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)- 6-isopropyl-1,3-oxazinan-2-one (6.50 mg, 43%). LC-MS Method 2 tR = 1.00 min, m/z = 453; 1H NMR (CD3OD): 60.82 (d, 3H), 0.89 (m, 2H), 0.99 (d, 3H), 1.17 (m, 2H), 1.35 (m, 6H), 1.58 (d, 3H), 1.62 (m, 2H), 1.85 (m, 1H), 1.96 (d, 1H), 2.09-2.18 (m, 2H), 5 2.68-2.78 (m, 1H), 3.11 (m, 1H), 3.37 (m, 1H), 5.81 (m, 1H), 6.40 (d, 2H), 6.78 (s, 1H), 7.31-7.42(m, 3H), 7.58 (d, 2H). EXAMPLE 86 ($)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-(1 -(2-hydroxyethyl)-6-oxo-1,6-1 o d ihydropy rid ίη-3-y IJpheny l)ethyl)-6-phenyl-1,3-oxaztnan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002224.tif" id="idf0224" />

The title compound was prepared from (S)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one and 5-bromo-1-(2-hydroxyethyl)pyridin-2(1H)-one following a 15 procedure analogous to that described in Example 20 Step 2. LC-MS Method 2 tR = 1.08 min, m/z = 513, 491; 1H NMR (CD3OD) δ 0.95 (s, 3H), 1.24 (s, 3H), 1.26 (s, 1H), 1.52 (d, 3H), 2.12 (s, 2H), 2.18 (m, 1H), 2.40-2.53 (m, 2H), 3.02 (m, 1H), 3.52 (m, 0.5H), 3.64 (m, 0.5H), 3.83 (t, 1H), 4.15 (t, 1H), 5.53(m, 1H), 6.61(m, 1H), 7.01 (d, 2H), 7.25-7.40(m, 7H), 7.79(m, 2H). 20 5-Bromo-1-(2-hydroxyethyl)pyridin-2(1H)-one was prepared from 5- bromopyridin-2(1 H)-one and 2-iodoethanol following a procedure analogous to that described in Example 20 Step 1. WO 2010/011314 PCT/US2009/004261 - 186- EXAMPLE 87 (S)-3-((S)-1-(4-(1-(2-fluoroethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one

OH OTf

Br.

Tf2O, Et3N —- CH2CI2i -78 °C to rt OTf

<img img-format="tif" img-content="drawing" file="IL210452AD0002225.tif" id="idf0225" />

‘0 -£&gt;-

Pd(PPh3)2CI2 CS2CO3

<img img-format="tif" img-content="drawing" file="IL210452AD0002226.tif" id="idf0226" />

F 10

Step 1

To a solution of 2-fluoroethanol (3.2 g, 50 mmol) and triethylamine (5.5 g, 55 mmol) in dichloromethane (60 mL) was added dropwise (CF3SO2)2O (15.5 g, 55 mmol) at -78 °C under N2. The mixture was stirred at 10*20 °C for 1 h, and treated with water (100 mL). The organic layer was washed with satd aq NaHCO3 (100 mL) and brine (100 mL), dried, and concentrated to give 2-fluoroethyl trifluoromethanesulfonate (8 g, yield 82%).

Step 2 A solution of 5-bromopyridin-2(7/-/)-one (100 mg, 0.58 mmol), 2-fluoroethyl 15 trifluoromethanesulfonate (1.1 g, 5.8 mmol), and K2CO3 (800 mg, 5.8 mmol) in DMF (3 mL) was stirred at rt overnight. 2-Fluoroethyl trifluoromethanesulfonate (1.1 g, 5.8 mmol) and K2CO3 (800 mg, 5.8 mmol) were added, and the mixture was treated with ethyl acetate (20 mL) and water (20 mL). The organic layer was washed with water (2 WO 2010/011314 PCT/US2009/004261 - 187 - x 20 mL) and brine (20 mL), dried over Na2SO4, concentrated, and purified by preparative, TLC (1:1 petroleum ether/EtOAc) to give two isomers. 5-bromo-1-(2-fluoroethyl)pyridin-2(iH)-one (30 mg, yield 24°/o). ’H NMR (CD3OD): &lt;5 4.25 (t, 1H), 4.32 (t, 1H),4.62 (t, 1K),4.74(t, 1H), 6.52 (d, 1H), 7.61 (dd 5 1H&gt;, 7.85 (s, 1H). 5-bromo-2-(2-fluoroethoxy) pyridine (30 mg, yield 24%). 1H NMR (CD3OD): 54.46 (t, 1H), 4.53 (t, 1H), 4.64 (t, 1H), 4.76 (t, 1H), 6.79 (d, 1H), 7.79 (dd, 1H), 8.18 (s, 1H), 10 Step 3

To a solution of ($)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-3-({S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3-oxazinan-2-one (20 mg, 0.041 mmol), 5-bromo-1-(2-fluoroethyl)pyridin-2(7W)-one (9.2 mg, 0.041 mmol), and Cs2CO3 (2 N, 0.2 mL, 0.41 mmol) in 1,4-dioxane (2 mL) was added Pd(PPh3)2CI2 (3 mg, 15 0.0041 mmol) under N2. The mixture was refluxed for 2 h, treated with EtOAc (10 mL)

and water (10 mL). The organic layer was dried over Na2SO&lt;, concentrated, and purified by preparative HPLC to give (SJ-3-((S)-1-(4“(1-(2-fiuoroethyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-phenyl-1,3-oxazinan-2-one (4.20 mg, 20%). LC-MS Method 2 tR = 1.01 min, m/z = 515,493; 'H NMR 20 (CD3OD); δ 0.97 (s, 3H), 1.28(8, 3H), 1.56 (d, 3H), 2.18 (s, 2H), 2.22 (m, 1H), 2.49 (m, 2H), 3.05 (m, 1H), 4.37 (t, 1H), 4.43 (t. 1H), 4.69 (t, 1H), 4.81 (t, 1H), 5.59 (q, 1H), 6.66 (d, 1H), 7.05 (d, 2H), 7.33 (m, 7H), 7.82 (m, 2H). EXAMPLE 88 25 (S)-3-((S)-1 -(4-( 1 -cyclopropyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyf)-6-(2- fluorophenyI)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one

o I

The title compound was prepared from (S)-6-(2-fluorophenyl)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)- WO 2010/011314 PCT/US2009/004261 - 188- 1,3-oxazinan-2-one and 1-cyclopropyl-4-iodopyridin-2(1H)-one following a procedure analogous to that described in Example 23 Step 9. LC-MS Method 2 tR - 1.05 min, m/z=505; 1H NMR (CDCI3)6 0.88 (m, 2H), 1.12 (s, 3H), 1.15 (s, 1H), 1.17 (s, 1H), 1.21 (s, 3H), 2.18-2.29 (m, 2H), 2.30-2.34 (m, 1H), 2.42 (d, 1H), 2.54 (d, 1H), 2.90 5 (m,1H), 3.35 (m, 1H), 5.70 (m, 1H), 6.32 (m, 1H), 6.68 (m, 1H), 6.98 (m, 1H), 7.09 (d, 2H), 7.18 (t, 1H),7.25-7.36 (m, 4H),7.50 (t,1H). EXAMPLE 89 (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1 -(4-(1 -(2-hydroxy-2-methylpropyl)-6-oxo-1,6-10 dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002227.tif" id="idf0227" />

Step 1

To a solution of compound 5-bromopyridin-2(1H)-one (348 mg, 2.0 mmol) and K2CO3 (830 mg, 6.0 mmol) in DMF (15 mL) was added ethyl bromoacetate dropwise. 15 The mixture was stirred at room temperature for 2 h, filtered, and the Filtrate was concentrated in vacuo. The residue was purified by prep TLC (1:1 PE/EtOAc) to afford ethyl 2-(5-bromo-2-oxopyridin-1(2H)-yl)acetate (300 mg, 57.7%). 1H NMR CDCI3: &lt;5 7.41-7.26 (m, 2H), 6.53-6.5 (d. 1H), 4.59 (s, 2H), 4.28-4.21 (q, 2H), 1.32-1-23 (q, 3H). 20

Step 2

To a solution of ethyl 2-(5-bromo-2-oxopyridin-1(2H)-yl)acetate (130 mg, 0.5 mmol) in anhydrousTHF (5 mL,) was added 1 M MeMgBr (5 mL, 5 mmol) dropwise with stirring at -78 °C. The reaction mixture was stirred at -78 °C for 1 h, quenched WO 2010/011314 PCT/US2009/004261 - 189 - with aq NH4CI (5 mL), and extractde with EtOAc (3x10 mL). The combined organic layer was dried and concentrated to give the crude final product, which was purified by preparative TLC (1:1 PEZEtOAc) to afford the 5-bromo-1-(2-hydroxy-2- methylpropyl)pyridin-2(1H)-one (65 mg, 52.9%). 5

Step 3

To a solution of 5-bromo-1-(2-hydroxy-2-methylpropyl)pyridin-2(1H)-one (20 mg, 81.3 mmol) in DME (6 mL) was added Pd(PPh3)4 (10 mg) under nitrogen. The mixture was stirred for 1 h at rt, and a solution of (S)-6-(2-hydroxy-2-methylpropyl)-6- 10 phenyl-3-((S)-1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethyl)-1,3- oxazinan-2-one (38.95 mg, 81.3 mmol) in EtOH (2 mL) and satd aq NaHCO3 (2 mL) were added. The resulting mixture was stirred at 100 °C for 2 h, quenched with water, and extracted with EtOAc. The combined organic layer was dried over anhydrous Na2SO4 and concentrated to give the crude product, which was purified by preparative 15 TLC and preparative HPLC to afford (S)-6-(2-hydroxy-2-methytpropyl)-3-((S)-1-(4-(1-(2-hydroxy-2-methylpropyl)-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one (6.5 mg, 15.5%). LC-MS Method 2 tR = 0.99 min, m/z = 519; *H NMR "(CDCI3): δ 7.60-7.57 (d, 1H), 7.43 (s, 1H), 7.36-7.26 (m, 5H), 7.15 (d, 2H), 7.01 (d, 2K), 6.70 (d, 1H), 2.85 (m, 1H), 5.69-5.66 (m, 1H), 4.13-4.09 (s, 2H), 4.05-3.98 (s, 20 1H), 2.89-2.86 (m, 1H), 2.44-2.36 (m, 1H), 2.28-2.16 (m, 5H), 1.58-1.53 (d, 3H), 1.33- 1.30 (s, 6H), 1.19 (s, 3H), 1.12 (s, 3H). EXAMPLE 90 3-((S)-1-{4-[1-(3-Hydroxy-2,2-dimethyl-propyl)-2-oxo-1,2-dihydro-pyridin-4-yl]-phenyl}- 25 ethyl)-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002228.tif" id="idf0228" />

2 M aqueous Na2CO3 solution (0.32 mL) was added to a mixture of 4-bromo-1-(3-hydroxy-2,2-dimethyl-propyl)-1H-pyridin-2-one (0.13 g) and (S)-6-(2-hydroxy-2- WO 2010/011314 PCT/US2009/004261 - 190 - methylpropy l)-6-pheny!-3-[(S)-1-(4-(4,4,5,5-tetramethy 1-1,3(2-dioxaborolan-2- yl)phenyl)ethyl]-1,3-oxazinan-2-one (0.15 g) in Ν,Ν-dimethylformamide (3 mL). The resulting mixture was sparged with argon for 5 min, before [1,1’- bis(diphenylphosphino)-ferrocene]dichloro-palladium(ll) dichloromethane complex (26 5 mg) was added. The mixture was heated to 100 °C and stirred at this temperature for 4 h. After cooling to ambient temperature, water was added and the resulting mixture was extracted with ethyl acetate. The combined organic extracts were washed with water and brine and dried (MgSO4). The solvent was evaporated and the residue was purified by HPLC on reversed phase (methanol/water/NH4OH) to afford the title 10 compound as a beige solid. Yield: 0.10 g (60% of theory); Mass spectrum (ESI+): m/z = 533 [M+Hf. 3-(4~Bromo-2-oxo-2H-pyridin-1-yl)-2,2-dimethyl-propionic acid methyl ester

<img img-format="tif" img-content="drawing" file="IL210452AD0002229.tif" id="idf0229" />

0 O 15 3-Bromo-2,2-dimethyl-propionic acid methyl ester (0.75 g) was added to a mixture of 4-bromo-1H-pyridin-2-one (0.55 g) and potassium carbonate (0.75 g) in Ν,Ν-dimethylformamide (10 mL) at room temperature. The mixture was heated to 60 °C and stirred at this temperature overnight. After stirring at 80 °C for another 8 h, the mixture was cooled to room temperature and water was added. The resultant mixture 20 was extracted with ethyl acetate and the combined organic extracts were washed with brine and dried (MgSO4). The solvent was evaporated and the residue was purified by chromatography on silica gel (cyclohexane/ethyl acetate 4:1) to afford the title compound; 3-(4-bromo-pyridin-2-yloxy)-2,2-dimethyl-propionic acid methyl ester (0.35 g) was also obtained from this reaction. Yield: 0.29 g (32% of theory); Mass spectrum 25 (ESI*): m/z = 288/300 (Br) [M+Hf. WO 2010/011314 PCT/US2009/004261 - 191 - 4-Bromo-1 ~(3-hydroxy-2,2-dimethyl-propyI)-1 H-pyridin-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002230.tif" id="idf0230" />

Br

O

Lithium borohydride (25 mg) was added to a solution of 3-(4-bromo-2-oxo-2H-pyridin-1-yl)-2,2-dimethyl-propionic acid methyl ester (0.29 g) in tetrahydrofuran (3 5 mL) chilled in an ice bath. Then methanol (45 pL) was added and the mixture was stirred in the cooling bath for 1 h and at room temperature overnight. The mixture was diluted with tetrahydrofuran and MgSC&gt;4 was added. The mixture was filtered and the filtrate was concentrated. The residue was purified by chromatography on silica gel (cyclohexane/ethyl acetate 1:1) to afford the title compound as a colorless oil. Yield: 10 0.13 g (49% of theory): Mass spectrum (ESI*): tn/z = 260/262 (Br) [M+Hf. EXAMPLE 91 3-((S)-1-(4-( 1-cyclopropyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2-hydroxy-2-methylpropyl)-6-(tetrahydro-2H-pyran-4-yl)-1,3-oxazinan-2-one 15

The title compound was prepared following procedures analogous to those described in Example 23 with the following changes. In Step 1 tetrahydro-2H-pyran- 4-carboxylic acid and carbonyl diimidazole were used in place of 2-fluorobenzoyl chloride and in Step 9 1-cyclopropyl-4-iodopyridin-2(1H)-one was used in place of 5- 20 bromo-1-methylpyridin-2(1H)-one. Two isomers were isolated.

Isomer 1. LC-MS Method 2 tR = 0.95 min, m/z = 495. Isomer 2. LC-MS Method 2 tR = 0.93 min, m/z = 495. WO 2010/011314 PCT/US2009/004261 - 192 - (S)-6-(2-hydroxy-2-methylpropyl)-3-((S)-1-(4-(1-trideuteromethyl-2-oxo-1,2- dihydropyridin-4-yl)phenyl)ethyl)-6-phenyl-1,3-oxazinan-2-one EXAMPLE 92

<img img-format="tif" img-content="drawing" file="IL210452AD0002231.tif" id="idf0231" />

The title compound was prepared following procedures analogous to those described in Example 48 Method 2 with the following changes. In Step 1 trideuteromethyl iodide was used in place of methyl iodide and in Step 2 PdClz(dppf) was used in place of PdCl2(PPh3)2- LC-MS Method'1 tR = 1.30 min, m/z = 464. 10 EXAMPLE 93 3-(&lt;S)-1 -(4-(1 -cyclopropyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(cyclopropylmethyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002232.tif" id="idf0232" />

15

The title compound was prepared following a procedure analogous to that described in Example 23 Steps 2 to 9. 2-cyclopropyl-N-methoxy-N-methylacetamide, prepared by CDI mediated coupling of 2-cyclopropylacetic acid and N,O-dimethylhydroxylamine, was used in Step 2. The two isomers of 3-((1 S)-1-(4-bromophenyl)ethyl)-6-(cyciopropylmethyl)-6-(2-methylallyl)-1,3-oxazinan-2-one prepared in Step 5 were separated by column chromatography. The two isomers were separately carried forward through Steps 6-9, using 1 -cyclopropyl-4-iodopyridin-2(1 H)-one in Step 9, to afford the two isomers of the title compound.

Isomer 1: LC-MS Method 2 tR = 1.04 min, m/z = 465, 447,

Isomer 2: LC-MS Method 2 tR = 1.06 min, m/z = 465, 447. 20 WO 2010/011314 PCT/TJS2009/004261 - 193 - 3“{(S)-1-(4-(1-cyclopropyl-2-oxo-1,2-dihydropyridin-4-yl)phenyl)ethyl)-6-(2- hydroxy-2-methylpropyl)-6-neopentyl-1,3-oxazinan-2-one EXAMPLE 94

<img img-format="tif" img-content="drawing" file="IL210452AD0002233.tif" id="idf0233" />

10

The title compound was prepared following a procedure analogous to that described in Example 23 Steps 2 to 9. N-methoxy-N^.S-trimethylbutanamide, prepared by HATU mediated coupling of 3,3-dimethylbutanoicacid and N,O-dimethylhydroxylamine, was used in Step 2. The two isomers of 3-((1 S)-1-(4-bromophenyl)ethyl)-6-(2-methylallyl)-6-neopentyl-1 ,3-oxazinan-2-one prepared in Step 5 were separated by column chromatography. The two isomers were separately carried forward through Steps 6-9, using 1-cyclopropyl-4-iodopyridin-2(1H)-one in Step 9, to afford the two isomers of the title compound.

Isomer 1: LC-MS Method 2 tR = 1.09 min, m/z = 503, 481,423.

Isomer 2: LC-MS Method 2 tR = 1.16 min, m/z = 481. 15 EXAMPLE 95 3-((S)-1-(4-(1-cyclopropyl-2-oxo-1,2-dihydropyridin-4-yI)phenyl)ethyl)-6-(3,3-difluorocyclobutyl)-6-(2-hydroxy-2-methylpropyl)-1,3-oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002234.tif" id="idf0234" />

20

The title compound was prepared following a procedure analogous to that described in Example 23 Steps 2 to 9. 3,3-difluoro-N-methoxy-N-methylcyclobutanecarboxamide, prepared by CDI mediated coupling of 3,3-difluorocyclobutanecarboxylic acid and N.O-dimethylhydroxylamine, was used in Step 2. The two isomers of 3-((S)-1-(4-bromophenyl)ethyl)-6-(3,3-difluorocyclobutyl)-6-(2-methylallyl)-1,3-oxazinan-2-one prepared in Step 5 were separated by column 25 WO 2010/011314 PCT/US2009/004261 -194 - chromatography. The two isomers were separately carried forward through Steps 6-9, using 1-cyclopropyl-4-iodopyridin-2(1H)-one in Step 9, to afford the two isomers of the title compound.

Isomer 1: LC-MS Method 1 tR = 1.08 min, m/z = 501. 5 Isomer 2: LC-MS Method 1 tR = 1.07 min, m/z = 501.

Examples 96-98 Intermediate 1 (S)-4-Bromo-1 -(1 -isocyanato-ethyl)-2-methyl-benzene

<img img-format="tif" img-content="drawing" file="IL210452AD0002235.tif" id="idf0235" />

Step 1: (/?)-2-Methyl-propane-2-sulfinic acid [1-(4-bromo-2-methyl-phenyl)r ethylidene]-amide

Titanium(IV) ethoxide (10.7 mL) was added to a solution of 1-(4-bromo-2- 15 methyl-phenyl)-ethanone (4.41 g) and (R)-2-methyl-2-propanesulfinamide (2.76 g) in tetrahydrofuran (45 mL). The resulting solution was heated to 65 °C and stirred at this temperature for 20 h. Then, the solution was cooled to ambient temperature and another portion of titanium(IV) ethoxide (5.4 mL) and (R)-2-methyl-2-propane-sulfinamide (1.25 g) were added. After stirring the solution at 65 °C for another 12 h, 20 the solution was cooled to ambient temperature and poured into brine. The resulting mixture was filtered over Celite and the organic phase of the filtrate was separated. The aqueous phase of the filtrate was extracted with ethyl acetate and the extracts were combined with the separated organic phase. The combined organic phases were washed with brine and dried (MgSO4) and the solvent was evaporated. The 25 residue was chromatographed on silica gel (cyclohexane/ethyl acetate 9:1 —&gt;1:1) to WO 2010/011314 PCT/US2009/004261 - 195 - afford the title compound. Yield: 6.24 g (95% of theory); Mass spectrum (ESI+): m/z = 316/318 (Br) [M+Hf.

Step 2: (R)-2-Methyl-propane-2-sulfinic acid [(S)-1-(4-bromo-2-methyl-phenyl)-ethylj-amide 5 Lithium tri-sec-butylborohydride (1 mol/L in tetrahydrofuran, 59.2 mL) was added to a solution of (R)-2-methyl-propane-2-sulfinic acid [1-(4-bromo-2-methyl-phenyl)-ethylidenej-amide (6.24 g) in tetrahydrofuran (50 mL) chilled in an ice bath. The solution was stirred for 2 h while warming to room temperature in the cooling bath. The solution was then cooled again in an ice bath prior to the careful addition of 10 water. The resulting mixture was extracted with ethyl acetate and the combined extracts were washed with water, saturated aqueous NaHCOa solution, and brine. After drying (MgSCU) and evaporating the solvent, the title compound was obtained that was directly submitted to the next reaction step. Yield: 8.85 g (ca. 75% pure); Mass spectrum (ESI*): m/z = 318/320 (Br) [M+Hf. 15 Step 3: (S)-1-(4-Bromo-2-methyl-phenyl)-ethylamine

Hydrochloric acid (4 mol/L in 1,4-dioxane, 46 mL) was added to a solution of (R)-2-methyl-propane-2-sulfinic acid [(S)-1 -(4-bromo-2-rnethyl-phenyf)-ethyl]-amide (crude from Step 2, 8.85 g, ca. 75% pure) in ethyl acetate (80 mL) at room temperature. The solution was stirred at room temperature for 1 h and then 20 concentrated. The residue was taken up in water and the resulting mixture was washed with diethyl ether. The aqueous phase was basified using aqueous 1 M NaOH solution and extracted with dichloromethane. The combined extracts were washed with brine, dried (MgSO4), and concentrated to afford the title compound. Yield: 4.04 g (905 of theory); Mass spectrum (ESI’): m/z = 214/216 (Br) [M+Hf. 25 Step 4: (S)-4-Bromo-1-(1-isocyanato-ethyl)-2-methyl-benzene

Triphosgene (2.24 g) was added at once to a vigorously stirred mixture of

NaHCO3 (3.65 g) in water (80 mL) and (S)-1-(4-bromo-2-methyl-phenyl)-ethylamine (4.04 g) in dichloromethane (80 mL) chilled in an ice bath. The cooling bath was removed and the mixture was stirred at room temperature for another 30 min. Then 30 the organic phase was separated and dried (MgSO4) and the solvent was evaporated to afford the isocyanate as an oil that was directly submitted to the next reaction step. Yield: 4.50 g (99% of theory); Mass spectrum (ESI'): m/z = 240/242 (Br) [M-H]\ WO 2010/011314 PCT/US2009/004261 - 196 -

Intermediate 2 (S)-1-Bromo-4-(1-isocyanato-ethyl)-2-methyl-benzene

<img img-format="tif" img-content="drawing" file="IL210452AD0002236.tif" id="idf0236" />

5 Step 1-. (R)-2-Methyl-propane-2-sulfinic acid [1-(4-bromo-3-methyl-phenyl)- ethylidene]-amide

The title compound was prepared from 1-(4-bromo-3-methyl-phenyl)-ethanone and (R)-2-methyl-2-propanesulfinamide following a procedure analogous to that described in Step 1 of Intermediate 1. Mass spectrum (ESI*}: m/z = 316/318 (Br) 10 [M+Hf.

Step 2: (R)-2-Methyl-propane-2-sulfinic acid [(S)-1-(4-bromo-3-methyl-phenyl)-ethylj-amide

The title compound was prepared from (R)-2-methyl-propane-2-sulfinic acid [1-(4-bromo-3-methyl-phenyl)-ethylidene]-amide following a procedure analogous to that 15 described in Step 2 of Intermediate 1. LC-MS (Method 5): tR = 4.04 min; Mass spectrum (ESI*): m/z = 318/320 (Br) [M+H]*:

Step 3; (S)-t-(4-Bromo-3-methyl-phenyl)-ethylamine

The title compound was prepared from (R)-2-methyl-propane-2-sulfinic acid [(S)-1-(4-bromo-3-methyl-phenyl)-ethyl]-amide following a procedure analogous to 20 that described in Step 3 of Intermediate 1. LC-MS (Method 4): tR = 3.56 min; Mass spectrum (ESI*): m/z = 214/216 (Br) [M+H]*

Step 4: (S)-1-Brom0-4-( 1-isocyanato-ethyl)-2-methyl-benzene

The title compound was prepared from (S)-1-(4-bromo-3-methyl-phenyl)-ethylamine and triphosgene following a procedure analogous to that described in Step 25 4 of Intermediate 1. Mass spectrum (ESI*): m/z = 272/274 (Br) [M+H+MeOH]*. WO 2010/011314 PCT/US2009/004261 - 197 -

Intermediate 3 5-B ro mo-2-isocy a nato methyl-1^-dimethyl-benzene

<img img-format="tif" img-content="drawing" file="IL210452AD0002237.tif" id="idf0237" />

Br

The title compound was prepared from 4-bromo-2,6-dimethyl-benzylamine and 5 triphosgene following a procedure analogous to that described in Step 4 of

Intermediate 1. Mass spectrum (El): m/z = 239/241 (Br) [Mf.

Intermediate 4 4-Bromo-1 -cyclopropyl· 1 H-pyridin-2-one 10 A flask charged with a stir bar, 4-bromo-1 H-pyridin-2-one (1,80 g), cyclopropylboronic acid (2.00 g), Cu(O2CCH3)2 (2.00 g), 2,2’-bipyridine (1.70 g)t Na2CO3 (2.47 g), and 1,2-dichloroethane (75 mL) was heated to 70 °C. The mixture was stirred at this temperature in air overnight. Then, further portions of 15 cyclopropylboronic acid (0.50 g) and Na2CO3 (0.55 g) were added and the mixture was stirred at reflux temperature for another 4 h. After cooling to ambient temperature, aqueous NH4CI solution was added and the resultant mixture was extracted with dichloromethane. The combined organic extracts were dried (MgSO4) and the solvent was evaporated. The residue was purified by chromatography on 20 silica gel (cyclohexane/ethyl acetate 50:50-&gt;35:65) to afford the title compound as an oil that crystallized on standing. Yield: 0.82 g (37% of theory); Mass spectrum (ESI*): m/z = 214/216 (Br) [M+H]*. WO 2010/011314 PCT/US2009/004261 - 198 -

Example 96 3-{(S)-1 -(4-(1 -Cyclopropyl-2-oxo-1,2-dihydro-pyridin-4-y!)-2-methy!-phenyl]-ethyl}-(S)-» 6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1 ,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002238.tif" id="idf0238" />

Step 1: 3-[(S)-1 -(4-Bromo-2-methyl-phenyl)-ethyl]-(R)-6-(2-methyl-allyl)-6-phenyl-[1,3]oxazinan-2-one

Lithium hexamethyldisilazide (1 mol/L in tetrahydrofuran, 18.7 mL) was added dropwise (at such a rate that the solution temperature maintains below 25 °C) to a to solution of 1-ch!oro-5-methyl-3-phenyl-hex-5-en-3-ol (3.82 g) and (S)-4-bromo-1-(1-isocyanato-ethyl)-2-methyl-benzene (4.49 g) in tetrahydrofuran (140 mL) chilled in an ice bath. The solution was stirred in the cooling bath for 30 min and at room temperature for another 60 min. Then acetic acid (1.9 mL) in water (40 mL) was slowly added to the reaction mixture. The resulting mixture was concentrated under 15 reduced pressure and the residue was taken up in tert-butyl methyl ether, The resulting solution was washed with water, dried (MgSO4), and concentrated. The residue was submitted to chromatography on silica gel (cyclohexane/ethyl acetate 90:10-&gt;40:60) to afford the title compound as a colorless solid. Besides the title WO 2010/011314 PCT/US2009/004261 - 199 - compound a diastereomer thereof, 3-[(S)-1-(4-bromo-2-methyl-phenyl)-ethyl]-6-(S)-(2-methyl-allyl)-6-phenyl-[1,3]oxazinan-2-one, was isolated as an oil {1.55 g, Mass spectrum (ESP): m/z = 428/430 (Br) [M+Hf). Yield: 1.34 g (18% of theory); Mass spectrum (ESP): m/z = 428/430 (Br) [M+Hf; ’H NMR (400 MHz, DMSO-de) 1.40 (d, J = 6.8 Hz, 3H), 1.53 (s, 3H), 1.71 (s, 3H), 1.81-190 (m, 1H), 1.98-2.08 (m, 1H), 2.43-ca. 2.51 (m, 3H), 2.86-2.94 (m, 1H), 4.58 (hardly resolved m, 1H), 4.77 (hardly resolved m, 1H), 5.30 (q, J = 6.8 Hz, 1H), 7.15-7.19 (m, 2H), 7.24-7.35 (m, 6H). The assignment of the stereogenic centers of the title compound is based on the comparison of the 1H NMR data with the data of the known analog 3-[(S)-1-(4-bromo-phenyl)-ethyll-(R)-6-(2-methyl-allyl)-6-phenyl-[1,33oxazinan-2-one.

Step 2: 3-[(S)-1 -(4-Bromo-2-methyl-phenyl)-ethyl]-(S)-6-(2-methyl-oxiranylmethyl)-6-pheny I-[ 1,3]oxazinan-2-one 34(S)-1-(4~Bromo-2-methyl-phenyl)-ethyl]-(/?)-6-(2-methyl-allyl)-6-pheny!- [1,3]oxazin-an-2-one (1.34 g) dissolved in dichloromethane (15 mL) was added to a solution of 3-chloroperoxybenzoic acid (77%, 0.81 g) in dichloromethane (15 mL) cooled to 5 °C. The cooling bath was removed and the solution was stirred at room temperature overnight. Aqueous 10% Na2SzO3 solution (10 mL) and aqueous saturated NaHCO3 solution (25 mL) were added and the resulting mixture was stirred for further 30 min. The organic phase was separated and washed with aqueous Na2S2O3 solution combined with aqueous saturated NaHCO3 solution, water, and brine. The organic phase was dried (MgSO^) and concentrated to furnish the title compound. Yield: 1.55 g (ca. 85-90% pure); LC-MS (Method 4): 1r = 4.28 min; Mass spectrum (ESP): m/z = 444/446 (Br) [M+Hf.

Step 3: 3-[(S)-1-(4-Bromo-2-methyl-phenyl)-ethyl]-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

Lithium triethylborohydride (1 mol/L in tetrahydrofuran, 4.2 mL) was added to an ice-cold solution of 3-[(S)-1-(4-bromo-2-methyl-phenyl)-ethyl]-(S)-6-(2-methyl-oxiranylmethyl)-6-phenyl-[1,3]oxazinan-2-one (1.55 g, ca. 85-90% pure ) in tetrahydrofuran (15 mL) at such a rate that the solution temperature remained below 10 °C. The resulting solution was stirred in the cooling bath for one more hour and at room temperature for another 2 h. Then, the solution was cooled in an ice bath and the reaction was quenched by the careful addition of water (7 mL). After the addition of aqueous hydrochloric acid and ethyl acetate (80 ml), the organic phase was WO 2010/011314 PCT/US2009/004261 -200- separated, washed with brine, and dried (MgSO4). The solvent was evaporated to afford the title compound. Yield: 1.48 g (95% of theory); LC-MS (Method 4): tR = 4.00 min; Mass spectrum (ESI+): m/z = 446/448 (Br) [M+H]+

Step 4: (S)-6-(2-Hydroxy-2-methyl-propyl)-3-{(S)-1-[2-methyl-4-(4,4,5,5- 5 tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyI]-ethyl}-6-phenyl-[1t3]oxazinan-2-one A flask charged with a stir bar, potassium acetate (1.14 g), bis(pinacolato)diboron (1.10 g), 3-[(S)-1-(4-bromo-2-methyl-phenyl)-ethyl]-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one (1.48 g), and dimethyl sulfoxide (20 mL) was sparged with argon for 10 min. Then, [1,Γ ιο bis(diphenylphosphino)ferrocene]dichloro-palladium(ll) dichloro-methane complex (0.27 g) was added and the mixture was heated to 90 °C and stirred at this temperature for 2.5 h. After cooling the mixture to ambient temperature, water and ethyl acetate were added and the resulting mixture was filtered over Celite. The aqueous phase of the filtrate was separated and extracted twice with ethyl acetate. 15 The organic extracts and the organic phase of the filtrate were combined and washed with water and brine and dried (MgSO4). The solvent was evaporated and the residue was chromatographed on silica gel (cyclohexane/ethyl acetate 1:1 —&gt;1:4) to afford the title compound. Yield: 1.23 g (75% of theory); Mass spectrum (EST): m/z = 494 [M+Hf. 20 Step 5: 3-{(S)-1 -(4-(1-Cyclopropyl-2-oxo-1,2-dihydro-pyridin-4-yl)-2-methyl- phenyl]-ethyl}-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one 2 M aqueous NaaCCh solution (0.41 mL) was added to a mixture of 4-bromo-1-cyclopropyl-1H-pyridin-2-one (0.11 g) and (S)-6-(2-hydroxy-2-methyl-propyl)-3-{(S)-1-[2-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethyl}-6-phenyl- 25 [1,3]oxazinan-2-one (0.20 g) in Ν,Ν-dimethylformamide (2 mL). The resulting mixture was sparged with argon for 10 min prior to the addition of [1.Γ-bis(diphenylphosphino)-ferrocene]dtchloro-palladium(ll) dichloromethane complex (33 mg). The mixture was heated to 100 °C and stirred at this temperature overnight. After cooling the mixture to ambient temperature, water was added and the resulting 30 mixture was extracted with ethyl acetate. The combined organic extracts were washed with water and brine and dried (MgSO4). The solvent was evaporated and the residue was purified by HPLC on reversed phase (methanol/water/NH4OH) to WO 2010/011314 PCT7US2009/004261 -201 - afford the title compound. Yield: 0.13 g (64% of theory); LC-MS (Method 5): tR = 3.43 min; Mass spectrum (ESf+): m/z = 501 [M-i-Hf.

Example 97 5 3-{(S)-1-[4-(1-Cyclopropyl-2-oxo-1,2-dihydro-pyridin-4-yl)-3-methyl-phenyl]-ethyl}-(S)- 6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

<img img-format="tif" img-content="drawing" file="IL210452AD0002239.tif" id="idf0239" />

Step 1: 3-[(S)-1 -(4-Bromo-3-methyl-phenyl)-ethyl]-(/?)-6-(2-methyl-allyl)-6- 10 phenyl-[1,3]oxazinan-2-one

The title compound was prepared from 1-chloro-5-methyl-3-phenyl-hex-5-en-3-ol and (S)-1-bromo-4-(1-isocyanato-ethyl)-2-methyl-benzene following a procedure analogous to that described in Step 1 of Example 96. Mass spectrum (ESI*): m/z = 428/430 (Br) [M+Hf; 1H NMR (400 MHz, DMSO-d6) 1.40 (d, J = 6.9 Hz, 3H), 1.55 (s, 15 3H), 2.13 (s, 3H) superimposed on 2.07-2.18 (m, 2H), 2.42-2.47 (m, 1H), 2.53 (broad s, 2H), 2.92-3.03 (m, 1H), 4.60 (hardly resolved m, 1H), 4.77 (hardly resolved m, 1H), 5.33 (q, J = 6.9 Hz, 1H), 6.62 (dd, J = 8.2 Hz, 2.0 Hz, 1H), 6.76 (hardly resolved d, 1H), 7.26-7.33 (m, 4H), 7.34-7.40 (m, 2H). The assignment of the stereogenic centers WO 2010/011314 PCT/US2009/004261 -202- of the title compound is based on the comparison of the 1H NMR data with the data of the known analog 3-[(S)-1-(4-bromo-phenyl)-ethyl]-(R)-6-(2-methyl-allyl)-6-phenyl- [1,3]oxazinan-2-one.

Step 2; 3-[(S)-1-(4-Bromo-3-methyl-phenyl)-ethyl]-(S)-6-(2-methyl-5 oxiranylmethy!)-6-phenyl-[1,3]oxazinan-2-one

The title compound was prepared from 3-[(S)-1-(4-bromo-3-methyl-phenyl)-ethyl]-(R)-6-(2-methyl-allyl)-6-phenyl-[1,3]oxazinan-2-one following a procedure analogous to that described in Step 2 of Example 96. LC-MS (Method 4): tR = 4.03 min; Mass spectrum (ESI*): m/z = 444/446 (Br) [M+Hf. 10 Step 3: 3-[(S)-1-(4-Bromo-3-methyl-phenyl)-ethyl]-(S)-6-(2-bydroxy-2-methyl- propyl)-6-phenyl-[1,3]oxazinan-2-one

The title compound was prepared from 3-[(S)-t-(4-bromo-3-methyl-phenyl)-ethyl]-(S)-6-(2-methyl-oxiranylmethyl)-6-phenyl-[1,3]oxazinan-2-one following a procedure analogous to that described in Step 3 of Example 96. LC-MS (Method 4): tR 15 = 4.03 min; Mass spectrum (ESI+): m/z = 446/448 (Br) [M+Hf.

Step 4: (S)-6-(2-Hydroxy-2-methyl-propyl)-3-{(S)-1-[3-rnethyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethyl}-6-phenyl-[1,3]oxazinan-2-one

The title compound was prepared from 3-[(S)-1-(4-bromo-3-methyl-phenyl)-ethyl]-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one following a 20 procedure analogous to that described in Step 4 of Example 96. Mass spectrum (ESI*): m/z = 494 [M+Hf.

Step 5: 3-{(S)-1-[4-(1-Cyclopropyl-2-oxo-1,2-dihydro-pyridin-4-yl)-3-methyl-phenyl]-ethyl}-(S)-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

The title compound was prepared from (S)-6-(2-hydroxy-2-methyl-propyl)-3-25 {($)-1-[3-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-ethyl}-6- phenyl-[1,3]oxazinan-2-one and 4-bromo-1-cyclopropyl-1 H-py rid in-2-one following a procedure analogous to that described in Step 5 of Example 96. LC-MS (Method 5): tR = 3.42 min; Mass spectrum (ESI*): m/z = 501 [M+H]*. WO 2010/011314 PCT/US2009/004261 -203 -

Example 98 3-[4-(1-Cyclopropyl-2-oxo-1t2-dihydro-pyridin-4-yl)-benzyl)-6-(2-hydroxy-2-methyl-

<img img-format="tif" img-content="drawing" file="IL210452AD0002240.tif" id="idf0240" />

Step 1: 3-(4-Bromo-2,6-dimethyl-benzyl)-6-(2-methyl-allyl)-6-phenyl-(1,3]oxazinan-2-one

The title compound was prepared from 1-chloro-5-methyl-3-phenyI-hex-5-en-3· ol and 5-bromo-2-isocyanatomethyl-1,3-dimethyl-benzene following a procedure 10 analogous to that described in Step 1 of Example 96. LC-MS (Method 5): tR = 4.95 min; Mass spectrum (ESI+): m/z = 428/430 (Br) [M+H]+.

Step 2: 3-(4-Bromo-2,6-dimethyl-benzyl)-6-(2-methyl-oxiranylmethyl)-6-phenyl- [1,3]oxazinan-2-one

The title compound was prepared from 3-(4-bromo-2,6-dimethyl-benzyl)-6-(2-15 methyl-ally1)-6-phenyl-[1,3]oxazinan-2-one following a procedure analogous to that described in Step 2 of Example 96. LC-MS (Method 4); tR ~ 4.05 min; Mass spectrum (ESI*): m/z = 444/446 (Br) [M+H]+. WO 2010/011334 PCT/US2009/004261 -204-

Step 3: 3-(4-Bromo-2,6-dimethyl-benzyl)-6-(2-hydroxy-2-methyl-propyl)-6- phenyl-[1,3]oxazinan-2-one

The title compound was prepared from 3-(4-bromo-2,6-dimethyl-benzyl)-6-(2- methyl-oxiranylmethyl)-6-phenyl-[1,3]oxazinan-2-one following a procedure analogous 5 to that described in Step 3 of Example 96. LC-MS (Method 4): tR = 4.05 min; Mass spectrum (ESf): m/z = 446/448 (Br) [M+Hf.

Step 4: 3-[2,6-Dimethyl-4-{4,4,5f5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzyl]- 6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one

The title compound was prepared from 3-(4-bromo-2,6-dimethyl-benzy 1)-6-(2- 10 hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one following a procedure analogous to that described in Step 4 of Example 96. Mass spectrum (ESI+): m/z = 494 [M+Hf.

Step 5: 3-(4-(1-Cyclopropyl-2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-6-(2-hydroxy-2-methyl-propyl)-6-phenyl-[1,3]oxazinan-2-one 15 The title compound was prepared from 3-[2,6-dimethy!-4-(4,415,5-tetramethyl· [1,3,2]dioxaborolan-2-yl)-benzyl3-6-(2-hydroxy-2-nnethyl-propyl)-6-phenyl- [1,3]oxazinan-2-one and 4-bromo-1 -cyclopropyl-1 H-pyridin-2-one following a procedure analogous to that described in Step 5 of Example 96. LC-MS (Method 5); tR = 3.53 min; Mass spectrum (ESI*): m/z = 501 [M+Hf. 20 BIOLOGICAL TEST EXAMPLE 1

The inhibition of a microsomal preparation of 11p-HSD1 by compounds of the invention was measured essentially as previously described (K. Solly, S.S. Mundt, H.J. Zokian, G.J. Ding, A. Hermanowski-Vosatka, B. Strulovici, and W. Zheng, High- 25 Throughput Screening of 11-Beta-Hydroxyseroid Dehydrogenase Type 1 in

Scintillation Proximity Assay Format. Assay Drug Dev Technol 3 (2005) 377-384). All reactions were carried out at rt in 96 well clear flexible PET Microbeta plates (PerkinElmer). The assay begins by dispensing 49 μΐ of substrate solution (50mM HEPES, pH 7.4, 100mM KCI, 5mM NaCI, 2mM MgCI2, 2 mM NADPH and 160 nM 30 [3H]cortisone (1 Ci/mmol)) and mixing in 1 pL of the test compounds in DMSO previously diluted in half-log increments (8 points) starting at 0.1 mM. After a 10 minute pre-incubation, 50 pL of enzyme solution containing microsomes isolated from CHO cells overexpressing human Ιΐβ-HSDI (10-20 pg/ml of total protein) was added, WO 2010/011314 PCT/US2009/004261 -205 - and the plates were incubated for 90 minutes at rt. The reaction was stopped by adding 50 pi of the SPA beads suspension containing^ μΜ 18p-glycyrrhetinic acid, 5 mg/ml protein A coated YSi SPA beads (GE Healthcare) and 3.3 pg/ml of anti-cortisol antibody (East Coast Biologies) in Superblock buffer (Bio-Rad). The plates were 5 shaken for 120 minutes at rt, and the SPA signal corresponding to [3H)cortisol was measured on a Microbeta plate reader. BIOLOGICAL TEST EXAMPLE 2

The inhibition of Ιΐβ-HSDI by compounds of this invention was measured in 10 whole cells as follows. Cells for the assay were obtained from two sources: fully differentiated human omental adipocytes from Zen-Bio, Inc.; and human omental preadipocytes from Lonza Group Ltd. Pre-differentiated omental adipocytes from Zen-Bio Inc. were purchased in 96-well plates and were used in the assay at least two weeks after differentiation from precursor preadipocytes. Zen-Bio induced 15 differentiation of pre-adipocytes by supplementing medium with adipogenic and lipogenic hormones (human insulin, dexamethasone, isobutylmethylxanthine and PPAR-gamma agonist). The cells were maintained in full adipocyte medium (DMEM/Ham’s F-12 (1:1, v/v), HEPES pH 7.4, fetal bovine serum, penicillin, streptomycin and Amphotericin B, supplied by Zen-Bio, Inc.) at 37°C, 5% CO2. 20 Pre-adipocytes were purchased from Lonza Group Ltd. and placed in culture in

Preadipocyte Growth Medium-2 supplemented with fetal bovine serum, penicillin, and streptomycin (supplied by Lonza) at 37°C, 5% CO2. Pre-adipocytes were differentiated by the addition of insulin, dexamethasone, indomethacin and isobutylmethylxanthine (supplied by Lonza) to the Preadipocyte Growth Medium-2. Cells 25 were exposed to the differentiating factors for 7 days, at which point the cells were differentiated and ready for the assay. One day before running the assay, the differentiated omental adipocytes were transferred into serum- and phenot-red-free medium for overnight incubation. The assay was performed in a total volume of 200 pL. The cells were pre-incubated with serum-free, phenol-red-free medium containing 30 0.1 % (v/v) of DMSO and various concentrations of the test compounds at least 1 h before [3H] cortisone in ethanol (50Ci/mmol, ARC, Inc.) was added to achieve a final concentration of cortisone of 100 nM. The cells were incubated for 3-4 hrs at 37°C, 5% CO2. Negative controls were incubated without radioactive substrate and WO 2010/011314 PCT/US2009/004261 -206- received the same amount of [3H] cortisone at the end of the incubation. Formation of [3H] cortisol was monitored by analyzing 25 pL of each supernatant in a scintillation proximity assay (SPA). (Solly, K.; Mundt, S. S.;Zokian, H.J.;Ding, G. J.; Hermanowski-Vosatka, A.; Strulovici, B.; Zheng, W. Assay Drug Dev. Technol. 2005, 5 3, 377-384). Many compounds of the invention showed significant activity in this assay.

TABLE OF BIOLOGICAL ASSAY RESULTS

Compound Biological Test Example 1 IC50 Range3 Average % inhibition at 100 nM EXAMPLE 1 ++ 90.3 EXAMPLE 2 ++ 89.1 EXAMPLE 3 ++ 95.6 EXAMPLE 4 ++ 95.2 EXAMPLE 5 ++ 95.6 EXAMPLE 6 ++ 92.6 EXAMPLE 7 ++ 75,9 EXAMPLE 8 ++ 84.5 EXAMPLE 9 ++ 86.2 EXAMPLE 10 ++ 95.8 EXAMPLE 11 ++ 84.1 EXAMPLE 12 ++ 84.2 EXAMPLE 13 ++ 90.0 EXAMPLE 14 ++ 91.0 EXAMPLE 15 ++ 92.9 EXAMPLE 16 ++ 95.6 EXAMPLE 17 Isomer 1 ++ 54.0 EXAMPLE 17 Isomer 2 # 14.8 EXAMPLE 18 Isomer 1 # 23.7 EXAMPLE 18 Isomer 2 ++ 42.6 WO 2010/011314 PCT/US2009/004261 -207- EXAMPLE 19 EXAMPLE 20 EXAMPLE 21 Isomer 1 EXAMPLE 21 Isomer 2 EXAMPLE 22 Isomer 1 EXAMPLE 22 Isomer 2 EXAMPLE 23 EXAMPLE 24 EXAMPLE 25 EXAMPLE 26 EXAMPLE 27 EXAMPLE 28 Isomer 1 EXAMPLE 28 Isomer 2 EXAMPLE 29 EXAMPLE 30 EXAMPLE 31 EXAMPLE 32 . EXAMPLE 33 EXAMPLE 34 EXAMPLE 35 EXAMPLE 36 EXAMPLE 37 EXAMPLE 38 EXAMPLE 39 EXAMPLE 40 EXAMPLE 41 EXAMPLE 42 EXAMPLE43 EXAMPLE44 EXAMPLE45 EXAMPLE 46 ++ 36.5 ++ 90.9 ++ 103.5 ++ 88.8 ++ 82.5 ++ 88.7 ++ 88.2 ++ 87.9 ++ 93.9 ++ 94.7 ++ 92.0 ++ 86.9 42.9 ++ 94.1 ++ 96.7 ++ 90.1 ++ 96.4 ++ 95.9 ++ 95.0 ++ 95.8 ++ 95.0 ++ 96.5 ++ 74.3 ++ 99.1 + + 95.9 ++ 88.7 ++ 88.4 ++ 96.6 + + 102.0 ++ 97.9 ++ 94.8 WO 2010/011314 PCT/US2009/004261 -208- EXAMPLE 47 EXAMPLE 48 EXAMPLE 49 EXAMPLE 50 EXAMPLE 51 EXAMPLE 52 EXAMPLE 53 EXAMPLE 54 EXAMPLE 55 EXAMPLE 56 EXAMPLE 57 EXAMPLE 58 EXAMPLE 59 EXAMPLE 60 EXAMPLE 61 EXAMPLE 62 EXAMPLE 63 EXAMPLE 64 EXAMPLE 65 EXAMPLE 66 EXAMPLE 67 EXAMPLE 68 EXAMPLE 69 EXAMPLE 70 EXAMPLE 71 EXAMPLE 72 EXAMPLE 73 EXAMPLE 74 EXAMPLE 75 EXAMPLE 84 Isomer 1 EXAMPLE 84 Isomer 2 ++ 100.1 ++ 95.0 ++ 97.4 ++ 97.1 ++ 93.4 ++ 95.4 ++ 96.6 ++ 96.0 ++ 96.6 ++ 102.8 ++ 102.2 ++ 104.7 ++ 95.9 ++ 94.5 ++ 96.2 ++ 96.9 ++ 96.2 ++ 94.9 ++ 96.1 ++ 96.0 ++ 97.7 ++ 95.6 ++ 98.1 ++ 96.5 ++ 92.2 ++ 95.6 ++ 99.2 ++ 95.0 ++ 87.4 # 16.2 # 8.0 WO 2010/011314 PCT/US2009/004261 -209- EXAMPLE 85 ++ 68.4 EXAMPLE 86 ++ 87.7 EXAMPLE 87 ++ 107.5 EXAMPLE 88 ++ 92.4 EXAMPLE 89 ++ 92.6 EXAMPLE 91 Isomer 1 22.5 EXAMPLE 91 Isomer 2 13.8 EXAMPLE 92 ++ 93.7 EXAMPLE 93 Isomer 1 ++ 86.4 EXAMPLE 93 Isomer 2 18.7 EXAMPLE 94 Isomer 1 41.9 EXAMPLE 94 Isomer 2 8.2 EXAMPLE 95 Isomer 1 12.8 EXAMPLE 95 Isomer 2 # 8.0 a ++ means IC50 = &lt;100 nM, + means IC50 = 100 -1000 nM, # means IC50 &gt; 100 nM, - means ICso &gt; 1000 nM. BIOLOGICAL TEST EXAMPLE 3

5 In vitro inhibition of 11 β-HSDI by test compounds was determined with HTRF (Homogeneous Time-Resolved Fluorescence) technology (cisbio international,

France) detecting cortisol generated from cortisterone by human liver microsomes. Briefly, compounds were incubated for 1 hour at 37 °C in Tris buffer (20 mM tris, 5 mM EDTA, pH 6.0) containing NADPH (200 μΜ) and cortisone (80 nM). Cortisol 10 generated in the reaction was then detected with a competitive immunoassay, involving two HTRF conjugates: cortisol linked to XL665 and anti-cortisol antibody labeled with Europium cryptate. The incubation period for detection reaction was typically 2 hours. The amount of cortisol was determined by reading the time-resolved fluorescence of the wells (Ex 320/75 nm; Em 615/8.5 nm and 665/7.5 nm). The ratio 15 of the two emission signals was then calculated (Em665*10000/Em615). Each assay contained incubations with vehicle controls instead of compound as controls for non-inhibited cortisol generation (100% CTL; 'high values’) and incubations with carbenoxolone as controls for fully inhibited enzyme and cortisol background (0% WO 2010/011314 PCT/US2009/004261 -210- CTL; 'low values'). Each assay also contained a calibration curve with cortisol to transform the fluorescent data into cortisol concentrations. Percent inhibition of each compound was determined relative to the carbenoxolone signal.

In following table the Ιΐβ-HSD 1 inhibitory activities, determined as described 5 above, wherein 100% indicates no inhibition and a value of zero or below zero indicates complete inhibition. TABLE OF BIOLOGICAL ASSAY RESULTS FOR BIOLOGICAL TEST 3

Example Average % control inhibition at 100 nM 75 -14 76 17 77 59 78 58 79 15 80 37 81 11 82 -12 83 54 90 4 96 21 97 47 98 67 10 BIOLOGICAL TEST EXAMPLE 4

The inhibition of a microsomal preparation of 1Ιβ-HSDI in the presence of

50% human plasma by compounds of the invention was measured as follows. Microsomes from CHO cells overexpressing human 11β-HSDI were diluted into reaction buffer consisting of 25 mM HEPES, pH 7.4, 50 mM KCI, 2.5 mM NaCI, 1 mM 15 MgCI2, and 50% (v/v) human plasma (BioChemed). The assay began by dispensing 49 μΙ of microsome solution into 96-well polypropylene plates and adding 1 μΙ of the WO 2010/011314 PCT/US2009/004261 -211 - test compounds in DMSO, previously diluted in half-log increments (8 points) starting at 1.0 mM. The reaction was initiated with the addition of 50 pi substrate solution consisting of reaction buffer with 2 mM NADPH and 160 nM [3-H]cortisone (1

Ci/mmol). The plates were incubated for 120 minutes at rt, and the reaction was 5 quenched with the addition of 1ΟΟμΙ acetonitrile with 20 mM cortisone and 20 mM cortisol. After a ten minute incubation at rt, 100 μΐ of each well was filtered through a Multiscreen HTS, HV filter plate (Millipore) and diluted with 100 μ! of reaction buffer without human plasma. [3-H]cortisone and [3-H]cortisol were separated by HPLC on a Zorbax SB-C8 column (4.6 x 250 mm, Agilent) with an isocratic elution at 25% 10 acetonitrile in water with 0.01% trifluoroacetic acid, and radioactivity was quantified with an in-line β-RAM (IN/US Systems, Inc.). BIOLOGICAL TEST EXAMPLE 5 (Fraction Unbound in Human Plasma) 15 Plasma protein binding of compounds was determined with Equilibrium Dialysis of spiked plasma against compound free dextrane buffer using a dialysis membrane with mass cutoff of 5000 Da. Compound concentrations in plasma and buffer after incubation were measured using HPLC/Mass spectrometry. 20 BIOLOGICAL TEST EXAMPLE 6 (CYP3A4 Inhibition)

The assay was based on a method published by Moody et al. (Xenobiotica 1999). The inhibition of cytochrome P450 3A4-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Erythromycin by the test compound was assayed at 37 °C with 25 human recombinant cytochrome P450 3A4. All assays were carried out on a robotic system in 96 well plates. The final incubation volume of 200 μΙ contained TRIS buffer (0.1 M), MgCb (5 mM), recombinant protein (40 pmol/ml), Erythromycin (50 μΜ) and the test compound either at four different concentrations in duplicate (e.g. highest concentration 10-50 μΜ with subsequent serial 1:5 dilutions) or at a concentration of 30 10 μΜ in triplicate. Following a short preincubation period, reactions were started with the cofactor (NADPH, 1mM) and stopped by addition of 50 μΙ aqueous trichloroacetic acid (10%;w/v). An aliquot of the incubate was transferred to 96 well solid phase extraction (SPE) plates and extracted on the cartridge. The resultant [14C]- WO 2010/011314 PCT/US2009/004261 -212- formaldehyde/formic acid was not retained on the cartridge and was therefore separated from the unmetabolized substrate by washing the SPE plates with water.

An aliquot of the eluates was transferred into well plates suitable for liquid scintillation counting. The rate of formation of [14C]- formaldehyde/formic acid in these 5 incubations was compared to a control activity containing no test compound. If the compound was tested at four concentrations, experimental IC50 values were calculated. BIOLOGICAL TEST EXAMPLE 7 10 (CYP2C9 Inhibition)

Using a procedure similar to that described in Biological Test Example 6, the inhibition of cytochrome P450 2C9-isoenzyme catalysed O-demethylation of [O-methyl-14C]-Naproxen by the test compound was assayed at 37 °C with human recombinant cytochrome P450 2C9. The experimental IC50 was calculated based on 15 % control at four different concentrations. BIOLOGICAL TEST EXAMPLE 8 (CYP2C19 Inhibition)

Using a procedure similar to that described in Biological Test Example 6, the 20 inhibition of cytochrome P450 2C19-isoenzyme catalysed N-demethylation of [N-methyl-14C]-Diazepam by the test compound was assayed at 37 °C with human recombinant cytochrome P450 2C19. The experimental IC50 was calculated based on % control at four different concentrations. 25 BIOLOGICAL TEST EXAMPLE 9 (CYP2C9 Inhibition)

The inhibition of recombinant CYP2C9 by compounds of the invention was measured using a commercial kit from Invitrogen (cat #2859). Supplied microsomes isolated from insect cells infected with a baculovirus engineered to express human 30 CYP2C9 were diluted to 10 mM in reaction buffer (100 mM potassium phosphate buffer, pH 8.0) with an NADPH generation system (3.33 mM glucose-6-phosphate and 0.4 U/ml glucose-6-phosphate dehydrogenase). 89 μΙ of this dilution were dispensed to each well of a 96-well, black, polystyrene plate and mixed with 1 μΙ of test WO 2010/011314 PCT/US2009/004261 -213- compound previously diluted in DMSO in half log increments starting at 3 mM. The assay was initiated by adding 10 μΙ of fluorogenic substrate n-octyloxymethylresorufin (OOMR, 20 μΜ.) with NADP (100 μΜ) diluted in reaction buffer. The plate was immediately placed in a Perkin Elmer Fusion plate reader. Reaction progress was 5 monitored by measuring fluorescence every two minutes for a total of twenty minutes (530 nM excitation filter /605 nM emission filter). TABLE OF BIOLOGICAL ASSAY RESULTS FOR BIOLOGICAL TESTS 1, 4 AND 5 EXAMPLE Biological Test Example 1 IC50 (nM) Biological Test Example 48 IC50 (nM) Shift11 Biological Test Example 5 (%) 1 1.51 2.84 1.88 2 0.31 15.54 50.94 3 1.59 3.85 2.42 4 1.80 5.60 3.12 5 1.25 3.80 3.04 6 2.36 4.07 1.72 7 35.07 nt 8 18.33 nt 9 4.29 13.12 3.06 10 2.91 13.13 4.51 11 5.94 13.51 2.27 12 5.38 31.75 5.90 13 7.22 nt 0.00 14 1.11 2,88 2.59 15 0.58 2.15 3.70 16 0.90 2.00 2.23 17 Isomer 1 75.98 nt 17 Isomer 2 &gt;100.00 nt 18 Isomer 1 &gt;100.00 nt WO 2010/011314 PCT/US2009/004261 -214- 18 Isomer 2 97.49 nt 19 95.38 nt 20 4.28 7.61 1.78 21 Isomer 1 3.89 4.72 1.21 21 Isomer 2 7.21 9.58 1.33 22 Isomer 1 14.87 75.86 5.10 22 Isomer 2 6.60 20.11 3.05 23 1.99 4.17 2.10 24 3.70 8.28 2.24 25 2.34 5.44 2.32 26 1.49 8.05 5.39 27 3.49 8.41 2.41 28 Isomer 1 &gt;100.00 nt 28 Isomer 2 8.89 nt 29 1.39 2.76 1.99 30 1.44 3.42 2.37 31 9.01 25.42 2.82 32 3.58 11.48 3.20 33 2.23 3.69 1.66 34 3.19 8.85 2.78 35 2.97 nt 36 2.03 13.62 6.72 37 1.67 6.44 3.85 38 5.18 nt 39 1.31 5.10 3.89 40 1.86 7.01 3.77 41 9.28 38.06 4.10 42 6.70 53.38 7.97 43 2.23 3.51 1.57 44 1.08 5.60 5.19 45 1.58 11.85 7.52 13.9 12.3 14.6 WO 2010/011314 PCT/US2009/004261 -215- 46 4.24 16.97 4.00 47 0.96 6.75 7.03 48 1.62 5.54 3.41 8.7 49 1.03 2.96 2.86 50 0.61 1.97 3.23 51 5.46 7.89 1.45 52 3.24 14.09 4.35 9.0 53 1.35 4.19 3.10 12.8 54 2.40 7.05 2.94 9.1 55 1.66 7.18 4.31 7.1 56 1.03 13.19 12.81 57 1.26 12.45 9.92 58 0.87 8.98 10.32 59 1.53 4.02 2.63 11.7 60 0,75 7.00 9.40 61 1.40 6.99 4.99 62 2.48 11.96 4.82 63 3.85 102.97 26.73 64 1.64 9.62 5.87 65 0.80 4.64 5.82 66 1.47 6.71 4.58 5.5 67 2.01 7.29 3.63 68 0.96 4.39 4.59 69 0.72 3.89 5.42 70 1.01 2.63 2.60 71 0.65 3.96 6.09 72 4.04 8.23 2.04 73 1.99 33.08 16.62 74 1.21 8.76 7.24 75 1.40 2.80 2.00 15.6 84 Isomer 1 &gt;100 nt WO 2010/011314 PCT/US2009/004261 -216- 84 Isomer 2 &gt;100 nt 85 42.9 nt 86 12.1 24.5 2.0 87 1.4 3.2 2.2 88 1.2 2.9 2.5 89 2.8 4.6 1.7 91 Isomer 1 &gt;100 nt 91 Isomer 2 &gt; 100 nt 92 1.8 6.2 3.4 93 Isomer 1 6.1 16.3 2.7 93 Isomer 2 &gt;100 94 Isomer 1 &gt;100 94 Isomer 2 &gt;100 95 Isomer 1 &gt;100 95 Isomer 2 &gt;100 a nt means not tested;b Shift is the IC5o determined in Biological Test Example 4 divided by the IC50 determined in Biological Test Example 1. TABLE OF E IIOLOGICAL ASSAY RESULTS FOR BIOLOGICAL TESTS 6-9 Biological Test Biological Test Biological Test Biological Test EXAMPLE Example 6 Example 7 Example 8 Example 9 CYP3A4, IC50 CYP2C9, IC50 CYP2C19, IC5D CYP2C9 IC50 ΙμΜ] EMMJ [μΜΙ iuM] 1 2 3 44 38 &gt;50 4 21 17 22 5 29 37 22 6 7 8 WO 2010/011314 PCT/US2009/004261 -217- 9 10 11 12 13 14 25 18 24 15 16 17 Isomer 1 17 Isomer 2 18 Isomer 1 18 Isomer 2 19 20 21 Isomer 1 21 Isomer 2 22 Isomer 1 22 Isomer 2 30.0 16.1 12.1 23 &gt;50 &gt;50 44 24 25 33 30 22 26 &gt;50 &gt;50 &gt;50 27 28.1 28.2 29 75 30 &gt;50 &gt;50 27 14.3 31 32 &gt;50 &gt;50 &gt;50 28.7 33 &gt;50 43 17 24.6 34 WO 2010/011314 PCT/VS2009/004261 -218- 35 36 37 48 43 &gt;50 24.8 38 30.0 39 40 &gt;50 &gt;50 13 27.9 41 42 43 10.5 44 45 15.2 46 47 12.1 48 &gt;50 &gt;50 &gt;50 30.0 49 32 29 46 14.8 50 14 11 27 5.1 51 52 48 14 8 20.3 53 &gt;50 &gt;50 &gt;50 30.0 54 &gt;50 &gt;50 18 55 &gt;50 29 13 24.3 56 57 58 8 3 2 59 &gt;50 &gt;50 37 17.7 60 61 &gt;50 40 18 62 48 &gt;50 38 63 64 &gt;50 33 17 65 &gt;50 &gt;50 25 WO 2010/011314 PCT/US2009/004261 - 219 - 66 18 10 11 67 28 41 34 68 43 47 28 69 23 38 &gt;50 70 28 &gt;50 23 71 6 17 24 72 73 74 41 35 8 75 23 19 24 76 10 4 9 77 &gt;50 &gt;50 34 78 47 39 40 79 &gt;50 &gt;50 &gt;50 80 &gt;50 &gt;50 3B 81 &gt;50 30 12 82 &gt;50 48 29 83 84 Isomer 1 84 Isomer 2 85 86 87 &gt;50 14 10 88 89 91 Isomer 1 91 Isomer 2 92 93 Isomer 1 93 Isomer 2 94 Isomer 1 &gt;50 28 &gt;50 28.5 WO 2010/011314 PCT/US2009/004261 -220- 94 Isomer 2 95 Isomer 1 95 Isomer 2 TABLE OF BIOLOGICAL ASSAY RESULTS FOR COMPARATOR COMPOUNDS IN BIOLOGICAL TESTS 1,4 AND 5

Comparator Compound Biological Test Example 1 IC50 (nM) Biological Test Example 4s IC50 (nM) Shift" Biological Test Example 5 (%) 1 0.77 11.97 15.51 2 1.80 14.16 7.88 3 0.75 17.74 23.63 0.3 4 1.44 15.24 10.57 5 0.51 18.50 36.10 6 1.48 37.58 25.39 7 0.99 41.90 42.43 8 0.72 17.85 24.74 9 0.55 11.86 21.45 0.3 10 1.79 53.49 29.91 11 0.55 13.40 24,59 0.7 12 1.08 19.54 18.12 0.4 13 0.76 6.32 8.30 14 1.30 8.94 6.90 15 0.79 8.94 11.32 a nt means not tested;b Shift is the IC50 determined in Biological Test Example 4 5 divided by the IC50 determined in Biological Test Example 1. WO 2010/011314 PCT/US2009/004261 -221 -

TABLE OF BIOLOGICAL ASSAY RESULTS FOR COMPARATOR COMPOUNDS IN BIOLOGICAL TESTS 6-9

Comparator Compound Biological Test Example 6 CYP3A4, IC50 [μΜ] Biological Test Example 7 CYP2C9, IC50 [μΜ] Biological Test Example 8 CYP2C19, IC50 [μΜ] Biological Test Example 9 CYP2C9 IC50 [uM] 1 27.0 2 1.4 3 7.4 4.1 5.7 4.9 4 5.1 5 9.9 5.1 8.3 3.7 6 4.4 2.3 8.6 5.0 7 4.0 8 5.3 2.4 5.6 3.0 9 7.0 3.1 9.3 2.5 10 3.6 11 14.1 6.3 12.5 5.5 12 4.9 4.6 9.5 2.5 12 4.9 3.9 10.1 13 4.4 5.6 &lt; 0.4 7.3 14 19.7 25,9 6.4 24.6 15 3.1 7.7 &lt; 0.4 9.5 WO 2010/011314 PCT/US2009/004261 -222- F Ά AF F C &amp;amp; ,-V o„ Of. NOf A AF Comparator 1 Comparator 2 ο 1 o cAP 111 F cAF f JL· N if A faV AF O'1 0 (I AF OH OH Comparator 3 Comparator 4 0 i o H I _ Ά&gt;Ά V V'A AAA A^ M A F 1! JL I &lt; .OH ? &gt;r HO Comparator 5 Comparator 6 0 V n ’Ό·ώ"υ oX Xaf A' oA OA 1 A A NH2 ΌΗ Comparator 7 Comparator 8 o 1 (/Άα II FO·· 0 cAn- A YA O' Y A '"'Ά, f NH F AA ΌΗ o 0 Comparator 9 Comparator 10 WO 2010/011314 PCT/US2009/004261 -223 - 0 v O ' V πχ O | X 1 O^NHz η&lt;Λ Comparator 11 Comparator 12 O 1 0 1 Λ Λ ? ι ιΡϊ ? i iPl I FJO"V 0 F OH OH Comparator 13 Comparator 14 0 I ?Λϊ ιΓΊ OP OH Comparator 15

The compounds of the invention are useful for ameliorating or treating disorders or diseases in which decreasing the level of cortisol is effective in treating a disease state. Thus, the compounds of the invention can be used in the treatment or 5 prevention of diabetes mellitus (e.g., type II diabetes), obesity, symptoms of metabolic syndrome, glucose intolerance, hyperglycemica, hypertension, hyperlipidemia, insulin resistance, cardiovascular disease, dyslipidemia, atherosclerosis, lipodystrophy, osteoporosis, glaucoma, Cushing's syndrome, Addison’s Disease, visceral fat obesity associated with glucocorticoid therapy, depression, anxiety, Alzheimer’s disease, 10 dementia, cognitive decline (including age-related cognitive decline), polycystic ovarian syndrome, infertility and hypergonadism. The compounds of the invention can be used as therapeutic agents for pseudo Cushing’s Syndrome associated with alcoholic liver disease. In addition, the compounds modulate the function of B and T cells of the immune system and can therefore be used to treat diseases such as 15 tuberculosis, leprosy and psoriasis. They can also be used to promote wound healing, particularly in diabetic patients. WO 2010/011314 PCT/US2009/004261 -224-

Additional diseases or disorders that are related to 11p-HSD1 activity include those selected from the group consisting of lipid disorders, hypertriglyceridemia, hypercholesterolemia, low HDL levels, high LDL levels, vascular restenosis, pancreatitis, abdominal obesity, neurodegenerative disease, retinopathy, 5 nephropathy, neuropathy, diabetes, coronary heart disease, stroke, peripheral vascular disease, Cushing’s syndrome, hyperinsulinemia, viral diseases, and Syndrome X. A further disease related to Ιΐβ-HSDI activity is pseudo Cushing’s Syndrome associated with alcoholic liver disease. A pharmaceutical composition of the invention may, alternatively or in addition 10 to an 11p-HSD1 inhibitor of the invention, comprise a pharmaceutically acceptable salt of a an 11 p-HSD1 inhibitor of the invention and one or more pharmaceutically acceptable carriers therefore. Alternatively, a pharmaceutical composition of the invention may comprise a compound of an 11p-HSD1 inhibitor of the invention or a pharmaceutical salt thereof as the only pharmaceutically active agent in the 15 pharmaceutical composition. The disclosed 11p-HSD1 inhibitors can be used alone or in a combination therapy with one or more additional agents for the treatment of diabetes, dyslipidemia, cardiovascular disease, hypertension, obesity, cancer or glaucoma.

The compositions of the invention are 11P-HSD1 inhibitors. Said compositions 20 contain compounds having a mean inhibition constant (IC50) against 11p-HSD1 of below about 1,000 nM; preferably below about 100 nM; more preferably below about 50 nM; even more preferably below about 5 nM; and most preferably below about 1 nM.

The invention includes a therapeutic method for treating or ameliorating an 25 11p-HSD1 mediated disorder in a subject in need thereof comprising administering to a subject in need thereof an effective amount of an 11p-HSD1 inhibitor of the invention, or an enantiomer, diastereomer, or pharmaceutically acceptable salt thereof or composition thereof. As used herein, “treating" or “treatment” includes both therapeutic and prophylactic treatment. Therapeutic treatment includes reducing the 30 symptoms associated with a disease or condition and/or increasing the longevity of a subject with the disease or condition. Prophylactic treatment includes delaying the onset of a disease or condition in a subject at risk of developing the disease or WO 2010/011314 PCT/US2009/004261 -225 - condition or reducing the likelihood that a subject will then develop the disease or condition in a subject that is at risk for developing the disease or condition.

An embodiment of the invention includes administering an Ιΐβ-HSDI inhibiting compound of the invention or composition thereof in a combination therapy with one 5 or more additional agents for the treatment of diabetes, dyslipidemia, cardiovascular disease, hypertension, obesity, cancer or glaucoma. Agents for the treatment of diabetes include insulins, such as Humulin® (Eli Lilly), Lantus® (Sanofi Aventis), Novolin (Novo Nordisk), and Exubera® (Pfizer); PPAR gamma agonists, such as Avandia® (rosiglitizone maleate, GSK) and Actos® (pioglitazone hydrochloride, 10 Takeda/Eli Lilly); sulfonylureas, such as Amaryl® (glimepiride, Sanofi Aventis),

Diabeta® (glyburide, Sanofi Aventis), Micro nase®/Glynase® (glyburide, Pfizer), and Glucotrol®/Glucotrol XL® and (glipizide, Pfizer); meglitinides, such as

Prandin®/NovoNorm® (repaglinide, Novo Nordisk), Starlix® (nateglinide, Novartis), and Glufast® (mitiglinide, Takeda); biguanides, such as Glucophase®/Glucophase 15 XR® (metformin HCI, Bristol Myers Squibb) and Glumetza (metformin HCI,

Depomed); thiazolidinediones; amylin analogs, GLP-1 analogs; DPP-IV inhibitors such as Januvia® (sitagliptin, Merck) and Galvus® (vildagliptin, Novartis); PTB-1B inhibitors; protein kinase inhibitors (including AMP-activated protein kinase inhibitors); glucagon antagonists, glycogen synthase kinase-3 beta inhibitors; glucose-6- 20 phoshatase inhibitors; glycogen phosphorylase inhibitors; sodium glucose co-transporter inhibitors, and alpha-glucosidase inhibitors, such as Precose®/Glucobay®/Prandase®/Glucor® (acarbose, Bayer) and Glyset® (miglitol, Pfizer). Agents for the treatment of dyslipidemia and cardiovascular disease include statins, fibrates, and ezetimbe. Agents for the treatment of hypertension include 25 alpha-blockers, beta-blockers, calcium channel blockers, diuretics, angiotensin converting enzyme (ACE) inhibitors, dual ACE and neutral endopeptidase (NEP) inhibitors, angiotensin-receptor blockers (ARBs), aldosterone synthase inhibitors, aldosterone-receptor antagonists, or endothelin receptor antagonist. Agents for the treatment of obesity include orlistat, phentermine, sibutramine and rimonabant. 30 An embodiment of the invention includes administering an 11 β-HSDt inhibiting compound of the invention or composition thereof in a combination therapy with one or more other Ιΐβ-HSDI inhibitors, or with combination products, such as Avandamet® (metformin HCI and rosiglitazone maleate, GSK); Avandaryl® WO 2010/011314 PCT/US2009/O04261 -226- (glimepiride and rosiglitazone maleate, GSK); Metaglip® (glipizide and metformin HCI,

Bristol Myers Squibb); and Glucovance® (glyburide and metformin HCI, Bristol Myers

Squibb).

The compounds of the present invention can be prepared and administered in 5 a wide variety of oral and parenteral dosage forms. Thus, the compounds of the present invention can be administered by injection, that is, intravenously, intramuscularly, intracutaneously, subcutaneously, intraduodenally, or intraperitoneally. Additionally, the compounds of the present invention can be administered intranasally or transdermally. It will be obvious to those skilled in the art 10 that the following dosage forms may comprise as the active ingredient, either compounds or a corresponding pharmaceutically acceptable salt of a compound of the present invention.

For preparing pharmaceutical compositions from the compounds of the present invention, pharmaceutically acceptable carriers can either be solid or liquid. Solid 15 form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a Finely divided solid which is in a mixture with the finely divided 20 active ingredient.

In tablets, the active ingredient is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

The powders and tablets preferably contain from about one to about seventy 25 percent of the active ingredient. Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium caboxymethylcellulose, a low-melting wax, cocoa butter, and the like. Tablets, powders, cachets, lozenges, fast-melt strips, capsules and pills can be used as solid dosage forms containing the active ingredient suitable for oral 30 administration.

For preparing suppositories, a low-melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first-melted and the active ingredient is dispersed WO 2010/011314 PCT/US2009/004261 -227 - homogeneously therein, as by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and thereby to solidify.

Liquid form preparations include solutions, suspensions, retention enemas, and emulsions, for example, water or water propylene glycol solutions. For parenteral 5 injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution.

Aqueous solutions suitable for oral administration can be prepared by dissolving the active ingredient in water and adding suitable colorants, flavors, stabilizing, and thickening agents as desired. Aqueous suspensions for oral 10 administration can be prepared by dispersing the finely divided active ingredient in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.

The pharmaceutical composition is preferably in unit dosage form. In such 15 form, the composition is subdivided into unit doses containing appropriate quantities of the active ingredient. The unit dosage form can be a packaged preparation, the package containing discrete quantities of, for example, tablets, powders, and capsules in vials or ampules. Also, the unit dosage form can be a tablet, cachet, capsule, or lozenge itself, or it can be the appropriate amount of any of these in packaged form. 20 The quantity of active ingredient in a unit dose preparation may be varied or adjusted from about 0.1 mg to about 1000.0 mg, preferably from about 0.1 mg to about 100 mg. The dosages, however, may be varied depending upon the requirements of the patient, the severity of the condition being treated, and the compound being employed. Determination of the proper dosage for a particular 25 situation is within the skill in the art. Also, the pharmaceutical composition may contain, if desired, other compatible therapeutic agents.

In therapeutic treatment or as a method-of-use as an inhibitor of Ιΐβ-HSDI or an inhibitor in the production of cortisol in the cell, the active ingredient is preferably administered orally in a solid dosage form as disclosed above in an amount of about 30 0.1 mg to about 100 mg per daily dose where the dose is administered once or more than once daily.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual WO 2010/011314 PCT/US2009/004261 - 228 - publication or patent application were specifically and individually designated as having been incorporated by reference. It is understood that the examples and embodiments described herein are for illustrative purposes only, and it will be appreciated that the invention is susceptible to modification, variation and change 5 without departing from the proper scope or fair meaning of the appended Cairns.

While this invention has been particularly shown and described with references to example embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims. cra&amp;amp;’an , crnxan rwzn ατα inia^n pnow pnszn irn πτ “|»oa ,ρνιη ηχΰπ naoana ma™ na^maa np’ioa .zruwan rwaa mpnan pmi1? oxnm οιηπη Pi?

<img img-format="tif" img-content="drawing" file="IL210452AD0002241.tif" id="idf0241" />

.(moia nannn) cras^an mwa